

REFINITIV

DELTA REPORT

10-K

PINC - PREMIER, INC.

10-K - JUNE 30, 2024 COMPARED TO 10-K - JUNE 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS 4556

█ **CHANGES** 526

█ **DELETIONS** 1926

█ **ADDITIONS** 2104

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended **June 30, 2023** **June 30, 2024**
OR

TRANSITION REPORT PURSUANT TO SECTION 13 ~~OF~~ OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____
Commission File Number: 001-36092

Premier, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

35-2477140

(I.R.S. Employer
Identification No.)

13034 Ballantyne Corporate Place

28277

Charlotte, North Carolina

(Zip Code)

(Address of principal executive offices)

Registrant's telephone number, including area code: (704) 357-0022

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, \$0.01 Par Value	PINC	NASDAQ Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer

Non-accelerated filer Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The aggregate market value of the Class A common stock held by non-affiliates of the registrant as of the last business day of the registrant's most recently completed second fiscal quarter was approximately **\$4,124.8 million** **\$2,657.9 million**. For purposes of the foregoing calculation only, executive officers and directors of the registrant have been deemed to be affiliates.

As of **August 17, 2023** **August 15, 2024**, there were **119,170,751** **100,187,927** shares of the registrant's Class A common stock, par value \$0.01 per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

The registrant's definitive proxy statement for its **2023** **2024** Annual Meeting of Stockholders to be held on or about **December 1, 2023** **December 6, 2024** is incorporated by reference into Part III hereof to the extent described herein.

PREMIER, INC.
FORM 10-K
TABLE OF CONTENTS

	Page
PART I	
ITEM 1. BUSINESS	6
ITEM 1A. RISK FACTORS	24
ITEM 1B. UNRESOLVED STAFF COMMENTS	47 49
ITEM 1C. CYBERSECURITY	49
ITEM 2. PROPERTIES	47 51
ITEM 3. LEGAL PROCEEDINGS	47 51
ITEM 4. MINE SAFETY DISCLOSURES	47 51
PART II	
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	48 52
ITEM 6. RESERVED	49 53
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	49 54
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	74 79
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	75 80
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	114 118
ITEM 9A. CONTROLS AND PROCEDURES	114 118
ITEM 9B. OTHER INFORMATION	114 118
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS	114 119
PART III	
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	115 120
ITEM 11. EXECUTIVE COMPENSATION	115 120
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	115 120
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	116 121
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES	116 121
PART IV	
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	117 122
ITEM 16. FORM 10-K SUMMARY	119 125
SIGNATURES	120 126

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements made in this Annual Report on Form 10-K for the fiscal year ended **June 30, 2023** **June 30, 2024** for Premier, Inc. (this "Annual Report") that are not statements of historical or current facts, such as those under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations," are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results or projections expressed or implied

by such forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in conditional or future tenses or that include terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to our beliefs and expectations regarding future events and trends affecting our business and are necessarily subject to risks and uncertainties, many of which are outside our control. Factors that could cause actual results to differ materially from those indicated in any forward-looking statement include, but are not limited to:

- competition which could limit our ability to maintain or expand market share within our industry;
- our reliance on administrative fees that we receive from suppliers to our group purchasing organization ("GPO") and ability to maintain and add new GPO members, which will depend in part on competitive pressure to increase the administrative fee share we pay to members;
- consolidation in the healthcare industry;
- potential delays in recognizing or increasing revenue if the sales cycle or implementation period takes longer than expected;
- the impact to our business if members of our group purchasing organization ("GPO") GPO programs reduce activity levels or terminate or elect not to renew their contracts on substantially similar terms or at all;
- our reliance on administrative fees that we receive from GPO suppliers;
- the rate at which the markets for our software as a service ("SaaS") or licensed-based clinical analytics products and services develop; develop and the potential for existing licensed-based customers to convert to SaaS subscriptions;
- the dependency of our members on payments from third-party payers;
- our ability to maintain third-party provider and strategic alliances or enter into new alliances;
- our ability to timely offer new and innovative products and services; services, including the integration of artificial intelligence and the risks associated with artificial intelligence due to the evolving nature of the technology and legal and regulatory framework;
- the portion of our revenues that we receive from our largest members and other customers;
- risks and expenses related to future acquisition opportunities and integration of previous or future acquisitions;
- acquisitions, including the impact on our business and stock price due to our evaluation of potential strategic alternatives; for impairments resulting from acquisitions;
- financial and operational risks associated with non-controlling investments in other businesses or other joint ventures that we do not control, particularly early-stage companies;
- pending and potential litigation;
- our reliance on Internet infrastructure, bandwidth providers, data center providers and other third parties and our own systems for providing services to our users;
- data loss or corruption due to failures or errors in our systems and service disruptions at our data centers, or breaches or failures of our security measures;
- the financial, operational, legal and reputational consequences of cyber-attacks or other data security breaches that disrupt our operations or result in the dissemination of proprietary or confidential information about us or our members or other third parties;
- our ability to use, disclose, de-identify or license data and to integrate third-party technologies;
- our use of "open source" software;
- our dependency on contract manufacturing facilities located in various parts of the world;
- inventory risk we face in the event of a potential material decline in demand or price for the personal protective equipment or other products we may have purchased at elevated market prices or fixed prices;
- our ability to attract, hire, integrate and retain key personnel;
- the impact of continuing uncertain economic conditions to our business operations due to, but not limited to, inflation and the risk of global recession;
- the impact of the continuing financial and operational uncertainty due to pandemics, epidemics or public health emergencies and associated supply chain disruptions; recessionary fears;
- the financial and operational uncertainty due to global economic macroeconomic, geopolitical, and political instability business conditions, trends and conflicts; events and the impact of any associated supply chain challenges;
- the impact of global climate change or by regulatory responses to such change;
- changes and uncertainty in the political, economic or regulatory environment affecting healthcare organizations, including with respect to the status of the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act of 2010 and pandemic-related public health and reimbursement measures; 2010;
- our compliance with complex international, federal and state laws, rules and regulations governing financial relationships among healthcare providers and the submission of false or fraudulent healthcare claims;
- interpretation and enforcement of current or future antitrust laws and regulations;
- compliance with complex federal, state and international privacy, security and breach notification laws;
- compliance with current or future laws, rules or regulations relating to information blocking provisions of the 21st Century Cures Act issued by the Office of the National Coordinator for Health Information Technology (the "ONC Rules") that may cause our certified Health Information Technology products to be regulated by the ONC Rules;
- compliance with current or future laws, rules or regulations adopted by the Food and Drug Administration applicable to our software applications that may be considered medical devices;
- adequate protection of our intellectual property and potential claims against our use of the intellectual property of third parties;
- potential for additional indirect tax liabilities, such as gross receipts and sales and use franchise and income tax liability taxes, in certain jurisdictions;

- changes in tax laws that materially impact our tax rate, income tax expense, anticipated tax benefits, deferred tax assets, cash flows and profitability and potential material tax disputes;
- the impact of payments required under notes payable to former limited partners related to the early termination of the Unit Exchange and Tax Receivable Acceleration Agreements (the "Unit Exchange Agreements") issued in connection with our August 2020 Restructuring on our overall cash flow and our ability to fully realize the expected tax benefits to match such fixed payment obligations under those notes payable;
- provisions in our certificate of incorporation and bylaws and provisions of Delaware law and other applicable laws that discourage or prevent strategic transactions, including a takeover of us;
- our indebtedness and our ability to obtain additional financing on favorable terms, including our ability to renew or replace our existing long-term credit facility at or before maturity;
- fluctuation of our quarterly cash flows, revenues and results of operations;
- failure to maintain an effective system of internal controls over financial reporting or an inability to remediate any weaknesses identified and the related costs of remediation;
- the impact on the price of our Class A common stock ("Common Stock") if we cease paying dividends or reduce dividend payments from current levels;
- the number of shares of Class A common stock Common Stock repurchased by us pursuant to any then existing Class A common stock Common Stock repurchase program and the timing of any such repurchases;
- the number of shares of Class A common stock Common Stock eligible for sale after the issuance of Class A common stock Common Stock in our August 2020 Restructuring and the potential impact of such sales; and
- the risk factors discussed under the heading "Risk Factors" in Item 1A herein.

More information on potential factors that could affect our financial results is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" or similarly captioned sections of this Annual Report and our other periodic and current filings made from time to time with the Securities and Exchange Commission ("SEC"), which are available on our website at <http://investors.premierinc.com/>. You should not place undue reliance on any of our forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, or future events or otherwise. Furthermore, we cannot guarantee future results, events, levels of activity, performance or achievements.

Market Data and Industry Forecasts and Projections

We use market data and industry forecasts and projections throughout this Annual Report and in particular, under Item 1. Business. We have obtained the market data from certain publicly available sources of information, including industry publications. We believe the data others have compiled are reliable, but we have not independently verified the accuracy of this information. While we are not aware of any misstatements regarding the industry data presented herein, forecasts and projections involve risks and uncertainties and are subject to change based on various factors, including those discussed under Item 1A. Risk Factors of this Annual Report. You should not place undue reliance on any such market data or industry forecasts and projections. We undertake no obligation to publicly update or revise any such market data or industry forecasts and projections, whether as a result of new information, future events or otherwise.

Trademarks, Trade Names and Service Marks

This Annual Report includes trademarks, trade names and service marks that we either own or license, such as but not limited to "100 Top Hospitals," "Acurity," "ASCENDrive,™," "Conductiv," "ConfigureNet™," "Contigo Health," "Essensa," "Health Design Plus," "Innovatix," "InterSecta,™," "KIINDO,™," "PINC AI™," "Premier," "PremierPro," "ProvideGx," "QUEST," "Remitra," "SURPASS," "S2S Global," "S2S Global" "SURPASS" and "TheraDoc" which are protected under applicable intellectual property laws. Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report may appear without the ®,™ or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. This Annual Report also may contain trademarks, trade names and service marks of other parties, and we do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

Certain Definitions

For periods prior to August 11, 2020, references to "member owners" are references to participants in our GPO programs that were also limited partners of Premier Healthcare Alliance L.P. ("Premier LP"), sometimes referred to as "LPs," that held Class B common units of Premier LP and shares of our Class B common stock.

For periods on or after August 11, 2020, references to "members" are references to health systems and other customers that utilize any of our programs or services, some of which were formerly member owners. owners who participated in our GPO programs and were also limited partners of Premier Healthcare Alliance L.P. ("Premier LP").

References to the "August 2020 Restructuring" are references to our corporate restructuring on August 11, 2020 in which we (i) eliminated our dual-class ownership structure, through an exchange under which member owners, who were limited partners of Premier LP converted their Class B common units in Premier LP and corresponding Class B common shares of Premier, Inc. into our Class A common stock, on a one-for-one basis, and (ii) exercised our right to terminate the Tax Receivable Agreement (the "TRA") by providing all former limited partners a notice of termination and the amount of the expected payment to be made to each limited partner pursuant to the early termination provisions of the TRA with a determination date of August 10, 2020. For additional information and details regarding the August 2020 Restructuring, see our Annual Report on Form 10-K for the fiscal year ended June 30, 2021.

References to the "Subsidiary Reorganization" are references to an internal legal organization reorganization of our corporate subsidiaries in December 2021 for the purpose of simplifying our subsidiary reporting structure. For additional information and details regarding the Subsidiary Reorganization, see our Quarterly Report on Form 10-Q for the period ended December 31, 2021.

References to "Prior Premier GP" are references to our former wholly owned subsidiary Premier Services, LLC, which was merged with and into Premier, Inc. with Premier, Inc. being the surviving entity as part of the Subsidiary Reorganization.

References to "adjacent markets" are references to the **non-traditional non-provider healthcare** markets penetrated by Premier, Inc.'s businesses and brands that are designed to diversify revenue for the Company. This includes PINC AI Clinical Decision Support serving providers and payers; PINC AI Applied Sciences serving biotech, pharmaceutical and medical device companies; Contigo Health that serves self-insured employers, including healthcare providers that are also payers ("payviders"); and Remitra that serves healthcare suppliers and providers.

PART I

Item 1. Business

The following discussion should be read in conjunction with our consolidated financial statements and accompanying notes thereto included elsewhere in this Annual Report on Form 10-K. The following discussion includes certain forward-looking statements. For a discussion of important factors which could cause actual results to differ materially from the results referred to in the historical information and the forward-looking statements presented herein, see "Item 1A. Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" contained in this Annual Report.

Our Company

Premier, Inc. ("Premier", the "Company", "we", "us" or "our"), a publicly held, for-profit corporation, incorporated in Delaware on May 14, 2013, is a leading technology-driven healthcare improvement company, uniting an alliance of United States ("U.S.") hospitals, health systems and other providers and organizations to transform healthcare. We partner with hospitals, health systems, physicians, employers, product suppliers, service providers and other healthcare providers and organizations with the common goal of improving and innovating in the clinical, financial and operational areas of their businesses to meet the demands of a rapidly evolving healthcare industry, and we continue to expand our capabilities to more fully address and coordinate care improvement and standardization in the employer, payer and life sciences markets. With integrated data and analytics, collaboratives, supply chain services, consulting and other services, Premier enables healthcare providers to deliver better care and outcomes at a lower cost. We believe that we play a critical role in the rapidly evolving healthcare industry, collaborating with members and other customers to co-develop long-term innovative solutions that reinvent and improve the way care is delivered to patients and paid for nationwide. We deliver value through a comprehensive technology-enabled platform that offers critical supply chain services, clinical, financial, operational and value-based care software as a service ("SaaS") as well as clinical and enterprise analytics licenses, consulting services, performance improvement collaborative programs, third-party administrator services, access to our centers of excellence program, cost containment and wrap network and digital invoicing and payables automation processes which provide financial support services to healthcare suppliers and providers. Additionally, we provide some of the various products and services noted above to non-healthcare businesses, including through our direct sourcing activities as well as continued access to our group purchasing organization ("GPO") programs for non-healthcare members whose contracts were sold to OMNIA Partners, LLC ("OMNIA") (refer below to *Sale of Non-Healthcare GPO Member Contracts*).

As a healthcare alliance, our mission, products and services, and long-term strategy have been developed in partnership with hospitals, health systems, physicians and other healthcare providers and organizations. We believe that this partnership-driven business model creates a relationship between our members and us that is characterized by aligned incentives and mutually beneficial collaboration. This relationship affords us access to critical de-identified proprietary data and encourages member participation in the development and introduction of new products and services. Our interaction with our members provides us additional insights into the latest challenges confronting the healthcare industry and innovative best practices that we can share broadly across the healthcare industry, including throughout our membership. This model has enabled us to develop size and scale, data and analytics assets, expertise and customer engagement required to accelerate innovation, provide differentiated solutions and facilitate growth.

We seek to address challenges facing healthcare providers through our comprehensive suite of solutions that we believe:

- improve the efficiency and effectiveness of the healthcare supply chain;
- deliver improvement in cost, quality and safety;
- innovate and enable success in emerging healthcare delivery and payment models to manage the health of populations;
- utilize data and analytics to drive increased connectivity as well as clinical, financial and operational improvement; and
- through employers, payers and life sciences, expand the capabilities within these markets to improve healthcare.

Our business model and solutions are designed to provide our members and other customers access to scale efficiencies, spread the cost of their development, provide actionable intelligence derived from anonymized data in our enterprise data warehouse, mitigate the risk of innovation and disseminate best practices to help our members and other customers succeed in their transformation to higher quality and more cost-effective healthcare.

We deliver our integrated platform of solutions that address the areas of clinical intelligence, margin improvement and value-based care through two business segments: Supply Chain Services and Performance Services. The Supply Chain Services segment includes our GPO program, supply chain co-management, purchased services and direct sourcing activities. The Performance Services segment consists of three sub-brands: *PINC AI*™, our technology and services platform with offerings

that help optimize performance in three main areas – clinical intelligence, margin improvement and value-based care – using advanced analytics to identify improvement opportunities, consulting and managed services for clinical and operational design, and workflow solutions to hardwire sustainable change in the provider, life sciences and payer markets; *Contigo Health*®, our direct-to-employer business which provides third-party administrator services and management of health-benefit programs that enable payviders and employers to contract directly with healthcare providers as well as partners with healthcare providers to provide employers access to a specialized care network through Contigo Health's centers of excellence program and cost containment and wrap network; and *Remitra*®, our digital invoicing and payables automation business which provides financial support services to healthcare suppliers and providers.

Fiscal 2023 Year 2024 Developments

Sales and Acquisitions

Acquisition of TRPN Direct Pay, Inc. and Devon Health, Inc. Assets Strategic Review

On October 13, 2022 February 5, 2024, we acquired, through announced that our consolidated subsidiary, Board of Directors concluded its exploration of strategic alternatives which we originally reported in May 2023. As part of the strategic review process, the Board of Directors has authorized us to seek partners for some or all of our holdings in Contigo Health, LLC ("Contigo Health"), certain assets and assumed certain liabilities of TRPN Direct Pay, Inc. and Devon Health, Inc. (collectively, "TRPN") for an adjusted purchase price of \$177.5 million. The assets acquired and liabilities assumed relate to certain businesses of TRPN our subsidiary focused on improving access providing comprehensive services that optimize employee health benefits, and SVS, LLC d/b/a S2S Global ("S2S Global"), our direct sourcing subsidiary.

Additionally, on February 2, 2024, our Board of Directors authorized the repurchase of up to quality healthcare and reducing \$1.0 billion of our outstanding Class A common stock ("Common Stock"). On February 5, 2024, under the cost share repurchase authorization, we entered into an accelerated share repurchase agreement (the "ASR Agreement") with Bank of medical claims through pre-negotiated discounts with network providers, including acute care hospitals, surgery centers, physicians and other continuum America, N.A. ("Bank of care providers in the United States. Contigo Health also agreed America") to license proprietary cost containment technology repurchase an aggregate of TRPN. TRPN has been integrated under Contigo Health and is reported as part \$400.0 million of shares of our Common Stock. Final settlement of the Performance Services segment. See Note 3 - Business Acquisitions accelerated share repurchase transaction pursuant to the accompanying consolidated financial statements for further information. ASR Agreement was completed on July 11, 2024. Refer to "Share Repurchase Authorization" within "Contractual Obligations" section of Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Sale of Non-Healthcare GPO Member Contracts

On June 14, 2023 July 25, 2023, we announced that we entered into sold substantially all of our non-healthcare GPO member contracts pursuant to an equity purchase agreement with OMNIA Partners, LLC ("OMNIA") to sell the contracts pursuant to which substantially all of our non-healthcare GPO members participate in our GPO program, for an estimated a purchase price of approximately \$800.0 million, subject to certain adjustments, \$723.8 million. For a period of at least 10 years following the closing, the non-healthcare GPO members will continue to be able to make purchases through our group purchasing contracts. The sale of the non-healthcare GPO contracts closed on July 25, 2023. See Note 20 10 - Subsequent Events Liability Related to the Sale of Future Revenues to the accompanying consolidated financial statements for further information.

Impact of Inflation

The While the U.S. inflation rate has declined from its peak in calendar year 2022, the U.S. economy is still experiencing the highest elevated rates of inflation since compared to the 1980s, recent past. We believe that we have continued to limit the impact of inflation on our members and believe that we maintain significantly lower inflation impacts across our diverse product portfolio than national levels. However, in certain areas of our business, there is still some level of risk and uncertainty for our members and other customers as labor costs, raw material costs and availability, rising higher interest rates and inflation continue to pressure supplier pricing as well as apply significant pressure on our margin.

We continue to evaluate the contributing factors, specifically logistics, raw materials and labor, that which have led to adjustments to selling prices. We have begun to see seen logistics costs normalize to pre-pandemic levels as well as some reductions in the costs of specific raw materials; however, the cost of labor remains high. We are continuously working to manage these price increases as market conditions change. The impact of inflation to on our aggregated product portfolio is partially mitigated by contract term price protection for a large portion of our portfolio, as well as negotiated price reductions in certain product categories such as pharmaceuticals. portfolio. See "Risk Factors — Risks Related to Our Business Operations" below in this Annual Report.

Furthermore, as while the Federal Reserve seeks may seek to curb rising inflation, reduce market interest rates, have steadily risen, and they may continue to rise, be elevated, increasing the cost of borrowing under our Credit Facility (as defined in Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements) as well as impacting our results of operations, financial condition and cash flows.

Geopolitical Tensions

Geopolitical tensions such as the ongoing military conflict between Russia and Ukraine and tensions between the U.S. and China, continue to affect the global economy and financial markets, as well as exacerbate ongoing economic challenges, including issues such as rising inflation, energy costs, logistics costs, tariffs and global supply-chain disruption.

We continue to monitor the impacts of the geopolitical tensions on macroeconomic conditions and prepare for any implications they may have on member demand, our suppliers' ability to deliver products, cybersecurity risks and our liquidity and access to capital. See "Risk Factors — Risks Related to Our Business Operations" below.

COVID-19 Pandemic, or Other Pandemics, Epidemics or Public Health Emergencies

The outbreak of the novel coronavirus ("COVID-19") and the resulting global pandemic impacted our sales, operations and supply chains, our members and other customers and workforce and suppliers. While both the U.S. and the World Health Organization declared an end to the COVID-19 pandemic as a public health emergency in May 2023, we remain subject to the potential risks associated with the resurgence of COVID-19 any future pandemic, epidemic or another pandemic remains other public health emergency, and the resulting impact uncertain impacts those events could have on our business, results of operations, financial conditions and condition, cash flows as well as and prospects of the U.S. and global economies is uncertain and cannot be predicted at this time, trading price of our Common Stock.

Refer to "Item 1A. Risk Factors" for significant risks we have faced and may continue to face as a result of the COVID-19 pandemic or other pandemics, epidemics or public health emergencies.

Industry Overview

According to data from the Centers for Medicare & Medicaid Services ("CMS"), healthcare expenditures are a large component of the U.S. economy and are expected to grow by an average of 5.4% 5.6% per year for the period 2022-2031 2023-2032, reaching 19.6% 19.7% of gross domestic product, or GDP, by 2031 2032. According to data from the 2021 2022 American Hospital Association's Annual Survey, published in the 2023 2024 edition of the AHA Hospital Statistics™, there were more than 5,100 U.S. community hospitals with approximately 788,000 784,200 staffed beds in the United States. Of these acute care facilities, approximately 3,600 were part of either multi-hospital or diversified single hospital systems, meaning they were owned, leased, sponsored or contract managed by a central organization. Based upon 2022 2023 reporting from the United States Department of Labor and healthcare industry sources, in addition to U.S. hospitals, there were approximately 851,000 859,000 facilities and providers across the continuum of care in the United States. These facilities include primary/ambulatory care, and post-acute care and other providers.

Healthcare Supply Chain Services Industry

According to CMS data, total spending on hospital services in the United States is projected to be **\$1.5 trillion** **\$1.4 trillion**, or approximately **31%** **27%** of total healthcare expenditures, in calendar year **2023**, **2024**. Expenses associated with the hospital supply chain, such as supplies as well as operational and capital expenditures, typically represent a material portion of a hospital's budget. With continued reimbursement rate pressure across government and managed care payers, a transitioning payment model from fee-for-service to value-based payment, and national health expenditures representing a material portion of the economy, healthcare providers are examining all sources of cost savings, with supply chain spending a key area of focus. We believe opportunities to drive cost out of the healthcare supply chain include improved pricing for medical supplies, pharmaceuticals, purchased services, facilities expenditures, food service **supplies**, **products**, and information technology, as well as appropriate resource utilization, mitigating pharmaceuticals and medical device shortages and increased operational efficiency.

From origination at the supplier to final consumption by the provider or patient, healthcare products pass through an extensive supply chain incorporating manufacturers, wholesalers, distributors, GPOs, pharmacy benefit managers, and retail, long-term care and integrated pharmacies, among others. In response to the national focus on health spending and managing healthcare costs, supply chain participants are seeking more convenient and cost-efficient ways to deliver products to patients and providers. We believe that improvements to the healthcare supply chain to bring it on par with other industries that have more sophisticated supply chain management can drive out material inefficiencies and cost.

Healthcare Performance Services Industry

State and federal budget pressures stemming from increased deficit spending and employer and consumer demands for lower costs, and the need for improved quality and outcomes have generated greater focus among healthcare providers on cost management, quality and safety, and value-based care. As a result, over the past two decades, the Department of Health and Human Services ("HHS") has pushed to move from fee-for-service to alternative payment models ("APMs"). APMs, such as capitated and bundled payment arrangements with accountable care organizations ("ACOs") and other providers, make healthcare providers more accountable for cost and quality goals. This movement was advanced further with the bipartisan enactment of the Medicare Access and CHIP Reauthorization Act, which created incentives for physicians to move to APMs and was recently extended by Congress in December 2022. This movement will continue given the strong bipartisan support for these models. Over the long-term, health systems will need to continually monitor performance and manage costs, while demonstrating high levels of quality and implementing new care delivery models.

We expect information technology to continue to play a key enabling role in workflow efficiency and cost reduction, performance improvement and care delivery transformation across the healthcare industry in both acute and continuum of care settings. In particular, the trends toward value-based payment models and healthcare require more sophisticated business intelligence, expanded data sets and technology solutions. To achieve higher-quality outcomes and control total cost of care, providers exhibit a strong and continuing need for more comprehensive data and analytic capabilities to help them understand their current and future performance, identify opportunities for improvement and manage value-based care risk. Similarly, our consulting services business is growing in the areas of business model strategy and redesign, process and margin improvement, labor productivity, non-labor cost management, clinical integration and change management.

Our Membership

Our current membership base includes many of the country's most progressive and forward-thinking healthcare organizations. The participation of these organizations in our membership provides us additional insights into the latest challenges confronting the industry we serve and innovative best practices that we can share broadly throughout our membership. We continually seek to add new members that are at the forefront of innovation in the healthcare industry. At **June 30, 2023** **June 30, 2024**, our members included more than 4,350 U.S. hospitals and health systems and approximately **300,000** **325,000** other providers and organizations. Over **450** **520** individuals, representing approximately **150** **180** of our U.S. hospital members, sit on **29** **28** of our strategic and sourcing committees, and as part of these committees, use their industry expertise to advise on ways to improve the development, quality and value of our products and services. In addition, at **June 30, 2023**, four senior executives from our U.S. hospital member systems served on our Board of Directors **for all or part of fiscal year 2024**, providing valuable and unique insights into the challenges faced by hospitals and hospital systems and the innovations necessary to address these challenges. No individual member or member systems **accounted for** **contributed to** more than 10% of our net revenue for the fiscal years ended **June 30, 2023** **June 30, 2024** and **2022**, **2023**. Total GPO purchasing volume by all members participating in our GPO was more than **\$83 billion** **\$84 billion** and **\$82 billion** **\$83 billion** for the calendar years **2022** **2023** and **2021**, **2022**, respectively.

The following table sets forth certain information with respect to retention rates for members participating in our GPO in the Supply Chain Services segment and renewal rates for our SaaS informatics products subscriptions and licenses in the Performance Services segment for the fiscal years shown:

	Year Ended June 30,			
	2023	2022	2021	3 Year Average
GPO retention rate ^{(a)(b)}	98%	97%	94%	96%
SaaS institutional renewal rate ^(c)	94%	96%	96%	95%

	Year Ended June 30,			
	2024	2023	2022	3 Year Average
GPO retention rate ^(a)	97%	98%	97%	97%
SaaS institutional renewal rate ^(b)	95%	94%	96%	95%

- (a) The GPO retention rate is calculated based upon the **previous fiscal year's** aggregate purchasing volume among all members participating in our GPO for such fiscal year less the **annualized** **previous year's** GPO purchasing volume for departed members for such fiscal year, divided by the **previous fiscal year's** aggregate purchasing volume among all members participating in our GPO for such fiscal year.
- (b) **Fiscal 2021 GPO retention rate decreased primarily as a result of amendments to GPO participation agreements, effective July 1, 2020, and the August 2020 Restructuring.**
- (c) The SaaS institutional renewal rate is calculated based upon the total number of members that have SaaS or license revenue in a given period that also have revenue in the corresponding prior year period divided by the total number of members that have SaaS or license revenue in the same period of the prior year.

Our Business Segments

We deliver our integrated platform of solutions that address the areas of clinical intelligence, margin improvement and value-based care and manage our business through two business segments: Supply Chain Services and Performance Services. Refer to Note 18 - Segments to the accompanying consolidated financial statements for further information. We have no significant foreign operations or revenues.

Supply Chain Services

Our Supply Chain Services segment assists our members and other customers in managing their non-labor expense and capital spend through a combination of products, services and technologies, including one of the largest national healthcare GPO programs in the United States serving acute and continuum of care sites, and providing supply chain co-management, purchased services, direct sourcing and supply chain resiliency activities. Membership in our GPO also provides access to certain supply chain-related SaaS informatics products and the opportunity to participate in our ASCENDrive™ and SURPASS® performance groups. Our Supply Chain Services segment consists of the following products and solutions:

Group Purchasing. Our portfolio of over **3,300** 3,400 contracts with over 1,400 suppliers provides our members with access to a wide range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, food and nutritional products and purchased services (such as clinical engineering and workforce solutions). We use our members' aggregate purchasing power to negotiate pricing discounts, improved quality and resiliency of products and improved contract terms with suppliers. Contracted suppliers pay us administrative fees based on the net negotiated price and purchase volume of goods and services sold to our members under the contracts we have negotiated. We also partner with other organizations, including regional GPOs, to extend our network base to their members.

Our contract portfolio is designed to offer our members a flexible solution comprised of multi-sourced supplier contracts, as well as pre-commitment and/or single-sourced contracts that offer higher discounts. Our multi-sourced contracts offer pricing tiers based on purchasing volume and/or commitment and multiple suppliers for many products and services. Our pre-commitment contracts require that a certain amount of our members commit in advance to a specified amount or percentage of purchasing volume before we enter into a contract with a particular supplier. Our single-source contracts are entered into with a specified supplier, and through this exclusive relationship, allow us to contract for products that meet our members' specifications. In the case of pre-commitment contracts, we provide the particular supplier with a list of members that have pre-committed to a specified amount or percentage of purchasing volume and the supplier directly handles the tracking and monitoring of fulfillment of such purchasing volume. In the case of single and multi-sourced contracts, we negotiate and execute the contracts with suppliers on behalf of our members and make such contracts available to our members to access. The utilization of such single and multi-sourced contracts is determined by each particular member with assistance from our field force. Since there are no specific fulfillment requirements needed in our single and multi-source contracts in order to obtain certain pricing levels, each particular member and supplier agree on the appropriate pricing tier based on expected purchasing volume with tracking and ongoing validation of such purchasing volume provided by the supplier. The flexibility provided by our expansive contract portfolio allows us to effectively address the varying needs of our members and the significant number of factors that influence and dictate these needs, including overall size, service mix, and the degree of integration between hospitals in a healthcare system.

We continually innovate our GPO programs and supply chain platforms while targeting multiple markets, including acute, and continuum of care and non-healthcare site settings. In addition to our core base of more than 4,350 acute care healthcare providers, Premier's continuum of care program, including non-healthcare, one of the largest in the United States, which covers over **80** 70 classes of trade, had approximately **300,000** 325,000 active members as of **June 30, 2023** June 30, 2024, which represents an increase of approximately **50,000** 25,000 members, or **20%** 8%, over fiscal year **2022** 2023. A number of these members in Premier's continuum of care program are affiliated, owned, leased or managed by our members.

Premier's continuum of care program includes direct members, group affiliates and healthcare provider offices affiliated, owned, leased or managed by health systems. Key classes of trade include long-term care pharmacies, skilled nursing and assisted living facilities, home infusion providers, home health providers and surgery centers. Premier continuum of care members have access to most of our GPO supplier contracts, including, but not limited to, pharmaceuticals, medical and surgical supplies, facilities, food and nutritional products and other purchased services.

Premier's continuum of care program provides business operations and technology to ensure members and other customers, including former non-healthcare members, are connected to agreements and receiving proper contracted pricing.

Supply Chain Co-Management. We manage and co-manage all or portions of the supply chain operations for contracted members to drive down costs through processes, including value analysis, product standardization and strategic resource allocation and improved operational efficiency.

Purchased Services Contracts. Our purchased services contracts business, which is separate from the purchased services under our national contract portfolio, includes Conductiv, Inc. ("Conductiv") and Conductiv Contracts, LLC ("Conductiv Contracts"). Conductiv is a SaaS provider of technology solutions and expert services that enable hospitals and other organizations to analyze, benchmark and source purchased service contracts independent of any existing GPO affiliation. Combined with our purchased services spend data and our performance improvement technology suite, we are able to be a single source provider for healthcare margin improvement. Conductiv Contracts is a regionally focused group purchasing organization independent of any existing GPO affiliation that exclusively focuses on purchased services contracting.

Direct Sourcing. Our direct sourcing business, **SVS, LLC d/b/a S2S Global**, ("S2S Global"), helps our members and other customers access a diverse product portfolio and helps provide transparency to manufacturing costs and competitive pricing. Through S2S Global, we facilitate the development of product specifications with our members and other customers, source or contract manufacture the products to member specifications and sell products directly to our members, other customers or distributors. By engaging with our members and other customers at the beginning of the sourcing process to define product specifications and then sourcing, or contract manufacturing, products to meet the exact needs of our members, we eliminate the need for unnecessary product features and specifications that may typically be included by suppliers and result in higher prices for our members without providing incremental value. Therefore, our direct sourcing activities benefit our members and other customers by providing them with an expanding portfolio of medical products through more efficient means, and with greater cost transparency, than if such products were purchased from other third-party suppliers. We market our direct sourcing activities to our members primarily under the PREMIERPRO® brand.

Supply Chain Resiliency Program. In partnership with our members, we have created a program designed to promote domestic and geographically diverse manufacturing and ensure a robust and resilient supply chain for essential medical products. The program is intended to provide a means to invest in or partner with businesses that can supply shortage

products, co-fund the development of affordable products that address specific market needs and create strategic sourcing contracts to ensure continuous supply for our members and customers. We believe this program is most successful when we are able to partner with our members through investments or long-term purchasing commitments on these initiatives.

Our Supply Chain Resiliency Program includes, but is not limited to, the following:

PRAM Holdings, LLC. We formed PRAM Holdings, LLC ("PRAM") in 2020 in partnership with member health systems to invest in Prestige Ameritech Ltd. ("Prestige"), a domestic manufacturer of masks, sterile intravenous solutions and other personal protective equipment ("PPE"), whereby our members obtain a direct domestic source to critical PPE.

DePre Holdings, LLC. We formed DePre Holdings, LLC ("DPH") in 2021 in partnership with member health systems to invest in DePre, LLC ("DePre"), a joint venture between DPH and DeRoyal Industries Inc., a global medical manufacturer, whereby our members obtain a direct source dedicated to the domestic production of isolation gowns.

ExPre Holdings, LLC. We formed ExPre Holdings, LLC ("ExPre") in 2022 in partnership with member health systems to invest in Exela Holdings, Inc. ("Exela"), a domestic manufacturer of proprietary and generic sterile injectable products, whereby our members obtain a direct source to certain critical pharmaceutical products.

Premco, LLC. We formed Premco, LLC ("Premco") in 2023 in partnership with member health systems to invest in Princo, LLC ("Princo"), a joint venture between Premco, Vario Labs LLC and Caretrust LLC, whereby our members obtain a direct source dedicated to the domestic production of incontinence pads.

SaaS Informatics Products. Members of our GPO have access to certain SaaS informatics products related to the supply chain and have the ability to purchase additional elements that are discussed in more detail below under "Our Business Segments - Performance Services".

Performance Groups. Our Performance Groups are highly committed purchasing programs, which enable members to benefit from coordinated purchasing decisions and maintain standardization across their facilities. Our Performance Groups include the ASCENDrive and the SURPASS Performance Groups.

ASCENDrive Performance Group. Our ASCENDrive Performance Group ("ASCENDrive") has developed a process to aggregate purchasing data for our members, enabling such members to benefit from committed group purchases within the Performance Group. Through ASCENDrive, members receive group purchasing programs, tiers and prices specifically negotiated for them and knowledge sharing with other member participants. As of **June 30, 2023** **June 30, 2024**, approximately **1,700** **900** U.S. hospital members, which represent over 131,000 hospital beds, acute care sites and 6,800 continuum of care sites participated in ASCENDrive. These hospital member participants have identified over **\$910.0 million** **\$1.1 billion** in additional savings as compared to their U.S. hospital peers not participating in ASCENDrive since its inception in 2009. For calendar year **2022** **2023**, these member participants had approximately **\$17.4 billion** **\$16.9 billion** in annual supply chain purchasing spend.

SURPASS Performance Group. Our SURPASS Performance Group ("SURPASS") builds upon and complements ASCENDrive and drives even greater savings for members at a correspondingly higher level of commitment. SURPASS brings together our most committed members that are able to coordinate purchasing decisions, review utilization and achieve and maintain standardization across their facilities. SURPASS utilizes our PACER (Partnership for the Advancement of Comparative Effectiveness Review) methodology, which brings together clinically led cohorts to make evidence-based decisions about physician and clinician preference items with the goal of materially reducing the total cost of care. As of **June 30, 2023** **June 30, 2024**, a group of **3340** members representing approximately **530** **560** acute care sites and **11,000** **10,250** continuum of care sites participate in SURPASS. These hospital member participants have identified over **\$273.0 million** **\$332.2 million** in additional savings via their efforts in more than **160** **130** categories since its inception in 2018. SURPASS has another 49 potential categories slated for the coming year as well as select initiatives related to utilization and standardization. For calendar year **2022** **2023**, these member participants had approximately **\$13.0 billion** **\$14.8 billion** in annual supply chain purchasing spend.

Performance Services

Our Performance Services segment consists of three sub-brands: PINC AI, Contigo Health and Remitra. Each sub-brand serves different markets but are all united in our vision to optimize provider performance and accelerate industry innovation for better, smarter healthcare. Our PINC AI platform enables us to better reflect our current product offerings and strategy to expand and responsibly incorporate artificial intelligence ("AI") across our portfolio of solutions. This platform further enables connectivity and scale between providers, the pharmaceutical, biotech, and medical device industry and payers, including large employers, to help lower the cost and improve the quality of care. We believe that we house one of the largest clinical, operational and financial datasets in the United States which enables actionable insight and real-world evidence needed to accelerate healthcare

improvements. We currently incorporate AI into several use cases, including prior authorization between payers and providers; clinical intelligence through the decision support process; and automating the invoicing and payables process. Our AI use cases are focused on helping key healthcare stakeholders improve the quality, efficiency and value of healthcare delivery. Using our data and scale, we seek to expand our AI capabilities, grow our overall portfolio of solutions and provide our members and customers with technologically advanced products so they can provide better, smarter healthcare.

PINC AI:

With a broad provider network, advanced analytics, and the incorporation and desired expansion of AI-powered technology backed by our large dataset, we believe PINC AI has the ability to accelerate ingenuity in healthcare.

PINC AI helps optimize performance in three main areas – clinical intelligence, margin improvement and value-based care – using advanced analytics to identify improvement opportunities, consulting services for clinical and operational design and workflow solutions to hardwire sustainable change.

Clinical intelligence solutions help drive greater clinical effectiveness and efficiency across the care continuum by:

- Surfacing analytics and peer benchmarking on hard-to-find, high-value quality improvement areas, helping providers improve care delivery;

- Delivering real-time clinical surveillance to help providers drive faster, more informed decisions regarding patient safety, including ongoing infection prevention (like COVID-19), antimicrobial stewardship, and reduction of hospital acquired conditions;
- Using AI-enabled clinical decision support integrated into the provider workflow to support evidence-based decisions by providers at the point of care, and improve prior authorization automation;
- Operating the **100 Top Hospitals®** program. A program that creates a national benchmark to provide hospitals and health systems accurate context through which to view their performance. This program includes the **100 Top Collaborative**, previously known as the **QUEST Collaborative**, which works to develop quality, safety and cost metrics with a consistency and standardization. We believe participation in the **QUEST 100 Top** Collaborative better prepares providers to deal with evolving and uncertain healthcare reform requirements and differentiate on care delivery in their markets; and
- Providing life sciences services through PINC AI Applied Science for the development of research, real-world evidence and clinical trials innovation for medical device, diagnostic and pharmaceutical companies.

Margin improvement solutions help lower total costs and improve provider operating margins by:

- Surfacing analytics and peer benchmarking on hard-to-find, supply savings and workforce management opportunities that lower costs without impacting quality;
- Optimizing workforce management with integrated financial reporting and budgeting across the continuum of care;
- Providing savings through an enterprise resource planning solution built specifically for healthcare;
- Deploying consulting services to deliver clinically integrated, margin improvement transformation throughout a health system; and
- Providing management services to insurance programs to assist U.S. hospital and healthcare system members with liability and benefits insurance services, along with risk management services to improve their quality, patient safety and financial performance while lowering costs.

Value-based care solutions help health systems implement effective models of care to succeed in new, value-based payment arrangements by:

- Surfacing analytics and peer benchmarking to help identify hard-to-find, population-based improvement opportunities necessary to take financial risk and succeed in value-based care;
- Optimizing and managing the physician enterprise to rationalize medical group investment via revenue enhancement, cost reduction strategies and implementation of sustainable evidence-based practices; and
- Participating in the Population Health Management, Bundled Payment and Physician Enterprise Collaboratives, for the opportunity to share value-based care and payment developmental strategies, programs and best practices.

The data yielded through PINC AI is de-identified and aggregated in what we believe to be the nation's leading comprehensive database, representing over 20 years of data from more than 1,000 hospitals spanning multiple therapeutic areas. A research team including clinicians, epidemiologists, health economists, health services researchers, statisticians and other subject matter experts leverage the dataset to deliver real world evidence, in partnership with Life Science

innovators. Studies, test methods, strategies and tools created can promote the adoption and integration of evidence-based practices to help improve outcomes and the quality and effectiveness of care.

Contigo Health:

Contigo Health creates new ways for clinicians, health systems and employers to work together supporting a common goal for all stakeholders to help increase access to high-quality care, enhance employee engagement, control costs and get employees back to work and life faster. Contigo Health delivers comprehensive services for optimizing employee health benefits, including:

- Contigo Health Sync Health Plan TPA empowers self-funded employers with a flexible approach to employee benefits to help improve access to quality care, achieve cost savings and improve health plan member satisfaction;
- Contigo Health Centers of Excellence 360 delivers access to high-quality care by bringing together specialty medical and behavioral health programs for a bundled cost through a network of healthcare facilities, surgeons, physicians and leading-edge virtual providers; and
- Contigo Health ConfigureNet Out-of-Network Wrap delivers an out-of-network wrap product to improve access to healthcare and reduce the cost of medical claims through pre-negotiated discounts with its network of 900,000 providers across the U.S. and Puerto Rico.

Remitra:

Remitra provides health systems and suppliers cost management solutions with our procure-to-pay technology designed to support greater efficiencies in the procurement process through automated purchasing and payment solutions.

- Remitra's Procure-to-Pay platform powers supplier and provider networks and uses optical character recognition to automate invoicing and payables. Remitra seeks to streamline financial processes, reduce errors and fraud, unlock cost and labor efficiencies and become a leading digital invoicing and payables platform for all of healthcare, agnostic of ERP, GPO or treasury partner.
- Remitra's Cash Flow Optimizer platform offers a financial solution for suppliers and providers including a reduction in days sales outstanding, improving on-time payments, improved working capital and a potential reduction over time of allowance of credit losses associated with bad debt.
- Remitra's Managed Account Payable services service offers a financial solution for acute and continuum of care members and other customers including an extension in days payable outstanding, improving on-time payments for suppliers and improving working capital for the customer.

Both Remitra's Cash Flow Optimizer platform and Managed Account Payable services offer financial solutions by leveraging Remitra's Procure-to-Pay platform and providing opportunities for financial improvements for suppliers, members and other customers.

The Performance Services sub-brands support Premier's long-term strategy to diversify revenue into adjacent markets, which we define as non-traditional markets penetrated by Premier's businesses and brands. This includes PINC AI Clinical Decision Support serving providers and payers; PINC AI Applied Sciences serving biotech, pharmaceutical and medical device companies; Contigo Health that serves self-insured employers, including payviders; and Remitra that serves healthcare suppliers and providers.

Segment Realignment for Fiscal Year 2025

Beginning in fiscal year 2025, we are realigning our portfolio of offerings and reporting our Remitra sub-brand as a component of our Supply Chain Services segment to align with our strategy and operations moving forward.

Pricing and Contracts

Supply Chain Services

GPO Programs:

Our GPO primarily generates revenue through administrative fees received from contracted suppliers for a percentage of the net negotiated purchase price of goods and services, including purchased services activities, sold to members under negotiated supplier contracts. Pursuant to the terms of GPO participation agreements entered into by the members, our members currently receive revenue share based upon purchasing by such member's owned, leased, managed and affiliated facilities through our GPO supplier contracts.

The majority of our current GPO participation agreements with our members have terms that commenced in July 2020 and primarily range from five to seven years. Generally, our GPO participation agreements may not be terminated without penalty except for cause or in the event of a change of control of the GPO member. The GPO member can terminate the GPO participation agreement at the end of the then-current term by notifying Premier of the member's decision not to renew. Our GPO participation agreements generally provide for liquidated damages in the event of a termination not otherwise permitted under the agreement.

The majority of our current GPO participation agreements with our members have terms that commenced in 2020. We have begun renewing these agreements over the past year and as of June 30, 2024, we have renewed and extended members that represent approximately 50% of the gross administrative fees associated with the member agreements that were extended in 2020. In fiscal year 2025, we are targeting additional member agreements for renewal that would address a cumulative total of approximately 75% of the gross administrative fees associated with the member agreements extended in 2020. We expect to target the remaining associated member agreements for renewal in fiscal years 2026 and 2027. Due to competitive market conditions, we have experienced, and expect to continue to experience requests to provide existing and prospective members increases in revenue share on incremental and/or overall purchasing volume.

Our GPO also generates revenue from suppliers through the members that participate in associated with our performance groups.

Supply Chain Co-Management:

In our supply chain co-management activities, we earn revenue in the form of a service fee for services performed under the supply chain management contracts. Service fees are billed as stipulated in the contract, and revenue is recognized on a proportional performance method as services are performed.

Purchased Services:

In our purchased services activities, Additionally, we generate revenue through administrative fees, as described above, subscription fees and term licenses. Subscription have a select number of agreements with incentive fees, which we generate through our SaaS-based products, are based generally billed on a monthly basis savings achievement and revenue is recognized as a single deliverable on a straight-line basis over the remaining contractual period following implementation. Revenue on licensing is recognized upon delivery of the software code and revenue from hosting and maintenance is recognized ratably over the life of the contract operational performance metrics.

Direct Sourcing:

In our direct sourcing activities, we earn revenue from product sales, including sales from aggregated purchases of certain products. Products are sold to our members and other customers through direct shipment and distributor and wholesale channels. Products are also sold to regional medical-surgical distributors and other non-healthcare industries (i.e., foodservice). We have contracts with our members and other customers that buy products through our direct shipment option, which usually do not provide a guaranteed purchase or volume commitment requirement.

Performance Services

Performance Services revenue consists of revenue generated through our three sub-brands: PINC AI, Contigo Health and Remitra. The main sources of revenue under PINC AI are (i) subscription agreements to our SaaS-based clinical intelligence, margin improvement and value-based care products, (ii) licensing revenue, (iii) professional fees for consulting services and (iv) other miscellaneous revenue including PINC AI data licenses, IT outsourcing, annual subscriptions to our performance improvement collaboratives, insurance services management fees and commissions from endorsed commercial insurance programs. Contigo Health's main sources of revenue are third-party administrator fees, fees from the centers of excellence program and cost containment and wrap network fees. Remitra's main source of revenue is fees from healthcare suppliers and providers.

PINC AI:

SaaS-based clinical analytics products subscriptions include the right to access our proprietary hosted technology on a SaaS basis, training and member support to deliver improvements in cost management, margin improvement, quality and safety, value-based care and provider analytics. Pricing varies by application and size of the healthcare system. Clinical analytics products subscriptions are generally three- to five-year agreements with automatic renewal clauses and annual price escalators that typically do not allow for early termination. These agreements do not allow for physical possession of the software. Subscription fees are typically billed on a monthly basis and revenue is recognized as a single deliverable on a straight-line basis over the remaining contractual period following implementation. Implementation involves the completion of data preparation services that are unique to each member's data set in order to access and transfer member data into our hosted SaaS-based clinical analytics products. Implementation is generally 60 to 240 days following contract execution before the SaaS-based clinical analytics products can be fully utilized by the member.

Enterprise analytics licenses include term licenses that range from three to ten years and offer clinical analytics products, improvements in cost management, quality and safety, value-based care and provider analytics. Pricing varies by application and size of healthcare system. Revenue on licensing is recognized upon delivery of the software code and revenue from hosting and maintenance is recognized ratably over the life of the contract.

Professional fees for consulting services are sold under contracts, the terms of which vary based on the nature of the engagement. These services typically include general consulting, report-based consulting, managed services and cost savings initiatives. Fees are billed as stipulated in the contract, and revenue is recognized on a proportional performance method as services are performed or when deliverables are provided. In situations where the contracts have significant contract performance guarantees or member acceptance provisions, revenue recognition occurs when the fees are fixed transaction price is considered variable and determinable is estimated and all contingencies, including any refund rights, have been satisfied, constrained. Fees are based either on the savings that are delivered or a fixed fee.

Other miscellaneous revenue generated through PINC AI includes:

- Revenue from PINC AI data licenses which provide customers data from the PINC AI healthcare database. The revenue from the data deliverables is recognized upon delivery of the data;
- Revenue from performance improvement collaboratives that support our offerings in cost management, quality and safety and value-based care and is recognized over the service period as the services are provided, which is generally one to three years; and
- Revenue through insurance services management fees are recognized in the period in which such services are provided. Commissions from endorsed commercial insurance programs are earned by acting as an intermediary in the placement of effective insurance policies. Under this arrangement, revenue is recognized at a point in time on

the effective date of the associated policies when control of the policy transfers to the customer and is constrained for estimated early terminations.

Contigo Health:

Contigo Health's main sources of revenue consists of third-party administrator fees, fees from the centers of excellence program and cost containment and wrap network fees.

- Revenue from third-party administrator fees consist of integrated fees for the processing of self-insured healthcare plan claims and is recognized in the period in which the services have been provided.
- Revenue from the centers of excellence program consist of administrative fees for access to a specialized care network of proven healthcare providers and is recognized in the period in which the services have been provided.
- Revenue from cost containment and wrap network fees consist of fees associated with the repricing of insurance claims and is estimated and recognized in the period in which the services have been provided.

Remitra:

The main source of revenue for Remitra primarily consists of fees from healthcare suppliers and providers. For fixed fee contracts, revenue is recognized in the period in which the services have been provided. For variable rate contracts, revenue is recognized as customers are invoiced. Additional revenue consists of fees from check replacement services which consist of monthly rebates from bank partners.

Revenue Concentration

Our customers consist of both GPO and non-GPO members that utilize our other products and services and other healthcare and non-healthcare businesses. Our top five customers generated revenue of approximately 15% 14% and 21% 15% of our consolidated net revenues for the years ended June 30, 2023 June 30, 2024 and 2022, 2023, respectively. No customer accounted for more than 10% of our net revenue during each of the years ended June 30, 2023 June 30, 2024 and 2022, 2023.

Intellectual Property

We offer our members a range of products to which we have appropriate intellectual property rights, including online services, best practices content, databases, electronic tools, web-based applications, performance metrics, business methodologies, proprietary algorithms, software products and consulting services deliverables. We own and control a variety of trade secrets, confidential information, trademarks, trade names, copyrights, domain names and other intellectual property rights that, in the aggregate, are of material importance to our business.

We protect our intellectual property by relying on federal, state and common law rights, as well as contractual arrangements. We are licensed to use certain technology and other intellectual property rights owned and controlled by others, and, similarly, other companies are licensed to use certain technology and other intellectual property rights owned and controlled by us.

Research and Development

Our research and development ("R&D") expenditures primarily consist of our strategic investment in internally-developed software to develop new and enhance existing SaaS- and license-based products offerings and new product development in the areas of cost management, quality and safety and value-based care. From time to time, we may experience fluctuations in our research and development expenditures including capitalized software development costs, across reportable periods due to the timing of our software development life cycles, with new product features and functionality, new technologies and upgrades to our service offerings.

Information Technology and Cybersecurity Risk Management

We rely on digital technology to conduct our business operations and engage with our members and business partners. The technology we, our members, and business partners use grows more complex over time as do threats to our business operations from cyber intrusions, denial of service attacks, manipulation and other cyber misconduct. Through a risk management approach that continually assesses and improves our Information Technology (IT) and cybersecurity threat deterrence capabilities, our Information Security and Risk Management groups have formed a functional collaboration to provide leadership and oversight when managing IT and cybersecurity risks.

Through a combination of Security, Governance, Risk and Compliance (GRC) resources, we (i) proactively monitor IT controls to better ensure compliance with legal and regulatory requirements, (ii) assess adherence by third parties we partner with to ensure that the appropriate risk management standards are met, (iii) ensure essential business functions remain available during a business disruption, and (iv) continually develop and update response plans to address potential IT or cyber incidents should they occur. Our GRC resources are designed to prioritize IT and cybersecurity risks areas, identify solutions that minimize such risks, pursue optimal outcomes and maintain compliance with contractual obligations. We also maintain an operational security function that has a real time 24x7x365 response capability that triages potential incidents and triggers impact mitigation protocols. These capabilities allow us to apply best practices and reduce exposure in the case of a security incident. For more information regarding the risks associated with these matters, see "Item 1A. Risk Factors-We could suffer a loss of revenue and increased costs, exposure to material legal liability, reputational harm, and other serious negative consequences if we sustain cyber-attacks or other data security breaches that disrupt our operations or result in the dissemination of proprietary or confidential information about us or our members or other third parties."

Competition

The markets for our products and services in both our Supply Chain Services segment and Performance Services segment are fragmented, highly competitive and characterized by rapidly evolving technology and product standards, user needs and the frequent introduction of new products and services. We have experienced and expect to continue to experience intense competition from a number of companies.

Our Supply Chain Services segment's competitors primarily compete with our group purchasing, direct sourcing and supply chain co-management activities.

- Our group purchasing business competes with other large GPOs such as HealthTrust Purchasing Group (a subsidiary of HCA Holdings, Inc.), Managed Health Care Associates, Inc. and Vizient, Inc. In addition, we compete against certain healthcare provider-owned GPOs and on-line online retailers in this segment.
- Our direct sourcing business competes primarily with private label offerings and programs, product manufacturers, and distributors, such as Cardinal Health, Inc., McKesson Corporation, Medline Industries, Inc. and Owens & Minor, Inc.
- Our supply chain co-management business competes with organizations that provide supply chain outsourcing or embedded resources and supply chain transformation services, such as The Resource Group and CPS Solutions, LLC.

Our Performance Services segment's competitors compete with our three sub-brands: PINC AI, Contigo Health and Remitra.

- The primary competitors of PINC AI range from smaller niche companies to large, well-financed and technologically sophisticated entities. Our primary competitors for PINC AI include (i) information technology providers such as Veradigm, Inc. (f/k/a Allscripts Healthcare Solutions, Inc.), Epic Systems Corporation, Health Catalyst, Inc., IBM Corporation, Infor, Inc., Oracle Corporation, Arcadia Solutions, LLC and Oracle Corporation, Innovaccer, Inc., and (ii) consulting and outsourcing firms such as Deloitte & Touche LLP, Evolent Health, Inc., Healthagen, LLC (a subsidiary of Aetna, Inc.), Huron Consulting, Inc., Guidehouse Consulting, Inc., Optum, Inc. (a subsidiary of UnitedHealth Group, Inc.) and Kaufman, Hall and Associates, LLC (a subsidiary of Vizient, Inc.).
- The primary competitors for Contigo Health include AmeriBen, Meritan Health, UMR, WebTPA and Benefit and Risk Management Services for our third-party administrative services product; Carrum Health, Transcarent, Edison Healthcare, AccessHope, Employer Direct Healthcare and MSK Direct for our Centers of Excellence product; and First Health, MultiPlan, Zelis and other wrap network providers and major carriers (such as Aetna, United and Cigna) for our ConfigureNet product.
- The primary competitors for Remitra include Global Healthcare Exchange, LLC (GHX) for our digital invoicing product, Coupa Software Inc. and Taulia for our digital payables product, and tier one treasury banks (e.g., JPMorgan Chase and Co., Wells Fargo, Bank of America, etc.) as well as niche factoring companies for our financing solutions product.

With respect to our products and services across both segments, we compete on the basis of several factors, including price, breadth, depth and quality of product and service offerings, ability to deliver clinical, financial and operational performance improvements through the use of products and services, quality and reliability of services, ease of use and convenience, brand recognition and the ability to integrate services with existing technology.

Government Regulation

General

The healthcare industry is highly regulated by federal and state authorities and is subject to changing legal, political, economic and regulatory influences. Factors such as changes in reimbursement policies for healthcare expenses, consolidation in the healthcare industry and general economic conditions affect the purchasing practices, operations and the financial health of healthcare organizations. In particular, changes in laws and regulations affecting the healthcare industry, such as increased regulation of the purchase and sale of medical products, or restrictions on permissible discounts and other financial arrangements, could require us to make unplanned and costly modifications to our products and services, and may result in delays or cancellations of orders or a reduction of funds and demand for our products and services.

We are subject to numerous risks arising from governmental oversight and regulation. You should carefully review the following discussion and the risks discussed under "Item 1A. Risk Factors" for a more detailed discussion.

Affordable Care Act

The passage of the Patient Protection and Affordable Care Act ("ACA") in 2010 aimed to expand access to affordable health insurance, control healthcare spending and improve healthcare quality. The law included provisions to tie Medicare provider reimbursement to healthcare quality and incentives, mandatory compliance programs, enhanced transparency disclosure requirements, increased funding and initiatives to address fraud and abuse and incentives to state Medicaid programs to promote community-based care as an alternative to institutional long-term care services. In addition, the law created an innovation center to test and scale new APMs and ACOs. These programs are creating fundamental changes in the delivery of healthcare.

Since its passage, the ACA has been subject to continued scrutiny and threats to repeal it in parts or in whole. The current Biden administration is supportive of the ACA and there are no imminent threats to it. ACA. However, any future changes may ultimately impact the provisions of the ACA or other laws or regulations that either currently affect, or may in the future affect, our business. We believe it is important to note that most of the controversy related to the ACA relates to coverage expansion and not the issues related to quality improvement and cost reduction which are core to our business.

U.S. Food and Drug Administration Regulation

The U.S. Food and Drug Administration ("FDA") extensively regulates, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, export, import, service and export surveillance, complaint handling, repair or recall of products, adverse event reporting and import other field safety corrective actions of pharmaceuticals and medical devices. Because certain of the products that we market and sell through our direct sourcing business are considered medical devices, our suppliers must comply with FDA requirements in the production, and we must comply with FDA regulations in the marketing and post-market monitoring, of these products. These products have in the past and may in the future be subject to penalties, product restriction or recall if we or our suppliers fail to comply with FDA requirements.

In addition, the FDA has the authority to regulate products that meet the definition of a medical device under the Federal Food, Drug, and Cosmetic Act. To the extent that functionality or intended use in one or more of our current or future software products causes the software it to be regulated as a medical device under existing or future FDA laws or regulations, including the 21st Century Cures Act, which addresses, among other issues, the patient safety concerns generated by cybersecurity risks to medical devices and the interoperability between medical devices, we could be required to register our these software product(s) with the FDA and undergo the applicable regulatory clearance or approval process, which may include being required require us to conduct clinical trials. There is risk that the software product may not be approved authorized by the FDA or that we may not be able to market the software product during the approval FDA review process. In addition, registering a software product with the FDA can be a costly and timely endeavor creating additional regulatory scrutiny and risk for Premier, the Company, as well as additional compliance requirements with all associated FDA laws, regulations and guidance. Even after regulatory authorization, additional regulatory review may be required if a material change is made to a device.

Civil and Criminal Fraud, Waste and Abuse Laws

We are subject to federal and state laws and regulations designed to protect patients, governmental healthcare programs and private health plans from fraudulent and abusive activities. These laws include anti-kickback restrictions and laws prohibiting the submission of false or fraudulent claims. These laws are complex and broadly worded, and their application to our specific products, services and relationships may not be clear and may be applied to our business in ways that we do not anticipate. Federal and state regulatory and law enforcement authorities have over time increased enforcement activities with respect to Medicare and Medicaid fraud, waste and abuse regulations and other reimbursement laws and rules. These laws and regulations include:

Anti-Kickback Laws. The federal Anti-Kickback Statute prohibits the knowing and willful offer, payment, solicitation or receipt of remuneration, directly or indirectly, in return for the referral of patients or arranging for the referral of patients, or in return for the recommendation, arrangement, purchase, lease or order of items or services that are covered, in whole or in part, by a federal healthcare program such as Medicare or Medicaid. The definition of "remuneration" has been broadly interpreted to include anything of value such as gifts, discounts, rebates, waiver of payments or providing anything at less than its fair market value. Many states have adopted similar prohibitions against kickbacks and other practices that are intended to influence the

purchase, lease or ordering of healthcare items and services regardless of whether the item or service is covered under a governmental health program or private health plan. Certain statutory and regulatory safe harbors exist that protect specified business arrangements from prosecution under the Anti-Kickback Statute if all elements of an applicable safe harbor are met,

however these safe harbors are narrow and often difficult to comply with. Congress has appropriated an increasing amount of funds in recent years to support enforcement activities aimed at reducing healthcare fraud and abuse.

The U.S. Department of Health and Human Services, or HHS, created certain safe harbor regulations which, if fully complied with, assure parties to a particular arrangement covered by a safe harbor that they will not be prosecuted under the Anti-Kickback Statute, Statute with respect to such arrangement. We structure operate our group purchasing services, pricing discount arrangements with suppliers, and revenue share arrangements with applicable members to meet the terms of in reliance on the safe harbor for GPOs set forth at 42 C.F.R. § 1001.952(j) and the discount safe harbor set forth at 42 C.F.R. § 1001.952(h). Although full compliance with the provisions of a safe harbor ensures against prosecution under the Anti-Kickback Statute, failure of a transaction or arrangement to fit within a safe harbor does not necessarily mean that the transaction or arrangement is illegal or that prosecution under the Anti-Kickback Statute will be pursued. From time to time, HHS, through its Office of Inspector General, makes formal and informal inquiries, conducts investigations and audits the business practices of GPOs, including our GPO, the result of which could be new rules, regulations or in some cases, a formal enforcement action.

To help ensure regulatory compliance with HHS rules and regulations, our members that report their costs to Medicare are required under the terms of the Premier Group Purchasing Policy to appropriately reflect all elements of value received in connection with our initial public offering ("IPO"), including under the various agreements entered into in connection therewith, on their cost reports. We are required to furnish applicable reports to such members setting forth the amount of such value, to assist their compliance with such cost reporting requirements. There can be no assurance that the HHS Office of Inspector General or the U.S. Department of Justice, or DOJ, will concur that these actions satisfy their applicable rules and regulations.

False Claims Act. Our business is also subject to numerous federal and state laws that forbid the submission or "causing the submission" of false or fraudulent information or the failure to disclose information in connection with the submission and payment of claims for reimbursement to Medicare, Medicaid or other governmental healthcare programs or private health plans. In particular, the False Claims Act, or FCA, prohibits a person from knowingly presenting or causing to be presented a false or fraudulent claim for payment or approval by an officer, employee or agent of the United States. In addition, the FCA prohibits a person from knowingly making, using, or causing to be made or used a false record or statement material to such a claim. Violations of the FCA may result in treble damages, material monetary penalties, and other collateral consequences including, potentially, exclusion from participation in federally funded healthcare programs. A claim that includes items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA.

Privacy and Security Laws. The Health Insurance Portability and Accountability Act of 1996, or HIPAA, contains substantial restrictions and requirements with respect to the use and disclosure of certain individually identifiable health information, referred to as "protected health information." The HIPAA Privacy Rule prohibits a covered entity or a business associate (essentially, a third party engaged to assist a covered entity with enumerated operational and/or compliance functions) from using or disclosing protected health information unless the use or disclosure is validly authorized by the individual or is specifically required or permitted under the HIPAA Privacy Rule and only if certain complex requirements are met. In addition to following these complex requirements, covered entities and business associates must also meet additional compliance obligations set forth in the HIPAA Privacy Rule. The HIPAA Security Rule establishes administrative, organizational, physical and technical safeguards to protect the confidentiality, integrity and availability

of electronic protected health information maintained or transmitted by covered entities and business associates. The HIPAA Security Rule requirements are intended to mandate that covered entities and business associates regularly re-assess the adequacy of their safeguards in light of changing and evolving security risks. Finally, the HIPAA Breach Notification Rule requires that covered entities and business associates, under certain circumstances, notify patients/beneficiaries, media outlets and HHS when there has been an improper use or disclosure of protected health information.

Our self-funded health benefit plan for our employees and our healthcare provider members (provided that these members engage in HIPAA-defined standard electronic transactions with health plans, which will be all or the vast majority) are directly regulated by HIPAA as "covered entities." Additionally, because most of our U.S. hospital members disclose protected health information to us so that we may use that information to provide certain data analytics, benchmarking, consulting or other operational and compliance services to these members, we are a "business associate" of those members. In these cases, in order to provide members with services that involve the use or disclosure of protected health information, HIPAA requires us to enter into "business associate agreements" with our covered entity members. Such agreements must, among other things, provide adequate written assurances:

- (i) as to how we will use and disclose the protected health information within certain allowable parameters established by HIPAA,
- (ii) that we will implement reasonable and appropriate administrative, organizational, physical and technical safeguards to protect such information from impermissible use or disclosure,
- (iii) that we will enter into similar agreements with our agents and subcontractors that have access to the information,
- (iv) that we will report breaches of unsecured protected health information, security incidents and other inappropriate uses or disclosures of the information, and
- (v) that we will assist the covered entity with certain of its duties under HIPAA.

With the enactment of the Health Information Technology for Economic and Clinical Health, or HITECH Act, the privacy and security requirements of HIPAA were modified and expanded. The HITECH Act applies certain of the HIPAA privacy and security requirements directly to business associates of covered entities. Prior to this change, business associates had contractual obligations to covered entities but were not subject to direct enforcement by the federal government. In 2013, HHS released final rules implementing the HITECH Act changes to HIPAA. These amendments expanded the protection of protected health information by, among other things, imposing additional requirements on business associates, further restricting the disclosure of protected health information in certain cases where the covered entity or business associate is remunerated in return for making the transaction, and modifying the HIPAA Breach Notification Rule, which has been in effect since September 2009, to create a rebuttable presumption that an improper use or disclosure of protected health information under certain circumstances requires notice to affected patients/beneficiaries, media outlets and HHS.

Transaction Requirements. HIPAA also mandates format, data content and provider identifier standards that must be used in certain electronic transactions, such as claims, payment advice and eligibility inquiries. Although our systems are fully capable of transmitting transactions that comply with these requirements, some payers and healthcare clearinghouses with which we conduct business may interpret HIPAA transaction requirements differently than we do or may require us to use legacy formats or include legacy identifiers as they make the transition to full compliance. In cases where payers or healthcare clearinghouses require conformity with their interpretations or require us to accommodate legacy transactions or identifiers as a condition of successful transactions, we attempt to comply with their requirements, but may be subject to enforcement actions as a result. In 2009, CMS published a final rule adopting updated standard code sets for diagnoses and procedures known as ICD-10 code sets and changing the formats to be used for electronic transactions subject to the ICD-10 code sets, known as Version 5010. All healthcare providers are required to comply with Version 5010 and use the ICD-10 code sets.

Other Federal and State Laws. In addition to our obligations under HIPAA there are other federal laws that impose specific privacy and security obligations, above and beyond HIPAA, for certain types of health information and impose additional sanctions and penalties. These rules federal laws are not preempted by HIPAA. Most states have enacted patient and/or beneficiary confidentiality laws that protect against the disclosure of confidential medical information, and many states have adopted or are considering adopting further legislation in this area, including privacy safeguards, security standards, data security breach notification requirements, and special rules for so-called "sensitive" health information, such as mental health, genetic testing results, or Human Immunodeficiency Virus, or HIV, status. These state laws, if more stringent than HIPAA requirements, are not preempted by the federal requirements, and we are required to comply with them as well. Moreover, various states have passed consumer privacy laws, while other states have considered similar bills. While most of the data we access or use is governed by HIPAA and exempt from such state consumer privacy laws, various areas of the Company's business and operations (such as marketing and human resources) may access or use data that may fall under one or more of the state consumer privacy laws.

We are unable to predict what changes to HIPAA or other federal or state laws or regulations might be made in the future or how those changes could affect our business or the associated costs of compliance.

Antitrust Laws

The Sherman Antitrust Act, Clayton Act, Robinson-Patman Act and related federal and state antitrust laws are complex laws that prohibit contracts in restraint of trade or other activities that are designed to or that have the effect of reducing competition in the market. The federal antitrust laws promote fair competition in business and are intended to create a level playing field so that both small and large companies are able to compete in the market. In their 1996 Statements of Antitrust Enforcement Policy in Health Care, or the Healthcare Statements, the DOJ and the U.S. Federal Trade Commission or FTC ("FTC"), set forth guidelines specifically designed to help GPOs gauge whether a particular purchasing arrangement may raise antitrust concerns and established an antitrust safety zone for joint purchasing arrangements among healthcare providers.

Earlier in 2023, the DOJ and FTC withdrew the Healthcare Statements, stating that they were outdated and overly permissive and indicating that the agencies would provide future guidance through case-by-case enforcement. In the absence of current guidance, we have continued to attempt to structure our contracts and pricing arrangements in accordance with the Healthcare Statements and believe that our GPO supplier contracts and pricing discount arrangements should not be found to violate the antitrust laws. No assurance can be given We cannot give any assurances that enforcement authorities will agree with this assessment. In addition, private parties also may bring suit for alleged violations under the U.S. antitrust laws. From time to time, the group purchasing industry comes under review by Congress and other governmental bodies with respect to antitrust laws, the scope of which includes, among other things, the relationships between GPOs and their members, distributors, manufacturers and other suppliers, as well as the services performed and payments received in connection with GPO programs.

Most recently, on February 14, 2024, the FTC and the U.S. Department of Health and Human Services issued a joint Request for Information ("RFI") for submission of comments regarding the impact of GPOs and wholesale drug distributors on access to generic pharmaceuticals. The comment period for the RFI expired on May 30, 2024.

Congress, the DOJ, the FTC, the U.S. Senate or another state or federal entity could at any time open a new investigation of the group purchasing industry, or develop new rules, regulations or laws governing the industry, that could adversely impact our ability to negotiate pricing arrangements with suppliers, increase reporting and documentation requirements, or otherwise require us to modify our arrangements in a manner that adversely impacts our business. We may also face private or government lawsuits alleging violations arising from the concerns articulated by these governmental factors or alleging violations based solely on concerns of individual private parties.

Health IT Certification Program

In 2009, Congress included in the American Recovery and Reinvestment Act a program to incentivize the adoption of health information technology by hospitals and ambulatory providers who participate in the Medicare and Medicaid programs. Congress further modified the incentive program for ambulatory providers under the Medicare Access and CHIP Reauthorization Act of 2015 ("MACRA"). Any developer of health information technology seeking to offer a product to assist hospitals or ambulatory healthcare providers to meet the requirements of these programs must obtain certification under the applicable certification criteria established by the Office of the National Coordinator for Health Information Technology ("ONC"). There are two types of **certification certifications** for health information developers seeking to participate in the certification program: 1) certification to all the certification criteria required to meet the definition of a "2015 Edition Base EHR"; or 2) certification as a Health IT Module, meeting specific certification criteria. Meeting the certification criteria as a "2015 Edition Base EHR" allows a developer of health information technology to offer a product that has all the capabilities needed for a hospital or an ambulatory provider to meet the requirements of the health IT incentive programs. A Health IT Module provides a specific set of capabilities. Hospitals or ambulatory providers seeking to avoid potential payment reductions must either implement a 2015 Base EHR using a single product, or multiple Health IT Modules that together have all of the capabilities of a 2015 Base EHR.

We currently have two products that are certified as Health IT Modules. To retain our certification, we must: 1) meet applicable conditions of certification and maintenance of certification requirements established by ONC; 2) pass testing conducted by an ONC-Authorized Testing Laboratory pursuant to test procedures developed by ONC; and 3) obtain certification from an ONC-Authorized Certification Body. ONC's conditions of certification and maintenance of certification requirements include communication restrictions that largely prevent us from limiting our customer's ability to communicate about the usability, interoperability, security or user experiences relating to our Health IT Modules. These regulations require us to review and modify current contract terms or inform customers that offending contract terms we previously entered into are no longer effective. We are also required to develop and execute a real-world testing plan, which would require us to demonstrate to our ONC-Authorized Certification Body that our Health IT Modules operate as designed when implemented in the field. Failure to properly implement these requirements could result in our two products losing their status as Health IT Modules, which could jeopardize the utility of the products for our customers. We work closely with our selected ONC-Authorized Testing Laboratory and ONC-Authorized Certification Body to meet these and other requirements of Health IT Certification Program. We are unable to predict what changes to the certification program might be made in the future or how those changes could affect our business or the associated costs of compliance.

ERISA and Other Laws Impacting Employer Group Health Plans

Many of the clients we serve sponsor employer group health plans, which are subject to the Employee Retirement Income Security Act of 1974, as amended ("ERISA"), the Internal Revenue Code, the ACA, Medicare Secondary Payer **statute, statutes**, HIPAA privacy, state insurance laws in some cases, and other laws and regulations governing group health plans. While compliance **for with** these laws and regulations governing group health plans is the responsibility of the employer that sponsors the health plan, in some cases, the employer may delegate certain health plan functions to a vendor, such as us. We protect ourselves from liability for these client health plans by virtue of contractual provisions insulating us from exposure and responsibility for the employer-plan sponsor's legal obligations.

Governmental Audits

Because we act as a GPO for healthcare providers that participate in governmental programs, our group purchasing services have in the past and may again in the future be subject to periodic surveys and audits by governmental entities or contractors for compliance with Medicare and Medicaid standards and requirements. **We are also subject to ordinary course audits by state and federal regulatory agencies regarding our general business operations.** We will continue to respond to these government reviews and audits but cannot predict what the outcome of any future audits may be or whether the results of any audits could materially or negatively impact our business, our financial condition or results of operations.

Corporate Compliance Department

We execute and maintain a compliance and ethics program that is designed to assist us and our employees in conducting operations and activities ethically with the highest level of integrity and in compliance with applicable laws and regulations and,

if violations occur, to promote early detection and prompt resolution. These objectives are achieved through education, monitoring, disciplinary action and other remedial measures we believe to be appropriate. We provide all of our employees with education that has been developed to communicate our standards of conduct, compliance policies and procedures as well as policies for monitoring, reporting and responding to compliance issues. We also provide all of our employees with a third-party toll-free number and Internet website address in order to report any compliance or privacy concerns. In addition, our Chief Ethics & Compliance Officer individually, and along with the Audit and Compliance Committee of the Board of Directors (**"Audit and Compliance Committee"**), helps oversee compliance and ethics matters across our business operations.

Human Capital Management

Our employees are our most critical assets. The success and growth of our business depends on our ability to attract, reward, retain, and develop diverse, talented, and high-performing employees at all levels of our organization, while sustaining an environment of anti-discrimination that ensures equal access to opportunities. To succeed in an ever-changing and competitive labor market, we have developed human capital management strategies, objectives and measures that drive recruitment and retention, support business performance, advance innovation, foster employee development and support our Mission — to improve the health of our communities, our Vision — to lead the transformation to high quality, cost effective healthcare, and our Values — integrity, passion for performance, innovation and a focus on people.

Our Mission, Vision and Values, together with our human capital strategies, objectives and measures, form a framework advanced through the following programs and initiatives:

<p>Support Employees' Financial, Health, and Social Well-Being</p> <ul style="list-style-type: none"> Competitive, reasonable, and equitable compensation programs designed to align pay and performance and attract and retain employees who are passionate about our mission and exemplify our values. Annual and long-term incentives designed to drive business and individual achievement. Comprehensive, competitive, and innovative health and welfare and retirement benefits to support our employees' physical, mental and financial health. Employee Stock Purchase Plan and equity compensation to provide financial value, align employees' interests with those of our shareholders and drive talent retention. Innovative programs to support all aspects of employee well-being, including physical, emotional, financial and social health. Generous and flexible time off programs. Social Responsibility Programs including paid Annual Volunteer Afternoon, volunteering hours and matching gifts to encourage and support giving back to the communities in which we serve. Flexible work environments - including remote and hybrid work options where possible - and enabled technology to enhance employee experience and connectedness in both virtual and in-person settings. <p>Recognize Employees' Performance and Contributions</p> <ul style="list-style-type: none"> Premier Individual and Team Values Awards to recognize employees who best exemplify Premier's core values. Susan D. DeVore President's Award to recognize the significant career accomplishments of select employees. Shirley T. Wang Wellness Warrior Award to recognize employees' commitment to and passion for well-being. Values in Action online portal to encourage employees in real time to publicly recognize and reward their peers for performance, innovation, focus on people and integrity. 	<p>Promote a Diverse, Equitable and Inclusive Workplace</p> <ul style="list-style-type: none"> Council on Diversity, Equity, Inclusion and Belonging. Belonging is led and sponsored by the executive team of the Company. Each executive sponsors one or more Employee Resource Group ("ERG"). Network of executive-sponsored, employee-led Employee Resource Groups ("ERGs") designed to build community and foster belonging and advancement of business strategy and employee experience through sharing of diverse thought and perspective. Groups include W.O.M.E.N., Military Veterans, Black Professionals, LGBTQ+, Asian American and Pacific Islander, Latin and Disabled Employees and Generations and their Allies groups. We also have a Field Services DEI Council ERG comprised of employees dedicated to supporting our members. Business resource groups where employees connect through work affinities such as Nursing, Diverse Talent Acquisition, Community Health Initiatives, Workplace Culture and Health Equity. Regular and ongoing review of compensation equity. Mentoring and networking programs. Recruiting outreach to drive diverse representation within our communities. Continuous listening strategies including semi-annual People First employee engagement survey to seek feedback on a variety of topics to continuously improve our human resources programs, practices and employee experience. <p>Create Opportunities to Grow and Develop</p> <ul style="list-style-type: none"> Comprehensive technology-enabled learning and development programs to foster connections, leadership competency and team and individual development. Leadership and Management development programs. Performance Management program including a formal, quarterly employee performance feedback cadence to drive high performance and reward excellence. Enterprise talent planning and career pathing. Tuition reimbursement program to support continuing education.
---	--

<p>Company Recognition</p> <ul style="list-style-type: none"> World's Most Ethical Company by the Ethisphere Institute for the 16th consecutive year. 2020 Golden Peacock Award Best in KLAs Value Based Consulting 2024 Newsweek - America's Greatest Workplaces for Global Excellence in Corporate Governance, Diversity, 2024 U.S. News & World Report, Best Companies to Work For (2023 & 2024) Inducted into Healthiest Employers Hall of Fame in 2023, 2023 2023 2024 Healthiest Employers of Charlotte by Charlotte Business Journal (1st place), 8th consecutive year in top 3, 3 2022 2023 Healthiest 100 Workplaces in America (23rd (21st place)) 2022 2023 Cigna Well-Being Award (Gold Level) LinkedIn's 2021 Top Companies in Charlotte, Biotech Week Boston DEIJ Award Finalist, 2023 2021 Prism International Charlotte Business Journal Power 100 DEI Leaders, 2023 Top 100 DEI Leaders, 2019-2023 Top Diversity Impact Award for Top 25 National ERGs Influencer, 2019-2023 10 Most Influential D&I Leaders, 2022

Employees

As of June 30, 2023 June 30, 2024, we employed approximately 2,800 2,900 people, all in the United States. We also engage contractors and consultants. Additionally, we regularly track and report internally on key talent metrics including workforce demographics, talent pipeline, diversity data and the engagement of our employees. None of our employees are working under a collective bargaining arrangement.

We conduct sales through our embedded field force, our dedicated national sales team, our Premier consultants, and other various sales teams, collectively comprised of approximately over 600 employees as of June 30, 2023 June 30, 2024.

Our field force works closely with our U.S. hospital members and other members to target new opportunities by developing strategic and operational plans to drive cost management and quality and safety improvement initiatives. As of **June 30, 2023** **June 30, 2024**, our field force was deployed to **seven** **six** geographic regions and several strategic/affinity members across the United States. This field force works at our member sites to identify and recommend best practices for both supply chain and clinical integration cost savings opportunities. The regionally deployed field force is augmented by a national team of subject matter specialists who focus on key areas such as lab, surgery, cardiology, orthopedics, imaging, pharmacy, information technology and construction. Our field force also assists our members in growing and supporting their continuum of care facilities.

Our national sales team provides national sales coverage for establishing initial member relationships and works with our field force to increase sales to existing members. Our regional sales teams are aligned with the **seven** **six** regions in our field force model.

Our Premier consulting team identifies and targets consulting engagements and wrap-around services for our major SaaS-based clinical analytics products and our GPO to enhance the member value from these programs.

Available Information

We file or furnish, as applicable, annual, quarterly and current reports, proxy statements and other information with the SEC. You may access these reports and other information without charge at a website maintained by the SEC. The address of this site is <https://www.sec.gov>. In addition, our website address is www.premierinc.com. We make available through our website the documents identified above, free of charge, promptly after we electronically file such material with, or furnish it to, the SEC.

We also provide information about our company through: **X**, formerly known as **Twitter**, (<https://twitter.com/x.com/premierha>), Facebook (<https://www.facebook.com/premierhealthcarealliance>), LinkedIn (<https://www.linkedin.com/company/6766>), YouTube (<https://www.youtube.com/user/premieralliance>), and Instagram (<https://instagram.com/premierha>).

Except as specifically indicated otherwise, the information available on our website, the SEC's website and the social media outlets identified above, is not and shall not be deemed a part of this Annual Report.

Item 1A. Risk Factors

Our business, operations, and financial position are subject to various risks. Before making an investment in our Class A common stock or other securities we may have outstanding from time to time, you should carefully consider the following risks, as well as the other information contained in this Annual Report. Any of the risks described below could materially harm our business, financial condition, results of operations and prospects, and as a result, the value of an investment in our Class A common stock or other securities we may have outstanding from time to time could decline, and you may lose part or all of such investment value. This section does not describe all risks that are or may become applicable to us, our industry or our business, and it is intended only as a summary of certain material risk factors. Some statements in this Annual Report, including certain statements in the following risk factors, constitute forward-looking statements. See the section titled "Cautionary Note Regarding Forward-Looking Statements" for a discussion of such statements and their limitations. More detailed information concerning other risks or uncertainties we face, as well as the risk factors described below, is contained in other sections of this Annual Report.

Risk Factors Summary

The following is a summary of the risk factors that could adversely affect our Company and the value of an investment in our Company's securities.

Risks Related to our Business Operations

- We face risks related to competition and consolidation in the healthcare industry.
- We may not be able to maintain or add new members for our group purchasing organization ("GPO") programs which will depend in part on competitive pressure to increase the share of administrative fees we receive from GPO suppliers that we pay to members. This competitive pressure has resulted in material increases in our average revenue share obligations in fiscal year 2024, and we expect to continue to see material increases in our average revenue share obligations to members, particularly as we continue to renew GPO participation agreements.
- We may experience delays recognizing or increasing revenue if the sales cycle or implementation period takes longer than expected.
- We face risks to our business if members of our group purchasing organization ("GPO") GPO programs reduce activity levels, terminate or elect not to renew their contracts on substantially similar terms or at all.
- We rely on administrative fees face the risks that we receive from GPO suppliers.
- We face increased pressure to increase the percentage of administrative fees we share with our GPO members as well as to provide enhanced value through savings guarantees and other arrangements, including as a result of very aggressive competition from other GPOs, which is likely to result in increases in revenue share obligations, some of which may be material, particularly as our current GPO participation agreements approach renewal or if a member undergoes a change of control that triggers a termination right, or as new members join our GPO program.
- We face risks of the markets for our software as a service ("SaaS") or licensed-based analytics products and services may develop more slowly than we expect, or that we may convert more SaaS-based products product subscriptions to license-based analytics products, which could adversely affect our revenue, growth rates and our ability to maintain or increase our profitability products.
- Our members are highly dependent on payments from third-party payers, such as Medicare and Medicaid, the denial or reduction of which could adversely affect demand for our products and services.
- Our growth may be affected by our ability to offer new and innovative products and services, including those incorporating artificial intelligence, as well as our ability to maintain third-party provider and strategic alliances or enter into new alliances.
- We face risks and expenses related to future acquisition opportunities and integration of acquisitions, as well as risks associated with non-controlling investments in other businesses or joint ventures.
- Our evaluation of potential strategic alternatives to enhance value for stockholders may not be successful and have negative impacts on our business and stock price.

- We rely on Internet infrastructure, bandwidth providers, data center providers and other third parties and face risks related to data loss or corruption and cyber-attacks or other data security breaches.
- We depend on our ability to use, disclose, de-identify or license data and to integrate third-party technologies.
- We face risks related to our use of "open source" software.
- We face risks associated with the integration of artificial intelligence technologies with our products and services because of the emerging nature of these technologies and the evolving legal and regulatory framework relating to their use.
- We face risks associated with our reliance on contract manufacturing facilities located in various parts of the world.
- We may face inventory risk for (i) the personal protective equipment or other products we may purchase at elevated prices during a supply shortage, and (ii) items we purchase in bulk or pursuant to fixed price purchase commitments if we cannot sell such inventory at or above our cost.
- We depend on our ability to attract, hire, integrate and retain key personnel.
- We have risks to our business operations due to continuing uncertain economic conditions, including but not limited to inflation and the risk of a global recession, recessionary fears, which could impair our ability to forecast and may harm our business, operating results, including our revenue growth and profitability, financial condition and cash flows.
- We may continue to face financial and operational uncertainty due to pandemics, epidemics or public health emergencies, such as the COVID-19 pandemic, and associated supply chain disruptions.
- We may face financial and operational uncertainty due to global economic macroeconomic, geopolitical and political instability business conditions, trends and conflicts, events, including inflation, generally, and the impact of any associated supply chain challenges.
- We may be adversely affected by global climate change or by regulatory responses to such change.

Risks Related to Healthcare, Health Information Technology and Employee Benefit Regulation Data Privacy Laws and Regulations

- We are subject to changes and uncertainty in the legal, political, economic and regulatory environment affecting healthcare organizations.
- We must comply with complex international, federal and state laws and regulations governing financial relationships among healthcare providers and the submission of false or fraudulent healthcare claims, antitrust and employee benefit laws and regulations and privacy, security and breach notification laws.
- We are and may continue to be subject to regulation for certain of our software products regarding health information technology artificial intelligence and medical devices.

Legal and Tax-Related Risks

- We are subject to litigation from time to time, including the pending stockholder derivative action against certain of our current and former officers and directors, time.
- We must adequately protect our intellectual property, and we face potential claims against our use of the intellectual property of third parties.
- We face tax risks, including potential gross receipts, sales and use, franchise and income tax liability in certain jurisdictions, potential future changes in tax laws and potential material tax disputes.

Risks Related to our Corporate Structure

- We are obligated to make payments under our Unit Exchange and Tax Receivable Acceleration Agreements, and we may not realize all of the expected tax benefits corresponding to the termination of our prior Tax Receivable Agreement.
- Provisions in our certificate of incorporation and bylaws and provisions of Delaware law may impede or prevent strategic transactions, including a takeover of the company.

Risks Related to our Capital Structure, Liquidity and Class A Common Stock

- We face risks related to our current and future indebtedness, including our existing long-term credit facility.
- We experience fluctuation face risks due to fluctuations in our quarterly cash flows, revenues and results of operations.
- We are required could experience adverse consequences if we fail to maintain an effective system of internal controls over financial reporting and remediate any material weaknesses and significant deficiencies identified.
- We face risks related to our Class A common stock, including potentially dilutive issuances and uncertainty regarding future dividend payments and stock repurchases.

For a more complete discussion of the material risks facing our business, see below.

Risks Related to Our Business Operations

We face intense competition, which could limit our ability to maintain or expand market share within our industry and harm our business and operating results.

The market for products and services in each of our operating segments is fragmented, intensely competitive and characterized by rapidly evolving technology and product standards, dynamic user needs and the frequent introduction of new products and services. We face intense competition from a number of companies, including the companies listed under "Item 1 - Business - Competition."

The primary competitors for our Supply Chain Services segment compete with our group purchasing, direct sourcing and supply chain co-management activities. Our group purchasing business competes with other large GPOs, including in certain cases GPOs owned by healthcare providers and on-line online retailers. Our direct sourcing business competes primarily with private label offerings and programs, product manufacturers and distributors. Our supply chain co-management business competes with organizations that provide supply chain outsourcing or embedded resources and supply chain transformations services.

The competitors in our Performance Services segment compete with our three sub-brands: PINC AI, Contigo Health and Remitra. The primary competitors of PINC AI range from smaller niche companies to large, well-financed and technologically sophisticated entities, and include information technology providers and consulting and outsourcing firms. The primary competitors for Contigo Health are smaller niche and larger well-financed healthcare and insurance companies and providers of wrap network services. The primary competitors for Remitra are smaller niche and larger technology companies and financial institutions.

With respect to our products and services in both operating segments, we compete based on several factors, including breadth, depth and quality of our product and service offerings, ability to deliver clinical, financial and operational performance improvement through the use of our products and services, quality and reliability of services, ease of use and convenience, brand recognition and the ability to integrate services with existing technology. Some of our current and potential competitors have larger scale, benefit from greater name recognition, and have substantially greater financial, technical and marketing resources. Other of our competitors have proprietary technology that differentiates their product and service offerings from our offerings. As a result of these competitive advantages, our competitors current and potential competitors may be able to respond more quickly to market forces, undertake more extensive have broader scale in marketing campaigns for their brands, products and services, and make more attractive offers to our current members and other customers and potential new members and other customers.

We also compete based on price in both of our Supply Chain Services and Performance Services businesses operating segments. We may be are subject to pricing pressures as a result of, among other things, competition within the industry, consolidation of healthcare industry participants, practices of managed care organizations, changes in laws and regulations applicable to our business operations, government action affecting reimbursement, financial stress experienced by our members and other customers, and increased revenue share obligations to members. In our Supply Chain Services segment, competitive we believe that some of our GPO competitors may offer higher revenue share arrangements to some of their customers compared to our average arrangements. Competitive pressure is likely to result has recently resulted in increases in our average revenue share obligations, some of which may be and we expect to continue to see material increases in our average revenue share obligations to members, particularly as our current we continue to renew additional GPO participation agreements approach that were extended at the time of our August 2020 Restructuring. As of June 30, 2024, we have renewed and extended members that represent approximately 50% of the gross administrative fees associated with the GPO member agreements that were extended in 2020. In fiscal year 2025, we are targeting additional member agreements for renewal or if that would address a cumulative total of approximately 75% of the gross administrative fees associated with the member undergoes agreements extended in 2020. We expect to target the remaining associated member agreements in fiscal years 2026 and 2027. We similarly expect that competitive pressure on revenue share may result in us entering into arrangements with members that undergo a change of control that triggers a termination right, or as new GPO members that join our GPO programs, programs, which increase our average revenue share obligations. Material increases in revenue share obligations to existing or new GPO members could adversely impact our business, financial condition and results of operations. In this competitive environment, we have experienced GPO member terminations during existing contractual periods, and we may not be able to retain our current GPO members or expand our member base at historical terms, on favorable terms or at all, and the all. The failure to do so retain and expand our GPO member base may adversely impact our business, financial condition and results of operations. Furthermore, if pricing of our other products and services experiences material downward pressure, our business will be less profitable, and our results of operations will be materially, adversely affected.

Furthermore, our Performance Services business also competes on features and functionality of the solutions we offer through our PINC AI, Contigo Health and Remitra brands.

Moreover, we expect that competition will continue to increase as a result of consolidation in both the healthcare information technology and healthcare services industries. If one or more of our competitors or potential competitors were to merge or partner with another of our competitors, or if new competitors were to enter the healthcare space, the change in the competitive landscape could also adversely affect our ability to compete effectively and could materially harm our business, financial condition, and results of operations.

Consolidation in the healthcare industry could have a material adverse effect on our business, financial condition and results of operations.

Many healthcare industry participants are consolidating to create larger and more integrated healthcare delivery systems with greater market power. We expect legal, regulatory and economic conditions to lead to additional consolidation in the healthcare industry in the future. As consolidation accelerates, the economies of scale of our members' organizations may grow. If a member experiences sizable growth following consolidation, it may determine that it no longer needs to rely on us and may reduce its demand for our products and services. Some of these large and growing healthcare systems and continuum of care providers may choose to contract directly with suppliers for certain supply categories, and some suppliers may seek to contract directly with the healthcare providers rather than with GPOs such as ours. In connection with any consolidation, our members may move their business to another GPO, particularly when the acquiring hospital or health system is a member of a competing GPO or where the post-acquisition management of our member is aligned with a competing GPO. In addition, as healthcare providers consolidate to create larger and more integrated healthcare delivery systems with greater market power, these providers have in the past tried and may in the future try to use their market power to negotiate materially increased revenue share obligations and fee reductions for our products and services across both of our business segments. Finally, consolidation may also result in the acquisition or future development by our members of products and services that compete with our products and services. Any of these potential results of consolidation could have a material adverse effect on our business, financial condition, and results of operations.

We may experience material delays in recognizing revenue or increasing revenue, or be required to reverse prior revenue recognition, if the sales cycle or implementation period with potential new members or customers takes longer than anticipated or our related project estimates are not accurate.

A key element of our strategy is to market the various products and services in our Supply Chain Services and Performance Services segments directly to healthcare providers and to increase the number of our products and services utilized by existing members, members and other customers. The evaluation and purchasing process is often lengthy and involves material technical evaluation and commitment of personnel by these organizations. Further, the evaluation process depends on a number of factors, many of which we may not be able to control, including potential new members' and other customers' internal approval processes, budgetary constraints for technology spending, member concerns about implementing new procurement methods and strategies and other timing effects. In addition, the contract or software implementation process for new products or services can take six months or more and, accordingly, delay our ability to recognize revenue from the sale of such products or services. If we experience an extended or delayed implementation cycle in connection with the sale of additional products and services to existing or new members or customers, it could have a material adverse effect on our business, financial condition and results of operations. In addition, we are required to use estimates to determine revenue recognition for performance-based consulting engagements. These estimates are based on a number of inputs from management regarding project timing, milestone and goal achievement and expected completion dates, each of which may change during the course of the engagement and could result in either delayed revenue recognition or revenue reversals resulting in out of period out-of-period revenue adjustments, which could have a material adverse effect on our results of operations. In addition, changes in accounting standards that impact revenue recognition as well as conversion of SaaS-based products product subscriptions to licensed-based products and services, as discussed in the below risk factor "The markets for our SaaS- or licensed-based products and services may develop more slowly than we expect, or we may convert more SaaS-based products product subscriptions to license-based products and services, which could adversely affect our revenue, growth rates and our ability to maintain or increase our profitability" could adversely impact our ability to recognize revenue consistent with our historical practices and could have a material adverse effect on our business, financial condition and results of operations.

If members of our GPO programs reduce activity levels or terminate or elect not to renew their contracts, our revenue and results of operations may decrease materially.

We Although we have GPO participation agreements with all most of our GPO members. Our GPO participation members, these agreements may generally be terminated for cause or in the event of a change of control of the GPO member. In addition, the GPO member can terminate the GPO participation agreement at the end of the then-current term by notifying us of the member's decision not to renew. Although we renewed most of our then existing GPO participation agreements primarily for terms of five to seven years at the beginning of fiscal year 2021, there can be no assurance that our GPO members will extend or renew their GPO participation agreements on the same or similar economic terms at the end of the term of the agreement, or at all, or that the GPO members will not terminate their GPO participation agreements for cause or due to a change of control of the GPO member. Similarly, there can be no assurance that GPO members will not seek to terminate their GPO participation agreements in the absence of any express right to do so, and if this occurs our remedies may not fully compensate us for the corresponding loss of revenues. Failure of our GPO members to maintain, extend or renew their GPO participation agreements on the same or similar economic terms, or at all, may have a material adverse impact on our business, financial condition and results of operations.

Our success in retaining member participation in our GPO programs depends upon our reputation, strong relationships with GPO members and our ability to deliver consistent, reliable and high-quality products and services, and a failure in any of these areas may result in the loss of GPO members. Some We believe that some of our GPO competitors offer higher revenue share arrangements to some of their customers compared to our average arrangements. Our ability to retain and expand participation in our GPO programs depends upon our ability to provide overall value to GPO members, including competitive revenue share arrangements, in an economically competitive environment. Competitive pressure has resulted in increases in our average revenue share obligations, and we expect to continue to see material increases in our average revenue share obligations to members, particularly as we continue to renew additional GPO participation agreements that were extended at the time of our August 2020 Restructuring. As of June 30, 2024, we have renewed and extended members that represent approximately 50% of the gross administrative fees associated with the member agreements that were extended in 2020. In fiscal year 2025, we are targeting additional member agreements for renewal that would address a cumulative total of approximately 75% of the gross administrative fees associated with the member agreements extended in 2020. We expect to target the remaining associated member agreements for renewal in fiscal years 2026 and 2027. In addition, GPO members may seek to modify or elect not to renew their contracts due to factors that are beyond our control and are unrelated to our performance, including a change of control of the GPO member, changes in their strategies, competitive analysis or business plans, changes in their supply chain personnel or management, or economic conditions in general. When contracts are reduced by modification or not renewed for any reason, we lose the anticipated future revenue associated with such contracts and, consequently, our revenue and results of operations may decrease materially.

Historically, we have enjoyed a strong strategic alignment with our GPO members, in many cases as a result of such GPO members being significant equity owners of both us and Premier LP. As a result of the August 2020 Restructuring, our former member-owners' equity holdings in Premier LP were canceled and converted into shares of our Class A common stock which is publicly traded on the NASDAQ Global Select Market ("NASDAQ") under the ticker symbol "PINC." Furthermore, former member-owners who received shares of our Class A common stock as part of the August 2020 Restructuring are have been free to sell those shares at any time. Any material reduction in our former member-owners' equity holdings in us could result in reduced alignment between us and such former member-owners, which may make it more difficult to retain these GPO members or to ensure that they extend or renew their GPO participation agreements on the same or similar economic terms, or at all, the failure of which may have a material adverse impact on our business, financial condition and results of operations.

We rely on the administrative fees we receive from our GPO suppliers, and the failure to maintain contracts with these GPO suppliers could have a generally negative effect on our relationships with our members and could adversely affect our business, financial condition and results of operations.

Historically, we have derived a substantial amount of our revenue from the administrative fees that we receive from our GPO suppliers. We maintain contractual relationships with these suppliers which provide products and services to our members at reduced costs and which pay us administrative fees based on the dollars spent by our members for such products and services. Our contracts with these GPO suppliers generally may be terminated upon 90 days' notice. A termination of any relationship or agreement with a GPO supplier would result in the loss of administrative fees pursuant to our arrangement with that supplier, which could adversely affect our business, financial condition and results of operations. In addition, if we lose a relationship with a GPO supplier we may not be able to negotiate similar arrangements for our members with other suppliers on the same terms and conditions or at all, which could damage our reputation with our members and adversely impact our ability to maintain our member agreements or expand our membership base and could have a material adverse effect on our business, financial condition and results of operations.

In addition, the U.S. Centers for Medicare and Medicaid Services, or CMS, which administers the Medicare and federal aspects of state Medicaid programs, has issued complex rules requiring pharmaceutical manufacturers to calculate and report drug pricing for multiple purposes, including the limiting of reimbursement for certain drugs. These rules generally exclude from the pricing calculation provide that administrative fees paid by pharmaceutical manufacturers to GPOs do not reduce the drug pricing calculation to the extent that such fees meet CMS's "bona fide service fee" definition. There can be no assurance that CMS will continue to allow this exclusion of GPO administrative fees from the pricing calculation, which could negatively affect the willingness of pharmaceutical manufacturers to pay administrative fees to us, which could have a material adverse effect on our member retention, business, financial condition and results of operations.

We derive a material portion of our revenues from our largest members and certain other customers, and the sudden loss of one or more of these members or customers could materially and adversely affect our business, financial condition and results of operations.

Our top five members and customers generated revenue of approximately 15% 14% and 21% 15% of our consolidated net revenues for the fiscal years ended June 30, 2023 June 30, 2024 and 2022, 2023. The sudden loss of any material customer, or a number of smaller customers that are participants in our group purchasing programs, or utilize any of our programs or services, or a material change in revenue share or other economic terms we have with such customers, could materially and adversely affect our business, financial condition and results of operations.

The markets for our SaaS- or SaaS-based product subscriptions and licensed-based products and services may develop more slowly than we expect, or we may convert more SaaS-based products to license-based products, which could adversely affect our revenue, growth rates and our ability to maintain or increase our profitability.

As SaaS licensing deals have become a more Our Performance Services segment generates revenue from both SaaS-based products subscriptions and term enterprise analytics licenses for our analytics products. Generally, SaaS-based transactions generate subscription fees revenue over the term of the contract, whereas revenue from licensed-based transactions is recognized upon delivery of the software code and revenue from maintenance and hosting fees is recognized over the term of the contract. Fluctuating customer demand for SaaS-based and licensed-based transactions, including the mix of SaaS-based and licensed-based transactions, can therefore result in material aspect volatility of our business, our success will depend on revenue, growth rates and profitability in any given quarter or year. Our customers have increasingly elected to enter into licensed-based transactions instead of renewing SaaS-based transactions, and the willingness timing and pricing of existing these conversions can contribute to this volatility. Furthermore, the

growth and potential new customers to increase their use profitability of our SaaS- or Performance Services segment depends on our ability to grow revenue from our licensed-based products and services as well as our ability to sell license-based and new SaaS-based products to existing and potential new customers subscriptions at rates sufficient to offset a rate that more than offsets the loss of SaaS-based product sales. Fluctuating member demand and timing for SaaS- or license-based products that materially alter our mix of SaaS- and licensed-based product sales and conversion of our customers from SaaS-based products subscriptions to license-based licensed-based products can result in volatility of revenue and lower growth rates in any given year which could materially adversely affect our business, financial condition and results of operations. Furthermore, services. In addition, many companies have invested substantial resources to integrate established enterprise software into their businesses and therefore may be reluctant or unwilling to switch to our products and services, and some companies may have concerns regarding the risks associated with the security and reliability of the technology delivery model associated with these products and services. If companies do not perceive the benefits of our SaaS-based products and licensed-based products and services, or have concerns regarding security or reliability, then the market for these products and services may not expand as much or develop as quickly as we expect, which would materially adversely affect our business, financial condition and results of operations.

Our members and other customers are highly dependent on payments from third-party healthcare payers, including Medicare, Medicaid and other government-sponsored programs, and reductions or changes in third-party reimbursement could adversely affect these members and other customers and consequently our business.

Our members and other customers derive a substantial portion of their revenue from third-party private and governmental payers, including Medicare, Medicaid and other government sponsored programs. Our sales and profitability depend, in part, on the extent to which coverage of and reimbursement for our products and services our members and other customers purchase or otherwise obtain through us is available to our members and other customers from governmental health programs, private health insurers, managed care plans and other third-party payers. These third-party payers are increasingly using their enhanced bargaining power to secure discounted reimbursement rates and may impose other requirements that adversely impact our members and other customers' ability to obtain adequate reimbursement for our products and services. If third-party payers do not approve our products and services for reimbursement or fail to reimburse for them adequately, our members and other customers may suffer adverse financial consequences which, in turn, may reduce the demand for and ability to purchase our products or services.

In addition, government actions or changes in laws or regulations could limit government spending generally for the Medicare and Medicaid programs, limit payments to healthcare providers and increase emphasis on financially accountable payment programs such as accountable care organizations, bundled payments and capitated primary care that could have a material adverse impact on our members and other customers and, in turn, on our business, financial condition and results of operations.

If we are unable to maintain our relationships with third-party providers or maintain or enter into new strategic alliances, relationships with other companies, we may be unable to grow our current base business.

Our business strategy includes entering into and maintaining strategic collaborations, alliances, partnerships and other affiliations with leading service providers, other companies. These companies may pursue relationships with our competitors, develop or acquire products and services that compete with our products and services, experience financial difficulties, be acquired by one of our competitors or other third party or exit the healthcare industry, any of which may adversely affect our relationship with them. In addition, in many cases, agreements with these companies may allow them to terminate their relationships with us for any reason with limited or no notice. If existing strategic relationships with third-party providers or strategic alliances other companies are adversely impacted or are terminated or if we are unable to enter into relationships with leading healthcare service providers and other GPOs, new strategic necessary for our business, we may be unable to maintain or increase our industry presence or effectively execute our business strategy.

If we are not able to timely offer new and innovative products and services, we may not remain competitive and our revenue and results of operations may suffer.

Our success depends on providing products and services within our Supply Chain Services and Performance Services segments that healthcare providers and other customers use to improve clinical, financial and operational performance. Information technology providers and other competitors are incorporating enhanced analytical tools and functionality and otherwise developing products and services that may become viewed as more efficient or appealing to our members, members or other customers. If we cannot adapt to rapidly evolving industry standards, technology capabilities (including artificial intelligence), and member and other customers' needs, including changing regulations and provider reimbursement policies, we may be unable fail to anticipate changes in meet our current and potential new members' and other customers' requirements that could make and our existing technology, products or service offerings could become obsolete. We must continue to invest material resources in software technology development or acquisitions in order to enhance our existing products and services, maintain or improve our product category rankings and introduce new high-quality products and services that members current and potential new members and other customers will want. If our enhanced existing or new products and services are not responsive to the needs of our members current or potential new members and other customers, are not appropriately timed with market opportunity or are not effectively brought to market, we may lose existing members or customers and be unable to obtain new members and other customers, which could have a material adverse effect on our business, financial condition or results of operations.

Our acquisition activities could result in operating difficulties, dilution, unrecoverable costs and other negative consequences, any of which may adversely impact our financial condition and results of operations.

Our business strategy includes growth through acquisitions of additional businesses and assets. Future acquisitions may not be completed on preferred terms and acquired assets or businesses may not be successfully integrated into our operations or provide anticipated financial or operational benefits. Any acquisitions we complete will involve risks commonly encountered in acquisitions of businesses or assets. Such risks include, among other things:

- failing to integrate the operations and personnel of the acquired businesses in an efficient, timely manner;
- failure of a selling party to produce all material information during the pre-acquisition due diligence process, or to meet their obligations under post-acquisition agreements;
- potential liabilities of or claims against an acquired company or its assets, some of which may not become known until after the acquisition;
- an acquired company's lack of compliance with applicable laws and governmental rules and regulations, and the related costs and expenses necessary to bring such company into compliance;
- an acquired company's general information technology controls or their legacy third-party providers may not be sufficient to prevent unauthorized access or transactions, cyber-attacks or other data security breaches;
- managing the potential disruption to our ongoing business;
- distracting management focus from our existing core businesses;
- encountering difficulties in identifying and acquiring products, technologies, or businesses that will help us execute our business strategy;

- entering new markets in which we have little to no experience;
- impairing relationships with employees, members and other customers, and strategic partners;
- failing to implement or remediate controls, procedures and policies appropriate for a public company at acquired companies lacking such financial, disclosure or other controls, procedures and policies, potentially resulting in a material weakness in our internal controls over financial reporting;
- unanticipated changes in market or industry practices that adversely impact our strategic and financial expectations of an acquired company, assets or business and require us to write-off or dispose of such acquired company, assets, or business;
- the amortization of purchased intangible assets;
- incurring expenses associated with an impairment of all or a portion of goodwill and other intangible assets due to the failure of certain acquisitions to realize expected benefits; and
- diluting the share value and voting power of existing stockholders.

In addition, anticipated benefits of our previous and future acquisitions may not materialize. Future acquisitions or dispositions of under-performing businesses could result in the incurrence of debt, material exit costs, contingent liabilities or amortization expenses, impairments or write-offs of goodwill and other intangible assets, any of which could harm our business, financial condition and results of operations. For example, during fiscal year 2024, our Contigo Health reporting unit reported impairment losses primarily as a result of our acquisition of TRPN Direct Pay, Inc. and Devon Health, Inc. In addition, expenses associated with potential acquisitions, including, among others, due diligence costs, legal, accounting, technology and financial advisory fees, travel and internal resources utilization, can be material. These expenses may be incurred regardless of whether any potential acquisition is completed. In instances where acquisitions are not ultimately completed, these expenses typically cannot be recovered or offset by the anticipated financial benefits of a successful acquisition. As we pursue our business strategy and evaluate opportunities, these expenses may adversely impact our results of operations and earnings per share.

We have recorded, and may record in the future, goodwill and intangible and other long-lived assets as a result of acquisitions and other investments, and changes in future business conditions could cause investments to become impaired and require substantial write-downs that would reduce our operating income.

We evaluate the recoverability of recorded goodwill and intangible and other long-lived asset amounts annually, or when impairment indicators are present, which could require an interim impairment test. The impairment test is based on several factors requiring management estimates, judgments and assumptions. We have experienced impairment charges in recent fiscal years, including an impairment charge of \$140.1 million in fiscal year 2024 for our Contigo Health reporting unit (see Note 8 - Goodwill and Intangible Assets to the accompanying consolidated financial statements for further information). Additional future impairment could result from, among other things, deterioration in the performance of our business or product lines, adverse market conditions and changes in the competitive landscape and a variety of other circumstances. The amount of any impairment is recorded as a charge to our statement of operations. We may never realize the full value of our goodwill and intangible and other long-lived assets, and any determination requiring the write-off of a significant portion of these assets may have an adverse effect on our financial condition and results of operations. Due to continual changes in business and market conditions, we cannot predict whether, and to what extent, our goodwill and intangible and other long-lived assets may be impaired in future periods. Our operating results may be negatively impacted by both the impairment and the underlying business circumstances or trends that triggers the impairment.

Our business and growth strategies also include non-controlling investments in other businesses and joint ventures. In the event the companies or joint ventures we invest in do not perform as well as expected, we could experience the loss of some or all of the value of our investment, which loss could adversely impact our financial condition and results of operations.

Although we conduct accounting, financial, legal and business due diligence prior to making investments, we cannot guarantee that we will discover all material issues that may affect a particular target business, or that factors outside the control of the target business and outside of our control will not later arise. Occasionally, current We have in the past and may in the future make investments are, and will be, made on a non-controlling basis, in which case and we have limited ability to influence the financial, or business and other operations of the companies in which we invest. invest on this basis. To the extent we invest in a financially underperforming or unstable company or an entity in its development stage that does not successfully mature, we may lose the value of our investment. We have in the past and may in the future be required to write down or write off our investment or recognize impairment or other charges that could adversely impact our financial condition or results of operations and our stock price. Even though these charges may be non-cash items and that do not have a material impact on our revenues or liquidity, they could impact our earnings and the fact that we report charges of this nature could contribute to negative market perceptions about us and our business strategy and our Class A common stock.

We cannot assure you that our evaluation of potential strategic alternatives to enhance value for stockholders will be successful; and there may be negative impacts on our business and stock price as a result of the process of exploring strategic alternatives.

In May 2023, we announced that our Board of Directors is evaluating potential strategic alternatives to enhance value for stockholders. The Board of Directors has established an independent Special Committee composed of independent directors to evaluate any alternatives that may involve actual or potential conflicts of interest and have engaged financial and legal advisors to assist in the process. The strategic process is ongoing. Our Board of Directors has not set a timetable for the strategic process, and as of June 30, 2023, the only decision made relating to any strategic alternatives is the definitive agreement we entered into with OMNIA Partners, LLC, a leading non-healthcare GPO, in June 2023, under which we sold substantially all of our non-healthcare GPO member contracts for an estimated purchase price of approximately \$800.0 million subject to certain adjustments. There can be no assurance that the strategic review process by our Board of Directors will result in any further transactions or any other strategic change or outcome, or as to the timing of any of the foregoing. Whether the process will result in any additional transactions, our ability to complete any transaction, and if our Board of Directors decides to pursue one or more transactions, will depend on numerous factors, some of which are beyond our control, including the interest of potential acquirers or strategic partners in a potential transaction, the value potential acquirers or strategic partners attribute to our businesses and their respective prospects, market conditions, interest rates and industry trends. Our stock price may be adversely affected if the evaluation does not result in additional transactions or if one or more transactions are consummated on terms that investors view as unfavorable to us. Even if one or more additional transactions are completed, there can be no assurance that any such transactions will be successful or have a positive effect on stockholder value. Our Board of Directors may also determine that no additional transaction is in the best interest of our stockholders.

In addition, our financial results and operations could be adversely affected by the strategic process and by the uncertainty regarding its outcome. The attention of management and our Board of Directors could be diverted from our core business operations, and we have diverted capital and other resources to the process that otherwise could have been used in our business operations, and we will continue to do so until the process is completed. We could incur substantial expenses associated with identifying and evaluating potential strategic alternatives, including those related to employee retention payments, equity compensation, severance pay and legal, accounting and financial advisor fees. In addition, the process could lead us to lose or fail to attract, retain and motivate key employees, and to lose or fail to attract customers or business partners, and could expose us to litigation. The

public announcement of a strategic alternative may also yield a negative impact on operating results if prospective or existing service providers are reluctant to commit to new or renewal contracts or if existing customers decide to move their business to a competitor. We do not intend to disclose developments or provide updates on the progress or status of the strategic process until our Board of Directors deems further disclosure is appropriate or required. Accordingly, speculation regarding any developments related to the review of strategic alternatives and perceived uncertainties related to the future of the Company could cause our stock price to fluctuate significantly.

We rely on Internet infrastructure, bandwidth providers, data center providers and other third parties and our own systems for providing services to our users, and any failure or interruption in the services provided by these third parties or our own systems, including from a cyber or other catastrophic event, could expose us to litigation and negatively impact our relationships with users, adversely affecting our brand, our business and our financial performance.

Our ability to deliver our products is dependent on the development and maintenance of the infrastructure of the Internet and other telecommunications services by third parties. This includes maintenance of a reliable network backbone with the necessary speed, data capacity and security for providing reliable Internet access and services and reliable telephone, Wi-Fi ~~facsimile~~ and ~~pager~~ other communications systems. We have experienced and expect that we will experience in the future interruptions and delays in these services and availability from time to time. We rely on internal systems as well as third-party suppliers, including bandwidth and telecommunications equipment providers, to provide our services. We have also migrated our data center operations to third-party data-hosting facilities. We do not maintain redundant systems or facilities for some of these services. In the event of a material cyber-attack or catastrophic event with respect to one or more of these providers, systems or facilities, we may experience an extended period of system unavailability, which could negatively impact our relationship with users. To operate without interruption, both we and our service providers must guard against:

- damage from fire, power loss, and other natural disasters;
- communications failures;
- software and hardware errors, failures, and crashes;
- cyber-attacks, viruses, worms, malware, ransomware and other malicious software programs;
- security breaches and computer viruses and similar disruptive problems; and
- other potential interruptions.

Any disruption in the network access, telecommunications or co-location services provided by our third-party providers or any failure of or by these third-party providers or our own systems to handle current or higher volume of use could materially harm our business. In addition, our operations could be impaired and our confidential information compromised if our service providers experience cyber-attacks on and breaches of their information technology systems. We exercise limited control over these third-party suppliers, which increases our vulnerability to problems with services they provide. Any errors, failures, interruptions or delays experienced in connection with these third-party technologies and information services or our own systems could negatively impact our relationships with users and adversely affect our business and financial performance and could expose us to third-party liabilities, some of which may not be adequately insured.

Data loss or corruption due to failures or errors in our systems and service disruptions at our data centers may adversely affect our reputation and relationships with existing members and other customers, which could have a negative impact on our business, financial condition and results of operations.

Because of the large amount of data that we collect and manage, it is possible that hardware failures or errors in our systems could result in data loss or corruption or cause the information that we collect to be incomplete or contain inaccuracies that our members and other customers regard as material. Complex software such as ours may contain errors or failures that are not detected until after the software is introduced or updated and new versions are released. Despite testing by us, from time to time we have discovered defects or errors in our software, and such defects or errors may be discovered in the future. Any defects or errors could expose us to risk of liability to members or other customers and the government and could cause delays in the introduction of new products and services, result in increased costs and diversion of development resources, require design modifications, decrease market acceptance or member satisfaction with our products and services or cause harm to our reputation.

Furthermore, our members and other customers might use our software together with products from other companies. As a result, when problems occur, it might be difficult to identify the source of the problem. Even when our software does not cause these problems, the existence of these errors might cause us to incur material costs, divert the attention of our technical personnel from our product development efforts, impact our reputation and lead to material member relations problems.

Moreover, our data centers and service provider locations store and transmit critical member data that is essential to our business. While these locations are chosen for their stability, failover capabilities and system controls, we do not directly control the continued or uninterrupted availability of every location. We have migrated our data center operations to third-party data-hosting facilities. Data center facilities are vulnerable to damage or interruption from natural disasters, fires, power loss, telecommunications failures, acts of terrorism, acts of war, and similar events. They are also subject to break-ins, sabotage, intentional acts of vandalism, cyber-attacks and similar misconduct. Despite precautions taken at these facilities, the occurrence of a natural disaster or an act of terrorism, could result in a decision to close the facilities without adequate notice or other unanticipated problems, which could cause lengthy interruptions in our service. These service interruption events could impair our ability to deliver services or deliverables or cause us to fail to achieve service levels required in agreements with our members or other customers, which could negatively affect our ability to retain existing or attract new members and attract new members other customers.

If our cyber and other security measures are breached or fail and unauthorized access to a member's data is obtained, or our members or customers fail to obtain proper permission for the use and disclosure of information, our services may be perceived as not being secure, our members and other customers may curtail or stop using our services and we may incur material liabilities.

Our services involve the web-based storage and transmission of members' and other customers' proprietary information, personal information of employees and protected health information of patients. From time to time, we may detect vulnerabilities in our systems, which, even if not resulting in a security breach, may reduce member confidence and require substantial resources to address. If our security measures are breached or fail as a result of third-party action, employee error, malfeasance, insufficiency, defective design or otherwise, someone may be able to obtain unauthorized access to member, employee or patient data. As a result, our reputation could be damaged, our business may suffer, and we could face damages for contract breach, penalties and fines for violation of applicable laws or regulations and material costs for notification to affected individuals, remediation and efforts to prevent future occurrences.

In addition to our cyber and other security measures, we rely upon third-party providers and our members and other customers as users of our system systems for key activities to promote security of the system those systems and the data within it them. On occasion, our providers providers' security systems have been breached and our members have failed to perform these activities. Failure of third-party providers, members or members customers to perform these activities may result in claims against us that could expose us to material expense and harm our reputation. In addition, our members or other customers may authorize or enable third parties to access their data or the data of their patients on our systems. Because we do not control such access, we cannot ensure the complete propriety of that access or integrity or security of such data in our systems. In addition, although

our development infrastructure is based in the U.S., we outsource development work for a portion of our products and services to persons outside the U.S., particularly India. We cannot guarantee that the cyber and other security measures and regulatory environment of our foreign partners are as robust as in the U.S. Any **security** breach of our **security systems resulting from access** by our members, **customers** or foreign partners could have a material adverse effect on our business, financial condition and results of operations.

Additionally, we require our members **or other customers** to provide necessary notices and to obtain necessary permissions and waivers for use and disclosure of the information that we receive. If our members **or other customers** do not obtain necessary permissions and waivers, then our use and disclosure of information that we receive from them or on their behalf may be limited or prohibited by state, federal, or international privacy laws or other laws. Any such failure to obtain proper permissions and waivers could impair our functions, processes and databases that reflect, contain or are based upon such data and may prevent use of such data. Moreover, we may be subject to claims or liability for use or disclosure of information by reason of our lack of a valid notice, permission or waiver. These claims or liabilities could subject us to unexpected costs and adversely affect our business, financial condition and results of operations.

We could suffer a loss of revenue and increased costs, exposure to material liability, reputational harm, and other serious negative consequences if we, our service providers or other suppliers, or our members or customers are subject to cyber-attacks or other data security breaches that disrupt our operations or result in the dissemination of proprietary or confidential information about us, or our members or customers, other third parties, parties, patients or employees.

We manage and store proprietary information and sensitive or confidential data relating to our operations. We may be subject to cyber-attacks on and breaches of the information technology systems we use for these purposes. Experienced computer programmers and hackers may be able to penetrate our network security and misappropriate or compromise our confidential information or that of third parties, create system disruptions, or cause shutdowns. Computer programmers and hackers also may be able to develop and deploy viruses, worms, malware, ransomware and other malicious software programs that attack our systems or products or otherwise exploit security vulnerabilities of our systems or products. In addition, hardware and operating system software and applications that we produce or procure from third parties may contain defects in design or manufacture, including "bugs" and other problems that could unexpectedly interfere with **or cause errors** in the operation of our systems.

We expend material capital to protect against the threat of security breaches, including cyber-attacks, viruses, worms, malware, ransomware and other malicious software programs. Substantial additional expenditures may be required before or after a cyber-attack or breach to mitigate in advance or to alleviate any problems caused by cyber-attacks and breaches, including unauthorized access to or theft of personal or patient data and protected health information stored in our information systems and the introduction of computer viruses, worms, malware, ransomware and other malicious software programs to our systems. Our remediation efforts may not be successful and could result in interruptions, delays or cessation of service and loss of existing or potential **members, new members or customers**.

While we provide our **domestic and foreign** employees and contractors training and regular reminders on important measures they can take to prevent breaches, we often identify attempts to gain unauthorized access to our systems. Given the rapidly evolving nature and proliferation of cyber threats, there can be no guarantee our training and network security measures or other controls will detect, prevent or remediate security or data breaches in a timely manner or otherwise prevent unauthorized access to, damage to, or interruption of our systems and operations. For example, it has been widely reported that many well-organized international interests, in certain cases with the backing of sovereign governments, are targeting the theft of patient information through the use of advanced persistent threats. In recent years, a number of hospitals have reported being the victim of ransomware attacks in which they lost access to their systems, including clinical systems, during the course of the attacks. We are likely to face attempted attacks in the future. Accordingly, we may be vulnerable to losses associated with the improper functioning, security breach or unavailability of our information systems as well as any systems used in acquired operations.

Breaches of our security measures and the unapproved use or disclosure of proprietary information or sensitive or confidential data about us, **or our members or customers, other third parties, patients or employees** could expose us, our members or **customers, other affected third parties, patients or employees** to a risk of loss or misuse of this information, result in litigation, governmental inquiry and potential liability for us, damage our brand and reputation or otherwise harm our business. Furthermore, we are exposed to additional risks because we rely in certain capacities on third-party data management providers whose possible security problems and security vulnerabilities are beyond our control. **Similarly, our operations could be impaired and our confidential information compromised if our service providers or other suppliers, our members or our customers experience cyber-attacks on and breaches of their information technology systems.**

We may experience cyber-security and other breach incidents that remain undetected for an extended period. Because techniques used to obtain unauthorized access or to sabotage systems change frequently and generally are not recognized until launched, we may be unable to anticipate these techniques or to implement adequate preventative measures to stop or mitigate any potential damage in a timely manner. Given the increasing cyber security threats in the healthcare industry, there can be no guarantee we will not experience business interruptions; data loss, ransom, misappropriation or corruption; theft or misuse of proprietary or patient information; or litigation and investigation related to any of those, any of which could have a material adverse effect on our financial position and results of operations and harm our business reputation. Although we do maintain commercially reasonable insurance policies for cyber-attacks, there can be no guarantee that insurance would be sufficient to cover our losses **or other consequences of interruptions to our business**, nor can it be guaranteed that insurance coverage would be available for every specific incident in accordance with the terms and conditions of the applicable policy coverage.

Any restrictions on our use of, or ability to license, data, or our failure to license data and integrate third-party technologies, could have a material adverse effect on our business, financial condition and results of operations.

We depend upon licenses from third parties, most of which are non-exclusive, for some of the technology and data used in our applications, and for some of the technology platforms upon which these applications are built and operate. We also obtain a portion of the data that we use from government entities and public records and from our members **and other customers** for specific member **or customer** engagements. We cannot assure that our licenses for information will allow us to use that information for all potential or contemplated applications and products. In addition, if our members **or customers** revoke their consent for us to maintain, use, de-identify and share their data, our data assets could be degraded.

In the future, data providers could withdraw their data from us or restrict our usage due to competitive reasons or because of new legislation or judicial interpretations restricting use of the data currently used in our products and services. In addition, data providers could fail to adhere to our quality control standards in the future, causing us to incur additional expense to appropriately utilize the data. If a substantial number of data providers were to withdraw or restrict their data, or if they fail to adhere to our quality control standards, and if we are unable to identify and contract with suitable alternative data suppliers and integrate these data sources into our service offerings, our ability to provide products and services to our members **or customers** would be materially and adversely impacted, resulting in a material adverse effect on our business, financial condition and results of operations.

We also integrate into our proprietary applications and use third-party software to maintain and enhance, among other things, content generation and delivery, and to support our technology infrastructure. Some of this software is proprietary and some is open source. Our use of third-party technologies exposes us to increased risks, including, but not limited to, risks associated with the integration of new technology into our solutions, the diversion of our resources from development of our own proprietary technology and our inability to generate revenue from licensed technology sufficient to offset associated acquisition and maintenance costs. These technologies may not be available to us in the future on commercially reasonable terms or at all and could be difficult to replace once integrated into our own proprietary applications. Our inability to obtain, maintain or comply with any of these licenses could delay development until equivalent technology can be identified, licensed and integrated, which would harm our business, financial condition and results of operations.

Most of our third-party licenses are non-exclusive and our competitors may obtain the right to access any of the technology covered by these licenses to compete directly with us. Our use of third-party technologies exposes us to increased risks, including, but not limited to, risks associated with the integration of new technology into our solutions, the diversion of our resources from development of our own proprietary technology and our inability to generate revenue from licensed technology sufficient to offset associated acquisition and maintenance costs. In addition, if our data suppliers choose to discontinue support of the licensed technology in the future, we might not be able to modify or adapt our own solutions.

Our use of "open source" software could adversely affect our ability to sell our products and subject us to possible litigation.

The products or technologies acquired, licensed or developed by us may incorporate so-called "open source" software, and we may incorporate open source software into other products in the future. There is little or no legal precedent governing the interpretation of many of the terms of certain of these licenses, and therefore the potential impact of these terms on our business is unknown and may result in unanticipated obligations or litigation regarding our products and technologies. For example, we may be subjected to certain conditions, including requirements that we offer our products that use particular open source software at no cost to the user, that we make available the source code for modifications or derivative works we create based upon, incorporating or using the open source software, and/or that we license such modifications or derivative works under the terms of the particular open source license. In addition, if we combine our proprietary software with open source software in a certain manner, under some open source licenses we could be required to release the source code of our proprietary software, which could substantially help our competitors develop products that are similar to or better than ours. If an author or other party that distributes such open source software ~~were~~ was to allege that we had not complied with the conditions of one or more of these licenses, we could be required to incur material legal costs defending ourselves against such allegations and could be subject to material damages.

Our use of artificial intelligence ("AI") technologies and the integration of AI technologies with our products and services may subject us to increased risk given the emerging nature of AI technologies and the evolving legal and regulatory framework relating to their use.

Our business increasingly relies on AI technologies to collect, aggregate, analyze and/or generate data or other materials or content. AI technology is highly complex and rapidly developing, and it is not possible for us to predict all of the legal, operational or technological risks that may arise relating to the use of AI. While AI and its uses are subject to a variety of existing laws and regulations, the legal and regulatory framework governing AI is rapidly evolving. In October 2023, President Biden issued the Executive Order on the Safe, Secure and Trustworthy Development and Use of Artificial Intelligence that established new standards for training, testing and cybersecurity of sophisticated artificial intelligence models, and directed federal agencies to promulgate additional regulations on the subject. Federal AI legislation has also been introduced in the U.S. Senate. Many other state and foreign government bodies and agencies have introduced or are currently considering new laws and regulations governing the use of AI technologies.

The adoption of new AI laws and regulations, or the interpretation of existing laws and regulations, could affect our development, use or commercialization of AI. We may not be able to anticipate how to respond to these rapidly evolving frameworks, and we may need to expend resources to adjust our products or services to meet new requirements. Failure to comply with such laws or regulations could subject us to legal or regulatory liability. The cost of complying with such laws or regulations could be significant and increase our operating expenses, which could have a material adverse effect on our business, financial condition and results of operations.

AI algorithms use machine learning and predictive analytics which may lead to flawed, biased, discriminatory, or inaccurate results, any of which may not be easily detectable by us. Such outcomes could potentially be in violation of existing or new laws or regulations governing AI and could potentially lead to other legal claims against us by third parties. There has recently been an increase in litigation in a number of jurisdictions, including the U.S., relating to the development, security and use of AI.

Our direct sourcing activities depend on contract manufacturing facilities located in various parts of the world, and any physical, financial, regulatory, environmental, labor or operational disruption or product quality issues could result in a reduction in sales volumes, the incurrence of substantial expenditures and the loss of product availability.

As part of our direct sourcing activities, we contract with manufacturing facilities in various parts of the world, including facilities in Bangladesh, Cambodia, Canada, China, India, Malaysia, Sri Lanka, Taiwan, Thailand, Turkey and Vietnam as well as domestically within the U.S. Operations at and securing products from these manufacturing facilities could be curtailed or partially or completely shut down as the result of a number of circumstances, most of which are outside of our control, such as but not limited to unscheduled maintenance, power conservation/shortages, an earthquake, hurricane, flood, tsunami or other natural disaster, material labor strikes or work stoppages, government implementation of export limitations or freezes, port or other shipping delays, political unrest or pandemics. We are also subject to some of these risks with manufacturers we contract with in the U.S. Any material curtailment of production at these facilities, or production issue resulting in a substandard product, could result in ~~litigation or governmental inquiry or materially~~ our inability to meet contractual sourcing commitments and reduced revenues and cash flows in our direct sourcing ~~activities~~ activities, and could result in ~~litigation or governmental inquiry arising from these circumstances~~. In addition, our business practices in international markets are subject to the requirements of the U.S. Foreign Corrupt Practices Act of 1977, as amended, any violation of which could subject us to material fines, criminal sanctions and other penalties. We expect all of our contracted manufacturing facilities to comply with all applicable laws, including labor, safety and environmental laws, and to otherwise meet our standards of conduct. Our ability to find manufacturing facilities that uphold these standards is a challenge, especially with respect to facilities located outside the U.S. We also are subject to the risk that one or more of these manufacturing facilities will engage in business practices in violation of our standards or applicable laws, which could damage our reputation and adversely impact our business and results of operations.

While we continue to promote domestic and geographically diverse manufacturing as part of our supply chain resiliency program, a material portion of the manufacturing for our direct sourcing activities is still conducted in China. As a result, our business, financial condition, results of operations and prospects are affected significantly by economic, political and legal developments in China as well as trade disputes between China and the U.S. and the potential imposition of bilateral tariffs. In addition, China has imposed export restrictions and new regulatory requirements on personal protective equipment, or PPE, and other medical equipment needed by our member hospitals. The imposition of tariffs or export restrictions on products imported by us from China could require us to (i) increase prices to our members or (ii) locate suitable alternative manufacturing capacity or relocate our operations from China to other countries. In the event we are unable to increase our prices or find alternative manufacturing capacity or relocate to an alternative base of operation outside of China on favorable terms, we would likely experience higher manufacturing costs and lower gross margins, which could have an adverse effect on our business

and results of operations. The Chinese economy differs from the economies of most developed countries in many respects, including the degree of government involvement, the level of development, the growth rate, the control of foreign exchange, access to financing and the allocation of resources.

Additionally, the facilities in Malaysia with which we contract are particularly susceptible to labor shortages, labor disputes and interruptions, rising labor costs as a result of minimum wage laws, scheduling and overtime requirements and forced or child labor.

Validation of our direct sourcing suppliers around the world can be challenging and our vetting process may not eliminate all associated risks, particularly since the information shared is largely dependent on the supplier level of transparency. If one or more of the manufacturing facilities we contract with engage in business practices in violation of our standards or applicable laws, we could experience damage to our reputation and suffer an adverse impact on our business, results of operations and reputation.

We may have inventory risk for product inventory we purchase at elevated market prices and items we purchase in bulk or pursuant to fixed price purchase commitments if we are unable to sell such inventory at or above our cost. As a result, we may experience a material adverse effect on our business, financial condition and results of operations.

From time to time, we purchase items as part of bulk purchases to resell to our members. We may have inventory risk for product inventory we purchase at elevated market prices and items we purchase in bulk or pursuant to fixed price purchase commitments if we are unable to sell such inventory at or above our cost. If we are unable to sell the products for more than our inventory cost, we could experience a material adverse effect on our business, financial condition and results of operations. In addition, as we strive to create a healthier global supply chain with more diversification in the country of origin, including a focus on supporting PPE and medical product manufacturing in the U.S. with our domestic sourcing initiatives, we may source more of our products from U.S.-based or near shore manufacturers, which may come at a higher acquisition cost than sourcing from Asia or other lower cost countries. If our GPO members are unwilling to pay higher prices for products made in the U.S. or near-shore locations, or if they choose to buy lower cost products manufactured in lower cost countries, now or in the future, this may impact our customer growth and results of operations if we have to lower prices to compete or sell our higher-cost inventory.

If we lose key personnel employees or if we are unable to attract, hire, integrate and retain key personnel, employees, our business would be harmed.

Our future success depends in part on our ability to attract, hire, integrate and retain key personnel, employees, including our executive officers, other senior leaders and other highly skilled technical, managerial, editorial, sales, marketing and customer service professionals. Competition for such personnel talented employees is intense and the labor market has tightened considerably in the last several recent years. We have from time to time in the past experienced, and we expect to continue to experience in the future, difficulty in hiring and retaining highly skilled talented employees with appropriate qualifications. Furthermore, We use equity awards as a key component of compensation for senior level employees in May 2023, we announced order to align employee interests with the interests of our stockholders, provide competitive compensation packages and encourage employee retention. Our stock price volatility or lack of positive performance may cause periods of time during which the value of equity awards might be less competitive, which may lessen the retentive attributes of these awards and cause the compensation that we are evaluating potential strategic alternatives which has the potential offer to discourage current personnel as well as prospective be less competitive. If we lose key employees from being a part of our Company. We unexpectedly, we cannot be certain of our ability to identify, hire and retain adequately qualified personnel, if we lose key personnel unexpectedly, replacement employees at or on a timely basis. In addition, to the extent we lose an executive officer or senior manager, leader, we may incur increased expenses in connection with the hiring, promotion or replacement of these individuals and the transition of leadership and critical knowledge. Failure to identify, hire and retain necessary key personnel talent could have a material adverse effect on our business, financial condition and results of operations.

Continued uncertain economic, political and other conditions, including inflation and the risk of a global recession recessionary fears, could impair our ability to forecast and may harm our business, operating results, including our revenue growth and profitability, financial condition and cash flows.

Continued global economic uncertainty, political conditions and fiscal challenges in the U.S. and abroad, such as inflation and potential economic the concern of slower growth or a recession, have, among other things, limited our ability to forecast future demand for our products and services, contributed to increased periodic volatility in customer demand, impacted availability of supplies and could constrain future access to capital for our suppliers, customers and partners. The impacts of these circumstances are global and pervasive, and the timing and nature of any ultimate resolution of these matters remain highly uncertain. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased trade sanctions, tariffs or other barriers to global trade, changes to fiscal and monetary policy and higher interest rates, could materially adversely impact the demand for our products and our operating results. Starting in fiscal 2022 We have been experiencing and continuing in fiscal 2023, we have experienced continue to experience inflationary pressure and other constraints in affecting both our supply chain. Supply Chain and Performance Services segments. Consequently, these concerns have challenged our business and we expect them to continue to challenge our business for the foreseeable future, which could cause harm to our operating results. Such conditions may result in the failure to meet our forecasted financial expectations and to achieve historical levels of revenue growth.

Our financial condition and results of operations for fiscal year 2023 and beyond may continue to be materially and adversely affected by future pandemics, epidemics or public health emergencies, such as emergencies.

The outbreak of the novel coronavirus ("COVID-19") and the resulting global pandemic,

and the impact on the healthcare industry impacted our sales, operations and supply chains, our members and other customers and workforce and suppliers. While both the U.S. and the World Health Organization declared an end to the COVID-19 pandemic as a public health emergency in May 2023, we remain subject to the potential risks associated with any future pandemic, epidemic or other public health emergency, and uncertain impacts those events could have on our business, result of operations, financial condition, cash flows and prospects of the health consequences for the U.S. population have been significantly mitigated by the availability trading price of vaccines and therapeutics to treat COVID-19 infections, our Class A Common Stock. Among other risks, future pandemics, epidemics or other public health emergencies have could lead to labor shortages, quarantines, travel and other restrictions, disruptions in the past global supply chain, financial and may continue operational harm to our members, customers and suppliers, and a general decline in the future to have adverse economic impacts both domestically overall U.S.

and internationally, including the potential for new worldwide economy and extended government imposed lock-downs, border restrictions and transportation capital markets. These and other bottlenecks.

As a result of future pandemics, epidemics or other public health emergencies our financial condition and results of operations may be adversely affected and we may face material risks due to a number of factors, including, but not limited to:

- Labor shortages in the healthcare workforce and corresponding increases in labor costs.
- Changes in the reduced demand for our products and services may create demand uncertainty from both material increases and decreases in demand and pricing or the ability of our members or other customers to pay for our products and services.
- Limited access to services, disruption in our members' facilities as well as travel restrictions limit their ability to participate in face-to-face events, such as committee meetings, operations and conferences, and limits our ability to foster relationships and effectively deliver existing or sell new products and services, to our members.
- Disruption to disruption in the global supply chain, particularly in China, may impact operation of suppliers that deliver products purchased by our members through our GPO or products contract manufactured through our direct sourcing business. Failure of our suppliers, contract manufacturers, distributors, contractors and other business partners to meet their obligations to our members and other customers, or to us, or material disruptions in their ability to do so due to their own financial or operational difficulties, may adversely impact our operations.
- We may continue to receive requests for contract modifications, payment waivers and deferrals, payment reductions or amended payment terms from our contract counterparties. We may continue to receive requests to delay service or payment adverse impacts on performance service contracts and we may continue to receive requests from our suppliers for increases to their contracted prices.
- A general decline in the overall economic and capital markets which could increase our cost of capital and adversely affect our ability to access the capital markets in the future.

The ultimate impact of pandemics, epidemics and public health emergencies on acceptable terms as may be needed for our business, results of operations, financial condition and cash flows is dependent on future developments, including the duration of any pandemic and the related length of its impact on the U.S. and global economies and their healthcare systems, which are uncertain and cannot be predicted at this time. The impact of pandemics, epidemics, another pandemic, epidemic or public health emergencies emergency may also exacerbate many of the other risks described in this "Risk Factors" section of the Annual Report. Despite our efforts to manage these impacts, their ultimate impact depends on factors beyond our knowledge or control, including the duration and severity of any outbreaks public health emergency and actions taken to contain its spread and mitigate its public health effects. The foregoing and other continued disruptions in our business as a result of pandemics, epidemics or public health emergencies could result in a material adverse effect on our business.

Our results of operations, financial condition, cash flows, prospects and the trading prices of our securities in the future.

We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, such as the ongoing military conflict between Russia and Ukraine and tensions between the U.S. and China, or weather events or natural disasters. Our business, financial condition and results of operations may be materially and adversely affected by any negative impact on the global economy and capital markets resulting from geopolitical tensions, events.

Geopolitical events such as war, terrorist activities, or civil unrest may disrupt or interrupt our operations or the operations of our vendors or other business partners. U.S. and global markets have continued to experience volatility and disruption as the result of current geopolitical tensions events, including the ongoing military conflict between Russia and Ukraine and the military conflict in the Middle East, as well as tensions between the U.S. and China. These geopolitical tensions issues have, and may continue to, lead to market disruptions, including significant volatility in commodity prices, energy, credit and capital markets, as well as supply chain interruptions, interruptions and increased transportation costs. In addition, further escalation in current or the development of new geopolitical issues could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional capital. These types of market and supply disruptions can similarly result from natural disasters such as hurricanes, tornadoes, floods, earthquakes and other severe weather and climate conditions (including those resulting from climate change). These events and circumstances could negatively impact our business, financial condition and results of operations.

We may be adversely affected by global climate change or by regulatory responses to such change.

Climate changes, such as change may lead to more frequent or more severe weather events or conditions, rising including sea temperatures and rising sea levels, among others, levels. The long-term impacts of climate change, including physical risks as well as the transition risks such as regulatory responses to climate change, are expected to be widespread and their long-term effects present potential negative effects to unpredictable. These impacts could adversely affect our business operations, financial condition and results of operations by decreasing availability of or increasing the costs of products and services, increasing compliance and operational costs and creating volatility and disruption to the global supply chain.

In addition, federal, state, and local governments could social attention to the issue new of climate change has resulted in both existing and pending international agreements and national, regional, or modify existing local legislation and regulations related regulatory measures to limit greenhouse gas emissions, such as cap and trade regimes, carbon taxes, restrictive permitting, increased fuel efficiency standards, and incentives or mandates for renewable energy, as well as legal and regulatory requirements requiring certain climate-related disclosures, and pressure from shareholders, ratings agencies, state agencies, the SEC, and other third parties to make various climate-related disclosures. We may also be subject to additional and more complex reporting requirements in the future relating to climate change.

Developments in climate change regulations are evolving, which may result in higher regulatory, compliance, credit, and these government actions reputational risks and costs. For example, the State of California recently passed the Climate Corporate Data Accountability Act and the Climate-Related Financial Risk Act that will impose broad climate-related disclosure obligations on companies doing business in California, including us. The SEC has also adopted rulemaking on climate change disclosures that could impact significantly increase compliance burdens and associated regulatory costs and complexity. Such measures have subjected us, and may subject our members, suppliers, to additional costs and restrictions and require significant operating and capital expenditures.

Increasing scrutiny and evolving expectations from customers, suppliers, regulators, investors, and other stakeholders with respect to our environmental, social and governance ("ESG") practices may impose additional costs on us or expose us to new or additional risks.

Companies are facing increasing scrutiny from regulators, investors, customers, suppliers, and other stakeholders related to their ESG practices. Investor advocacy groups, investment funds and influential investors are increasingly focused on these practices, especially as they relate to the environment, health and safety, diversity, labor conditions and human rights. Also, customers and suppliers may impose ESG-related requirements as a condition to doing business with us. Increased ESG-related compliance costs

could increase our overall operational costs. Failure to adapt to or comply with regulatory requirements or investor or other stakeholder expectations and standards, or our failure to meet our own ESG-related targets or goals that we publish, could negatively impact our reputation and our stock price. Similarly, our inability to meet any ESG-related conditions of customers or suppliers or other companies that we seek to do business with could have a material adverse impact on our business, financial condition, or results of operations. New government regulations could also result in new or more stringent forms of ESG oversight and expanding mandatory and voluntary reporting, diligence, and disclosure. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, share price, financial condition, or results of operations.

Risks Related to Healthcare, Health Information Technology and Employee Benefit Regulation Data Privacy Laws and Regulations

The healthcare industry is highly regulated. Any material changes in the political, economic or regulatory environment that affect the GPO business or the purchasing practices and operations of healthcare organizations, or that lead to consolidation in the healthcare industry, could reduce the funds available to providers to purchase our products and services or otherwise require us to modify our services.

Our business, financial condition and results of operations depend upon conditions affecting the healthcare industry generally and hospitals and health systems particularly, as well as our ability to increase the number of programs and services that we sell to our members and other customers. The life sciences and healthcare industry is highly regulated by federal and state authorities and is subject to changing political, economic and regulatory influences. Factors such as changes in reimbursement policies for healthcare expenses, consolidation in the healthcare industry, regulation, litigation and general economic conditions affect the purchasing practices, operations and the financial health of healthcare organizations. In particular, changes in regulations affecting the healthcare industry, such as increased regulation of the purchase and sale of medical products, tariffs, new quality measurement and payment models, data privacy and security, government price controls, modification or elimination of applicable regulatory safe harbors, regulation of third-party administrators or restrictions on permissible discounts and other financial arrangements, could require us to make unplanned modifications of our products and services, result in delays or cancellations of orders or reduce funds and demand for our products and services.

The Patient Protection and Affordable Care Act, ("ACA"), or ACA, designed to expand access to affordable health insurance, control healthcare spending and improve healthcare quality, set the industry moving in a clear direction on access to health insurance, payment, quality and cost management. In addition, many states have adopted or are considering changes in healthcare laws or policies in part due to state budgetary shortfalls.

Although there appears to be greater certainty and a continuation of the policies and directions set forth in the ACA with subsequent to the 2021 U.S. Supreme Court decision upholding the ACA and the stated priorities of the Biden administration, healthcare will continue to be a highly contentious area, particularly if the 2024 U.S. presidential election were to result in a change of administration. This environment is creating risks for healthcare providers and our business that could cause a material adverse effect on our business and financial performance.

If we fail to comply with complex federal and state laws and regulations governing financial relationships among healthcare providers and submission of false or fraudulent claims to government healthcare programs, we may be subject to civil and criminal penalties or loss of eligibility to participate in government healthcare programs.

Anti-Kickback Regulations

We are subject to federal and state laws and regulations designed to protect patients, government healthcare programs and private health plans from fraudulent and abusive activities. These laws include anti-kickback restrictions and laws prohibiting the submission of false or fraudulent claims. These laws are complex, and their application to our specific products, services and relationships may not be clear and may be applied to our business in ways that we do not anticipate. Federal and state regulatory and law enforcement authorities have over time increased enforcement activities with respect to Medicare and Medicaid fraud, waste and abuse regulations and other reimbursement laws and rules. From time to time, we and others in the healthcare industry have received inquiries or requests to produce documents in connection with such activities. We could be required to expend material time and resources to comply with these requests, and the attention of our management team could be diverted to these efforts. Furthermore, if we are found to be in violation of any federal or state fraud, waste and abuse laws, we could be subject to civil and criminal penalties and we could be excluded from participating in federal and state healthcare programs such as Medicare and Medicaid. The occurrence of any of these events could materially harm our business, financial performance and financial condition.

Provisions in Title XI of the Social Security Act, commonly referred to as the federal Anti-Kickback Statute, prohibit the knowing and willful offer, payment, solicitation or receipt of remuneration, directly or indirectly, in return for the referral of patients or arranging for the referral of patients, or in return for the recommendation, arrangement, purchase, lease or order of items or services that are covered, in whole or in part, by a federal healthcare program such as Medicare or Medicaid. The definition of "remuneration" has been broadly interpreted to include anything of value such as gifts, discounts, rebates, waiver of payments or providing anything at less than its fair market value. Many states have adopted similar prohibitions against kickbacks and other practices that are intended to influence the purchase, lease or ordering of healthcare items and services regardless of whether the item or service is covered under a governmental health program or private health plan. Although certain statutory and regulatory safe harbors exist, these safe harbors are narrow and often difficult to comply with. Congress

has appropriated an increasing amount of funds in recent years to support enforcement activities aimed at reducing healthcare fraud, waste and abuse. We operate our group purchasing services, pricing discount arrangements with suppliers, and revenue share arrangements with applicable members in reliance on certain of these safe harbors. We cannot assure you that our arrangements will be protected by such safe harbors or that such increased enforcement activities will not directly or indirectly have an adverse effect on our business, financial condition or results of operations. Any determination by a state or federal agency that any of our activities violate any of these laws could subject us to civil or criminal penalties, could require us to change or terminate some portions of our operations or business or could disqualify us from providing services to healthcare providers doing business with government programs and, thus, could have a material adverse effect on our business, financial condition and results of operations.

CMS has provided specific guidance on the proper treatment on Medicare cost reports of revenue distributions received from GPOs, including us. To assist our members that report their costs to Medicare to comply with these guidelines, such members are required under the terms of the Premier Group Purchasing Policy to appropriately reflect all elements of value received in connection with our IPO, including under agreements entered into in connection therewith, on their cost reports. We furnish applicable reports to such members setting forth the amount of such value, to assist their compliance with such cost reporting requirements. Any determination by a state or federal agency that the provision of such elements of value violate any of these laws could subject us to civil or criminal penalties, could require us to change or terminate some portions of our operations or business, or could disqualify us from providing services to healthcare providers doing business with government programs, and, thus could have a material adverse effect on our business, financial condition and results of operations.

There is no safe harbor to the Anti-Kickback Statute that is applicable in its entirety across all of the agreements with our members, and no assurance can be given that the U.S. Department of Health and Human Services, or HHS, Office of Inspector General (which administers the Anti-Kickback Statute) or other regulators or enforcement authorities will

agree with our assessment. Any determination by a state or federal agency that the terms, agreements and related communications with members, or our relationships with our members violates the Anti-Kickback Statute or any other federal or state laws could subject us to civil or criminal penalties, could require us to change or terminate some portions of our operations or business and could disqualify us from providing services to healthcare providers doing business with government programs and, thus, result in a material adverse effect on our business, financial condition and results of operations.

False Claims Regulations

Our business is also subject to numerous federal and state laws that forbid the submission or "causing the submission" of false or fraudulent information or the failure to disclose information in connection with the submission and payment of claims for reimbursement to Medicare, Medicaid, other federal healthcare programs or private health plans. In particular, the False Claims Act, or FCA, prohibits a person from knowingly presenting or causing to be presented a false or fraudulent claim for payment or approval by an officer, employee or agent of the U.S. In addition, the FCA prohibits a person from knowingly making, using, or causing to be made or used a false record or statement material to such a claim. Violations of the FCA may result in treble damages, material monetary penalties and other collateral consequences, potentially including exclusion from participation in federally funded healthcare programs. The minimum and maximum per claim monetary damages for FCA violations occurring on or after November 2, 2015 and assessed after **January 30, 2023** **February 12, 2024** are from **\$13,508** **\$13,946** to **\$27,018** **\$27,894** per claim, respectively, and will be periodically readjusted for inflation. If enforcement authorities find that we have violated the FCA, **it such violations** could have a material adverse effect on our business, financial condition and results of operations. Pursuant to the ACA, a claim that includes items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA.

These laws and regulations may change rapidly and it is **frequently** unclear how they apply to **various aspects** of our business. Errors created by our products or consulting services that relate to entry, formatting, preparation or transmission of claim or cost report information by our members may be determined or alleged to be in violation of these laws and regulations. Any failure of our businesses or our products or services to comply with these laws and regulations, or the assertion that any of our relationships with suppliers or members violated the Anti-Kickback Statute and therefore caused the submission of false or fraudulent claims, could (i) result in substantial civil or criminal liability, (ii) adversely affect demand for our services, (iii) invalidate all or portions of some of our member contracts, (iv) require us to change or terminate some portions of our business, (v) require us to refund portions of our services fees, (vi) cause us to be disqualified from serving members doing business with government payers, and (vii) have a material adverse effect on our business, financial condition and results of operations.

ERISA Regulatory Compliance

As a threshold matter, the obligation for compliance with the Employee Retirement Income Security Act of 1974, as amended, ("ERISA"), the Internal Revenue Code (the "Code"), the ACA, the Health Insurance Portability and Accountability Act (together with its amendments related to the Health Information Technology for Economic and Clinical Health Act, "HIPAA"), the Mental Health Parity and Addiction Equity Act, the Newborns' and Mothers' Health Protection Act, the Women's Health and Cancer Rights Act, the Consolidated Omnibus Budget Reconciliation Act ("COBRA"), the Genetic Information Nondiscrimination Act of 2008, and other laws governing self-funded group health plans (collectively "Employee Benefit Laws") generally rests with our clients as plan sponsors to whom we provide third-party administrative ("TPA") services. That is, employers/clients that sponsor group health plans generally bear the obligation of complying with Employee Benefit Laws,

rather than entities, like us, that provide TPA services related to the group health plans. In certain cases, however, TPAs to ERISA plans can become "co-fiduciaries" with their clients and, therefore, can be liable for ERISA compliance in a limited capacity. We could become a co-fiduciary either by (1) entering a contractual obligation to be an ERISA fiduciary or (2) by acting as an ERISA fiduciary based on functions performed. Under ERISA, fiduciary status flows from actions, and TPAs who exercise certain functions, including any discretionary authority or discretionary responsibility over plan administration or exercise any authority or control with respect to management or disposition of plan assets are generally "functional fiduciaries" with respect to (and limited to) the functions performed by the TPA that trigger fiduciary status.

We undertake no express liability under ERISA for our clients' ERISA-governed plans in our template **contracts**. **contracts**, and we generally do not act in fiduciary with respect to our clients' ERISA-governed plans. However, deviations from this standard language contained in final contracts could subject us to liability for breaches of fiduciary duty under ERISA (and related claims, such as ERISA prohibited transactions).

If current or future antitrust laws and regulations are interpreted or enforced in a manner adverse to us or our business, we may be subject to enforcement actions, penalties and other material limitations on our business.

We are subject to federal and state laws and regulations designed to protect competition which, if enforced in a manner adverse to us or our business, could have a material adverse effect on our business, financial condition and results of operations. Over the last decade or so, the group purchasing industry has been the subject of multiple reviews and inquiries by the U.S. Senate and its members with respect to antitrust laws. Additionally, the U.S. **General Accounting Government Accountability** Office, or GAO, has published several reports examining GPO pricing, contracting practices, activities and fees. We and several other operators of GPOs have responded to GAO inquiries in connection with the development of such reports. **Most recently, on February 14, 2024, the U.S. Federal Trade Commission ("FTC") and the U.S. Department of Health and Human Services issued a joint Request For Information ("RFI") for submission of comments regarding the impact of GPOs and wholesale drug distributors on access to generic pharmaceuticals. The comment period for the RFI expired on May 30, 2024.** No assurance can be given regarding any further inquiries or actions arising or resulting from these **comments**, **policy initiatives**, **examinations** and **reports**, or any related impact on our business, financial condition or results of operations.

Congress, the **DOJ**, **U.S. Department of Justice**, the **Federal Trade Commission**, or **FTC**, the U.S. Senate or another state or federal entity could at any time open a new investigation of the group purchasing industry, or develop new rules, regulations or laws governing the industry, that could adversely impact our ability to negotiate pricing arrangements with suppliers, increase reporting and documentation requirements, or otherwise require us to modify our arrangements in a manner that adversely impacts our business, financial condition and results of operations. We may also face private or government lawsuits alleging violations arising from the concerns articulated by these governmental factors or alleging violations based solely on concerns of individual private parties.

If we are found to be in violation of the antitrust laws, we could be subject to significant civil and criminal penalties or damages. The occurrence of any of these events could materially harm our business, financial condition and results of operations.

Complex international, federal and state privacy laws, as well as security and breach notification laws, may increase the costs of operation and expose us to civil and criminal government sanctions and third-party civil litigation.

We must comply with extensive federal and state requirements regarding the use, retention, security and re-disclosure of patient/beneficiary healthcare information. The Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which

we refer to collectively as "HIPAA," "HIPAA," contain substantial restrictions and complex requirements with respect to the use and disclosure of "Protected Health Information" as defined by HIPAA. The HIPAA Privacy Rule prohibits a covered entity or a business associate from using or disclosing Protected Health Information unless the use or disclosure is validly authorized by the individual or is specifically required or permitted under the HIPAA Privacy Rule and only if certain complex requirements are met. The HIPAA Security Rule establishes administrative, organizational, physical and technical safeguards to protect the privacy, integrity and availability of electronic Protected Health Information maintained or transmitted by covered entities and business associates. The HIPAA Breach Notification Rule requires that covered entities and business associates, under certain circumstances, notify patients/beneficiaries and HHS when there has been an improper use or disclosure of Protected Health Information.

Our self-funded health benefit plan for our employees, the Premier, Inc. Health & Welfare Plan, our healthcare provider members, Performance Services customers, and health plan clients are directly regulated by HIPAA as "covered entities." Most of our hospital members/customers and health plan clients disclose Protected Health Information to us so that we may provide payment and operations services. Accordingly, we are a "business associate" of those covered entities and are required to protect such Protected Health Information under HIPAA.

Any failure or perceived failure of our products or services to meet HIPAA standards and related regulatory requirements could expose us to certain notification, penalty and/or enforcement risks, damage our reputation, adversely affect demand for our products and services and/or force us to expend material capital, research and development and/or other resources to modify our products or services to ensure compliance with HIPAA.

In addition to our obligations under HIPAA, there are other federal and state laws that include specific privacy and security obligations, above and beyond HIPAA, for certain types of health information and/or personally identifiable information and may expose us to additional sanctions and penalties. All 50 states, the District of Columbia, Guam, Puerto Rico and the Virgin Islands have enacted various types of legislation requiring the protection of personally identifiable information and/or notice to individuals of security breaches of their identifiable information. Organizations must review each state's definitions, mandates and notification requirements and timelines to appropriately prepare and notify affected individuals and government agencies, including the attorney general in many states, in compliance with such state laws. Further, most states have enacted patient and/or beneficiary confidentiality laws that protect against the disclosure of confidential medical information, and many states have adopted or are considering adopting further legislation in this area, including privacy safeguards, security standards and special rules for so-called "sensitive" health information, such as mental health, genetic testing results, HIV status and biometric data. These state laws, if more stringent than HIPAA requirements, are not preempted by the federal requirements, and we are required to comply with them as well. The federal government also regulates the confidentiality of substance use disorder treatment records. These regulations, promulgated under 42 C.F.R. Part 2, apply to federally supported substance use disorder treatment programs and lawful holders of substance use disorder treatment records that originated from such programs. For some aspects of our business, we may be considered a lawful holder of treatment records protected under 42 C.F.R. Part 2 and therefore have responsibilities to protect substance use disorder treatment records in ways that go beyond the HIPAA requirements.

Data privacy laws and regulations are constantly evolving and can be the subject of significant change and/or interpretative application, and new laws and regulations continue to be proposed on both the state and national level. States continue to pass personal information privacy laws protecting its their resident consumers' data and affording individual rights, such as access, deletion and prevention of certain types of uses and disclosures of their personally identifiable information. These laws vary state-by-state and organizations must review each state's definitions and requirements to ensure compliance. Currently, various states, including California, Colorado, Connecticut, Indiana, Iowa, Kentucky, Maryland, Minnesota, Montana, Nevada, New Hampshire, New Jersey, Oregon, Tennessee, Texas, Utah, Vermont, Virginia and Virginia Washington have passed general data consumer privacy laws, while other states consider similar bills. While most data accessed or used by Premier is governed by HIPAA and is therefore exempt from many of the state general consumer privacy laws, various areas of Premier (such as marketing and human resources) may access or use data that may fall under one or more state general consumer privacy laws. Also, in April 2024, the U.S. Congress released a discussion draft of a national privacy bill with bipartisan and bicameral support, known as the American Privacy Rights Act ("APRA"). APRA would enact new customer data protections with respect to sensitive data, such as health, biometric and genetic data, and would impose new compliance obligations with respect to such data.

We are unable to predict what changes to HIPAA or other federal or state laws or regulations might be made in the future, what new laws or regulations may be enacted in the future, or how those changes or new laws or regulations could affect the demand for our products and services, our business or the associated costs of compliance.

Failure to comply with any of the international, federal and state standards regarding individuals' data rights privacy, identity theft prevention and detection and data security may subject us to penalties, including civil monetary penalties and, in some circumstances, criminal penalties. In addition, such failure may materially injure our reputation and adversely affect our ability to retain and attract new members or customers and, accordingly, adversely affect our financial performance.

New requirements

Requirements related to the interoperability of health information technology promulgated by the Office of the National Coordinator for Health Information Technology and enforced by the HHS Office of Inspector General could increase the costs of operation and expose us to civil government sanctions.

On May 1, 2020, the Office of the National Coordinator ("ONC") for Health Information Technology promulgated final regulations under the authority of the 21st Century Cures Act ("ONC Rules") to impose new which imposed conditions to obtaining and maintaining certification of certified health information technology and prohibit prohibited certain actors - developers of certified health information technology, health information networks, health information exchanges and healthcare providers - from engaging in activities that are likely to interfere with the access, exchange or use of electronic health information (information blocking). The final regulations further defined Under ONC Rules, certain exceptions to these considerations are permitted for certain activities, that are permissible, even though they may have the effect of interfering with the access, exchange or use of electronic health information. The information subject to the information blocking restrictions is limited to electronic individually identifiable health information to the extent that it would be included in a designated record set. Until October 6, 2022, In June 2023, the HHS Office of Inspector General released a final rule that incorporated civil monetary penalties of up to \$1.0 million per violation against developers of certified health information subject to the technology, health information networks or health information exchanges for activities that constitute information blocking restrictions is further limited to the data elements represented in the U.S. Core Data for Interoperability standard, that occur after September 1, 2023.

Under the ONC Rules, we are considered a "health IT developer" because of the government certifications we hold in our TheraDoc and eCQM solutions. As such, we have evaluated and assessed the applicability of the ONC Rules to our TheraDoc and eCQM solutions, and we have determined that the ONC Rules currently do not apply to the data we hold on TheraDoc and eCQM solutions because the data is not part of any designated record set. Further, our customers contractually agree that the data that we maintain and process on behalf of our customers does not qualify as a designated record set. We will continue to assess our products and services to discern whether or not they fall under the purview of the ONC Rules. On June 27, 2023, the HHS Office of Inspector General posted a final rule to incorporate its new civil monetary penalty authority for activities that constitute information blocking. Once effective, the HHS Office of Inspector General may impose information blocking penalties against developers of certified health information technology, health information networks or health information exchanges of up to \$1 million per violation. The HHS Office of Inspector General's civil monetary penalty authority for information blocking will begin 60 days after the final rule is published in the Federal Register. Any application of ONC Rules

or similar regulations to our business could adversely affect our financial results by increasing our compliance and operating costs, slowing our time to market for our solutions, and making it uneconomical to offer some products.

If we become subject or our suppliers fail to regulation by the comply with applicable Food and Drug Administration because the functionality in one ("FDA") laws and regulations with respect to certain products sold by our direct sourcing business or more if any of our software applications causes the software it to be regulated as a medical device, our financial results we may not be able to market these products and related services and may be adversely impacted due subject to increased operating costs stringent penalties, product restrictions or delayed commercialization recall.

Because certain of regulated software the products that we market and sell through our direct sourcing business are considered medical devices, our suppliers must comply with FDA requirements in the production, and we must comply with FDA regulations in the marketing and post-market monitoring of these products.

The Food These products have in the past and **Drug Administration ("FDA")** may in the future be subject to penalties, product restrictions or recall if we or our suppliers fail to comply with FDA requirements. In addition, the **FDA** has the authority to regulate products that meet the definition of a medical device under the Federal Food, Drug, and Cosmetic Act. To the extent that functionality or intended use in one or more of our current or future software products causes the software it to be regulated as a medical device under existing or future FDA laws or regulations, including the 21st Century Cures Act, which addresses, among other issues, the patient safety concerns generated by cybersecurity risks to medical devices and the interoperability between medical devices, we could be required to:

- to register our company and list our FDA-regulated products these software product(s) with the **FDA**;
- obtain pre-market **FDA** and undergo the applicable regulatory clearance from or approval process, which may require us to conduct clinical trials. There is risk that a software product that is considered a medical device may not be authorized by the **FDA** based on demonstration of substantial equivalence or that we may not be able to market the software product during the **FDA** review process. In addition, registering a legally marketed device before marketing our regulated products or obtain **FDA** approval by demonstrating software product with the safety and effectiveness of the regulated products prior to marketing;
- submit to inspections by the **FDA**; and
- comply with various **FDA** regulations, including the agency's quality system regulation, compliant handling and medical device reporting regulations, requirements for medical device modifications, increased rigor of the secure development life cycle in the development of medical devices and the interoperability of medical devices and electronic health records, requirements for clinical investigations, corrections and removal reporting regulations, and post-market surveillance regulations.

The **FDA** can impose extensive requirements governing pre- be a costly and post-market activities, such as clinical investigations involving timely endeavor, creating additional regulatory scrutiny for the use of a regulated product, **Company**, as well as conditions relating additional compliance requirements with **FDA** laws, regulations and guidance. Even after regulatory authorization, additional regulatory review may be required if a material change is made to clearance or approval, labeling and manufacturing of a regulated product. In addition, the **FDA** can impose extensive requirements governing development controls and quality assurance processes. **device**. Any application of **FDA** regulations to our business could therefore adversely affect our financial results by increasing our operating costs, slowing our time to market for regulated software products, subjecting us to additional government oversight and regulatory inspections and making it uneconomical to offer some those software products.

Legal and Tax-Related Risks

We are subject to litigation from time to time, which could have a material adverse effect on our business, financial condition and results of operations.

We participate in businesses and activities that are subject to substantial litigation. We are from time to time involved in litigation, which may include claims relating to contractual disputes, product liability, torts or personal injury, employment, antitrust, intellectual property or other commercial or regulatory matters. Additionally, if current or future government regulations are interpreted or enforced in a manner adverse to us or our business, specifically those with respect to antitrust or healthcare laws, we may be subject to enforcement actions, penalties, damages and other material limitations on our business.

Furthermore, as a public company, we may become subject to stockholder inspection demands under Delaware law, and derivative or other similar litigation that can be expensive, divert human and financial capital to less productive uses, and benefit a limited number of stockholders rather than stockholders at large. **The For example, as described in Part I, Item III of this Annual Report, the August 2020 Restructuring resulted in (i) the announcement of several investigations by private law firms of possible securities law violations; (ii) stockholder inspection demands seeking to investigate possible breaches of fiduciary duties; and (iii) the filing of a stockholder derivative complaint on March 4, 2022, captioned City of Warren General Employees' Retirement System v. Michael Alkire, et al., Case No. 2022-0207-JTL.** The complaint, purportedly brought on behalf of Premier, was filed in the Delaware Court of Chancery against our current and former Chief Executive Officers and current and certain former directors. We are were named as a nominal defendant in the complaint. **The lawsuit alleges that the named officers and directors breached their fiduciary duties and committed corporate waste by approving agreements between Premier and certain of the former LPs that provided for accelerated payments as consideration for the early termination of the tax receivable agreement ("TRA") with such LPs. (See "Item 3. Legal Proceedings".) The complaint asserts that the aggregate early termination payment amounts of \$473.5 million exceeded the alleged value of the tax assets underlying the TRA by approximately \$225.0 million. The complaint seeks unspecified damages, costs and expenses, including attorney fees, and declaratory and other equitable relief. Since the lawsuit is purportedly brought on behalf of Premier, and we are only a nominal defendant, the alleged damages were allegedly suffered by us. The City of Warren General Employees' Retirement System case, or any other matters referenced above that result This matter was settled in formal litigation, may have an adverse impact on our financial condition, reputation, results of operations or stock price.** **June 2024.**

From time to time, we have been named as a defendant in class action antitrust lawsuits brought by suppliers or purchasers of medical products. Typically, these lawsuits have alleged the existence of a conspiracy among manufacturers of competing products, distributors and/or operators of GPOs, including us, to deny the plaintiff access to a market for certain products, to raise the prices for products and/or to limit the plaintiff's choice of products to buy. No assurance can be given that we will not be subjected to similar actions in the future or that any such existing or future matters will be resolved in a manner satisfactory to us or which will not harm our business, financial condition or results of operations.

We may become subject to additional litigation or governmental investigations in the future. These claims may result in material defense costs or may compel us to pay material fines, judgments or settlements, which, if uninsured, could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition,

certain litigation matters could adversely impact our commercial reputation, which is critical for attracting and retaining customers, suppliers and member participation in our GPO programs. Further, stockholder and other litigation may result in adverse investor perception of our company, negatively impact our stock price and increase our cost of capital.

Failure to protect our intellectual property and claims against our use of the intellectual property of third parties could cause us to incur unanticipated expense and prevent us from providing our products and services, which could adversely affect our business, financial condition and results of operations.

Our success depends in part upon our ability to protect our core technology and intellectual property. To accomplish this, we rely on a combination of intellectual property rights, including trade secrets, copyrights and trademarks, as well as customary contractual and confidentiality protections and internal policies applicable to employees, contractors, members, **customers** and business partners. These protections may not be adequate, however, and we cannot assure you that they will prevent misappropriation of our intellectual property. In addition, parties that gain access to our intellectual property might fail to comply with the terms of our agreements and policies and we may not be able to enforce our rights adequately against these parties. The disclosure to, or independent development by, a competitor of any trade secret, know-how or other technology not protected by a patent could materially and adversely affect any competitive advantage we may have over such competitor. The process of enforcing our intellectual property rights through legal proceedings would likely be burdensome and expensive and our ultimate success cannot be assured. Our failure to adequately protect our intellectual property and proprietary rights could adversely affect our business, financial condition and results of operations.

In addition, we could be subject to claims of intellectual property infringement, misappropriation or other intellectual property violations as our applications' functionalities overlap with competitive products, and third parties may claim that we do not own or have rights to use all intellectual property used in the conduct of our business or acquired by us. We could incur substantial costs and diversion of management resources defending any such claims. Furthermore, a party making a claim against us could secure a judgment awarding substantial damages as well as injunctive or other equitable relief that could effectively block our ability to provide products or services. Such claims also might require indemnification of our members **or other customers** at material expense.

A number of our contracts with our members **or other customers** contain indemnity provisions whereby we indemnify them against certain losses that may arise from third-party claims that are brought in connection with the use of our products.

Our exposure to risks associated with the protection and use of intellectual property may be increased as a result of acquisitions, as we have limited visibility into the development process of acquired entities or businesses with respect to their technology or the care taken by acquired entities or businesses to safeguard against infringement risks. In addition, third parties may make infringement and similar or related claims after we have acquired technology that had not been asserted prior to our acquisition thereof.

If we

Our products and services are required subject to collect gross receipt taxes in some states, and an increase in those taxes or the imposition of additional gross receipt or sales and use taxes on the our products and services we sell in certain jurisdictions or online, we may be subject to tax liability for past sales, future sales may decrease and other states could have a material adverse effect on our business, financial condition may be materially and adversely affected, or results of operations.

Sales Certain states impose a gross receipts tax **is currently not imposed** on the administrative fees we collect in connection with our GPO programs. If **sales** the amount of gross receipts taxes that we have to pay were to materially increase, either because a gross receipts tax **were** was imposed **in the future** on such fees, by more states and/or at a higher tax rate than currently applicable, the profitability of our GPO programs **may** could be materially and adversely affected.

Rules and regulations applicable **affected** as these amounts are not directly passed through to our customers. We do not pay or collect any sales and use **tax** vary materially by tax jurisdiction. In addition, the applicability of these rules given the nature of or similar taxes in any states based on our belief that our products and services **are not** subject to change.

We **may lose** such taxes in any states. If we were to become obligated to collect sales or incur material costs should **various tax jurisdictions** and use taxes in any states in connection with our GPO programs, the imposition of these taxes could also harm our business by potentially leading to a decrease in sales and the profitability of our GPO programs. Our business could similarly be **successful** in **imposing** **harmed** if states seek to impose gross receipts or sales and use taxes on a broader range of products and services than those currently so taxed, including products and services sold online.

The imposition by states of indirect taxes, such as gross receipts taxes and sales and use taxes, is a complex and evolving issue. The laws and regulations governing these taxes vary materially by tax jurisdiction and are subject varying and changing interpretations. Their applicability to our products and services requires significant judgment on an ongoing basis. Taxing authorities in states where we do not pay gross receipts taxes and do not collect sales and use taxes on our products and services could assert that such taxes are applicable.

We cannot assure you that we will not be subject to gross receipts or sales and use taxes in states where we currently believe no such taxes are required. We have previously identified certain jurisdictions where we now believe we may have been obligated to, but did not pay gross receipts taxes and are taking steps necessary to remediate those deficiencies. A successful assertion by one or more taxing authorities that we should pay gross receipts taxes or collect sales and use or other taxes on the **sale** of our **solutions** sales we have deemed nontaxable could result in substantial tax liabilities for past and future sales, decrease our ability to compete and otherwise harm our business.

If one or more taxing authorities determines that taxes should have, but have not, been paid with respect to our products and services, including products and services sold online, we **may be liable** for past taxes in addition to taxes going forward. Liability for past taxes may also include **very** substantial interest and penalty **charges**, **charges** as well as **audit** **defense costs**. If we are required to collect and pay back taxes (and **the** **any** associated interest and penalties) and if our members fail or refuse to reimburse us for all or a portion of these amounts, we will have incurred unplanned costs that may be substantial. Moreover, imposition of such taxes on our services going forward **will** could effectively increase the cost of such services to our members and may adversely affect our ability to retain existing members or to gain new members in the areas in which such taxes are imposed.

Changes in tax laws could materially impact our effective tax rate, income tax expense, anticipated tax benefits, deferred tax assets, cash flows and profitability.

Continued economic and political conditions in the U.S. could result in changes in U.S. tax laws beyond those enacted in connection with the **TCJA** Tax Cuts and Jobs Act ("TCJA") on December 22, 2017 and the Coronavirus Aid, Relief, and Economic Security Act ("CARES") on March 27, 2020. Further changes to U.S. tax laws could impact how U.S. corporations are taxed. Although we cannot predict whether or in what form such changes will pass, if enacted into law, they could have a material impact on our effective tax rate, income tax expense, ability to fully realize anticipated tax benefits that correspond to our fixed payment obligations associated with the acceleration of our **TRA**, **tax receivable agreement**, deferred tax assets, results of operations, cash flows and profitability.

A loss of a major tax dispute could result in a higher tax rate on our earnings, which could result in a material adverse effect on our financial condition and results of operations.

Income tax returns that we file are subject to review and examination. We recognize the benefit of income tax positions we believe are more likely than not to be sustained upon challenge by a tax authority. If any tax authority successfully challenges our positions or if we lose a material tax dispute, our effective tax rate on our earnings could increase substantially and result in a material adverse effect on our financial condition.

Risks Related to Our Corporate Structure

Payments required under the Unit Exchange and Tax Receivable Acceleration Agreements (the "Unit Exchange Agreements") entered into in connection with the August 2020 Restructuring will continue to reduce the amount of overall cash flow that would otherwise be available to us. In addition, we may not be able to realize all or a portion of the expected tax benefits that correspond to our fixed payment obligations associated with the August 2020 early termination and acceleration of our TRA, the then-existing Tax Receivable Agreement ("TRA") with certain member-owners pursuant to the Unit Exchange Agreements.

We entered into the Unit Exchange and Tax Receivable Acceleration Agreements effective as of July 1, 2020 (the "Unit Exchange Agreements"), in July 2020, with a substantial majority of our member-owners. Pursuant to the terms of the Unit Exchange Agreements, we elected to terminate the then-existing TRA with those member-owners upon payment to the those member-owners of the discounted present value of the tax benefit payments otherwise owed to them over a 15-year period under the TRA. As a result of the acceleration and termination of the TRA, we are obligated agreed to pay our member-owners approximately \$472.6 million in aggregate. Of that amount, an aggregate of \$201.2 million \$101.5 million remains payable in equal quarterly installments through the quarter ending June 30, 2025. Due to the payments required under the Unit Exchange Agreements, our overall cash flow and discretionary funds will be reduced, which may limit our ability to execute our business strategies or deploy capital for preferred use. In addition, if we do not have available capital on hand or access to adequate funds to make these required payments, our financial condition would be materially adversely impacted.

The payments required upon termination of the TRA are based upon the present value of all forecasted future payments that would have otherwise been made under the TRA. These payments are fixed obligations of ours and could ultimately exceed the actual tax benefits that we realize. Additionally, if our actual taxable income were insufficient or there were adverse changes in applicable law or regulations, we may be unable to realize all or a portion of these expected benefits and our cash flows and stockholders' equity could be negatively affected.

Our certificate of incorporation and bylaws and provisions of Delaware law may discourage or prevent strategic transactions, including a takeover of our company, even if such a transaction would be beneficial to our stockholders.

Provisions contained in our certificate of incorporation and bylaws and provisions of the Delaware General Corporation Law, or DGCL, could delay or prevent a third party from entering into a strategic transaction with us, even if such a transaction would benefit our stockholders. For example, our certificate of incorporation and bylaws:

- divide our Board of Directors into three classes with staggered three-year terms, which may delay or prevent a change of our management or a change in control;
- authorize our Board of Directors to issue "blank check" preferred stock in order to increase the aggregate number of outstanding shares of capital stock and thereby make a takeover more difficult and expensive;
- do not permit cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;
- do not permit stockholders to take action by written consent;
- provide that special meetings of the stockholders may be called only by or at the direction of the Board of Directors, the chair of our Board of Directors or the chief executive officer;
- require advance notice to be given by stockholders of any stockholder proposals or director nominees;
- require a super-majority vote of the stockholders to amend our certificate of incorporation; and
- allow our Board of Directors to make, alter or repeal our bylaws but only allow stockholders to amend our bylaws upon the approval of 66 2/3% or more of the voting power of all of the outstanding shares of our capital stock entitled to vote.

In addition, we are subject to the provisions of Section 203 of the DGCL which limits, subject to certain exceptions, the right of a corporation to engage in a business combination with a holder of 15% or more of the corporation's outstanding voting securities or certain affiliated persons.

These restrictions could limit stockholder value by impeding the sale of our company and discouraging potential takeover attempts that might otherwise be financially beneficial to our stockholders.

Risks Related to Our Capital Structure, Liquidity and Class A Common Stock

We may not realize anticipated benefits of our share repurchase authorization, and failure to fully utilize the authorization after its announcement may negatively impact the price of our Class A common stock.

On February 2, 2024, our Board of Directors authorized the repurchase of up to \$1.0 billion of our outstanding shares of Class A common stock. On February 5, 2024, under the share repurchase authorization, we entered into an accelerated share repurchase agreement to repurchase an aggregate of \$400.0 million of shares of our Class A common stock. Under the terms of the agreement, we made a payment of \$400.0 million to Bank of America in February 2024, and in February and July 2024 we received (and retired) an aggregate of 19.9 million shares of our Class A common stock as full settlement of the accelerated share repurchase transaction.

As of the date of this Annual Report, we have not made any repurchases pursuant to the share repurchase authorization other than pursuant to the accelerated share repurchase transaction described above. As a result, we may repurchase up to \$600 million more shares of Class A common stock pursuant to the authorization. However, we are not obligated to repurchase any additional shares, and the timing, manner, and volume of further share repurchases, if any, will be determined at management's discretion, based on market conditions, the market price of the Class A common stock, applicable legal requirements, potential alternative opportunities for investment of capital and other factors. The

repurchase program may be limited, suspended or discontinued at any time without prior notice. The timing of additional repurchases pursuant to the authorization, if any, could affect our stock price and increase its volatility. In addition, the existence of a share repurchase program could cause our stock price to be higher than it would be in the absence of such a program and could potentially reduce the market liquidity for our stock. We cannot guarantee that we will repurchase any additional shares, and there can be no assurance that any share repurchases will enhance stockholder value because the stock price of our common stock may decline below the levels at which we effect repurchases, and short-term stock price fluctuations could reduce the effectiveness of the repurchase program.

Repurchasing our Class A common stock reduces the amount of cash we have available to fund working capital, capital expenditures, strategic acquisitions or investments, other business opportunities, and other general corporate projects. We may need to use borrowings under our existing credit facility to consummate further share repurchases.

We may need to obtain additional financing which may not be available or may be on unfavorable terms and result in dilution to, or a diminution of the rights of, our stockholders and cause a decrease in the price of our Class A common stock.

We may need to raise additional funds in order to, among other things:

- finance unanticipated working capital requirements;
- develop or enhance our technological infrastructure and our existing products and services;
- fund strategic relationships;
- comply with new laws, regulations, rules or judicial orders;
- respond to competitive pressures; and/or
- acquire complementary businesses, assets, technologies, products or services.

Additional financing may not be available on terms favorable to us, or at all. If adequate funds are not available or are not available on acceptable terms, our ability to fund our expansion growth strategy, repurchase shares of Class A common stock under our share repurchase program, take advantage of unanticipated opportunities, develop or enhance technology or services or otherwise respond to competitive pressures would be materially limited. If we raise additional funds by issuing equity or convertible debt securities, our then-existing stockholders may be diluted and holders of these newly issued securities may have rights, preferences or privileges senior to those of our then-existing stockholders. The issuance of these securities may cause a material decrease in the trading price of our Class A common stock or the value of your investment in us.

If we cannot Our inability to refinance or replace our existing credit facility at or before maturity it could have a material adverse effect on our ability to fund our ongoing cash requirements. Current or future indebtedness could adversely affect our business and our liquidity position.

We have a five-year \$1 billion unsecured revolving credit facility (the "Credit Facility"), with a maturity date of December 12, 2027. As of ~~June 30, 2023~~ June 30, 2024, we had \$215.0 million ~~there were no borrowings~~ outstanding under the Credit Facility and any outstanding indebtedness would be payable on or before that date. If we are not able Facility. Our ability to refinance or replace our Credit Facility at or before maturity or do so on acceptable terms ~~it would~~ could have a material adverse effect on our ability to fund our ongoing working capital requirements, business strategies, acquisitions and related business investments, future cash dividend payments, if any, or repurchases of Class A common stock under any ~~then existing~~ then-existing or future stock repurchase programs, if any.

Our indebtedness may increase from time to time in the future for various reasons, including fluctuations in operating results, capital expenditures and potential acquisitions. Any indebtedness we incur and restrictive covenants contained in the agreements related thereto could:

- make it difficult for us to satisfy our obligations, including making interest payments on our other debt obligations;
- limit our ability to obtain additional financing to operate our business;
- require us to dedicate a substantial portion of our cash flow to payments on our debt, reducing our ability to use our cash flow to fund capital expenditures and working capital and other general operational requirements;
- limit our flexibility to execute our business strategy and plan for and react to changes in our business and the healthcare industry;
- place us at a competitive disadvantage relative to some of our competitors that have less debt than us;
- limit our ability to pursue acquisitions; and
- increase our vulnerability to general adverse economic and industry conditions, including changes in interest rates or a downturn in our business or the economy.

The occurrence of any one of these events could cause us to incur increased borrowing costs and thus have a material adverse effect on our cost of capital, business, financial condition and results of operations or cause a material decrease in our liquidity and impair our ability to pay amounts due on our indebtedness.

Our Credit Facility contains, among other things, restrictive covenants that will limit our and our subsidiaries' ability to finance future operations or capital needs or to engage in other business activities. The Credit Facility restricts, among other things, our ability and the ability of our subsidiaries to incur additional indebtedness or issue guarantees, create liens on our assets, make distributions on or redeem equity interests, make investments, transfer or sell properties or other assets, and engage in mergers, consolidations or acquisitions. Furthermore, the Credit Facility includes cross-default provisions and requires us to meet specified financial ratios and tests. In addition, any debt securities we may issue or indebtedness we incur in the future may have similar or more restrictive financial or operational covenants that may limit our ability to execute our business strategies or operate our Company.

Our quarterly revenues and results of operations have fluctuated in the past and may continue to fluctuate in the future, which could adversely affect the value of our Class A common stock, our revenues and our liquidity.

Fluctuations in our quarterly results of operations may be due to a number of factors, some of which are not within our control, including:

- our ability to offer new and innovative products and services;
- regulatory changes, including changes in healthcare laws;
- unforeseen legal expenses, including litigation and settlement costs;

- the purchasing and budgeting cycles of our members; members and other customers;
- the lengthy sales cycles for our products and services, which may cause material delays in generating revenues or an inability to generate revenues;
- pricing pressures with respect to our future sales;
- the timing and success of new product and service offerings by us or by our competitors;
- fluctuations in customer demand for enterprise licenses or SaaS-based subscriptions to our analytics technology; and the timing of enterprise analytics license agreements;
- member decisions regarding renewal or termination of their contracts and the timing of these decisions, especially those involving our larger member relationships;
- the amount and timing of costs related to the maintenance and expansion of our business, operations and infrastructure;
- the amount and timing of costs related to the development, adaptation, acquisition, or integration of acquired technologies or businesses;
- the financial condition of our current and potential new members; members and other customers;
- general economic and market conditions and economic conditions specific to the healthcare industry;
- the amount and timing of any write-offs of impaired assets recorded in connection with acquisitions and investments;
- the amount and timing of expenses related to significant, unusual or discrete events, which are recorded in the period in which the events occur, including litigation or other dispute-related settlement payments;
- technical difficulties or interruptions in our services; and
- the impact of potential any future pandemics, epidemics or public health emergencies including the COVID-19 pandemic and any variants, on the economy and healthcare industry.

Our quarterly results of operations may vary materially in the future and period-to-period comparisons of our results of operations may not be meaningful. You should not rely on the results of one quarter as an indication of future performance. If our quarterly results of operations fall below the expectations of securities analysts or investors, the price of the Class A common stock could decline substantially. In addition, any adverse impacts on the Class A common stock may harm the overall reputation of our organization, cause us to lose members or customers and impact our ability to raise additional capital in the future.

If we fail to maintain an effective system of integrated internal controls, we may not be able to report our financial results accurately, we may determine that our prior financial statements are not reliable, or we may be required to expend material financial and personnel resources to remediate any weaknesses, any of which could have a material adverse effect on our business, financial condition and results of operations.

Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be evaluated frequently. Section 404 of the Sarbanes-Oxley Act requires public companies to conduct an annual review and evaluation of their internal controls and attestations of the effectiveness of internal controls by independent auditors. Maintaining effective internal controls has been and will continue to be costly and may divert management's attention.

We have identified material weaknesses in our internal controls over financial reporting in the past. Our future evaluation of our internal controls over financial reporting may identify additional material weaknesses that may cause us to (i) be unable to report our financial information on a timely basis or (ii) determine that our previously issued financial statements should no longer be relied upon because of a material error in such financial statements, and thereby result in adverse regulatory consequences, including sanctions by the SEC, violations of NASDAQ listing rules or stockholder litigation. In the event that we identify a material weakness in our internal control over financial reporting that resulted in an error in previously-reported financial statements, we may need to amend previously reported such financial statements, and will we would be required to implement a remediation plan to address the identified weakness, which will would likely result in our expending material financial and personnel resources to remediate the identified weakness. There also resources. The occurrence of such events could be result in a negative reaction in the financial markets due to a loss of investor confidence in us and the reliability of our financial statements. Confidence in the reliability of our financial statements, also could suffer if we or our independent registered public accounting firm were to report a material weakness in our internal controls over financial reporting. The occurrence of any of these events could materially adversely affect our business, financial condition and results of operations and could also lead to a decline in the price of our Class A common stock.

There can be no assurance we will pay dividends on our Class A common stock at current levels or at all, and failure to pay any such dividends could have a material adverse impact on our stock price and your investment in Premier.

Since September 2020, we have paid quarterly cash dividends on our Class A common stock. The continued payment of dividends and the rate of any such dividends will be at the discretion of our Board of Directors after taking into account various factors, including our business, operating results and financial condition, current and anticipated capital requirements and cash needs, plans for expansion and any legal or contractual limitations on our ability to pay dividends. If we cease paying dividends, we could experience a material adverse impact on our stock price and your investment may could materially decline, and as a result, capital appreciation in the price of our Class A common stock, if any, may be your only source of gain on an investment in our Class A common stock.

Our future issuance of common stock, preferred stock, limited partnership units or debt securities could have a dilutive effect on our common stockholders and adversely affect the market value of our Class A common stock.

In the future, we could issue a material number of shares of Class A common stock, which could dilute our existing stockholders materially and have a material adverse effect on the market price for the shares of our Class A common stock. Furthermore, the future issuance of shares of preferred stock with voting rights may adversely affect the voting power of our common stockholders, either by diluting the voting power of our common stock if the preferred stock votes together with the common stock as a single class or by giving the holders of any such preferred stock the right to block an action on which they have a separate class vote even if the action were approved by the holders of our common stock. The future issuance of shares of preferred stock with dividend or conversion rights, liquidation preferences or other economic terms favorable to the holders of preferred stock could adversely affect the market price for our Class A common stock by making an investment in the Class A common stock less attractive. In addition to potential equity issuances described above, we also may issue debt securities that would rank senior to shares of our Class A common stock.

Upon our liquidation, holders of our preferred shares, if any, and debt securities and instruments will receive a distribution of our available assets before holders of shares of our Class A common stock. We are not required to offer any such additional debt or equity securities to existing stockholders on a preemptive basis. Therefore, additional issuances of

our Class A common stock, directly or through convertible or exchangeable securities, warrants or options, will dilute the holders of shares of our existing Class A common stock and such issuances, or the anticipation of such issuances, may reduce the market price of shares of our Class A common stock. Any preferred shares, if issued, would likely have a preference on distribution payments, periodically or upon liquidation, which could limit our ability to make distributions to holders of shares of our Class A common stock. Because our decision to issue debt or equity securities or otherwise incur debt in the future will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future capital raising efforts.

Item 1B. Unresolved Staff Comments

None.

Item 1C. Cybersecurity

Risk Management Strategy

We have a comprehensive cybersecurity risk management strategy to assess, identify, and manage material risks from cybersecurity threats. The core of this strategy is our digital risk and security program, which is integrated into our overall enterprise risk framework and is based on industry standards and established frameworks such as National Institute of Standards and Technology (NIST) and other guidelines. Our program is designed to help protect our systems, data, and operations from potential cyber threats, ensure the continuity of business operations, ensure we comply with applicable privacy and other laws and regulations, and meet our commitments to our members, customers, suppliers, employees, and other stakeholders.

We employ a comprehensive, cross-functional approach to our cybersecurity strategy across our technology, legal, compliance, risk, finance, and other teams to assess, identify, and manage cybersecurity threats and respond to cybersecurity incidents when they occur. This integration helps ensure that the breadth of potential impacts from cybersecurity risks are considered and that our approach to managing these risks is consistent and coordinated across teams within our business. Through our digital risk and security program, our cybersecurity risk is regularly evaluated, and we regularly report this assessment of our cybersecurity risk to our executive management team and to the Audit and Compliance Committee and the Board of Directors.

We have devoted, and expect to continue devoting, significant financial and personnel resources to maintain and improve our digital risk and security program.

Cybersecurity Tools

Our digital risk and security program deploys technical safeguards designed to help protect our information systems from cybersecurity threats. Such safeguards are regularly evaluated and improved based on vulnerability assessments, cybersecurity threat intelligence and incident response experience.

Risk Assessment; Third Party Assessments and Audits

We use a combination of internal resources and external assessors, consultants, and auditors to conduct our cybersecurity risk assessments. At least annually, we conduct cybersecurity risk assessments that take into account information from internal stakeholders, known information security vulnerabilities, and information from external sources (e.g., reported security incidents that have impacted other companies, industry trends, and evaluations by third parties and consultants). We examine our cybersecurity controls, capabilities, programs, operating effectiveness, and incident response preparedness against industry standards and established frameworks, such as NIST and other guidelines. These assessments, which include third party audits for certain aspects of our cybersecurity, examine our end-to-end security practices, including data centers, infrastructure, and operations, and cover both physical as well as digital environments. Material results of assessments and audits are reported to our executive management team, the Audit and Compliance Committee, and the Board of Directors. The results of the assessment and audits are used to drive alignment on, and prioritization of, initiatives to enhance our cybersecurity, and we seek to adjust our cybersecurity strategies and resources accordingly. We have also obtained certain industry certifications and attestations that demonstrate our dedication to protecting the data our members, customers, suppliers, employees, and other stakeholders.

Incident Response Planning

We have established an Incident Response Policy for identifying, responding to, containing, eradicating, and recovering from security breaches and other cybersecurity incidents, as well as communicating with relevant stakeholders. Our Incident Response Policy sets forth incident response and communication responsibilities for our employees, management, and Board of

Directors. We regularly test and evaluate the effectiveness of the policy as part of our cybersecurity assessments described above.

Third-Party Vendors

We have implemented controls designed to identify and mitigate cybersecurity threats associated with our use of third-party service providers, suppliers, and other vendors. We use a variety of inputs in such risk assessments, including information supplied by vendors and in some cases attestations from objective, reputable, and licensed assessors. Where appropriate, our contracts with vendors require agreement and adherence to commercially reasonable security, confidentiality, and privacy contractual terms. Vendors are subject to security risk assessments at the time of onboarding and are thereafter periodically monitored and reassessed depending on risk level and our cybersecurity practices and in light of evolving cybersecurity standards and legal and regulatory requirements.

Education and Awareness

We promote a culture of security awareness among our employees, and our policies require each of our employees to contribute to our cybersecurity efforts. We regularly remind employees of the importance of handling and protecting the data of members, customers, suppliers, employees and others, including through our Security Awareness Training Program delivered to new hires and on an annual basis. This training, which includes "phishing" exercises, is designed to enhance employee awareness of how to detect, respond to, and report potential cybersecurity threats as well as best behavioral practices to mitigate the risk of becoming subject to a cybersecurity incident.

Governance

Board of Directors Oversight

The Board of Directors considers cybersecurity risk as part of its risk oversight function and has delegated oversight of cybersecurity and other information technology risks to the Audit and Compliance Committee. The Audit and Compliance Committee oversees the development, implementation, and effectiveness of our strategies to monitor, mitigate, and respond to cybersecurity risks, as well as our procedures, policies and resources for risk assessment and risk management. In this role, the Audit and Compliance Committee receives updates from management on these matters, including the results of risk assessments and audits and the progress of risk reduction initiatives, on a quarterly basis or more frequently as needed. In addition, management updates the Audit and Compliance Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser potential impact.

The full Board of Directors receives updates from the Audit and Compliance Committee on its oversight of cybersecurity risk on a quarterly basis or more frequently as needed. In addition, the full Board of Directors also receives periodic briefings from management on the digital risk and security program.

Management's Role

Our Chief Information Security Officer, Chief Privacy Officer, and Vice President, Risk Management and Compliance work in collaboration as our Digital Risk Management ("DRM") group and have primary responsibility for our digital risk and security program. These individuals have extensive experience in their roles at the Company and in prior roles at other companies in the areas of information technology and security, data protection and privacy, and risk management and compliance, respectively. The members of the DRM group, among other things, continuously review and evaluate our cybersecurity risks to: identify technical and business risks; assess the potential impacts of identified risks; develop mitigation strategies to control or reduce risk where needed; communicate to others to ensure that risk owners and stakeholders as well as executive leadership have visibility into identified risks; and monitor identified risks and applicable risk response efforts.

On a daily basis, our information technology team monitors, identifies, and classifies potential cybersecurity incidents or threats and is responsible for notifying members of the DRM group of such matters as appropriate based on risk to our organization. Upon learning of any material incidents or threats, the members of the DRM group are responsible for informing our executive leadership, other functional teams, and the Audit and Compliance Committee or Board of Directors, as appropriate.

Risks from Cybersecurity Threats

As of the date of this report, we are not aware of any cybersecurity threats that have materially affected or are reasonably likely to materially affect our business strategy, results of operations or financial condition; however, see "Item 1A. Risk Factors" in this Annual Report for a discussion of effects that a cybersecurity threat or incident could have on our business strategy, results of operations or financial condition. We cannot provide assurances that we will not experience cybersecurity incidents in the future or that any future cybersecurity incidents will not materially affect us, including our business strategy, results of operations, or financial condition.

Item 2. Properties

As of **June 30, 2023** **June 30, 2024**, we occupy our Charlotte, North Carolina headquarters under a **long-term** lease which expires in 2026 and includes options for us, at our discretion, to renew the lease for up to 15 years in total beyond that date. We also lease or sublease nine smaller facilities across **five** **six** states, which includes our New York, New York office which we occupy under a **long-term** lease which expires in 2026. We believe that our headquarters, as well as our smaller leased facilities, are suitable for our use and are, in all material respects, adequate for our present and expected needs, and will continue to evaluate our real estate needs.

We generally conduct the operations of our Supply Chain Services segment and our Performance Services segment across our property locations. See Note 17 - Commitments and Contingencies to the accompanying consolidated financial statements for more information about our operating leases.

Item 3. Legal Proceedings

We operate businesses that are subject to substantial litigation from time to time. We are periodically involved in litigation, arising in the ordinary course of business or otherwise, which from time to time may include claims relating to contractual disputes, product liability, tort or personal injury, employment, antitrust, intellectual property or other commercial or regulatory matters. If current or future government regulations are interpreted or enforced in a manner adverse to us or our business, including without limitation those with respect to antitrust or healthcare laws, we may be subject to enforcement actions, penalties, damages and material limitations on our business.

From time to time we have been named as a defendant in class action antitrust lawsuits brought by suppliers or purchasers of medical products. Typically, these lawsuits have alleged the existence of a conspiracy among manufacturers of competing products, distributors and/or operators of GPOs, including us, to deny the plaintiff access to a market for certain products, to raise the prices for products and/or limit the plaintiff's choice of products to buy. We believe that we have at all times conducted our business affairs in an ethical and legally compliant manner and have successfully resolved all such actions. No assurance can be given that we will not be subjected to similar actions in the future or that any such existing or future matters will be resolved in a manner satisfactory to us or which will not harm our business, financial condition or results of operations.

On March 4, 2022, a shareholder derivative complaint captioned *City of Warren General Employees' Retirement System v. Michael Alkire, et al.*, Case No. 2022-0207-JTL, purportedly brought on behalf of Premier, was filed in the Delaware Court of Chancery (the "Court") against our current and former Chief Executive Officers and current and certain former directors. We **are** **were** named as a nominal defendant in the complaint. The lawsuit **alleges** **alleged** that the named officers and directors breached their fiduciary duties and committed corporate waste by approving agreements between Premier and certain of the former LPs that provided for accelerated payments as consideration for the early termination of the TRA with such LPs. The complaint **asserts** **asserted** that the aggregate early termination payment amounts of \$473.5 million exceeded the alleged value of the tax assets underlying the TRA by approximately \$225.0 million.

The complaint **seeks** **sought** unspecified damages, costs and expenses, including attorney fees, and declaratory and other equitable relief. Since the lawsuit **is** **was** purportedly brought on behalf of Premier, and we **are** **were** only a nominal defendant, the alleged damages were allegedly suffered by us. We and the individual defendants **deny** **denied** the allegations in the complaint. On February 16, 2024, the parties to the litigation entered into a settlement agreement, which was approved by the Court at a hearing on June 25, 2024. Pursuant to the settlement agreement, in consideration of a full and final release and discharge of claims in the complaint without any admission of fault, in July 2024 we received \$71.0 million in cash from our directors' and **intend** **officers**' insurance carriers, which included a \$14.0 million fee and expense award to **vigorously** **defend** **the** **litigation**. In **light** **plaintiff's** **counsel** that reduced the amount of the **fact** **that** **net** **cash** **settlement** **retained** **by** **Premier** **to** \$57.0 million. Because the lawsuit is in an early stage derivative complaint was brought on behalf of us and the claims do for our benefit, stockholders will not specify an amount of damages, we cannot predict the ultimate outcome receive any direct payment of the suit. cash settlement amount but will indirectly benefit from the settlement being paid by the insurance carriers to us.

Additional information relating to certain legal proceedings in which we are involved is included in Note 17 - Commitments and Contingencies, to the accompanying consolidated financial statements, which is incorporated herein by reference.

Item 4. Mine Safety Disclosures

Not applicable.

PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our Class A common stock ("Common Stock") is publicly traded on the NASDAQ Global Select Market ("NASDAQ") under the ticker symbol "PINC."

Based on the records of our Class A common stock Common Stock transfer agent, as of August 17, 2023 August 15, 2024, there were 119,170,751 100,187,927 shares of our Class A common stock Common Stock issued and outstanding, held by 90 85 holders of record. Because a substantial portion of our Class A common stock Common Stock is held by brokers and other institutions on behalf of shareholders, we are unable to estimate the total number of beneficial owners currently holding our Class A common stock. Common Stock.

Dividend Policy

During fiscal year 2023, 2024, our Board of Directors declared regular quarterly cash dividends of \$0.21 per share on our outstanding shares of Class A common stock, Common Stock, which were paid on September 15, 2022 September 15, 2023, December 15, 2022 December 15, 2023, March 15, 2023 March 15, 2024 and June 15, 2023 June 15, 2024.

On August 10, 2023 August 8, 2024, our Board of Directors declared a quarterly cash dividend of \$0.21 per share, payable on September 15, 2023 September 15, 2024 to stockholders of record on September 1, 2023 September 1, 2024.

The actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our Board of Directors each quarter after consideration of various factors, including our results of operations, financial condition and capital requirements, earnings, general business conditions, restrictions imposed by our current Credit Facility and any future financing arrangements, legal restrictions on the payment of dividends and other factors our Board of Directors deems relevant. We currently expect quarterly dividends to continue to be paid on or about December 15, March 15, June 15 and September 15, respectively.

Recent Sales of Unregistered Securities

All sales of unregistered securities during the fiscal year ended June 30, 2023 June 30, 2024 have been previously reported in filings with the SEC.

Securities Authorized for Issuance Under Equity Compensation Plans

The information required by Item 201(d) of Regulation S-K is provided under "Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters—Equity Compensation Plan Information", incorporated herein by reference.

Purchase of Equity Securities

No shares of Class A common stock Common Stock were repurchased during the fiscal year three months ended June 30, 2023 June 30, 2024.

Company Stock Performance

The performance graph below shows a five-year comparison of the total cumulative return, assuming reinvestment of all dividends, had \$100 been invested at the close of business on June 30, 2018 June 30, 2019, in each of:

- our Class A common stock; Common Stock;
- the NASDAQ Composite stock index ("NASDAQ Composite Index");
- a customized peer group of companies previously used by us (the "Prior Peer Group"); and
- a customized peer group of eleven thirteen companies selected by us that we believe is better aligned with our company (the "Peer Group").

We have used the Peer Group, a group selected in good faith and used by our compensation committee Compensation Committee of the Board of Directors ("compensation committee" Compensation Committee) for peer comparison benchmarking purposes because we believe this group provides an accurate representation of our peers. Our compensation committee Compensation Committee reviewed and, in consultation with its independent consultant, selected the companies in our fiscal year 2023 2024 Peer Group in April 2022. Our compensation committee Compensation Committee will continue to review and reconfigure our Peer Group as it deems necessary in consultation with its independent consultant.

The Peer Group graph line consists of the following eleven 13 companies: Amedisys, Inc., AMN Healthcare Services, Inc., ASGN Incorporated, Evolent Health, Inc., Evolent Health, Dentsply Sirona, Inc., FTI Consulting Inc., Huron Consulting Group Inc., Omnicell Inc.,

Owens & Minor Inc., Patterson Companies, Inc., Pedatrix Medical Group Inc., R1 RCM Inc. and Veradigm Inc.

Our fiscal year 2024 peer group was modified from our fiscal year 2023 peer group by adding Amedisys, Inc. and Dentsply Sirona Inc. as part of the annual review of our peer group by the Compensation Committee to ensure that the size and composition of the peer group remains appropriate.

The information contained in the performance graph below shall not be deemed "soliciting material" or to be "filed" with the SEC nor shall such information be deemed incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent we specifically incorporate it by reference into such filing.

The comparisons in the graph below are based upon historical data and are not indicative of, nor intended to forecast, future performance of our common stock. Common Stock. Research Data Group, Inc. provided the data for the indices presented below. We assume no responsibility for the accuracy of the indices' data, but we are not aware of any reason

to doubt its accuracy.

4395

Value of Investment as of June 30 ^(a) :	Value of Investment as of June 30 ^(a) :	2018	2019	2020	2021	2022	2023	2019	2020	2021	2022	2023	2024
Company/Index Name	Company/Index Name												
Company/Index Name	Company/Index Name												
Premier, Inc.	Premier, Inc.												
Class A	Class A												
Common	Common												
Stock	Stock	\$100.00	\$107.50	\$ 94.23	\$ 97.80	\$102.50	\$ 81.64						
NASDAQ	NASDAQ												
Composite	Composite												
Index	Index	\$100.00	\$107.78	\$136.82	\$198.71	\$152.16	\$191.93						
Prior Peer Group													
Peer Group	Peer Group	\$100.00	\$ 92.60	\$ 87.83	\$159.09	\$155.00	\$139.42						

(a) Assumes \$100 invested on ~~June 30, 2018~~ ~~June 30, 2019~~, including reinvestment of dividends for periods from ~~2018-2023~~ ~~2019-2024~~. We began paying cash dividends in September 2020.

We will neither make nor endorse any predictions as to future stock performance or whether the trends depicted in the graph above will continue or change in the future. The stock price performance included in this graph is not necessarily indicative of future stock price performance.

Item 6. Reserved

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our consolidated financial statements and the notes thereto included elsewhere in this Annual Report. This discussion is designed to provide the reader with information that will assist in understanding our consolidated financial statements, the changes in certain key items in those financial statements from year to year, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our consolidated financial statements. In addition, the following discussion includes certain forward-looking statements. For a discussion of important factors, including the continuing development of our business and other factors which could cause actual results to differ materially from the results referred to in the forward-looking statements, see "Item 1A. Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" contained in this Annual Report.

Business Overview

Our Business

Premier, Inc. ("Premier", "Premier," the "Company", "Company," "we", or "our") is a leading technology-driven healthcare improvement company, uniting an alliance of U.S. hospitals, health systems and other providers and organizations to transform healthcare. We partner with hospitals, health systems, physicians, employers, product suppliers, service providers, payers and other healthcare providers and organizations with the common goal of improving and innovating in the clinical, financial and operational areas of their businesses to meet the demands of a rapidly evolving healthcare industry. We deliver value through a comprehensive technology-enabled platform that offers critical supply chain services, clinical, financial, operational and value-based care software-as-a-service ("SaaS") as well as clinical and enterprise analytics licenses, consulting services, performance improvement collaborative programs, third-party administrator services, access to our centers of excellence program, cost containment and wrap network and digital invoicing and payment automation processes for healthcare suppliers and providers. We also continue to expand our capabilities to more fully address and coordinate care improvement and standardization in the employer, payer and life sciences markets. We also provide some of the various products and services noted above to non-healthcare businesses.

We generated net revenue, net income and Adjusted EBITDA (a financial measure not determined in accordance with generally accepted accounting principles ("Non-GAAP")) for the periods presented as follows (in thousands):

	Year Ended June 30,		
	2023	2022	2021
Net revenue	Year Ended June 30,	Year Ended June 30,	Year Ended June 30,
Net revenue	2024		

Net revenue	Net revenue	\$ 1,336,095	\$ 1,432,901
Net income	Net income	174,887	268,318
Net income			
Net income			
Non-GAAP Adjusted EBITDA	Non-GAAP Adjusted EBITDA	499,783	498,682

Non-GAAP Adjusted EBITDA

Non-GAAP Adjusted EBITDA

See "Our Use of Non-GAAP Financial Measures" and "Results of Operations" below for a discussion of our use of Non-GAAP Adjusted EBITDA and a reconciliation of net income to Non-GAAP Adjusted EBITDA.

Strategic Review

On February 5, 2024, we announced that our Board of Directors concluded its exploration of strategic alternatives which we originally reported in May 2023. As part of the strategic review process, the Board of Directors has authorized us to seek partners for some or all of our holdings in Contigo Health, LLC ("Contigo Health"), our subsidiary focused on providing comprehensive services that optimize employee health benefits, and S2S Global, our direct sourcing subsidiary.

Additionally, on February 2, 2024, our Board of Directors authorized the repurchase of up to \$1.0 billion of our outstanding Class A common stock ("Common Stock"). On February 5, 2024, under the share repurchase authorization, we entered into an accelerated share repurchase agreement (the "ASR Agreement") with Bank of America, N.A. ("Bank of America") to repurchase an aggregate of \$400.0 million of shares of our Common Stock. Final settlement of the accelerated share repurchase transaction pursuant to the ASR Agreement was completed on July 11, 2024. Refer to "Share Repurchase Authorization" within "Contractual Obligations" section of Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations for more information.

Our Business Segments

Our business model and solutions are designed to provide our members and other customers access to scale efficiencies, spread the cost of their development, provide actionable intelligence derived from anonymized data in our enterprise data warehouse, mitigate the risk of innovation and disseminate best practices to help our members and other customers succeed in their transformation to higher quality and more cost-effective healthcare. We deliver our integrated platform of solutions that address the areas of clinical intelligence, margin improvement and value-based care through two business segments: Supply Chain Services and Performance Services.

Segment net revenue was as follows (in thousands):

		Year Ended June 30,				% of Net Revenue							
		Year Ended June 30,				Year Ended June 30,							
Net revenue:	Net revenue:	2023	2022	Change	2023	2022	Net revenue:	2024	2023	Change	2024	2023	
Supply Chain Services	Supply Chain Services	\$ 899,955	\$ 1,031,946	(\$131,991)	(13)%	67 %	72 %	Services	\$ 886,303	\$ 899,955	(\$13,652)	(2)	(2)%
Performance Services	Performance Services	436,177	400,983	35,194	9 %	33 %	28 %	Services	460,329	436,177	24,152	24,152	6 %
Segment net revenue	Segment net revenue	\$ 1,336,132	\$ 1,432,929	\$ (96,797)	(7)%	100 %	100 %	Segment net revenue	\$ 1,346,632	\$ 1,336,132	\$ 10,500	1	1 %
												100 %	100 %

Our Supply Chain Services segment includes one of the largest national healthcare group purchasing organization ("GPO") programs in the United States, serving acute and continuum of care sites and providing supply chain co-management, purchased services and direct sourcing activities.

Our Performance Services segment consists of three sub-brands: P/INC A/™, our technology and services platform with offerings that help optimize performance in three main areas – clinical intelligence, margin improvement and value-based care – using advanced analytics to identify improvement opportunities, consulting and managed services for clinical and operational design, and workflow solutions to hardwire sustainable change in the provider, payer and life sciences and payer markets; Contigo Health®, our direct-to-employer business which provides third-party administrator services and management of health-benefit

health benefit programs that enable healthcare providers that are also payers (e.g. payviders) and employers to contract directly with healthcare providers as well as partner with the healthcare providers to provide employers access to a specialized care network through Contigo Health's centers of excellence program and cost containment and wrap network; and Remitra®, our digital invoicing and payables automation business which provides financial support services to healthcare suppliers and providers. Each sub-brand serves different markets but are all united in our vision to optimize provider performance and accelerate industry innovation for better, smarter healthcare. For additional information, please see "Performance Services" above.

Beginning in fiscal year 2025, our Remitra sub-brand will be reported as a component of our Supply Chain Services segment to align with our strategy and operations moving forward.

Sales and Acquisitions

Acquisition of TRPN Direct Pay, Inc. and Devon Health, Inc. Assets

On October 13, 2022, we acquired, through our consolidated subsidiary, Contigo Health, LLC ("Contigo Health"), certain assets and assumed certain liabilities of TRPN Direct Pay, Inc. and Devon Health, Inc. (collectively, "TRPN") for an adjusted purchase price of \$177.5 million. The assets acquired and liabilities assumed relate to businesses of TRPN focused on improving access to quality healthcare and reducing the cost of medical claims through pre-negotiated discounts with network providers, including acute care hospitals, surgery centers, physicians and other continuum of care providers in the U.S. Contigo Health also agreed to license proprietary cost containment technology of TRPN. TRPN is being integrated under Contigo Health and is reported as part of the Performance Services segment. See Note 3 - Business Acquisitions to the accompanying consolidated financial statements for further information.

Sale of Non-Healthcare GPO Member Contracts

On **June 14, 2023** July 25, 2023, we announced that we entered into sold substantially all of our non-healthcare GPO member contracts pursuant to an equity purchase agreement with OMNIA Partners, LLC ("OMNIA") to sell the contracts pursuant to which substantially all of our non-healthcare GPO members participate in our GPO program, for an estimated purchase price of approximately \$800.0 million, subject to certain adjustments, \$723.8 million. For a period of at least 10 years following the closing, the non-healthcare GPO members will continue to be able to make purchases through our group purchasing contracts. The sale of the non-healthcare GPO member contracts closed on July 25, 2023. See Note **20** **10** - Subsequent Events Liability Related to the Sale of Future Revenues to the accompanying consolidated financial statements for further information.

Market and Industry Trends and Outlook

We expect that certain trends and economic or industrywide factors will continue to affect our business, in both the short- and long-term. We have based our expectations described below on assumptions made by us and on information currently available to us. To the extent our underlying assumptions about, or interpretation of, available information prove to be incorrect, our actual results may vary materially from our expected results. See "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors."

Trends in the U.S. healthcare market as well as the broader U.S. and global economy affect our revenues and costs in the Supply Chain Services and Performance Services segments. The trends we see affecting our current business include the impact of inflation on the broader economy, the significant increase in input costs in healthcare, including the rising cost of labor, and the impact of the implementation of current or future healthcare legislation. Implementation of healthcare legislation could be disruptive for Premier and our customers, impacting revenue, reporting requirements, payment reforms, shift in care to the alternate site market and increased data availability and transparency. To meet the demands of this environment, there will be increased focus on scale and cost containment and healthcare providers will need to measure and report on and bear financial risk for outcomes. Over the long-term, we believe these trends will result in increased demand for our Supply Chain Services and Performance Services solutions in the areas of cost management, quality and safety, and value-based care; however, there are uncertainties and risks that may affect the actual impact of these anticipated trends, expected demand for our services or related assumptions on our business. See "Cautionary Note Regarding Forward-Looking Statements" for more information.

Impact of Inflation

The While the U.S. inflation rate has declined from its peak in calendar year 2022, the U.S. economy is still experiencing the highest elevated rates of inflation since compared to the 1980s. recent past. We believe that we have continued to limit the impact of inflation on our members and believe that we maintain significantly lower inflation impacts across our diverse product portfolio than national levels. However, in certain areas of our business, there is still some level of risk and uncertainty for our members and other customers as labor costs, raw material costs and availability, rising higher interest rates and inflation continue to pressure supplier pricing as well as apply significant pressure on our margin.

We continue to evaluate the contributing factors, specifically logistics, raw materials and labor, that which have led to adjustments to selling prices. We have begun to see seen logistics costs normalize to pre-pandemic levels as well as some reductions in the costs of specific raw materials; however, the cost of labor remains high. We are continuously working to manage these price increases as market conditions change. The impact of inflation to on our aggregated product portfolio is partially mitigated by contract term price protection for a large portion of our portfolio, as well as negotiated price reductions in certain product categories such as pharmaceuticals, portfolio. See "Risk Factors", Factors — Risks Related to Our Business Operations" in this Annual Report.

Furthermore, as while the Federal Reserve seeks may seek to curb rising inflation, reduce market interest rates, have steadily risen, and they may continue to rise, be elevated, increasing the cost of borrowing under our Credit Facility (as defined in Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements) as well as impacting our results of operations, financial condition and cash flows.

Geopolitical Tensions

Geopolitical tensions such as the ongoing military conflict between Russia and Ukraine and tensions between the U.S. and China, continue to affect the global economy and financial markets, as well as exacerbate ongoing economic challenges, including issues such as rising inflation, energy costs, logistics costs, tariffs and global supply-chain disruption.

We continue to monitor the impacts of geopolitical tensions on macroeconomic conditions and prepare for any implications they may have on member demand, our suppliers' ability to deliver products, cybersecurity risks and our liquidity and access to capital. See "Risk Factors", Factors - Risks Related to Our Business Operations" in this Annual Report.

COVID-19 Pandemic or Other Pandemics, Epidemics or Public Health Emergencies

In addition to the trends in the U.S. healthcare market discussed above, the outbreak of the novel coronavirus ("COVID-19") and the resulting global pandemic and the impact on the healthcare industry impacted our sales, operations and supply chains, our members and other customers and workforce and suppliers. As a result of pandemics, epidemics or public health emergencies, we may face material risks including, but not limited to:

- Labor shortages in the healthcare workforce and corresponding increases in labor costs.
- Changes in the demand for our products and services may create demand uncertainty from both material increases and decreases in demand and pricing for our products and services.
- Limited access to our members' facilities as well as travel restrictions limit their ability to participate in face-to-face events, such as committee meetings and conferences, and limits our ability to foster relationships and effectively deliver existing or sell new products and services to our members.
- Disruption to the global supply chain, particularly in China, may impact products purchased by our members through our GPO or products contract manufactured through our direct sourcing business. Failure of our suppliers, contract manufacturers, distributors, contractors and other business partners to meet their obligations to our members, other customers or to us, or material disruptions in their ability to do so due to their own financial or operational difficulties, may adversely impact our operations.

- We may continue to receive requests for contract modifications, payment waivers and deferrals, payment reductions or amended payment terms from our contract counterparties. We may continue to receive requests to delay service or payment on performance service contracts and we may continue to receive requests from our suppliers for increases to their contracted prices.
- A general decline in the overall economic and capital markets which could increase our cost of capital and adversely affect our ability to access the capital markets in the future.

While both the U.S. and the World Health Organization declared an end to the COVID-19 pandemic as a public health emergency in May 2023, we remain subject to the potential risks associated with the resurgence of COVID-19 any future pandemic, epidemic or another pandemic remains other public health emergency, and the resulting impact uncertain impacts those events could have on our business, results of operations, financial conditions and condition, cash flows as well as and prospects of the trading price of our Common Stock. Among other risks, future pandemics, epidemics or other public health emergencies could lead to labor shortages, quarantines, travel and other restrictions, disruptions in the global supply chain, financial and operational harm to our members, customers, and suppliers, and a general decline in the overall U.S. and global economies is uncertain worldwide economy and cannot capital markets. These and other risks of future pandemics, epidemics and other public health emergencies could lead to reduced demand for our products and services or the ability of our customers to pay for our products and services, disruption in our operations and our ability to deliver our products and services, disruption in the operation of suppliers that deliver products to our members, and adverse impacts on our ability to access capital on acceptable terms as may be predicted at this time. needed for our business. The impact of the COVID-19 pandemic or another pandemic, epidemic or public health emergency may also exacerbate many of the other risks described in the "Item 1A. Risk Factors" section. Despite our efforts to manage these impacts, their ultimate impact depends on factors beyond our knowledge or control, including the duration and severity of any outbreak public health emergency and actions taken to contain its spread and mitigate its public health effects. The foregoing and other continued disruptions in our business as a result of the COVID-19 pandemic, variants thereof, recurrences or similar pandemics could result in a material adverse effect on our business, results of operations, financial condition, cash flows, prospects and the trading prices of our securities in the near-term and through fiscal 2023 and beyond.

Critical Accounting Policies and Estimates

Below is a discussion of our critical accounting policies and estimates. These and other significant accounting policies are set forth under Note 2 - Significant Accounting Policies to the accompanying consolidated financial statements for more information.

Business Combinations

We account for acquisitions of a business using the acquisition method. All of the assets acquired, liabilities assumed, contractual contingencies and contingent consideration are generally recognized at their fair value on the acquisition date. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Acquisition-related costs are recorded as expenses in the Consolidated Statements of Income and Comprehensive Income.

Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, we typically use the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset's life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.

Goodwill

Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. We perform our annual goodwill impairment testing on the first day of the last fiscal quarter of our fiscal year unless impairment indicators are present, which could require an interim impairment test.

Under accounting rules, we may elect to perform a qualitative assessment to determine if an impairment is more likely than not to have occurred. This qualitative assessment requires an evaluation of any excess of fair value over the carrying value for a reporting unit and significant judgment regarding potential changes in valuation inputs, including a review of our most recent long-range projections, analysis of operating results versus the prior year, changes in market values, changes in discount rates and changes in terminal growth rate assumptions. If it is determined that an impairment is more likely than not to exist, then we are required to perform a quantitative assessment to determine whether or not goodwill is impaired and to measure the amount of goodwill impairment, if any.

A goodwill impairment charge is recognized for the amount by which the reporting unit's carrying amount exceeds its fair value. We determine the fair value of a reporting unit using a discounted cash flow analysis as well as market-based approaches. Determining fair value requires the exercise of significant judgment, including judgment about appropriate discount rates, perpetual growth rates and the amount and timing of expected future cash flows. The cash flows employed in the discounted cash flow analyses are based on the most recent budget and long-term forecast. The discount rates used in the discounted cash flow analyses are intended to reflect the risks inherent in the future cash flows of the respective reporting units. The market comparable approach estimates fair value using market multiples of various financial measures compared to a set of comparable public companies and recent comparable transactions.

Our most recent interim analysis as of March 31, 2024 consisted of a quantitative assessment of the Informatics and Technology Services ("ITS") and Contigo Health reporting units and resulted in a pre-tax impairment charge of \$140.1 million, including \$16.5 million for goodwill within the Contigo Health reporting unit. As a result, the Contigo Health reporting unit's goodwill was fully impaired. The interim analysis did not result in impairment within the ITS reporting unit. Our most recent annual impairment testing as of April 1, 2023 April 1, 2024 consisted of a qualitative assessment over all reporting units and did not result in impairment. We also performed a quantitative assessment on the ITS reporting unit and resulted determined that goodwill was not impaired as the fair value exceeded the carrying value of the entity by 2.3%. Goodwill in \$56.7 million the amount of \$578.9 million is included in impairment losses within our Contigo Health the ITS reporting unit. During the quantitative assessment, the fair value of the reporting unit was computed using a discounted cash flow analysis and Direct Sourcing market-based approach. The discounted cash flow model is based on the most recent budget and long-term forecast plus a terminal value based on capitalizing the last period's cash flows using a perpetual growth rate. Our significant assumptions in the discounted cash flow model include, but are not limited to, a discount rate utilizing a weighted average cost of capital and the amount and timing of expected future cash flows utilizing revenue growth rates (including perpetual growth rate) and EBITDA margin percentages of the reporting units unit's business. These assumptions were developed in consideration of current market conditions and future expectations, which include, but were not limited to, new product offerings, market demand and impacts from competition. Refer to Note 8 - Goodwill and Intangible Assets to the accompanying consolidated financial statements for further information on the impairment losses recognized in fiscal years 2024 and 2023.

Revenue Recognition

We account for a contract with a customer when the contract is **approved and the parties are committed to perform their respective obligations**, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of collection.

Revenue is recognized when, or as, control of a promised product or service transfers to a customer, in an amount that reflects the consideration to which we expect to be entitled in exchange for transferring those products or services. If the consideration promised in a contract includes a variable amount, we estimate the amount to which we expect to be entitled using either the expected value or most likely amount method. Our contracts may include terms that could cause variability in the transaction price, including, for example, revenue share, rebates, discounts and variable fees based on performance.

We only include estimated amounts of consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. These estimates require management to make complex, difficult or subjective judgments, and to make estimates about the effect of matters inherently uncertain. As such, we may not be able to reliably estimate variable fees based on performance in certain long-term arrangements due to uncertainties that are not expected to be resolved for a long period of time or when our experience with similar types of contracts is limited. Estimates of variable consideration and the determination of whether to include estimated amounts of consideration in the transaction price are based on information (historical, current and forecasted) that is reasonably available to us, taking into consideration the type of customer, the type of transaction and the specific facts and circumstances of each arrangement. Additionally, management performs periodic analyses to verify the accuracy of estimates for variable consideration.

Although we believe that our approach in developing estimates and reliance on certain judgments and underlying inputs is reasonable, actual results could differ which may result in exposure of increases or decreases in revenue that could be material.

Performance Obligations

A performance obligation is a promise to transfer a distinct good or service to a customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Contracts may have a single performance obligation as the promise to transfer individual goods or services is not separately identifiable from other promises, and therefore, not distinct, while other contracts may have multiple performance obligations, most commonly due to the contract covering multiple deliverable arrangements (licensing, fees, subscription, fees, professional fees for consulting services, etc.).

Net Administrative Fees Revenue

Net administrative fees revenue is a single performance obligation earned through a series of distinct daily services and includes maintaining a network of members to participate in the group purchasing program and providing suppliers efficiency in contracting and access to our members. Revenue is generated through administrative fees received from suppliers and is included in **service net administrative fees revenue** in the accompanying Consolidated Statements of Income and Comprehensive Income.

Through our GPO programs, we aggregate member purchasing power to negotiate pricing discounts and improve contract terms with suppliers. Contracted suppliers pay us administrative fees which generally represent 1% to 3% of the purchase price of goods and services sold to members under the contracts we have negotiated. Administrative fees are variable consideration and are recognized as earned based upon estimated purchases by our members utilizing analytics based on historical member spend and updates for current trends and expectations. Administrative fees are estimated due to the difference in timing of when a member purchases on a supplier contract and when we receive the purchasing information. Member and supplier contracts substantiate persuasive evidence of an arrangement. We do not take title to the underlying equipment or products purchased by members through our GPO supplier contracts. Administrative fee revenue receivable is included in contract assets in the accompanying Consolidated Balance Sheets.

Generally, we pay a revenue share to members equal to a percentage of gross administrative fees, which is estimated according to the members' contractual agreements with us using a portfolio approach based on historical revenue fee share percentages and adjusted for current or anticipated trends. Revenue share is recognized as a reduction to gross administrative fees revenue to arrive at a net administrative fees revenue, and the corresponding revenue share liability is included in revenue share obligations in the accompanying Consolidated Balance Sheets.

Products Revenue

Direct sourcing generates revenue primarily through products sold to our members, other customers or distributors. Revenue is recognized once control of products has been transferred to the customer and is recorded net of discounts and rebates offered to customers. Discounts and rebates are estimated based on contractual terms and historical trends.

Software Licenses, Other Services and Support Revenue

We generate software licenses, other services and support revenue through **Performance Supply Chain Services and Performance Services**.

Within Supply Chain Services, revenue is generated through the GPO, supply chain co-management and SaaS-based purchased services activities.

GPO. GPO revenue generating activities include revenue from technology solutions, including purchased services, and from suppliers through the members that participate in our performance groups.

Supply Chain Co-Management. Supply chain co-management activities generate revenue in the form of a service fee for services performed under the supply chain management contracts. Service fees are billed as stipulated in the contract, and revenue is recognized on a proportional performance method as services are performed.

Within Performance Services, which provides technology with wrap-around service offerings, revenue is generated through our three sub-brands: PINC AI, Contigo Health and Remitra. The main sources of revenue under PINC AI consists of subscriptions to our SaaS-based clinical intelligence, margin improvement and value-based care products, licensing revenue, professional fees for consulting services and other miscellaneous revenue including PINC AI data licenses, annual subscriptions to our performance improvement collaboratives, insurance services management fees and commissions from endorsed commercial insurance programs. Contigo Health's main sources of revenue are third-party

administrator fees, fees from the centers of excellence program and cost containment and wrap network fees. Remitra's main source of revenue is fees from healthcare suppliers and providers.

PINC AI

SaaS-based Products Subscriptions. SaaS-based clinical analytics subscriptions include the right to access our proprietary hosted technology on a SaaS basis, training and member support to deliver improvements in cost management, margin improvement, quality and safety, value-based care and provider analytics. SaaS arrangements create a single performance obligation for each subscription within the contract in which the nature of the obligation is a stand-ready obligation, and each day of service meets the criteria for over time recognition. Pricing varies by application and size of healthcare system. Clinical analytics products subscriptions are generally three- to five-year agreements with automatic renewal clauses and annual price escalators that typically do not allow for early termination. These agreements do not allow for physical possession of the software. Subscription fees are typically billed on a monthly basis and revenue is recognized as a single deliverable on a straight-line basis over the remaining contractual period following implementation. Implementation involves the completion of data preparation services that are unique to each member's data set in order to access and transfer member data into our hosted SaaS-based clinical analytics products. Implementation is generally 60 to 240 days following contract execution before the SaaS-based clinical analytics products can be fully utilized by the member.

Software Licenses. Enterprise analytics licenses include term licenses that range from three to ten years and offer clinical analytics products, improvements in cost management, quality and safety, value-based care and provider analytics. Pricing varies by application and size of healthcare system. Revenue on licensing is recognized upon delivery of the software code, and revenue from hosting and maintenance is recognized ratably over the life of the contract.

Consulting Services. Professional fees for consulting services are sold under contracts, the terms of which vary based on the nature of the engagement. These services typically include general consulting, report-based consulting and cost savings initiatives. Promised services under such consulting engagements are typically not considered distinct and are regularly combined and accounted for as one performance obligation. Fees are billed as stipulated in the contract, and revenue is recognized on a proportional performance method as services are performed or when deliverables are provided. In situations where the contracts have significant contract performance guarantees, the performance guarantees are estimated and accounted for as a form of variable consideration when determining the transaction price. In the event that guaranteed savings levels are not achieved, we may have to perform additional services at no additional charge in order to achieve the guaranteed savings or pay the difference between the savings that were guaranteed and the actual achieved savings. Occasionally, our entitlement to consideration is predicated on the occurrence of an event such as the delivery of a report for which client acceptance is required. However, except for event-driven point-in-time transactions, the majority of services provided within this service line are delivered over time due to the continuous benefit provided to our customers.

Consulting arrangements can require significant estimates for the transaction price and estimated number of hours within an engagement. These estimates are based on the expected value which is derived from outcomes from historical contracts that are similar in nature and forecasted amounts based on anticipated savings for the new agreements. The transaction price is generally constrained until the target transaction price becomes more certain.

Other Miscellaneous Revenue.

- Revenue from PINC AI data licenses which provide customers data from the PINC AI healthcare database. The revenue from the data deliverables is recognized upon delivery of the data.
- Revenue from performance improvement collaboratives that support our offerings in cost management, quality and safety, and value-based care **and** is recognized over the service period as the services are provided, which is generally one to three years. Performance improvement collaboratives revenue is considered one performance obligation and is generated by providing customers access to online communities whereby data is housed and available for analytics and benchmarking.
- Insurance services management fees are recognized in the period in which such services are provided. Commissions from insurance carriers for sponsored insurance programs are earned by acting as an intermediary in the placement of effective insurance policies. Under this arrangement, revenue is recognized at a point in time on the effective date of the associated policies when control of the policy transfers to the customer and is constrained for estimated early terminations.

Contigo Health

Contigo Health revenue consists of third-party administrator fees, fees from the centers of excellence program and cost containment and wrap network fees. Third-party administrator fees consist of integrated fees for the processing of self-insured healthcare plan claims. Revenue is recognized in the period in which the services have been provided. Fees from the centers of excellence program consist of administrative fees for access to a specialized care network of proven healthcare providers. Revenue is recognized in the period in which the services have been provided. Cost containment and wrap network fees consist of fees associated with the repricing of insurance claims. Revenue is estimated and recognized in the period in which the services have been provided.

Remitra

Revenue for Remitra primarily consists of fees from healthcare suppliers and providers as well as members and other customers. For fixed fee contracts, revenue is recognized in the period in which the services have been provided. For variable rate contracts, revenue is recognized as customers are invoiced. Additional revenue consists of fees from check replacement services which consist of monthly rebates from bank partners.

Within Supply Chain Services, revenue is generated through the GPO, supply chain co-management and SaaS-based purchased services activities.

GPO. The GPO generates revenue from suppliers through the members that participate in our performance groups.

Supply Chain Co-Management. Supply chain co-management activities generate revenue in the form of a service fee for services performed under the supply chain management contracts. Service fees are billed as stipulated in the contract, and revenue is recognized on a proportional performance method as services are performed.

Purchased Services. Purchased services generate revenue through subscription fees for SaaS-based products and term licenses. Subscription fees are generally billed on a monthly basis and revenue is recognized as a single deliverable on a straight-line basis over the remaining contractual period following implementation. Revenue on licensing is recognized upon delivery of the software code and revenue from hosting and maintenance is recognized ratably over the life of the contract.

Multiple Deliverable Arrangements

We enter into agreements where the individual deliverables discussed above, such as SaaS subscriptions, term licenses and consulting services, are bundled into a single service arrangement. These agreements are generally provided over a time period ranging from approximately three months to five years after the applicable contract execution date. On occasion, agreements may range up to ten years. We use judgment in determining the stand-alone selling price ("SSP") for products and services. Revenue, including both fixed and variable consideration, is allocated to the individual performance obligations within the arrangement based on the stand-alone selling price SSP. We typically establish a SSP range for our products and services which is reassessed on a periodic basis or when it is facts and circumstances change. Term licenses are sold separately only as a bundled arrangement that includes the rights to a term license and support. In determining the SSP of license and support in a stand-alone arrangement, term license arrangement, we apply observable inputs using the value relationship between support and term license, and the average economic life of our products.

Software Development Costs

Costs associated with internally-developed computer software that are incurred prior to reaching technological feasibility are considered research and development and expensed as incurred. These costs consist of employee-related compensation and benefit expenses and third-party consulting fees of technology professionals, net of capitalized labor. During the development stage and once the project has reached technological feasibility, direct consulting costs and payroll and payroll-related costs for employees that are directly associated with each project are capitalized. Capitalized software costs are included in property and equipment, net in the accompanying Consolidated Balance Sheets. Capitalized costs are amortized on a straight-line basis over the estimated useful lives of the related software applications of up to five years and amortization is included in cost of revenue or selling, general and administrative expenses in the accompanying Consolidated Statements of Income and Comprehensive Income, based on the software's end use. Replacements and major improvements are capitalized, while maintenance and repairs are expensed as incurred. Some of the more significant estimates and assumptions inherent in this process involve determining the stages of the software development project, the direct costs to capitalize and the estimated useful life of the capitalized software.

Income Taxes

We account for income taxes under the asset and liability approach. Deferred tax assets or liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates as well as net operating losses and credit carryforwards, which will be in effect when these differences reverse. We provide a valuation allowance against net deferred tax assets when, based upon the available evidence, it is more likely than not that the deferred tax assets will not be realized.

We prepare and file tax returns based on interpretations of tax laws and regulations. Our tax returns are subject to examination by various taxing authorities in the normal course of business. Such examinations may result in future tax, interest and penalty assessments by these taxing authorities.

In determining our tax expense for financial reporting purposes, we establish a reserve when there are transactions, calculations, and tax filing positions for which the tax determination is uncertain, and it is more likely than not that such positions would not be sustained upon examinations.

We adjust tax reserve estimates periodically based on the changes in facts and circumstances, such as ongoing examinations by, and settlements with, varying taxing authorities, as well as changes in tax laws, regulations and interpretations. The consolidated tax expense of any given year includes adjustments to prior year income tax reserve and related estimated interest charges that are considered appropriate. Our policy is to recognize, when applicable, interest and penalties on uncertain income tax positions as part of income tax expense.

New Accounting Standards

New accounting standards that we have recently adopted as well as those that have been recently issued but not yet adopted by us, if any, are included in Note 2 - Significant Accounting Policies to the accompanying consolidated financial statements, which is incorporated herein by reference.

Key Components of Our Results of Operations

Net Revenue

Net revenue consists of net administrative fees revenue, software licenses, other services and support revenue and products revenue.

Supply Chain Services

Supply Chain Services revenue is comprised of:

- net administrative fees revenue which consists of gross administrative fees received from suppliers, reduced by the amount of revenue share paid to members;
- software licenses, other services and support revenue which consist of supply chain co-management and purchased services revenue; and
- products revenue which consists of inventory sales.

The success of our Supply Chain Services revenue streams is influenced by our ability to negotiate favorable contracts with suppliers and members, the number of members that utilize our GPO supplier contracts and the volume of their purchases, the impact of changes in the defined allowable reimbursement amounts determined by Medicare, Medicaid and other managed care plans, and the number of members and other customers that purchase products through our direct sourcing activities, the continued impact of members' and other customers' elevated inventory levels on our direct sourcing business and the impact of competitive pricing. Refer We believe that some of our GPO competitors may offer higher revenue share arrangements to some of their customers compared to our average arrangements. As we have renewed certain GPO member contracts during fiscal year 2024, competitive pressure has resulted in increases in our average fee share paid to members, a trend that is expected to continue, particularly as we continue to renew GPO member contracts that were extended at the time of our August 2020 Restructuring. As of June 30, 2024, we have renewed and extended members that represent approximately 50% of the gross administrative fees associated with the member agreements that were extended in 2020. In fiscal year 2025, we are targeting additional member agreements for renewal that would address a cumulative total of approximately 75% of the gross administrative fees associated with the member agreements extended in 2020. We expect to target the remaining associated member agreements for renewal in fiscal years 2026 and 2027. Also refer to "Impact of Inflation" within "Liquidity and Capital

Resources" section of Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations for discussion of inflation and its impact on our Supply Chain Services' businesses.

Performance Services

Performance Services revenue is comprised of the following software licenses, other services and support revenue:

- healthcare information technology license and SaaS-based clinical intelligence, margin improvement and value-based care products subscriptions, license fees, professional fees for consulting services, PINC AI data licenses, performance improvement collaborative and other service subscriptions and insurance services management fees and commissions from endorsed commercial insurance programs under our PINC AI technology and services platform;
- third-party administrator fees, fees from the centers of excellence program and cost containment and wrap network fees for Contigo Health; and
- fees from healthcare suppliers and providers for Remitra.

Our Performance Services growth will depend upon the expansion of PINC AI, Contigo Health and Remitra to new and existing members and other customers, renewal of existing subscriptions to our SaaS and licensed software products our ability to and the shift some from recurring subscription-based agreements to enterprise analytics licenses at a sufficient rate to offset the loss of reductions in recurring SaaS-based revenue.

Cost of Revenue

Cost of revenue consists of cost of services and software licenses revenue and cost of products revenue.

Cost of services and software licenses revenue includes expenses related to employees, consisting of compensation and benefits, benefits-related costs, and outside consultants who directly provide services related to revenue-generating activities, including consulting services to members and other customers, third-party administrator services and implementation services related to our SaaS and licensed software products along with associated amortization of certain capitalized contract costs. Amortization of contract costs represent amounts that have been capitalized and reflect the incremental costs of obtaining and fulfilling a contract including costs related to implementing SaaS informatics tools. Cost of services and software licenses revenue also includes expenses related to hosting services, related data center capacity costs, third-party product license expenses and amortization of the cost of internally-developed software applications.

Cost of products revenue consists of purchase and logistics costs for direct sourced medical products and commodity products and is influenced by the manufacturing and transportation costs associated with direct sourced medical and commodity products. Refer to "Impact of Inflation" within "Liquidity and Capital Resources" section of Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations for discussion of inflation and its impact on our Supply Chain Services' businesses.

Operating Expenses

Operating expenses includes selling, general and administrative ("SG&A") expenses, research and development expenses and amortization of purchased intangible assets.

SG&A expenses are directly associated with selling and administrative functions and support of revenue-generating activities including expenses to support and maintain our software-related products and services. SG&A expenses primarily consist of compensation- and benefits-related costs; travel-related expenses; business development expenses, including costs for business acquisition opportunities; non-recurring strategic initiative and financial restructuring-related expenses; indirect costs such as insurance, professional fees and other general overhead expenses; and amortization of certain contract costs. Amortization of contract costs represent amounts, including sales commissions, that have been capitalized and reflect the incremental costs of obtaining and fulfilling a contract. SG&A expenses can also include impairment of assets which includes goodwill impairment charges recognized when the reporting unit's carrying amount exceeds its fair value and impairment losses on intangibles and other long-lived assets when the carrying value of the asset subject to amortization may not be recoverable from the estimated cash flows expected to result from its use and eventual disposition (see Note 5 - Fair Value Measurements and Note 8 - Goodwill and Intangible Assets to the accompanying consolidated financial statements for further information).

Research and development expenses consist of employee-related compensation and benefit expenses and third-party consulting fees of technology professionals, net of capitalized labor, incurred to develop our software-related products and services prior to reaching technological feasibility.

Amortization of purchased intangible assets includes the amortization of all identified intangible assets.

Other Income, Net

Other income, net, primarily includes interest income and expense and equity in net income of unconsolidated affiliates that is generated from our equity method investments. Other income, net, may also include, but is not limited to, realized and unrealized gains or losses on deferred compensation plan assets and gains or losses on the disposal of assets.

- Interest income is primarily related to interest earned on investments in money market funds while interest expense is primarily related to funds borrowed through our Credit Facility as well as imputed interest on non-interest bearing debt (see Note 9 - Debt and Notes Payable and Note 10 - Liability Related to the Sale of Future Revenues to the accompanying consolidated financial statements for further information).
- Our equity method investments primarily consist of our interests in Exela Holdings, Inc. ("Exela") and Prestige Ameritech Ltd. ("Prestige"). As of March 3, 2023, our investment in FFF Enterprises, Inc. ("FFF") was no longer accounted for under the equity method of accounting as a result of the March 3, 2023 amendment. Prior to the March 3, 2023 amendment, our investment in FFF was accounted for as an equity method investment and a pro rata portion of the equity in net income was included in other income, net (see Note 4 - Investments to the accompanying consolidated financial statements for further information).
- Other income, net, also includes, but is not limited to, the fiscal year 2022 gain recognized due to the termination of the FFF Put Right and derecognition of the associated liability (see Note 5 - Fair Value Measurements to the accompanying consolidated financial statements for further information), interest income and expense, realized and unrealized gains or losses on deferred compensation plan assets, gains or losses on the disposal of assets, and any impairment on our assets or held-to-maturity investments. liability.

Income Tax Expense

See Note 15 - Income Taxes to the accompanying consolidated financial statements for discussion of income tax expense.

Net Income Income/Loss Attributable to Non-Controlling Interest

We recognize net income income/loss attributable to non-controlling interest for non-Premier ownership in our consolidated subsidiaries which hold interest in our equity method investments (see Note 4 - Investments to the accompanying consolidated financial statements for further information). At **June 30, 2023** **June 30, 2024**, we recognized net income loss attributable to non-controlling interests held by member health systems or their affiliates in the consolidated subsidiaries holding the our equity method investments, including but not limited to the 74% and 85% interest held in PRAM Holdings, LLC ("PRAM") and ExPre Holdings, LLC ("ExPre"), respectively. In partnership with member health systems or their affiliates, these investments are part of our long-term supply chain resiliency program to promote domestic and geographically diverse manufacturing and to help ensure a robust and resilient supply chain for essential medical products.

As of **June 30, 2023** **June 30, 2024**, we owned 93% of the equity interest in Contigo Health and recognized net income loss attributable to non-controlling interest for the 7% of equity held by certain customers of Contigo Health.

Our Use of Non-GAAP Financial Measures

The other key business metrics we consider are EBITDA, Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted Net Income, Adjusted Earnings per Per Share and Free Cash Flow, which are all Non-GAAP financial measures. Non-GAAP financial measures are not an alternative to GAAP and may be different from Non-GAAP financial measures used by other companies, but we believe they are useful for understanding our performance for the reasons described below.

We define EBITDA as net income before income or loss from discontinued operations, net of tax, interest and investment income or expense, net, income tax expense, depreciation and amortization and amortization of purchased intangible assets. We define Adjusted EBITDA as EBITDA before merger and acquisition-related expenses and non-recurring, non-cash or non-operating items and including equity in net income of unconsolidated affiliates items. For all Non-GAAP financial measures, we consider non-recurring items to be income or expenses and other items that have not been earned or incurred within the prior two years and are not expected to recur within the next two years. Such items include certain strategic initiative and financial restructuring-related expenses. Non-operating items include gains or losses on the disposal of assets and interest and investment income or expense.

We define Segment Adjusted EBITDA as the segment's net revenue less cost of revenue and operating expenses directly attributable to the segment excluding depreciation and amortization, amortization of purchased intangible assets, merger and acquisition-related expenses and non-recurring or non-cash items, and including equity in net income of unconsolidated affiliates items. Operating expenses directly attributable to the segment include expenses associated with sales and marketing, general and administrative, and product development activities specific to the operation of each segment. General and administrative corporate expenses that are not specific to a particular segment are not included in the calculation of Segment Adjusted EBITDA. Segment Adjusted EBITDA also excludes any income and expense that has been classified as discontinued operations.

We have revised the definitions for Adjusted EBITDA and Segment Adjusted EBITDA from the definitions reported in the Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (the "2023 Annual Report") to exclude the impact of equity earnings in unconsolidated affiliates. For comparability purposes, prior year Non-GAAP financial measures are presented based on the current definitions.

We define Adjusted Net Income as net income attributable to Premier (i) excluding income or loss from discontinued operations, net, (ii) excluding income tax expense, (iii) excluding the impact of adjustment of redeemable limited partners' capital to redemption amount, (iv) excluding the effect of non-recurring or non-cash items, including certain strategic initiative and financial restructuring-related expenses, (v) assuming, for periods prior to our August 2020 Restructuring, the exchange of all the Class B common units for shares of Class A common stock, which results in the elimination of non-controlling interest in Premier LP and (vi) reflecting an adjustment for income tax expense on Non-GAAP net income before income taxes at our estimated annual effective income tax rate, adjusted for unusual or infrequent items, items and (v) excluding the equity in net income of unconsolidated affiliates. We define Adjusted Earnings per Per Share as Adjusted Net Income divided by diluted weighted average shares (see Note 12 - Earnings Per Share to the accompanying consolidated financial statements for further information). We have revised the definition for Adjusted Net Income from the definition reported in the 2023 Annual Report to (1) remove the exclusion of the impact of adjustment of redeemable limited partners' capital to redemption amount, (2) remove the impact of the exchange of all Class B common units for shares of Class A common stock for periods prior to our August 2020 Restructuring and the resulting elimination of non-controlling interest in Premier LP and (3) add the exclusion of equity earnings in unconsolidated affiliates. For comparability purposes, prior year Adjusted Net Income is presented based on the current definition.

We define Free Cash Flow as net cash provided by operating activities from continuing operations less (i) early termination payments to certain former limited partners that elected to execute a Unit Exchange and Tax Receivable Acceleration Agreement ("Unit Exchange Agreement") in connection with our August 2020 Restructuring and (ii) purchases of property and equipment. Free Cash Flow does not represent discretionary cash available for spending as it excludes certain contractual obligations such as debt repayments.

Adjusted EBITDA and Free Cash Flow are supplemental financial measures used by us and by external users of our financial statements and are considered to be indicators of the operational strength and performance of our business. Adjusted EBITDA and Free Cash Flow measures allow us to assess our performance without regard to financing methods and capital structure and without the impact of other matters that we do not consider indicative of the operating performance of our business. More specifically, Segment Adjusted EBITDA is the primary earnings measure we use to evaluate the performance of our business segments.

We use Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Per Share to facilitate a comparison of our operating performance on a consistent basis from period to period that, when viewed in combination with our results prepared in accordance with GAAP, provides a more complete understanding of factors and trends affecting our business. We believe Adjusted EBITDA and Segment Adjusted EBITDA assist our Board of Directors, management and investors in comparing our operating performance on a consistent basis from period to period because they remove the impact of earnings elements attributable to our asset base (primarily depreciation and amortization), certain items outside the control of our management team, e.g. taxes, other non-cash items (such as impairment of intangible assets, purchase accounting adjustments and stock-based compensation), non-recurring items (such as strategic initiative and financial restructuring-related expenses) and income and expense that has been classified as discontinued operations from our operating results. We believe

Adjusted Net Income and Adjusted Earnings per Per Share assist our Board of Directors, management and investors in comparing our net income and earnings per share on a consistent basis from period to period because these measures remove non-cash (such as impairment of intangible assets, purchase accounting adjustments and stock-based compensation) and non-recurring items (such as strategic initiative and financial restructuring-related expenses), and eliminate the variability of non-controlling interest that primarily resulted from member owner exchanges and equity in net income of Class B common units for shares of Class A common stock unconsolidated affiliates. We believe Free Cash Flow is an important measure because it represents the cash that we generate after payment of tax distributions to limited partners, payments to certain former limited partners that elected to execute a Unit Exchange Agreement in connection with our August 2020 Restructuring and capital investment to maintain existing products and services and ongoing

business operations, as well as development of new and upgraded products and services to support future growth. Our Free Cash Flow ~~allows us~~ assists our efforts to ~~enhance seek~~ ~~enhancement of~~ stockholder value through acquisitions, partnerships, joint ventures, investments in related businesses and debt reduction.

Despite the importance of these Non-GAAP financial measures in analyzing our business, determining compliance with certain financial covenants in our Credit Facility, measuring and determining incentive compensation and evaluating our operating performance relative to our competitors, EBITDA, Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted Net Income, Adjusted Earnings ~~per~~ ~~Per~~ Share and Free Cash Flow are not measurements of financial performance under GAAP, may have limitations as analytical tools and should not be considered in isolation from, or as an alternative to, net income, net cash provided by operating activities, or any other measure of our performance derived in accordance with GAAP.

Some of the limitations of the EBITDA, Adjusted EBITDA and Segment Adjusted EBITDA measures include that they do not reflect: our capital expenditures or our future requirements for capital expenditures or contractual commitments; changes in, or cash requirements for, our working capital needs; the interest expense or the cash requirements to service interest or principal payments under our Credit Facility; income tax payments we are required to make; and any cash requirements for replacements of assets being depreciated or amortized. In addition, EBITDA, Adjusted EBITDA, Segment Adjusted EBITDA and Free Cash Flow are not measures of liquidity under GAAP, or otherwise, and are not alternatives to cash flows from operating activities.

Some of the limitations of the Adjusted Net Income and Adjusted Earnings ~~per~~ ~~Per~~ Share measures are that they do not reflect income tax expense or income tax payments we are required to make. In addition, Adjusted Net Income and Adjusted Earnings ~~per~~ ~~Per~~ Share are not measures of profitability under GAAP.

We also urge you to review the reconciliation of these Non-GAAP financial measures included elsewhere in this Annual Report. To properly and prudently evaluate our business, we encourage you to review the consolidated financial statements and related notes included elsewhere in this Annual Report and to not rely on any single financial measure to evaluate our business. In addition, because the EBITDA, Adjusted EBITDA, Segment Adjusted EBITDA, Adjusted Net Income, Adjusted Earnings ~~per~~ ~~Per~~ Share and Free Cash Flow measures are susceptible to varying calculations, such Non-GAAP financial measures may differ from, and may therefore not be comparable to, similarly titled measures used by other companies.

Non-recurring and non-cash items excluded in our calculation of Adjusted EBITDA, Segment Adjusted EBITDA and Adjusted Net Income consist of stock-based compensation, acquisition- and disposition-related expenses, strategic initiative and financial restructuring-related expenses, gain or loss on FFF Put and Call Rights, income and expense that has been classified as discontinued operations and other reconciling items. More information about certain of the more significant items follows below.

Income tax expense on adjusted income

Adjusted Net Income, a Non-GAAP financial measure as defined ~~below~~ ~~above~~ in "Our Use of Non-GAAP Financial Measures", is calculated net of taxes based on our estimated annual effective tax rate for federal and state income tax, adjusted for unusual or infrequent items, as we are a consolidated group for tax purposes with all of our subsidiaries' activities included. The tax rate used to compute the Adjusted Net Income was 27% and 26% for ~~both~~ the years ended **June 30, 2023** **June 30, 2024** and **2022**.

~~As a result of 2023, respectively. This increase primarily relates to the Subsidiary Reorganization, one of our consolidated subsidiaries is expected to have sufficient decrease in pre-tax book income to utilize its net operating loss and other permanent tax adjustments offset by an increase in research and development credit carryforwards. During the first quarter of fiscal 2022, we assessed the future realization of our deferred tax assets as a result of our plan to complete the Subsidiary Reorganization by the end of the second quarter of fiscal year 2022. On December 1, 2021, we completed the Subsidiary Reorganization. We reassessed the valuation allowance release as of June 30, 2022. In fiscal year 2022, we released \$32.3 million of deferred tax valuation allowance primarily related to finite-lived net operating losses and research and development credit carryforwards. As a result of the Subsidiary Reorganization, we have offset ordinary income of \$3.1 million during fiscal year 2022. The remaining \$29.2 million of valuation allowance related to finite-lived net operating losses and research and development credit carryforwards is expected to be released and utilized in future periods.~~

credits.

Stock-based compensation

In addition to non-cash employee stock-based compensation expense, this item includes non-cash stock purchase plan expense of \$0.6 million for both the years ended **June 30, 2023** **June 30, 2024** and **2022**, respectively, (see Note 13 - Stock-Based Compensation to the accompanying consolidated financial statements for further information).

Acquisition- and disposition-related expenses

Acquisition-related expenses include legal, accounting and other expenses related to acquisition activities, one-time integration expenses and gains and losses on the change in fair value of earn-out liabilities. Disposition-related expenses include severance and retention benefits and financial advisor fees, ~~and~~ legal fees ~~and~~ other expenses related to disposition activities.

Strategic initiative and financial restructuring-related expenses

Strategic initiative and financial restructuring-related expenses include legal, accounting and other expenses related to strategic initiative and financial restructuring-related activities.

Gain or loss on FFF Put and Call Rights

See Note 5 - Fair Value Measurements to the accompanying consolidated financial statements for further information.

Impairment of assets

Impairment of assets relates to impairment of long-lived assets.

Other reconciling items

Other reconciling items ~~includes, include, but is are~~ not limited to, gains and losses on ~~disposals~~ ~~disposal~~ of long-lived assets, ~~and~~ imputed interest on ~~notes payable~~ ~~non-interest bearing debt~~ and any impact from non-controlling interest on ~~adjustments~~ to former limited partners, net (loss) income attributable to stockholders.

Results of Operations for the Years Ended **June 30, 2023 **June 30, 2024** and **2022****

The following table presents our results of operations for the fiscal years presented (in thousands, except per share data):

		Year Ended June 30,			
		2023		2022	
		Amount	% of Net Revenue	Amount	% of Net Revenue
Year Ended June 30,					
Year Ended June 30,					
Year Ended June 30,					
		2024			
		Amount		Amount	
		Amount		Amount	
		Amount		Amount	
Net revenue:					
Net revenue:					
Net revenue:	Net revenue:				
Net administrative fees	Net administrative fees	\$ 611,035	46 %	\$ 601,128	42 %
Net administrative fees	Net administrative fees				
Software licenses, other services and support	Software licenses, other services and support				
Software licenses, other services and support	Software licenses, other services and support	480,401	36 %	438,267	31 %
Services and software licenses	Services and software licenses	1,091,436	82 %	1,039,395	73 %
Services and software licenses	Services and software licenses				
Products	Products				
Products	Products	244,659	18 %	393,506	27 %
Net revenue	Net revenue	1,336,095	100 %	1,432,901	100 %
Net revenue					
Net revenue					
Cost of revenue:					
Cost of revenue:					
Cost of revenue:	Cost of revenue:				
Services and software licenses	Services and software licenses	218,087	16 %	183,984	13 %
Services and software licenses	Services and software licenses				
Products	Products				
Products	Products	221,719	17 %	363,878	25 %
Cost of revenue	Cost of revenue	439,806	33 %	547,862	38 %
Cost of revenue					
Cost of revenue					
Gross profit					
Gross profit					
Gross profit	Gross profit	896,289	67 %	885,039	62 %

Operating expenses	Operating expenses	654,196	49	%	624,966	44	%
Operating expenses							
Operating expenses							
Operating income							
Operating income	Operating income	242,093	18	%	260,073	18	%
Other income, net	Other income, net	7,905	1	%	66,827	5	%
Other income, net							
Other income, net							
Income before income taxes	Income before income taxes	249,998	19	%	326,900	23	%
Income before income taxes							
Income tax expense							
Income tax expense	Income tax expense	75,111	6	%	58,582	4	%
Net income	Net income	174,887	13	%	268,318	19	%
Net loss (income) attributable to non-controlling interest		139	—	%	(2,451)	—	%
Net income							
Net income							
Net loss attributable to non-controlling interest							
Net loss attributable to non-controlling interest							
Net loss attributable to non-controlling interest							
Net income attributable to stockholders	Net income attributable to stockholders	\$ 175,026	13	%	\$ 265,867	19	%
Net income attributable to stockholders							
Net income attributable to stockholders							
Earnings per share attributable to stockholders:							
Earnings per share attributable to stockholders:							
Earnings per share attributable to stockholders:	Earnings per share attributable to stockholders:						
Basic	Basic	\$ 1.47			\$ 2.21		
Basic							
Basic							
Diluted	Diluted	\$ 1.46			\$ 2.19		
Diluted							
Diluted							

For the following Non-GAAP financial measures and reconciliations of our performance derived in accordance with GAAP to the Non-GAAP financial measures, refer to "Our Use of Non-GAAP Financial Measures" for further information regarding items excluded in our calculation of Adjusted EBITDA, Segment Adjusted EBITDA, Non-GAAP Adjusted Net Income and Non-GAAP Adjusted Earnings Per Share. The definitions for Adjusted EBITDA, Segment Adjusted EBITDA and Adjusted Net Income were revised from those reported in the 2023 Annual Report. For comparability purposes, prior year Non-GAAP financial measures are presented based on the current definitions in the above section "Our Use of Non-GAAP Financial Measures".

The following table provides certain Non-GAAP financial measures for the fiscal years presented (in thousands, except per share data).

Year Ended June 30,

		2023		2022					
		Year Ended June 30,		Year Ended June 30,					
				Year Ended June 30,					
		2024							
Certain Non-GAAP Financial Data:									
Certain Non-GAAP Financial Data:									
Certain Non-GAAP Financial Data:	Certain Non-GAAP Financial Data:								
Adjusted EBITDA	Adjusted EBITDA	\$ 499,783	37%	\$ 498,682	35%				
Adjusted EBITDA									
Adjusted EBITDA									
Non-GAAP Adjusted Net Income									
Non-GAAP Adjusted Net Income	Non-GAAP Adjusted Net Income	299,330	22%	302,738	21%				
Non-GAAP Earnings Per Share	Non-GAAP Earnings Per Share	2.50	nm	2.49	nm				
Non-GAAP Adjusted Earnings Per Share									
Non-GAAP Adjusted Earnings Per Share									
nm = Not meaningful									

The following table provides the reconciliation of net income to Adjusted EBITDA and the reconciliation of income before income taxes to Segment Adjusted EBITDA (in thousands):

		Year Ended June 30,			
		2023	2022		
		Year Ended June 30,		Year Ended June 30,	
2024		2024		2023	
Net income	Net income	\$174,887	\$268,318		
Interest expense, net		14,470	11,142		
Interest (income) expense, net					
Income tax expense	Income tax expense	75,111	58,582		
Depreciation and amortization	Depreciation and amortization	85,691	85,171		
Amortization of purchased intangible assets	Amortization of purchased intangible assets	48,102	43,936		
EBITDA	EBITDA	398,261	467,149		
Stock-based compensation	Stock-based compensation	14,355	46,809		

Acquisition- and disposition- related expenses	Acquisition- and disposition- related expenses	17,151	11,453
Strategic initiative and financial restructuring- related expenses	Strategic initiative and financial restructuring- related expenses	13,831	18,005
Equity in net loss (income) of unconsolidated affiliates			
Gain on sale of investment in unconsolidated affiliates			
Gain on sale of investment in unconsolidated affiliates			
Gain on sale of investment in unconsolidated affiliates			
Impairment of assets	Impairment of assets	56,718	18,829
Gain on FFF Put and Call Rights			
Other reconciling items, net ^(a)	Other reconciling items, net ^(a)	(533)	547
Adjusted EBITDA		\$499,783	\$498,682
Other reconciling items, net ^(a)			
Other reconciling items, net ^(a)			
Total Adjusted EBITDA			
Income before income taxes	Income before income taxes	\$249,998	\$326,900
Equity in net income of unconsolidated affiliates		(16,068)	(23,505)
Interest expense, net		14,470	11,142
Gain on FFF Put and Call Rights			
Other (income) expense, net		(6,307)	9,646
Income before income taxes			
Income before income taxes			
Equity in net loss (income) of unconsolidated affiliates			
Interest (income) expense, net			
Other income, net			
Other income, net			
Other income, net			

Operating income	Operating income	242,093	260,073
Depreciation and amortization	Depreciation and amortization	85,691	85,171
Amortization of purchased intangible assets	Amortization of purchased intangible assets	48,102	43,936
Stock-based compensation	Stock-based compensation	14,355	46,809
Acquisition- and disposition-related expenses	Acquisition- and disposition-related expenses	17,151	11,453
Strategic initiative and financial restructuring-related expenses	Strategic initiative and financial restructuring-related expenses	13,831	18,005
Equity in net income of unconsolidated affiliates		16,068	23,505
Deferred compensation plan expense (income)		5,422	(9,401)
Deferred compensation plan expense			
Impairment of assets			
Impairment of assets			
Impairment of assets	Impairment of assets	56,718	18,829
Other reconciling items, net (b)	Other reconciling items, net (b)	352	302
Adjusted EBITDA		\$499,783	\$498,682
Total Adjusted EBITDA			
Segment Adjusted EBITDA:			
Adjusted EBITDA:			
Adjusted EBITDA:			
Adjusted EBITDA:			
Supply Chain Services			
Supply Chain Services			
Supply Chain Services	Supply Chain Services	\$499,431	\$500,854
Performance Services	Performance Services	123,859	126,938
Segment Adjusted EBITDA			
Corporate	Corporate	(123,507)	(129,110)
Adjusted EBITDA		\$499,783	\$498,682
Total Adjusted EBITDA			

(a) Other reconciling items, net is primarily attributable to dividend income for the year ended June 30, 2023.
 Other reconciling items, net is primarily attributable to loss on disposal of long-lived assets for the year ended June 30, 2022, income.
 (b) Other reconciling items, net is attributable to other miscellaneous expenses.

The following table provides the reconciliation of net income attributable to stockholders to Non-GAAP Adjusted Net Income and the reconciliation of the numerator and denominator for earnings per share attributable to stockholders to Non-GAAP Adjusted Earnings per Share for the years presented (in thousands).^(a)

		Year Ended June 30,			
		2023	2022		
		Year Ended June 30,		Year Ended June 30,	
				2024	2023
Net income attributable to stockholders	Net income attributable to stockholders	\$175,026	\$265,867		
Net (loss) income attributable to non-controlling interest		(139)	2,451		
Income tax expense					
Income tax expense	Income tax expense	75,111	58,582		
Amortization of purchased intangible assets	Amortization of purchased intangible assets	48,102	43,936		
Stock-based compensation	Stock-based compensation	14,355	46,809		
Acquisition- and disposition-related expenses	Acquisition- and disposition-related expenses	17,151	11,453		
Strategic initiative and financial restructuring-related expenses	Strategic initiative and financial restructuring-related expenses	13,831	18,005		
Equity in net loss (income) of unconsolidated affiliates					
Gain on sale of investment in unconsolidated affiliates					
Gain on sale of investment in unconsolidated affiliates					
Gain on sale of investment in unconsolidated affiliates					
Impairment of assets	Impairment of assets	56,718	18,829		
Gain on FFF Put and Call Rights		—	(64,110)		
Other reconciling items, net ^(a)	Other reconciling items, net ^(a)	4,345	7,284		

Non-GAAP adjusted income before income taxes	Non-GAAP adjusted income before income taxes	404,500	409,106
Income tax expense on adjusted income before income taxes	Income tax expense on adjusted income before income taxes		
(b)	(b)	105,170	106,368

Non-GAAP Adjusted Net Income	Non-GAAP Adjusted Net Income	\$299,330	\$302,738
------------------------------------	------------------------------------	-----------	-----------

Reconciliation of denominator for earnings per share attributable to stockholders to Non-GAAP
Adjusted Earnings per Share

Reconciliation of denominator for earnings per
share attributable to stockholders to Non-GAAP
Adjusted Earnings Per Share

Reconciliation of denominator for earnings per
share attributable to stockholders to Non-GAAP
Adjusted Earnings Per Share

Reconciliation of denominator for earnings per
share attributable to stockholders to Non-GAAP
Adjusted Earnings Per Share

Weighted average:	Weighted average:		
Basic weighted average shares outstanding	Basic weighted average shares outstanding	118,767	120,220

Basic weighted average shares
outstanding

Basic weighted average shares
outstanding

Dilutive securities	Dilutive securities	1,122	1,448
Weighted average shares outstanding - diluted	Weighted average shares outstanding - diluted	119,889	121,668

(a) Other reconciling items, net is primarily attributable to loss on disposal of long-lived assets, and imputed interest on notes payable to former limited partners, partners and the impact from non-controlling interest on adjustments to net income attributable to stockholders, including the portion of impairment of assets attributable to Contigo Health's non-controlling interest.

(b) Reflects income tax expense at an estimated effective income tax rate of 27% and 26% of non-GAAP Non-GAAP adjusted net income before income taxes for both the years ended June 30, 2023 June 30, 2024 and 2022, 2023, respectively.

The following table provides the reconciliation of basic earnings per share attributable to stockholders to Non-GAAP Adjusted Earnings per Per Share for the periods presented:

Year Ended June 30,			
		2023	2022
Year Ended June 30,			
2024		2024	2023

Basic	Basic		
Basic	earnings per		
earnings per	share		
share	attributable		
attributable to			
stockholders	stockholders	\$1.47	\$2.21
Net (loss) income attributable			
to non-controlling interest		—	0.02
Income tax expense	Income tax expense	0.63	0.49
Amortization of purchased intangible assets	Amortization of purchased intangible assets	0.41	0.37
Stock-based compensation	Stock-based compensation	0.12	0.39
Acquisition- and disposition-related expenses	Acquisition- and disposition-related expenses	0.14	0.10
Strategic initiative and financial restructuring-related expenses	Strategic initiative and financial restructuring-related expenses	0.12	0.15
Equity in net loss (income) of unconsolidated affiliates			
Gain on sale of investment in unconsolidated affiliates			
Gain on sale of investment in unconsolidated affiliates			
Gain on sale of investment in unconsolidated affiliates			
Impairment of assets	Impairment of assets	0.48	0.16
Gain on FFF Put and Call Rights		—	(0.53)
Other reconciling items, net ^(a)	Other reconciling items, net ^(a)	0.04	0.06
Impact of corporation taxes ^(b)	Impact of corporation taxes ^(b)	(0.89)	(0.88)
Impact of dilutive shares	Impact of dilutive shares	(0.02)	(0.05)
Non-GAAP	Non-GAAP		
Adjusted	Adjusted		
Earnings	Earnings		
Per Share	Per Share	\$2.50	\$2.49

(a) Other reconciling items, net is primarily attributable to loss on disposal of long-lived assets, and imputed interest on notes payable to former limited partners, partners and the impact from non-controlling interest on adjustments to net income attributable to stockholders, including the portion of impairment of assets attributable to Contigo Health's non-controlling interest.

(b) Reflects income tax expense at an estimated effective income tax rate of 27% and 26% of non-GAAP Non-GAAP adjusted net income before income taxes for both the years ended June 30, 2023 June 30, 2024 and 2022, respectively.

Consolidated Results - Comparison of the Years Ended June 30, 2023 June 30, 2024 to 2022 2023

The variances in the material factors contributing to the changes in the consolidated results are discussed further in "Segment Results" below.

Net Revenue

Net revenue decreased increased by \$96.8 million \$10.3 million, or 7% 1%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023 primarily due to a \$24.2 million, or 6%, increase in Performance Services due to higher software license and consulting services revenue over the prior year, partially offset by a decrease of \$148.8 million \$13.7 million, or 2%, in Supply Chain Services, of which \$30.9 million of the decline is related to products revenue. This The Supply Chain Services revenue decrease was partially offset by increases of \$42.1 million \$9.8 million and \$7.5 million in net administrative fees and software licenses, other services and support, revenue and \$9.9 million in net administrative fees revenue, respectively.

Cost of Revenue

Cost of revenue decreased increased by \$108.1 million \$18.5 million, or 20% 4%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023 primarily due to a decrease of \$142.2 million in cost of products revenue partially offset by an increase of \$34.1 million \$50.8 million in cost of services and software licenses revenue primarily due to higher personnel costs in both Supply Chain Services and Performance Services, partially offset by a decrease of \$32.3 million in cost of products revenue.

Operating Expenses

Operating expenses increased by \$29.2 million \$105.8 million, or 5% 16%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023 primarily due to increases an increase of \$24.7 million \$108.1 million in SG&A expenses driven by the Contigo Health goodwill, intangible and \$4.2 million other long-lived assets impairment and higher fiscal year 2024 performance-related compensation expense compared to the prior year, partially offset by a decrease of \$1.4 million in amortization of intangible assets, research and development.

Other Income, Net

Other income, net decreased increased by \$58.9 million \$13.9 million during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023. The decrease increase was primarily due to:

- increase of \$15.8 million in interest income, net, in the current year due to interest earned from the investment of cash received from the sale of non-healthcare contracts in money market funds and lower outstanding loan balances in the current year compared to the prior year;
- current year gain of \$64.1 million \$11.0 million on the FFF Put Right sale of investment in unconsolidated affiliate; and
- change in deferred compensation plan expense as a result of the termination and corresponding derecognition of the FFF Put Right liability in fiscal year 2022 (see Note 5 - Fair Value Measurements to the accompanying consolidated financial statements for further information) market changes.

These increases were partially offset by a decrease of \$7.4 million \$16.4 million in equity in net income of unconsolidated affiliates primarily due to the prior year change in classification of our investment in FFF from equity method, to cost, adjusted for impairment, plus or minus observable market changes as well as lower current year performance from our other equity method investments. In addition, as of March 3, 2023, FFF is no longer being accounted for under the equity method of accounting (see Note 4 - Investments to the accompanying consolidated financial statements for further information)

- increase of \$3.3 million in interest expense in the current year due to higher interest rates and outstanding loan balances.

These decreases were partially offset by a change in deferred compensation plan expense as a result of market changes.

Income Tax Expense

We recorded an income tax expense of \$43.1 million and \$75.1 million for the years ended June 30, 2023 compared to income tax expense of \$58.6 million for the year ended June 30, 2022 June 30, 2024 and 2023, respectively. The income tax expense resulted in effective tax rates of 30% 29% and 18% 30% for the years ended June 30, 2023 June 30, 2024 and 2022, 2023, respectively. The change in the effective tax rate is primarily attributable to the prior year's one-time deferred tax benefit associated with a decrease in the remeasurement of the deferred tax asset due to apportionment and valuation allowance release as a result of the 2021 Subsidiary Reorganization state law changes when compared to prior year (see Note 15 - Income Taxes to the accompanying consolidated financial statements for further information).

Net Loss (Income) Attributable to Non-Controlling Interest

Net loss (income) attributable to non-controlling interest decreased increased by \$2.6 million \$12.7 million during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023, primarily due to our consolidated subsidiaries with non-controlling interests incurring a decrease larger net loss in the portion of net income attributable current year, primarily related to non-controlling interests in our consolidated subsidiaries, the aforementioned impairment loss on Contigo Health.

Adjusted EBITDA

Adjusted EBITDA, a Non-GAAP financial measure as defined in "Our Use of Non-GAAP Financial Measures", increased decreased by \$1.1 million \$37.9 million, or less than 1% 8%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023 driven by an increase decreases of \$5.6 million \$16.7 million, \$10.1 million and \$11.0 million in Supply Chain Services, Performance Services and Corporate Adjusted EBITDA, respectively. These decreases were primarily due to higher personnel

costs partially offset by decreases of \$3.0 million in increased software licenses, other services and \$1.5 million in Performance Services support and Supply Chain Services Adjusted EBITDA, respectively, net administrative fees revenue.

Segment Results

Supply Chain Services

The following table presents our results of operations and Adjusted EBITDA, a Non-GAAP financial measure, in the Supply Chain Services segment for the fiscal years presented (in thousands):

		Year Ended June 30,																		
		2023	2022	Change																
Year Ended June 30,																				
Year Ended June 30,																				
Year Ended June 30,																				
		2024																		
		2024																		
		2024								2023		Change								
Net revenue:	Net revenue:																			
Net administrative fees	Net administrative fees																			
Net administrative fees	Net administrative fees																			
Net administrative fees	Net administrative fees	\$ 611,035	\$ 601,128	\$ 9,907	2 %	\$ 620,831	\$	\$ 611,035	\$	\$ 9,796	2	\$ 2	2 %							
Software licenses, other services and support	Software licenses, other services and support																			
Software licenses, other services and support	Software licenses, other services and support	44,261	37,312	6,949	19 %	51,750	44,261	44,261	7,489	7,489	17									
Services and software licenses	Services and software licenses																			
Services and software licenses	Services and software licenses	655,296	638,440	16,856	3 %	672,581	655,296	655,296	17,285	17,285	3									
Products	Products	244,659	393,506	(148,847)	(38) %	Products	213,722	244,659	244,659	(30,937)	(30,937)	(13)	(1)							
Net revenue	Net revenue	899,955	1,031,946	(131,991)	(13) %	Net revenue	886,303	899,955	899,955	(13,652)	(13,652)	(2)	(2)							
Cost of revenue:	Cost of revenue:																			
Services and software licenses	Services and software licenses																			
Services and software licenses	Services and software licenses	17,989	14,869	3,120	21 %															
Services and software licenses	Services and software licenses																			
Services and software licenses	Services and software licenses																			
Products	Products	221,719	363,878	(142,159)	(39) %	Products	189,464	221,719	221,719	(32,255)	(32,255)	(15)	(1)							
Cost of revenue	Cost of revenue	239,708	378,747	(139,039)	(37) %	Cost of revenue	237,866	239,708	239,708	(1,842)	(1,842)	(1)	(1)							
Gross profit	Gross profit	660,247	653,199	7,048	1 %	Gross profit	648,437	660,247	660,247	(11,810)	(11,810)	(2)	(2)							
Operating expenses:	Operating expenses:																			
Selling, general and administrative	Selling, general and administrative																			
Selling, general and administrative	Selling, general and administrative																			
Selling, general and administrative	Selling, general and administrative	208,113	212,436	(4,323)	(2) %	215,344	208,113	208,113	7,231	7,231	3	3	3							

Research and development	Research and development	390	397	(7)	(2)%	Research and development	412	390	390	22	22	6
Amortization of intangibles	Amortization of intangibles	31,900	32,428	(528)	(2)%	Amortization of intangibles	31,088	31,900	31,900	(812)	(812)	(3)
Operating expenses	Operating expenses	240,403	245,261	(4,858)	(2)%	Operating expenses	246,844	240,403	240,403	6,441	6,441	3
Operating income	Operating income	419,844	407,938	11,906	3 %	Operating income	401,593	419,844	419,844	(18,251)	(18,251)	(4)
Depreciation and amortization	Depreciation and amortization	22,525	22,996									
Amortization of purchased intangible assets	Amortization of purchased intangible assets	31,900	32,428									
Amortization of purchased intangible assets	Amortization of purchased intangible assets											
Acquisition- and disposition-related expenses	Acquisition- and disposition-related expenses	6,849	1,915									
Equity in net income of unconsolidated affiliates	Equity in net income of unconsolidated affiliates	15,765	22,869									
Acquisition- and disposition-related expenses	Acquisition- and disposition-related expenses											
Acquisition- and disposition-related expenses	Acquisition- and disposition-related expenses											
Impairment of assets	Impairment of assets											
Impairment of assets	Impairment of assets											
Impairment of assets	Impairment of assets	2,296	12,695									
Other reconciling items, net	Other reconciling items, net	252	13									
Other reconciling items, net	Other reconciling items, net											
Segment Adjusted EBITDA	Segment Adjusted EBITDA	\$499,431	\$ 500,854	\$ (1,423)	— %							
Segment Adjusted EBITDA	Segment Adjusted EBITDA											
Segment Adjusted EBITDA	Segment Adjusted EBITDA											

Net Revenue

Supply Chain Services segment revenue decreased by \$132.0 million \$13.7 million, or 13% 2%, during the year ended **June 30, 2023** **June 30, 2024** compared to the year ended **June 30, 2022** **June 30, 2023** driven by a decrease of \$148.8 million \$30.9 million in products revenue, which was partially offset by increases of \$9.9 million \$9.8 million and \$6.9 million \$7.5 million in net administrative fees and software licenses, other services and support revenue, respectively.

Net Administrative Fees Revenue

Net administrative fees revenue increased \$9.9 million \$9.8 million, or 2%, during the year ended **June 30, 2023** **June 30, 2024** compared to the year ended **June 30, 2022** **June 30, 2023**, primarily driven by one-time contractual payments received from certain GPO members due to early termination in breach of their contracts and increased utilization and further penetration of our contracts by existing members, the addition of new members to our contract portfolio and fees paid by certain departed members. These increases in net administrative fees revenue were partially offset by an increase in the aggregate blended revenue share paid to members as a result of renewal of GPO contracts at a higher fee

share than provided in historical agreements due to market dynamics described above under "Net Revenue" within "Key Components of our Results of Operations" section of Item 7 - Management's Discussion and the departure Analysis of members from accessing our supplier GPO contract portfolio. Financial Condition and Results of Operations.

Products Revenue

Products revenue decreased by \$148.8 million \$30.9 million, or 38% 13%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023 primarily a result of lower demand and pricing for certain high-volume commodity products and other previously high-demand supplies due to members' and other customers' elevated inventory levels and continued utilization of excess inventory purchased during the COVID-19 pandemic. exiting product categories with lower margin profiles.

Software Licenses, Other Services and Support Revenue

Software licenses, other services and support revenue increased by \$6.9 million \$7.5 million, or 19% 17%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023, primarily due to an increase in supply chain co-management fees driven by new agreements partially offset by a decrease in purchased services technology license and subscription revenue driven by growth due to timing of license revenue in service fees associated with our committed purchasing programs as well as licensing revenue generated during the prior year.

Cost of Revenue

Supply Chain Services segment cost of revenue decreased by \$139.0 million \$1.8 million, or 37% 1%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023, primarily attributable to the decrease in cost of products revenue of \$142.2 million \$32.3 million in relation to the aforementioned decrease in products revenue due to the prior year increase in demand, fluctuations in as well as lower product costs lower logistics costs and lower inventory reserves in the current year. The decreases in costs of products revenue were partially offset by an increase of \$3.1 million \$30.4 million in cost of services and software licenses revenue primarily due to an increase in personnel costs and consulting services expenses associated with the aforementioned increase headcount in purchased services revenue, direct support of new engagements within our supply chain co-management business.

Operating Expenses

Operating expenses decreased increased by \$4.9 million \$6.4 million, or 2% 3%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023 primarily due to an increase in SG&A expenses of \$7.2 million. The decrease increase in SG&A expenses was primarily due to a decrease net increase in SG&A acquisition- and disposition-related expenses of \$4.3 million as a result driven by the change in the fair value of the cost-savings plan enacted during Acurity and Nexera earn-out liability, an increase in depreciation expense related to increased capitalized software in the current year as well as and an increase in technology subscriptions. These increases were partially offset by a decrease in impairment of long-lived assets due to the prior year goodwill impairment in our Direct Sourcing reporting unit and a decrease in employee-related expenses (see Note 78 - Supplemental Balance Sheet Information Goodwill and Intangible Assets to the accompanying consolidated financial statements for further information) partially offset by an increase in acquisition- and disposition-related expenses related to the sale of our non-healthcare GPO member contracts.

Segment Adjusted EBITDA

Segment Adjusted EBITDA in the Supply Chain Services segment decreased by \$1.4 million \$16.7 million, or 3%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023, due to lower demand higher personnel costs associated with increased headcount primarily in support of growth in our supply chain co-management business and pricing of our products revenue as a result of members' and other customers' elevated inventory levels and a decrease in equity earnings from our investments in unconsolidated affiliates. These decreases were higher fiscal year 2024 performance-related compensation expense compared to the prior year partially offset by the aforementioned increases in net administrative fees revenue and software licenses, other services and support revenue as well as lower logistics costs and inventory reserves products cost in our direct sourcing business.

Performance Services

The following table presents our results of operations and Adjusted EBITDA in the Performance Services segment for the fiscal years presented (in thousands):

Year Ended June 30,			2023	2022	Change
Year Ended June 30,					
Year Ended June 30,					
Year Ended June 30,					
Year Ended June 30,					
2024					
2024					
2024					
					2023
					Change
Net revenue:	Net revenue:				
Software	Software				
licenses, other	licenses, other				
services and	services and				
support	support				
Software licenses, other services					
and support					

Software licenses, other services and support													
SaaS-based products subscriptions													
SaaS-based products subscriptions													
SaaS-based products subscriptions	SaaS-based products subscriptions	\$187,618	\$193,586	\$(5,968)	(3)%	\$179,601	\$	\$187,618	\$	\$	\$	(8,017)	(4)
Consulting services	Consulting services	80,292	64,087	16,205	25%	Consulting services	92,560	80,292	80,292	12,268	12,268		
Software licenses	Software licenses	72,376	65,621	6,755	10%	Software licenses	85,168	72,376	72,376	12,792	12,792		
Other	Other	95,891	77,689	18,202	23%	Other	103,000	95,891	95,891	7,109	7,109		
Net revenue	Net revenue	436,177	400,983	35,194	9%								
Net revenue								460,329		436,177		24,152	
Cost of revenue: Cost of revenue:													
Services and software licenses													
Services and software licenses													
Services and software licenses	Services and software licenses	200,098	169,116	30,982	18%	220,483	200,098	200,098	20,385	20,385	20,385		1
Cost of revenue	Cost of revenue	200,098	169,116	30,982	18%	Cost of revenue	220,483	200,098	200,098	20,385	20,385		20,385
Gross profit	Gross profit	236,079	231,867	4,212	2%	Gross profit	239,846	236,079	236,079	3,767	3,767		3,767
Operating expenses:	Operating expenses:												
Selling, general and administrative	Selling, general and administrative	228,001	170,677	57,324	34%								
Selling, general and administrative													
Selling, general and administrative													
Research and development	Research and development	4,150	3,754	396	11%	Research and development	2,703	4,150	4,150	(1,447)	(1,447)		
Amortization of intangibles	Amortization of intangibles	16,202	11,508	4,694	41%	Amortization of intangibles	16,186	16,202	16,202	(16)	(16)		
Operating expenses	Operating expenses	248,353	185,939	62,414	34%	Operating expenses	335,087	248,353	248,353	86,734	86,734		
Operating (loss) income		(12,274)	45,928	(58,202)	(127)%								
Operating loss						Operating loss	(95,241)		(12,274)		(82,967)		
Depreciation and amortization	Depreciation and amortization	54,804	53,166										
Amortization of purchased intangible assets	Amortization of purchased intangible assets	16,202	11,508										
Amortization of purchased intangible assets													
Amortization of purchased intangible assets													

Acquisition- and disposition-related expenses	Acquisition- and disposition-related expenses	10,302	9,538
Equity in net income of unconsolidated affiliates		303	636
Acquisition- and disposition-related expenses			
Acquisition- and disposition-related expenses			
Impairment of assets			
Impairment of assets			
Impairment of assets	Impairment of assets	54,422	6,134
Other reconciling items, net	Other reconciling items, net	100	28
Other reconciling items, net			
Other reconciling items, net			
Segment	Segment		
Adjusted EBITDA	Adjusted EBITDA	\$123,859	\$126,938
		(\$3,079)	(2) %
Segment Adjusted EBITDA			
Segment Adjusted EBITDA		\$ 113,440	\$ 123,556
			\$ (10,116)

Net Revenue

Net revenue in our Performance Services segment increased by \$35.2 million \$24.2 million, or 9% 6%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023. The increase was primarily attributable to growth of \$18.2 million in other net revenue driven by incremental revenue from the TRPN acquisition and growth in Contigo Health, growth of \$16.2 million in consulting services under our PINC AI platform and growth of \$6.8 million \$12.8 million in software licenses driven by an increased number of increase in enterprise analytics license revenue during the current year compared to the prior year, growth of \$12.3 million in consulting services driven by new agreements entered into during the current year year under our PINC AI platform as well as an increase of \$7.1 million in other revenue driven by increases in Remitra revenue and other certain products under our PINC AI platform. These increases in net revenue were partially offset by a decrease of \$8.0 million in SaaS-based products subscriptions revenue primarily due to the conversion of SaaS-based products to licensed-based products, products in recent periods and contract expirations that did not renew.

Cost of Revenue

Cost of services and software licenses revenue in our Performance Services segment increased by \$31.0 million \$20.4 million, or 18% 10%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023, primarily due to increased consulting services as well higher personnel costs associated with increased headcount including costs to support revenue our Contigo Health business and to support growth in our adjacent markets within the PINC AI platform, an increase in employee-related expenses including higher fiscal year 2024 performance-related compensation expense compared to the prior year and Contigo Health business, including incremental expenses associated with the TRPN acquisition. an increase in consulting services expenses. These increases were partially offset by a decrease in depreciation for assets related to cost of revenue.

Operating Expenses

Performance Services segment operating expenses increased by \$62.4 million \$86.7 million, or 34% 35%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023. The increase was primarily due to goodwill impairment of \$54.4 million related to the \$85.7 million increase in impairments at Contigo Health (see Note 8 - Goodwill and Intangible Assets to the accompanying consolidated financial statements for further information), as well as higher personnel costs employee-related expenses associated with increased headcount and employee travel and meeting expenses as a result of higher fiscal year 2024 performance-related compensation expense compared to the easing of pandemic-related travel restrictions during the current prior year. These increases were partially offset by the impact of the cost-savings plan enacted during the current year. In addition, operating expense increased by \$4.7 million as a result of higher amortization of purchased intangible assets decrease in acquisition- and disposition-related expenses primarily attributable related to the prior year TRPN acquisition (see Note 8 - Goodwill and Intangible Assets to the accompanying consolidated financial statements). lower than anticipated payout of an earn-out liability.

Segment Adjusted EBITDA

Segment Adjusted EBITDA in the Performance Services segment decreased by \$3.1 million \$10.1 million, or 2% 8%, during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023, primarily due to the aforementioned increases in cost of revenue and operating expenses partially offset by the aforementioned increase in net revenue.

Corporate

The following table summarizes corporate expenses and Adjusted EBITDA for the fiscal years presented (in thousands):

		Year Ended June 30,				
		2023	2022	Change		
		Year Ended June 30,				
		Year Ended June 30,				
		Year Ended June 30,				
		2024				
		2024				
				2023		Change
Operating expenses:	Operating expenses:					
Selling, general and administrative	Selling, general and administrative	\$ 165,477	\$ 193,794	\$(28,317) (15)%		
Selling, general and administrative	Selling, general and administrative				\$ 178,380	\$ 165,477
Operating expenses	Operating expenses					\$ 12,903
Operating expenses	Operating expenses					8 %
Operating expenses	Operating expenses	165,477	193,794	(28,317) (15)%	178,380	165,477
Operating loss	Operating loss	(165,477)	(193,794)	28,317 (15)%	Operating loss (178,380)	(165,477)
Depreciation and amortization	Depreciation and amortization	8,362	9,009		(165,477)	(165,477)
Stock-based compensation	Stock-based compensation	14,355	46,809			
Stock-based compensation	Stock-based compensation					
Strategic initiative and financial restructuring-related expenses	Strategic initiative and financial restructuring-related expenses	13,831	18,005			
Deferred compensation plan expense (income)	Deferred compensation plan expense (income)	5,422	(9,401)			
Strategic initiative and financial restructuring-related expenses	Strategic initiative and financial restructuring-related expenses					
Strategic initiative and financial restructuring-related expenses	Strategic initiative and financial restructuring-related expenses					
Deferred compensation plan expense	Deferred compensation plan expense					
Deferred compensation plan expense	Deferred compensation plan expense					
Other reconciling items, net	Other reconciling items, net					
Other reconciling items, net	Other reconciling items, net					
Other reconciling items, net	Other reconciling items, net	—	262			

Adjusted EBITDA	Adjusted EBITDA	\$ (123,507)	\$ (129,110)	\$ 5,603	(4)%			
Adjusted EBITDA						\$ (134,529)	\$ (123,507)	\$ (11,022)
Operating Expenses								9 %

Corporate operating expenses decreased increased by **\$28.3 million** **\$12.9 million**, or **15% 8%**, during the year ended **June 30, 2023** **June 30, 2024** compared to the year ended **June 30, 2022** **June 30, 2023** primarily due to a decrease an increase in stock-based compensation expense as a result of lower achievement of performance share awards lower in the prior year, higher employee-related expenses including higher fiscal year 2024 performance-related compensation expense compared to the prior year and an increase in deferred compensation plan income due to market changes. These increases were partially offset by a decrease in professional fees related to strategic initiative and financial restructuring-related activities and a decrease in performance-related compensation expense. In addition, there was a net decrease in operating expenses as a result of the cost-savings plan enacted during the current year. These decreases were partially offset by deferred compensation plan income in the current year compared to deferred compensation expense in the prior year due to market changes. expenses.

Adjusted EBITDA

Adjusted EBITDA increased decreased by **\$5.6 million** **\$11.0 million**, or **4% 9%**, during the year ended **June 30, 2023** **June 30, 2024** compared to the year ended **June 30, 2022** **June 30, 2023** primarily due to a decrease the aforementioned increases in performance-related compensation and a net decrease in expenses as a result of the cost-savings plan enacted during the current year, employee-related expenses.

Results of Operations for the Years Ended **June 30, 2022 **June 30, 2023** and **2021****

A discussion of changes in our results of operations from fiscal year **2021** **2022** to fiscal year **2022** **2023** has been omitted from this Annual Report but may be found in "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Form 10-K for the fiscal year ended **June 30, 2022** **June 30, 2023**, filed with the SEC on **August 16, 2022** **August 22, 2023**, which is available free of charge on the SEC's website at www.sec.gov and our website at <http://investors.premierinc.com>.

Off-Balance Sheet Arrangements

As of **June 30, 2023** **June 30, 2024**, we did not have any off-balance sheet arrangements.

Liquidity and Capital Resources

Our principal source of cash has been primarily cash provided by operating activities. From time to time we have used, and expect to use in the future, borrowings under our Credit Facility (as defined in Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements for more information) as a source of liquidity to fund acquisitions and related business investments as well as general corporate activities. Our primary cash requirements include operating expenses, working capital fluctuations, revenue share obligations, tax payments, capital expenditures, dividend payments on our **Class A Common**

common stock, Stock, if and when declared, repurchases of **Class A common stock Common Stock** pursuant to stock repurchase programs in place from time to time, acquisitions and related business investments and general corporate activities. Our capital expenditures typically consist of internally-developed software costs, software purchases and computer hardware purchases.

As of **June 30, 2023** **June 30, 2024** and **2022, 2023**, we had cash and cash equivalents of **\$89.8 million** **\$125.1 million** and **\$86.1 million** **\$89.8 million**, respectively.

Credit Facility

As of June 30, 2024, we had no outstanding borrowings under our Credit Facility. At June 30, 2023 and 2022, there was we had \$215.0 million and \$150.0 million, respectively, of outstanding borrowings under our Credit Facility. During the year ended **June 30, 2023** **June 30, 2024**, we borrowed \$285.0 million had no new borrowings and repaid **\$135.0 million** **\$215.0 million** of borrowings under the Prior Loan Agreement (as defined in Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements) which were used to partially fund the TRPN acquisition (see Note 3 - Business Acquisitions to the accompanying consolidated financial statements for more information). During the year ended June 30, 2023, we borrowed \$185.0 million and repaid \$270.0 million under the Credit Facility which was used for general corporate purposes. All outstanding borrowings under the Credit Facility as of June 30, 2023 were repaid in July and August 2023. Facility.

We expect cash generated from operations and borrowings under our Credit Facility to provide us with adequate liquidity to fund our anticipated working capital requirements, revenue share obligations, tax payments, capital expenditures, notes payable, including notes payable to former LPs, limited partners ("LP"), dividend payments on our **Class A common stock, Common Stock**, if and when declared, repurchases of **Class A common stock Common Stock** pursuant to stock repurchase programs in place from time to time and to fund business acquisitions. Our capital requirements depend on numerous factors, including funding requirements for our product and service development and commercialization efforts, our information technology requirements and the amount of cash generated by our operations. We believe that we have adequate capital resources at our disposal to fund currently anticipated capital expenditures, business growth and expansion, and current and projected debt service requirements. However, strategic growth initiatives will likely require the use of one or a combination of various forms of capital resources including available cash on hand, cash generated from operations, borrowings under our Credit Facility and other long-term debt and, potentially, proceeds from the issuance of additional equity or debt securities.

Cash Dividends

On **August 10, 2023** **August 8, 2024**, our Board of Directors declared a cash dividend of \$0.21 per share, payable on **September 15, 2023** **September 15, 2024** to stockholders of record on **September 1, 2023** **September 1, 2024**.

Sale of Non-Healthcare GPO Member Contracts

On **June 14, 2023** **July 25, 2023**, we announced that we entered into sold substantially all of our non-healthcare GPO member contracts pursuant to an equity purchase agreement with OMNIA to sell the contracts pursuant to which substantially all of our non-healthcare GPO members participate in our GPO program for an estimated a purchase price of approximately \$800.0 million subject to certain adjustments, \$723.8 million. As of June 30, 2024, we have received cash of \$681.4 million including a true-up adjustment the closing payment and payments out of escrow based on post-closing adjustments. The final cash payment of \$42.4 million was paid out of escrow in July 2024. See Note 10 - Liability

Related to the purchase price to be paid within approximately eight months following such closing date. On July 25, 2023, the transaction closed and Premier subsequently received \$689.2 million in cash consideration which includes \$151.0 million in escrow. See Note 20 - Subsequent Events Sale of Future Revenues to the accompanying consolidated financial statements for further information.

Discussion of Cash Flows for the Years Ended **June 30, 2023** **June 30, 2024** and **2022**

A summary of net cash flows follows (in thousands):

		Year Ended June 30,			
		2023	2022		
		Year Ended June 30,		Year Ended June 30,	
		2024		2024	2023
Net cash provided by (used in):	Net cash provided by (used in):				
Operating activities	Operating activities	\$444,543	\$444,234		
Investing activities	Investing activities	(273,622)	(139,440)		
Financing activities	Financing activities	(167,266)	(347,789)		
Effect of exchange rate changes on cash flows	Effect of exchange rate changes on cash flows	(5)	(3)		
Net increase (decrease) in cash and cash equivalents	\$ 3,650	\$ (42,998)			
Net increase in cash and cash equivalents					

Net cash provided by operating activities was flat decreased by \$148.0 million for the year ended **June 30, 2023** **June 30, 2024** compared to the year ended **June 30, 2022** **June 30, 2023**. The decrease was primarily due to an increase of \$162.3 million of cash paid for income taxes in the current year on proceeds received from the sale of non-healthcare GPO member contracts and associated future revenues to OMNIA, an increase of \$64.0 million in cash paid for costs directly related to revenue-generating activities including and primarily due to employee-related expenses associated with increased headcount to support both our Supply Chain Services and Performance Services segments and an increase in miscellaneous expenses, including income taxes paid from business operations. These decreases to cash were partially offset by a decrease of cash paid for operating expenses of \$59.8 million primarily due to a decrease in performance-related compensation relating to the prior fiscal year performance that was paid during the year and an increase of \$21.6 million in cash receipts due to higher collections during the current period.

Net cash used in investing activities increased decreased by \$134.2 million \$205.2 million for the year ended **June 30, 2023** **June 30, 2024** compared to the year ended **June 30, 2022** **June 30, 2023**. The increase decrease in net cash used in investing activities was primarily due to the cash outlay of \$177.5 million for the TRPN acquisition in the prior year and cash received of \$12.8 million in the current year offset by for the cash outlay sale of an investment in the prior year for investments in Exela and Qventus, Inc. an unconsolidated affiliate. The increase decrease was partially offset by a net decrease increase in purchases of property and equipment and other investing activities.

equipment.

Net cash used in financing activities decreased increased by \$180.5 million \$25.5 million for the year ended **June 30, 2023** **June 30, 2024** compared to the year ended **June 30, 2022** **June 30, 2023**. The decrease increase in net cash used in financing activities was primarily driven by the prior year cash outflow \$400.0 million paid as part of \$250.1 million for the ASR Agreement to repurchase of Class A common stock under the fiscal 2022 stock repurchase program. The prior year cash outflow was partially offset by lower cash inflows in the current year due to a decrease of \$31.7 million in proceeds from the issuance of Class A common stock in connection with the exercise of outstanding stock options, a decrease of \$23.2 million in other financing activities primarily driven by proceeds from member health systems that acquired membership interests in ExPre in the prior year our Common Stock and a decrease of \$10.0 million \$280.0 million in net borrowings under our Credit Facility Facility. These uses of cash were partially offset by net proceeds from the sale of future revenues of \$649.9 million in the current year (see Note 10 - Liability Related to the Sale of Future Revenues to the accompanying consolidated financial statements for further information) as well as higher cash outflow of \$3.8 million a decrease in cash dividends paid paid of \$5.0 million as a result of the impact of the ASR Agreement.

Discussion of Non-GAAP Free Cash Flow for the Years Ended **June 30, 2023** **June 30, 2024** and **2022**

We define Non-GAAP Free Cash Flow as net cash provided by operating activities from continuing operations less (i) early termination payments to certain former limited partners that elected to execute a Unit Exchange Agreement in connection with our August 2020 Restructuring and (ii) purchases of property and equipment. Non-GAAP Free Cash Flow does not represent discretionary cash available for spending as it excludes certain contractual obligations such as debt repayments under our Credit Facility.

A summary of Non-GAAP Free Cash Flow and reconciliation to net cash provided by operating activities for the periods presented follows (in thousands):

		Year Ended June 30,			
		2023	2022		
		Year Ended June 30,		Year Ended June 30,	
		2024	2024	2023	
Net cash provided by operating activities	Net cash provided by operating activities	\$444,543	\$444,234		
Early termination payments to certain former limited partners that elected to execute a Unit Exchange Agreement					
(a) Purchases of property and equipment	Purchases of property and equipment	(82,302)	(87,440)		
Early termination payments to certain former limited partners that elected to execute a Unit Exchange Agreement					
(a)		(97,806)	(95,948)		
Non-GAAP Free Cash Flow	Non-GAAP Free Cash Flow	\$264,435	\$260,846		

(a) Early termination payments to certain former limited partners that elected to execute a Unit Exchange Agreement in connection with our August 2020 Restructuring are presented in our Consolidated Statements of Cash Flows under "Payments made on notes payable". During the year ended **June 30, 2023** June 30, 2024, we paid \$102.7 million to members including imputed interest of **\$4.9 million** \$3.0 million which is included in net cash provided by operating activities. During the year ended **June 30, 2022** June 30, 2023, we paid \$102.7 million to members including imputed interest of **\$6.7 million** \$4.9 million which is included in net cash provided by operating activities. See Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements for further information.

Non-GAAP Free Cash Flow **increased** decreased by **\$3.6 million** \$148.7 million for the year ended **June 30, 2023** June 30, 2024 compared to the year ended **June 30, 2022** June 30, 2023 primarily due to the aforementioned \$148.0 million decrease in purchases net cash provided by operating activities, which was driven by cash taxes paid on OMNIA proceeds of property and equipment \$162.3 million.

See "Our Use of Non-GAAP Financial Measures" above for additional information regarding our use of Non-GAAP Free Cash Flow.

Contractual Obligations

The following table presents our contractual obligations as of **June 30, 2023** June 30, 2024 (in thousands):

Payments Due by Period

Contractual Obligations	Contractual Obligations	Payments Due by Period					Payments Due by Period			
		Less Than 5 Years			Greater Than 5 Years		Contractual Obligations		Payments Due by Period	
		Total	1 Year	1-3 Years	Years	Years	Total	Less Than 1 Year	1-3 Years	3-5 Years
Notes payable to former limited partners (a)	Notes payable to former limited partners (a)	\$205,370	\$102,685	\$102,685	\$ —	\$ —				
Other notes payable (b)	Other notes payable (b)	2,280	1,546	734	—	—				
Operating lease obligations (c)	Operating lease obligations (c)	35,099	12,381	21,394	1,324	—				
Deferred consideration (d)	Deferred consideration (d)	60,000	30,000	30,000	—	—				
Total contractual obligations	Total contractual obligations	\$302,749	\$146,612	\$154,813	\$1,324	\$ —				

- (a) Notes payable to former limited partners represent the amount of the expected payment to be made to each former limited partner pursuant to the early termination provisions of the TRA (each such amount an "Early Termination Payment"). See Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements for more information.
- (b) Other notes payable are non-interest bearing and generally have stated maturities of three to five years from the date of issuance. See Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements for more information.
- (c) Future contractual obligations for leases represent future minimum payments under noncancelable operating leases primarily for office space. See Note 17 - Commitments and Contingencies to the accompanying consolidated financial statements for more information.
- (d) Deferred consideration to be paid pursuant to the purchase agreement for the acquisition of substantially all of the assets and certain liabilities of Acurity, Inc. and Nexera, Inc. in fiscal year 2020.

Credit Facility

Outstanding borrowings under the Credit Facility (as defined in Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements for more information) bear interest on a variable rate structure with borrowings bearing interest at either the secured overnight financing rate ("SOFR") plus an adjustment of 0.100% plus an applicable margin ranging from 1.250% to 1.750% or the prime lending rate plus an applicable margin ranging from 0.250% to 0.750%. We pay a commitment fee ranging from 0.125% to 0.225% for unused capacity under the Credit Facility. At **June 30, 2023** **June 30, 2024**, the interest rate on outstanding borrowings under the Credit Facility was 6.470% and the commitment fee was 0.125%.

The Credit Facility contains customary representations and warranties as well as customary affirmative and negative covenants. We were in compliance with all such covenants at **June 30, 2023** **June 30, 2024**. The Credit Facility also contains customary events of default, including a cross-default of any indebtedness or guarantees in excess of \$75.0 million. If any event of default occurs and is continuing, the administrative agent under the Credit Facility may, with the consent, or shall, at the request of a majority of the lenders under the Credit Facility, terminate the commitments and declare all of the amounts owed under the Credit Facility to be immediately due and payable.

Proceeds from borrowings under the Credit Facility may generally be used to finance ongoing working capital requirements, including permitted acquisitions, repurchases of Class A common stock or Common Stock pursuant to stock repurchase programs, in place from time to time, dividend payments, if and when declared, and other general corporate activities. At **June 30, 2023** **June 30, 2024**, we had no outstanding borrowings of \$215.0 million under the Credit Facility with \$785.0 million \$995.0 million of available borrowing capacity after reductions for outstanding borrowings and outstanding letters of credit. All outstanding borrowings under the Credit Facility as of June 30, 2023 were repaid in July and August 2023.

The above summary does not purport to be complete, and is subject to, and qualified in its entirety by reference to, the complete text of the Credit Facility, as amended and restated, which is filed as Exhibit 10.1 in our quarterly report for the period ended December 31, 2022. 10.24 to this Annual Report. See also Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements.

Notes Payable to Former Limited Partners

At June 30, 2024, \$102.7 million remains to be paid without interest in four equal quarterly installments to former limited partners that elected to execute Unit Exchange Agreements ending in the quarter ended June 30, 2025. See Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements for further information.

Other Notes Payable

At June 30, 2024, we had commitments of \$1.0 million for other obligations under notes payable. Other notes payable have stated maturities between three to five years from the date of issuance and are non-interest bearing. See Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements for further information.

Sale of Non-Healthcare GPO Member Contracts

At June 30, 2024, we have non-recourse commitments of \$651.2 million, net of imputed interest of \$14.2 million, for the sale of future revenues due to OMNIA in connection to the sale of non-healthcare GPO member contracts. The liability will be paid.

without interest, in monthly payments from net administrative fees received in connection with the sold contracts commencing during the first quarter of fiscal year 2024 and continuing for at least 10 years. See Note 10 - Liability Related to the Sale of Future Revenues to the accompanying consolidated financial statements for further information.

Cash Dividends

In each of **September 15, 2022** **September 15, 2023**, **December 15, 2022** **December 15, 2023**, **March 15, 2023** **March 15, 2024** and **June 15, 2023** **June 15, 2024**, we paid a cash dividend of \$0.21 per share on outstanding shares of **Class A common stock**, our **Common Stock**. On **August 10, 2023** **August 8, 2024**, our Board of Directors declared a cash dividend of \$0.21 per share, payable on **September 15, 2023** **September 15, 2024** to stockholders of record on **September 1, 2023** **September 1, 2024**.

We currently expect quarterly dividends to continue to be paid on or about December 15, March 15, June 15 and September 15, respectively. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our Board of Directors each quarter after consideration of various factors, including our results of operations, financial condition and capital requirements, earnings, general business conditions, restrictions imposed by our current Credit Facility and any future financing arrangements, legal restrictions on the payment of dividends and other factors our Board of Directors deems relevant.

Share Repurchase Authorization

On February 2, 2024, our Board of Directors authorized the repurchase of up to \$1.0 billion of our outstanding Common Stock. On February 5, 2024, under the share repurchase authorization, we entered into the ASR Agreement with Bank of America to repurchase an aggregate of \$400.0 million of shares of our Common Stock. Under the terms of the ASR Agreement, we made a payment of \$400.0 million to Bank of America and on February 8 and 9, 2024, received initial deliveries of 15.0 million shares of our Common Stock (and then retired), or \$320.0 million, based on the closing price on February 7, 2024 of \$21.29 per share. On July 11, 2024, as final settlement of the accelerated share repurchase transaction under the ASR Agreement, we received from Bank of America (and then retired) an additional 4.8 million shares of our Common Stock. In total, we repurchased 19.9 million shares of our Common Stock at an average price of \$20.12 per share under the ASR Agreement, which represents the volume-weighted average share price of our Common Stock during the term of the ASR Agreement less a price adjustment.

Fiscal 2023 Year 2024 Developments

Impact of Inflation

The While the U.S. inflation rate has declined from its peak in calendar year 2022, the U.S. economy is **still** experiencing **the highest elevated rates of inflation since compared to the 1980s**, **recent past**. **We believe that we** have continued to limit the impact of inflation on our members and believe that we maintain significantly lower inflation impacts across our diverse product portfolio than national levels. However, in certain areas of our business, there is still some level of risk and uncertainty for our members and other customers as labor costs, raw material costs and availability, **rising higher** interest rates and inflation continue to pressure supplier pricing as well as apply significant pressure on our margin.

We continue to evaluate the contributing factors, specifically logistics, raw materials and labor, **that which** have led to adjustments to selling prices. We have **begun to see seen** logistics costs normalize to **pre-pandemic levels** as well as some reductions in the costs of specific raw materials; however, the cost of labor remains high. We are continuously working to manage **these** price increases as market conditions change. The impact of inflation **to on** our aggregated product portfolio is partially mitigated by contract term price protection for a large portion of our **portfolio**, as well as negotiated price reductions in certain product categories such as pharmaceuticals. **portfolio**. See "Risk Factors — Risks Related to Our Business Operations" **below** in this Annual Report.

Furthermore, **as while** the Federal Reserve **seeks** **may seek** to **curb rising inflation**, **reduce** market interest rates, **have steadily risen**, and **they** **may continue to rise**, **be elevated**, increasing the cost of borrowing under our Credit Facility (as defined in Note 9 - Debt and Notes Payable to the accompanying consolidated financial statements) as well as impacting our results of operations, financial condition and cash flows.

Geopolitical Tensions

Geopolitical tensions **such as the ongoing military conflict between Russia and Ukraine and tensions between the U.S. and China**, continue to affect the global economy and financial markets, as well as exacerbate ongoing economic challenges, including issues such as rising inflation, energy **costs**, logistics **costs** and global supply-chain disruption.

We continue to monitor the impacts of the geopolitical tensions on macroeconomic conditions and prepare for any implications they may have on member demand, our suppliers' ability to deliver products, cybersecurity risks and our liquidity and access to capital. See "Risk Factors — Risks Related to Our Business Operations", as well as "Market and Industry Trends and Outlook" within Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of this Annual Report for further discussion.

COVID-19 Pandemic or Other

Pandemics, Epidemics or Public Health Emergencies

The outbreak of the novel coronavirus ("COVID-19") **COVID-19** and the resulting global pandemic **and the impact on the healthcare industry** impacted our sales, operations and supply chains, our members and other customers and workforce and suppliers. While both the U.S. and the World Health Organization declared an end to the COVID-19 pandemic as a public health emergency in May 2023, we remain subject to the potential risks associated with **a resurgence of COVID-19** **any future pandemic, epidemic or another pandemic** **remains** **other** **public health emergency**, and the resulting **impact** **uncertain** **impacts** those events could have on our business, results of operations, financial **conditions** and **condition**, cash flows as **well as** and the U.S. and global economies is **uncertain** and cannot be predicted at this time, prospects of the trading price of our Common Stock.

Refer to "Item 1A. Risk Factors" for **significant** **further** **discussion** of the **material** **risks** we **have faced** and **may continue to face** as a result of the COVID-19 pandemic or other pandemics, epidemics or public health emergencies. **face**.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

Our exposure to market risk related primarily to the increase or decrease in the amount of any interest expense we must pay with respect to outstanding debt instruments. At **June 30, 2023** **June 30, 2024**, we had **\$215.0 million** **no** outstanding borrowings under our Credit Facility. At June 30, 2023, a one-percent increase or decrease in the interest rate charged on outstanding borrowings under the Credit Facility would increase or decrease interest expense over the next twelve months by \$2.2 million.

We invest our excess cash in a portfolio of individual cash equivalents. We do not hold any material derivative financial instruments. We do not expect changes in interest rates to have a material impact on our results of operations or financial position. We plan to mitigate default, market and investment risks of our invested funds by investing in low-risk securities.

Foreign Currency Risk

Substantially all of our financial transactions are conducted in U.S. dollars. We do not have significant foreign operations and, accordingly, do not believe we have market risk associated with foreign currencies.

Item 8. Financial Statements and Supplementary Data

Our consolidated financial statements and related notes are filed together with this Annual Report. See the index to financial statements under Item 15(a) for a list of financial statements filed with this report, and under this item.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)	7681
Report of Independent Registered Public Accounting Firm on Internal Controls Over Financial Reporting (PCAOB ID: 42)	7883
Consolidated Balance Sheets	7984
Consolidated Statements of Income and Comprehensive Income	8085
Consolidated Statements of Stockholders' Equity	8186
Consolidated Statements of Cash Flows	8387
Notes to Consolidated Financial Statements	8488

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Premier, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Premier, Inc. (the Company) as of **June 30, 2023** **June 30, 2024** and **2022**, 2023, the related consolidated statements of income and comprehensive income, stockholders' equity and cash flows for each of the three years in the period ended **June 30, 2023** **June 30, 2024**, and the related notes and financial statement schedule listed in the Index at Item 15(a)(2) (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at **June 30, 2023** **June 30, 2024** and **2022**, 2023, and the results of its operations and its cash flows for each of the three years in the period ended **June 30, 2023** **June 30, 2024**, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of **June 30, 2023** **June 30, 2024**, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated **August 22, 2023** **August 20, 2024** expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters Matter

The critical audit **matters** **matter** communicated below **are matters** **is a matter** arising from the current period audit of the financial statements that **were** **was** communicated or required to be communicated to the audit committee and that: (1) **relate** **relates** to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of **the** **critical audit** **matters** **matter** does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit **matters** **matter** below, providing **a** **separate** **opinions** **opinion** on the critical audit **matters** **matter** or on the accounts or disclosures to which **they relate**, **it relates**.

Valuation of Goodwill

Description of the Matter

At **June 30, 2023** **June 30, 2024**, the Company's goodwill was **\$1,012.4 million**, **\$995.9 million**, of which **\$578.9 million** relates to the **Informatics and Technology Services ("ITS") reporting unit**. As discussed in Note 2 to the consolidated financial statements, goodwill is tested for impairment annually at the reporting unit level on the first day of the last fiscal quarter of the fiscal year unless impairment indicators are present **which that** could require an interim impairment test. The Company's goodwill is initially assigned to its reporting units as of the acquisition date.

Auditing management's annual goodwill impairment test was especially complex and highly judgmental due to the estimation required to determine the fair value of the **ITS reporting units, unit**. Fair value is estimated by management based on an income approach using a discounted cash flow model as well as market-based approaches. In particular, the **fair value estimates are estimate** is sensitive to changes in **highly subjective significant assumptions**, such as the **amount and timing of expected future cash flows, perpetual revenue growth rates and discount rates, EBITDA margins**, which are affected by expected future market or economic conditions.

How We Addressed the Matter in Our Audit We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company's goodwill impairment testing process. For example, we tested controls over management's review of the significant **inputs and assumptions** discussed above used in determining the **ITS reporting unit's fair values, value**. We also tested management's controls over the completeness and accuracy of the data used in the valuation.

To test the estimated fair **values value** of the Company's **ITS reporting units, unit**, our audit procedures included, among others, evaluating the Company's selection of the valuation methodologies, evaluating the significant assumptions used, and evaluating the completeness and accuracy of the underlying data supporting the significant assumptions and estimates. For example, we compared the significant assumptions used by management to current industry and economic trends, historical financial results and other relevant factors. We performed sensitivity analyses of significant assumptions to evaluate the change in the fair **values value** of the **ITS reporting units, unit** resulting from changes in the **inputs and assumptions**. We assessed the historical

accuracy of management's projections and involved our valuation specialists to assist in our evaluation of the methodologies and certain significant assumptions. We also evaluated the reconciliation of the estimated aggregate fair value of the reporting units to the market capitalization of the Company.

Valuation of Intangible Assets

Description As disclosed in Note 3 to the consolidated financial statements, in fiscal 2023 the Company acquired certain assets and liabilities of TRPN Direct Pay, Inc. and Devon Health, Inc. for consideration of \$177.5 million, which included the acquisition of intangible assets of \$116.6 million. The Company has accounted for the acquisition as a business combination whereby the purchase price was assigned to tangible and intangible assets acquired and liabilities assumed based on fair values.

Auditing the Company's accounting for the acquisition was especially complex due to the estimation uncertainty involved in determining the fair value of the acquired provider network intangible asset. The higher estimation uncertainty was primarily due to the sensitivity of the fair value to the revenue growth rate assumptions impacting the amount and timing of projected future cash flows and to the discount rate. These significant assumptions are forward-looking and could be affected by future market or economic conditions.

How We Addressed the Matter in Our Audit We obtained an understanding, evaluated the design, and tested the operating effectiveness adequacy of the Company's controls over the valuation of the provider network intangible asset. This disclosure

asset. This disclosures included testing controls over the estimation process supporting the recognition and measurement of the intangible asset, including management's evaluation of underlying assumptions and estimates used to determine the fair value. in

Note 2.

To test the estimated fair value of the provider network intangible asset, we performed audit procedures that included, among others, evaluating the Company's selection of the valuation methodologies, evaluating the significant assumptions used, and evaluating the completeness and accuracy of the underlying data supporting the significant assumptions and estimates. For example, we compared the significant assumptions to current industry and economic trends, historical results of the acquired business and to other relevant factors. We also performed sensitivity analyses of the significant assumptions to evaluate the change in the fair value resulting from changes in the assumptions. We involved our valuation specialists to assist in our evaluation of the methodologies used by the Company and testing certain significant assumptions used to value the intangible asset.

/s/ Ernst & Young LLP

We have served as the Company's auditor since 1991.

Raleigh, North Carolina
August 22, 2023 20, 2024

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of Premier, Inc.

Opinion on Internal Control over Financial Reporting

We have audited Premier, Inc.'s internal control over financial reporting as of **June 30, 2023** **June 30, 2024**, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Premier, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of **June 30, 2023** **June 30, 2024**, based on the COSO criteria.

As indicated in the accompanying Management's Report on Internal Control over Financial Reporting, management's assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of the business combination related to certain acquired assets of TRPN Direct Pay, Inc. and Devon Health, Inc., which is included in the 2023 consolidated financial statements of the Company and constituted 3.9% of total assets as of June 30, 2023 and less than 1% of net revenues for the year then ended. Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of the business combination related to certain acquired assets of TRPN Direct Pay, Inc. and Devon Health, Inc.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the **June 30, 2023** **June 30, 2024** consolidated financial statements of the Company and our report dated **August 22, 2023** **August 20, 2024** expressed an unqualified opinion thereon.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP

Raleigh, North Carolina
August 22, 2023 **August 20, 2024**

		PREMIER, INC.		Consolidated Balance Sheets (In thousands, except per share data)	
(In thousands, except share data)		(In thousands, except share data)			
		June 30, 2023		June 30, 2022	
		June 30, 2023		June 30, 2022	
Assets	Assets	2024	2023	2024	2023
Cash and cash equivalents	Cash and cash equivalents	\$ 89,793	\$ 86,143		

Accounts receivable (net of \$2,878 and \$2,043 allowance for credit losses, respectively)	115,295	114,129
Contract assets (net of \$885 and \$755 allowance for credit losses, respectively)	299,219	260,061
Cash and cash equivalents		
Cash and cash equivalents		
Accounts receivable (net of \$1,455 and \$2,878 allowance for credit losses, respectively)		
Contract assets (net of \$1,248 and \$885 allowance for credit losses, respectively)		
Inventory	Inventory	76,932
Prepaid expenses and other current assets	Prepaid expenses and other current assets	60,387
Total current assets	Total current assets	641,626
Property and equipment (net of \$662,554 and \$578,644 accumulated depreciation, respectively)	212,308	213,379
Intangible assets (net of \$265,684 and \$217,582 accumulated amortization, respectively)	430,030	356,572
Property and equipment (net of \$742,063 and \$662,554 accumulated depreciation, respectively)		
Intangible assets (net of \$295,955 and \$265,684 accumulated amortization, respectively)		
Goodwill	Goodwill	1,012,355
Deferred income tax assets	Deferred income tax assets	653,629
Deferred compensation plan assets	Deferred compensation plan assets	50,346
Investments in unconsolidated affiliates	Investments in unconsolidated affiliates	231,826
Operating lease right-of-use assets	Operating lease right-of-use assets	29,252
Other assets	Other assets	110,115
Total assets	Total assets	\$3,371,487
		\$3,357,127

Liabilities and stockholders' equity	Liabilities and stockholders' equity
Liabilities and stockholders' equity	
Liabilities and stockholders' equity	
Accounts payable	
Accounts payable	Accounts payable \$ 54,375 \$ 44,631
Accrued expenses	Accrued expenses 47,113 40,968
Revenue share obligations	Revenue share obligations 262,288 245,395
Accrued compensation and benefits	Accrued compensation and benefits 60,591 93,638
Deferred revenue	Deferred revenue 24,311 30,463
Current portion of notes payable to former limited partners	Current portion of notes payable to former limited partners 99,665 97,806
Line of credit and current portion of long-term debt	Line of credit and current portion of long-term debt 216,546 153,053
Current portion of liability related to the sale of future revenues	
Other current liabilities	Other current liabilities 50,574 47,183
Total current liabilities	Total current liabilities 815,463 753,137
Long-term debt, less current portion	Long-term debt, less current portion 734 2,280
Notes payable to former limited partners, less current portion	Notes payable to former limited partners, less current portion 101,523 201,188
Deferred compensation plan obligations	Deferred compensation plan obligations 50,346 47,436
Deferred consideration, less current portion	— 28,702
Operating lease liabilities, less current portion	Operating lease liabilities, less current portion 21,864 32,960

Operating lease liabilities, less current portion			
Operating lease liabilities, less current portion			
Liability related to the sale of future revenues, less current portion			
Other liabilities	Other liabilities	47,202	42,574
Total liabilities	Total liabilities	1,037,132	1,108,277
Commitments and contingencies (Note 17)	Commitments and contingencies (Note 17)		Commitments and contingencies (Note 17)
Stockholders' equity:	Stockholders' equity:		
Class A common stock, \$0.01 par value, 500,000,000 shares authorized; 125,587,858 shares issued and 119,158,483 outstanding at June 30, 2023 and 124,481,610 shares issued and 118,052,235 outstanding at June 30, 2022		1,256	1,245
Treasury stock, at cost; 6,429,375 shares at both June 30, 2023 and 2022, respectively		(250,129)	(250,129)
Class A common stock, \$0.01 par value, 500,000,000 shares authorized; 111,456,454 shares issued and 105,027,079 outstanding at June 30, 2024 and 125,587,858 shares issued and 119,158,483 outstanding at June 30, 2023			
Class A common stock, \$0.01 par value, 500,000,000 shares authorized; 111,456,454 shares issued and 105,027,079 outstanding at June 30, 2024 and 125,587,858 shares issued and 119,158,483 outstanding at June 30, 2023			
Class A common stock, \$0.01 par value, 500,000,000 shares authorized; 111,456,454 shares issued and 105,027,079 outstanding at June 30, 2024 and 125,587,858 shares issued and 119,158,483 outstanding at June 30, 2023			
Treasury stock, at cost; 6,429,375 shares at both June 30, 2024 and 2023, respectively			
Additional paid-in capital	Additional paid-in capital	2,178,134	2,166,047
Retained earnings	Retained earnings	405,102	331,690

Accumulated other comprehensive loss	Accumulated other comprehensive loss	(8)	(3)
Total stockholders' equity	Total stockholders' equity	<u>2,334,355</u>	<u>2,248,850</u>
Total liabilities and stockholders' equity	Total liabilities and stockholders' equity	<u><u>\$3,371,487</u></u>	<u><u>\$3,357,127</u></u>

See accompanying notes to the consolidated financial statements.

				Consolidated Statements of Income and Comprehensive Income			(in thousands, except share data)
				PREMIER, INC.			
				(in thousands, except per share data)			
(in thousands, except per share data)				(in thousands, except per share data)			
				Year Ended June 30,			
				2023	2022	2021	
				Year Ended June 30,			
				2024	2023	2022	
Net revenue:				Net revenue:			
Net administrative fees							
Net administrative fees							
Net administrative fees	Net administrative fees	\$ 611,035	\$ 601,128	\$ 572,700			
Software licenses, other services and support	Software licenses, other services and support	480,401	438,267	404,330			
Services and software licenses	Services and software licenses	1,091,436	1,039,395	977,030			
Products	Products	244,659	393,506	744,122			
Net revenue	Net revenue	1,336,095	1,432,901	1,721,152			
Cost of revenue:	Cost of revenue:						
Services and software licenses	Services and software licenses						
Products	Products	218,087	183,984	170,773			
Services and software licenses	Services and software licenses						
Products	Products	221,719	363,878	713,045			
Cost of revenue	Cost of revenue	439,806	547,862	883,818			
Gross profit	Gross profit	896,289	885,039	837,334			
Operating expenses:	Operating expenses:						
Selling, general and administrative	Selling, general and administrative	601,554	576,879	532,326			

Selling, general and administrative				
Selling, general and administrative				
Research and development	Research and development	4,540	4,151	3,338
Amortization of purchased intangible assets	Amortization of purchased intangible assets	48,102	43,936	44,753
Operating expenses	Operating expenses	654,196	624,966	580,417
Operating income	Operating income	242,093	260,073	256,917
Equity in net income of unconsolidated affiliates		16,068	23,505	21,073
Interest expense, net		(14,470)	(11,142)	(11,964)
Gain (loss) on FFF Put and Call Rights		—	64,110	(27,352)
Equity in net (loss) income of unconsolidated affiliates				
Interest income (expense), net				
Gain on FFF Put and Call Rights				
Other income (expense), net	Other income (expense), net	6,307	(9,646)	11,967
Other income (expense), net		7,905	66,827	(6,276)
Other income, net				
Income before income taxes	Income before income taxes	249,998	326,900	250,641
Income tax expense (benefit)		75,111	58,582	(53,943)
Income tax expense				
Net income				
Net income				
Net income	Net income	174,887	268,318	304,584
Net loss (income) attributable to non-controlling interest	Net loss (income) attributable to non-controlling interest	139	(2,451)	(17,062)
Adjustment of redeemable limited partners' capital to redemption amount		—	—	(26,685)
Net loss (income) attributable to non-controlling interest				
Net loss (income) attributable to non-controlling interest				
Net income attributable to stockholders				
Net income attributable to stockholders				

Net income attributable to stockholders	Net income attributable to stockholders	\$ 175,026	\$ 265,867	\$ 260,837
Comprehensive income: Comprehensive income:	Comprehensive income: Comprehensive income:			
Comprehensive income: Comprehensive income:	Net income Net income			
Net income	Net income	\$ 174,887	\$ 268,318	\$ 304,584
Comprehensive loss (income) attributable to non-controlling interest	Comprehensive loss (income) attributable to non-controlling interest	139	(2,451)	(17,062)
Foreign currency translation loss	Foreign currency translation loss	(5)	(3)	—
Comprehensive income attributable to stockholders	Comprehensive income attributable to stockholders	\$ 175,021	\$ 265,864	\$ 287,522
Weighted average shares outstanding:	Weighted average shares outstanding:			
Weighted average shares outstanding:	Weighted average shares outstanding:			
Basic	Basic	118,767	120,220	116,527
Diluted	Diluted	119,889	121,668	117,532
Earnings per share attributable to stockholders:	Earnings per share attributable to stockholders:			
Earnings per share attributable to stockholders:	Earnings per share attributable to stockholders:			
Basic	Basic	\$ 1.47	\$ 2.21	\$ 2.24
Diluted	Diluted	1.46	2.19	2.22

See accompanying notes to the consolidated financial statements.

PREMIER, INC. Consolidated Statements of Stockholders' Equity (In thousands, except share data)											
	Class A		Class B		Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total Stockholders' Equity		
	Common Stock	Shares	Common Stock	Shares					—	—	—
Balance at June 30, 2020		71,627	\$ 716	50,213	\$ —	—	—	138,547	\$ —	—	\$ 139,263

Balance at July 1, 2020	71,627	716	50,213	—	—	—	138,547	—	—	139,263
Impact of change in accounting principle	—	—	—	—	—	—	—	(1,228)	—	(1,228)
Adjusted balance at July 1, 2020	71,627	716	50,213	—	—	—	138,547	(1,228)	—	138,035
Exchange of Class B common units for Class A common stock by member owners	70	1	(70)	—	—	—	2,436	—	—	2,437
Increase in additional paid-in capital related to quarterly exchange by member owners, including associated TRA revaluation	—	—	—	—	—	—	37,319	—	—	37,319
Increase in additional paid-in capital related to final exchange by member owners, including TRA termination	—	—	—	—	—	—	517,526	—	—	517,526
Issuance of Class A common stock under equity incentive plan	598	6	—	—	—	—	9,350	—	—	9,356
Issuance of Class A common stock under employee stock purchase plan	94	1	—	—	—	—	3,245	—	—	3,246
Stock-based compensation expense	—	—	—	—	—	—	35,425	—	—	35,425
Repurchase of vested restricted units for employee tax-withholding	—	—	—	—	—	—	(3,114)	—	—	(3,114)
Net income	—	—	—	—	—	—	—	304,584	—	304,584
Net income attributable to non-controlling interest	—	—	—	—	—	—	5,217	(17,062)	—	(11,845)
Adjustment of redeemable limited partners' capital to redemption amount	—	—	—	—	—	—	—	(26,685)	—	(26,685)
Reclassification of redeemable limited partners' capital to permanent equity	—	—	—	—	—	—	1,750,840	3,767	—	1,754,607
Final exchange of Class B common units for Class A common stock by member owners	50,144	501	(50,143)	—	—	—	(501)	—	—	—
Early termination payments to former member owners	—	—	—	—	—	—	(438,967)	—	—	(438,967)
Dividends (\$0.19 per share)	—	—	—	—	—	—	—	(93,584)	—	(93,584)
Adjustment in additional paid-in capital related to consolidated investment	—	—	—	—	—	—	318	(318)	—	—
Distribution of investment in unconsolidated affiliate to non-controlling interests	—	—	—	—	—	—	(4,095)	—	—	(4,095)
Capital contributions	—	—	—	—	—	—	1,958	—	—	1,958
Non-controlling interest in consolidated investments	—	—	—	—	—	—	3,690	—	—	3,690
Balance at June 30, 2021	122,533 \$	1,225	— \$	—	— \$	— \$	2,059,194 \$	169,474 \$	— \$	2,229,893
Issuance of Class A common stock under equity incentive plan	1,843	18	—	—	—	—	37,748	—	—	37,766
Issuance of Class A common stock under employee stock purchase plan	105	2	—	—	—	—	3,849	—	—	3,851
Treasury stock	(6,429)	—	—	—	6,429	(250,129)	—	—	—	(250,129)
Stock-based compensation expense	—	—	—	—	—	—	46,229	—	—	46,229
Repurchase of vested restricted units for employee tax-withholding	—	—	—	—	—	—	(10,866)	—	—	(10,866)
Net income	—	—	—	—	—	—	—	268,318	—	268,318
Net income attributable to non-controlling interest	—	—	—	—	—	—	2,451	(2,451)	—	—
Change in ownership of consolidated entity	—	—	—	—	—	—	202	(142)	—	60
Dividends (\$0.20 per share)	—	—	—	—	—	—	—	(97,082)	—	(97,082)
Distribution of investment in unconsolidated affiliate to non-controlling interests	—	—	—	—	—	—	4,095	(6,427)	—	(2,332)
Non-controlling interest in consolidated investments	—	—	—	—	—	—	23,145	—	—	23,145
Foreign currency translation adjustment	—	—	—	—	—	—	—	—	(3)	(3)
Balance at June 30, 2022	118,052 \$	1,245	— \$	—	6,429 \$	(250,129) \$	2,166,047 \$	331,690 \$	(3) \$	2,248,850

PREMIER, INC.

(In
thousands,
except per
share data)

(In thousands, except per share data)

	Class A	Common Stock	Class A	Common Stock	Class A	Common Stock	Shares	Treasury Stock	Additional Paid-in Capital	Retained Earnings	Other	Accumulated Comprehensive Loss	Total Stockholders' Equity
Balance at													
June 30, 2021													
Issuance of													
Class A													
common stock													
under equity													
incentive plan													
Issuance of													
Class A													
common stock													
under													
employee stock													
purchase plan													
Treasury stock													
Stock-based compensation													
expense													
Stock-based compensation													
expense													
Stock-based compensation													
expense													
Repurchase of													
vested													
restricted units													
for employee													
tax-withholding													
Net income													
Net income													
attributable to													
non-controlling													
interest													
Change in													
ownership of													
consolidated													
entity													
Dividends													
(\$0.20 per													
share)													

Distribution of investment in unconsolidated affiliate to non-controlling interests							
Non-controlling interest in consolidated investments							
Foreign currency translation adjustment							
Balance at June 30, 2022							
Balance at June 30, 2022							
Balance at June 30, 2022							
Issuance of Class A common stock under equity incentive plan							
Issuance of Class A common stock under employee stock purchase plan							
	Class A	Class B				Accumulated	
	Common Stock	Common Stock	Treasury Stock	Additional	Other	Total	
Stock-based compensation expense				Paid-In Capital	Retained Earnings	Comprehensive Loss	Stockholders' Equity
	Shares	Amount	Shares	Amount	Shares	Amount	
Issuance of Class A common stock under equity incentive plan	967	9	—	—	—	—	
Issuance of Class A common stock under employee stock purchase plan	139	2	—	—	—	4,135	—
Stock-based compensation expense				Additional Capital	Other Earnings	Total Loss	Stockholders' Equity
Stock-based compensation expense	—	—	—	—	—	13,734	—
Repurchase of vested restricted units for employee tax-withholding	Repurchase of restricted units for employee tax-withholding	—	—	—	—	(13,427)	—
Net income	Net income	—	—	—	—	174,887	—
Net loss attributable to non-controlling interest	Net loss attributable to non-controlling interest	—	—	—	—	(139)	139

Change in ownership of consolidated entity	Change in ownership of consolidated entity	—	—	—	—	—	106	—	—	106
Dividends (\$0.21 per share)	Dividends (\$0.21 per share)	—	—	—	—	—	(100,883)	—	—	(100,883)
Distribution of investment in unconsolidated affiliate to non-controlling interests	Distribution of investment in unconsolidated affiliate to non-controlling interests	—	—	—	—	—	(731)	—	—	(731)
Non-controlling interest in consolidated investments										
Foreign currency translation adjustment	Foreign currency translation adjustment	—	—	—	—	—	—	—	(5)	(5)
Non-controlling interest related to acquisition		—	—	—	—	—	1,019	—	—	1,019
Other	Other	—	—	—	—	—	590	—	—	590
Balance at June 30, 2023	Balance at June 30, 2023	119,158	\$ 1,256	—	\$ —	6,429	\$(250,129)	\$2,178,134	\$405,102	\$ (8)
Issuance of Class A common stock under equity incentive plan										
Issuance of Class A common stock under employee stock purchase plan										
Treasury stock										
Retirement of Class A common Stock										
Stock-based compensation expense										
Repurchase of vested restricted units for employee tax-withholding										
Net income										
Net loss attributable to non-controlling interest										
Change in ownership of consolidated entity										

Dividends (\$0.21 per share)
Foreign currency translation adjustment
Foreign currency translation adjustment
Foreign currency translation adjustment
Balance at June 30, 2024
Balance at June 30, 2024
Balance at June 30, 2024

See accompanying notes to the consolidated financial statements.

			PREMIER, INC.			Consolidated Statements of Cash Flows			(In thousands)
			Year Ended June 30,						
			2023	2022	2021				
			Year Ended June 30,	Year Ended June 30,	Year Ended June 30,				
			2024	2024	2023	2024	2023	2022	
Operating	Operating	activities							
Net income	Net income								
Net income	Net income								
Net income	Net income	\$174,887	\$268,318	\$304,584					
Adjustments to	Adjustments to								
reconcile net	reconcile net								
income to net	income to net								
cash provided	cash provided								
by operating	by operating								
activities:	activities:								
Depreciation	Depreciation								
and	and								
amortization	amortization	133,793	129,107	121,062					
Equity in net income of									
unconsolidated affiliates		(16,068)	(23,505)	(21,073)					
Depreciation and amortization									
Depreciation and amortization									
Equity in net									
loss (income)									
of									
unconsolidated									
affiliates									
Deferred	Deferred								
income taxes	income taxes	71,403	56,792	(83,692)					
Stock-based	Stock-based								
compensation	compensation	13,734	46,229	35,425					
Impairment of	Impairment of								
assets	assets	56,718	18,829	—					
(Gain) loss on FFF Put and									
Call Rights		—	(64,110)	27,352					
Gain on FFF									
Put and Call									
Rights									

Other, net	Other, net	6,501	5,803	9,358
Changes in operating assets and liabilities, net of the effects of acquisitions:	Changes in operating assets and liabilities, net of the effects of acquisitions:			
Accounts receivable, inventories, prepaid expenses and other assets		64,253	124,659	(68,008)
Accounts receivable				
Accounts receivable				
Accounts receivable				
Contract assets	Contract assets	(41,088)	(47,219)	(51,685)
Accounts payable, accrued expenses, deferred revenue, revenue share obligations and other liabilities		(19,590)	(70,669)	134,079
Inventory				
Prepaid expenses and other assets				
Accounts payable				
Revenue share obligations				
Accrued expenses, deferred revenue and other liabilities				
Net cash provided by operating activities	Net cash provided by operating activities	444,543	444,234	407,402
Investing activities	Investing activities			
Purchases of property and equipment	Purchases of property and equipment	(82,302)	(87,440)	(88,876)
Purchases of property and equipment				
Purchases of property and equipment				
Sale of investment in unconsolidated affiliates				

Acquisition of businesses and equity method investments, net of cash acquired	Acquisition of businesses and equity method investments, net of cash acquired	(187,750)	(26,000)	(84,463)
Investment in unconsolidated affiliates	Investment in unconsolidated affiliates	(2,060)	(16,000)	—
Other	Other	(1,510)	(10,000)	(1,229)
Net cash used in investing activities	Net cash used in investing activities	(273,622)	(139,440)	(174,568)
Financing activities	Financing activities			
Payments made on notes payable		(100,859)	(99,243)	(50,713)
Payments on notes payable				
Payments on notes payable				
Proceeds from credit facility	Proceeds from credit facility	470,000	325,000	225,000
Payments on credit facility	Payments on credit facility	(405,000)	(250,000)	(225,000)
Proceeds from sale of future revenues				
Payments on liability related to the sale of future revenues				
Cash dividends paid	Cash dividends paid	(100,233)	(96,455)	(92,898)
Repurchase of Class A common stock				
Payments on deferred consideration related to acquisition of business	Payments on deferred consideration related to acquisition of business	(27,927)	(28,586)	(29,217)
Proceeds from exercise of stock options under equity incentive plan	Proceeds from exercise of stock options under equity incentive plan	6,078	37,766	9,356
Repurchase of Class A common stock (held as treasury stock)		—	(250,129)	—
Distributions to limited partners of Premier LP		—	—	(9,949)
Payments to limited partners of Premier LP related to tax receivable agreements		—	—	(24,218)
Other, net	Other, net	(9,325)	13,858	(5,358)

Net cash used in financing activities	Net cash used in financing activities	(167,266)	(347,789)	(202,997)
Effect of exchange rate changes on cash flows	Effect of exchange rate changes on cash flows	(5)	(3)	—
Net increase (decrease) in cash and cash equivalents	Net increase (decrease) in cash and cash equivalents	3,650	(42,998)	29,837
Cash and cash equivalents at beginning of year		86,143	129,141	99,304
Cash and cash equivalents at beginning of period				
Cash and cash equivalents at end of period	Cash and cash equivalents at end of period	\$ 89,793	\$ 86,143	\$129,141

See accompanying notes to the consolidated financial statements.

PREMIER, INC.

Notes to Consolidated Financial Statements

Information presented in the Notes to Consolidated Financial Statements are as of **June 30, 2023** **June 30, 2024** unless otherwise specifically noted.

(1) ORGANIZATION AND BASIS OF PRESENTATION

Organization

Premier, Inc. ("Premier" or the "Company") is a publicly held, for-profit Delaware corporation located in the United States. The Company is a holding company with no material business operations of its own. The Company's primary asset is its equity interest in its wholly owned subsidiary Premier Healthcare Solutions, Inc., a Delaware corporation ("PHSI"). The Company conducts substantially all of its business operations through PHSI and its other consolidated subsidiaries. The Company, together with its subsidiaries and affiliates, is a leading technology-driven healthcare improvement company that unites hospitals, health systems, physicians, employers, product suppliers, service providers, and other healthcare providers and organizations to improve and innovate in the clinical, financial and operational areas of their businesses to meet the demands of a rapidly evolving healthcare industry and continues to expand its capabilities to more fully address and coordinate care improvement and standardization in the employer, payer and life sciences markets. Additionally, the Company also provides some of the various products and services noted above to non-healthcare businesses, including through **our** **its** direct sourcing activities as well as continued access to **our** **its** group purchasing organization ("GPO") programs for non-healthcare members whose contracts were sold to OMNIA Partners, LLC ("OMNIA") (see Note **2010 - Subsequent Events** **Liability Related to the Sale of Future Revenues**).

The Company's business model and solutions are designed to provide its members and other customers access to scale efficiencies, spread the cost of their development, provide actionable intelligence derived from anonymized data in the Company's enterprise data warehouse, mitigate the risk of innovation and disseminate best practices to help the Company's members and other customers succeed in their transformation to higher quality and more cost-effective healthcare.

The Company, together with its subsidiaries and affiliates, delivers its integrated platform of solutions through two business segments: Supply Chain Services and Performance Services. See Note 18 - Segments for further information related to the Company's reportable business segments. **We have** **The Company** has no significant foreign operations or revenues. The Supply Chain Services segment includes one of the largest national healthcare GPO programs in the United States, **as well as provides** **serving acute and continuum** **of care sites and providing** supply chain co-management, purchased services and direct sourcing activities. The Performance Services segment consists of three sub-brands: **PINC AI™**, the Company's technology and services platform with offerings that help optimize performance in three main areas – clinical intelligence, margin improvement and value-based care – using advanced analytics to identify improvement opportunities, consulting and managed services for clinical and operational design, and workflow solutions to hardwire sustainable change in the provider, **payer** and **life sciences** and **payer** markets; **Contigo Health®**, the Company's direct-to-employer business which provides third-party administrator services and management of health-benefit programs that enable healthcare providers that are also payers (e.g., payviders) and employers to contract directly with healthcare providers as well as **partners** **partner** with healthcare providers to provide employers access to a specialized care network through Contigo Health's centers of excellence program and cost containment and wrap network; and **Remitra®**, the Company's digital invoicing and payables automation business which provides financial support services to healthcare suppliers and providers.

Principles of Consolidation

The accompanying consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC and in accordance with U.S. generally accepted accounting principles ("GAAP") and include the assets, liabilities, revenues and expenses of all majority-owned subsidiaries over which the Company exercised control and when applicable, entities for which the Company had a controlling financial interest or was the primary beneficiary. All intercompany transactions have been eliminated upon consolidation. The **consolidated** financial statements reflect all adjustments that, in the opinion of management, are necessary for a fair presentation of results of operations and financial condition

for the periods shown, consisting of normal recurring adjustments, unless otherwise disclosed. Certain amounts in prior periods have been reclassified to conform to the current period presentation. The Company believes that the disclosures are adequate to make the information presented not misleading.

Supplementary Cash Flows Information

The following table presents supplementary cash flows information for the years ended **June 30, 2023** **June 30, 2024**, **2022** **2023** and **2021** **2022** (in thousands):

	Year Ended June 30,		
	2023	2022	2021
Supplemental schedule of cash flows information:			
Interest paid	\$ 18,712	\$ 11,256	\$ 11,888
Income taxes paid	4,593	3,103	44,011
Supplemental schedule of non-cash investing and financing activities:			
Non-cash investment in unconsolidated affiliates	8,819	—	—
Non-cash additions to property and equipment	2,731	402	755
Accrued dividend equivalents	1,032	963	686
Increase in redeemable limited partners' capital for adjustment to fair value, with offsetting decrease in stockholders' equity	—	—	26,685
Decrease in redeemable limited partners' capital, with offsetting increase in stockholders' equity related to quarterly exchanges by member owners	—	—	(2,437)
Net increase in deferred tax assets related to departures and quarterly exchanges by member owners and other adjustments	—	—	331
Net increase in deferred tax assets related to final exchange by member owners	—	—	284,852
Reclassification of redeemable limited partners' capital to additional paid in capital	—	—	1,754,607
Decrease in additional paid-in capital related to notes payable to members, net of discounts	—	—	438,967
Net increase in additional paid-in capital related to departures and quarterly exchanges by member owners and other adjustments	—	—	37,319
Increase in additional paid-in capital related to final exchange by member owners	—	—	517,526

	Year Ended June 30,		
	2024	2023	2022
Supplemental schedule of cash flows information:			
Interest paid	\$ 16,309	\$ 18,712	\$ 11,256
Income taxes paid	168,585	4,593	3,103
Supplemental schedule of non-cash investing and financing activities:			
Non-cash additions to property and equipment	\$ 6,446	\$ 2,731	\$ 402
Accrued dividend equivalents	1,934	1,032	963
Accrued excise taxes related to repurchase of Class A common stock	2,992	—	—
Non-cash investment in unconsolidated affiliates	—	8,819	—

Use of Estimates in the Preparation of Financial Statements

The preparation of the Company's consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates are evaluated on an ongoing basis, including, but not limited to, estimates for net administrative fees revenue, software licenses, other services and support revenue, contract assets, deferred revenue, contract costs, allowances for credit losses, reserves for net realizable value of inventory, obsolete inventory, useful lives of property and equipment, stock-based compensation, deferred tax balances including valuation allowances on deferred tax assets, uncertain tax positions, values of investments not publicly traded, projected future cash flows used in the evaluation of asset impairments, values of call rights, values of earn-out liabilities and the allocation of purchase prices. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

(2) SIGNIFICANT ACCOUNTING POLICIES

Business Combinations

The Company accounts for acquisitions of a business using the acquisition method. All of the assets acquired, liabilities assumed, contractual contingencies and contingent consideration are recognized at their fair value on the acquisition date. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Acquisition costs are recorded as expenses in the Consolidated Statements of Income and Comprehensive Income.

Several valuation methods may be used to determine the fair value of assets acquired and liabilities assumed. For intangible assets, the Company typically uses the income method. This method starts with a forecast of all of the expected future net cash flows for each asset. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. Some of the more significant estimates and assumptions inherent in the income method or other methods include the amount and timing of projected future cash flows, the discount rate selected to measure the risks inherent in the future cash flows and the assessment of the asset's life cycle and the competitive trends impacting the asset, including consideration of any technical, legal, regulatory or economic barriers to entry. Determining the useful life of an intangible asset also requires judgment as different types of intangible assets will have different useful lives and certain assets may even be considered to have indefinite useful lives.

Cash and Cash Equivalents

Cash and cash equivalents include cash and highly liquid investments with remaining maturities of three months or less at the time of acquisition.

Fair Value of Financial Instruments

The fair value of an asset or liability is based on the assumptions that market participants would use in pricing the asset or liability. Valuation techniques consistent with the market approach, income approach and/or cost approach are used to measure fair value. The Company follows a three-tiered fair value hierarchy when determining the inputs to valuation techniques. The

fair value hierarchy prioritizes the inputs to valuation techniques into three broad levels in order to maximize the use of observable inputs and minimize the use of unobservable inputs. The levels of the fair value hierarchy are as follows:

Level 1: consists of financial instruments whose values are based on quoted market prices for identical financial instruments in an active market;

Level 2: consists of financial instruments whose values are determined using models or other valuation methodologies that utilize inputs that are observable either directly or indirectly, including (i) quoted prices for similar assets or liabilities in active markets, (ii) quoted prices for identical or similar assets or liabilities in markets that are not active, (iii) pricing models whose inputs are observable for substantially the full term of the financial instrument and (iv) pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the financial instrument; and

Level 3: consists of financial instruments whose values are determined using pricing models that utilize significant inputs that are primarily unobservable, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

Accounts Receivable

Financial instruments, other than marketable securities, that subject the Company to potential concentrations of credit risk consist primarily of the Company's receivables and contract assets (see below for discussion of contract assets). Receivables consist largely of amounts due from hospital and healthcare system members for services and products. The Company maintains an allowance for expected credit losses. This allowance is an estimate and is regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the member and other customer base and age of the receivable balances, both individually and in the aggregate. As receivables are generally due within one year, changes to economic conditions are not expected to have a significant impact on ~~our~~ the estimate of expected credit losses. However, economic conditions are monitored on a quarterly basis to determine if any adjustments are deemed necessary. Provisions for the allowance for expected credit losses attributable to bad debt are recorded in selling, general and administrative expenses in the accompanying Consolidated Statements of Income and Comprehensive Income. Accounts deemed uncollectible are written off, net of actual recoveries. If circumstances related to specific customers change, the Company's estimate of the recoverability of receivables could be further adjusted.

Contract Assets

Supply Chain Services contract assets represent estimated member ~~and other customer~~ purchases on supplier contracts for which administrative fees have been earned but not collected. Historically, the Company has not recognized a provision ~~an~~ allowance for credit losses for contract assets associated with administrative fees. Performance Services contract assets represent revenue earned for services provided which the Company is not contractually able to bill as of the end of the respective reporting period. Under ASC Topic 326, the Company includes Performance Services' contract assets in the reserving process and assesses the risk of loss similar to the methodology of the Company's receivables, since the contract assets are reclassified to receivables when the Company becomes entitled to payment. Accordingly, a reserve is applied upon recognition of the contract asset. Certain contract assets are due for periods greater than one year, and changes to economic conditions may have an impact on these receivables. The Company monitors economic conditions on a quarterly basis to determine if changes to the reserve are necessary.

Inventory

Inventory consisting of finished goods, primarily medical products, are stated at the lower of cost or net realizable values on an average cost basis. The Company performs periodic assessments to determine the existence of obsolete, slow-moving and unusable inventory and records necessary provisions to reduce such inventory to net realizable value. As of ~~June 30, 2023~~ ~~June 30, 2024~~ and ~~2022, 2023~~, these provisions were ~~\$10.8 million~~ ~~\$2.9 million~~ and ~~\$19.2 million~~ ~~\$10.8 million~~, respectively.

Property and Equipment, Net

Property and equipment is recorded at cost, net of accumulated depreciation. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the Consolidated Statements of Income and Comprehensive Income for the respective period. Depreciation is calculated over the estimated useful lives of the related assets using the straight-line method. Capitalized modifications to leased properties are amortized using the straight-line method over the shorter of the lease term or the assets' estimated useful lives. See Note 7 - Supplemental Balance Sheet Information.

Costs associated with internally-developed computer software that are incurred in the preliminary project stage are expensed as incurred. During the development stage and once the project has reached technological feasibility, direct consulting costs and payroll and payroll-related costs for employees that are directly associated with each project are capitalized. Capitalized software costs are included in property and equipment, net in the accompanying Consolidated Balance Sheets. Capitalized costs are amortized on a

straight-line basis over the estimated useful lives of the related software applications of up to five years, and amortization is included in cost of revenue or selling, general and administrative expenses in the accompanying Consolidated Statements of Income and Comprehensive Income based on the software's end use. Replacements and major improvements are capitalized, while maintenance and repairs are expensed as incurred. Some of the more significant estimates and assumptions inherent in this process involve determining the stages of the software development project, the direct costs to capitalize and the estimated useful life of the capitalized software. The Company capitalized costs related to internally-developed software of **\$77.8 million** **\$73.4 million** and **\$48.7 million** **\$77.8 million** during the years ended **June 30, 2023** **June 30, 2024** and **2022, 2023**, respectively.

The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset or asset group may not be recoverable from the estimated cash flows expected to result from its use and eventual disposition. In cases where the undiscounted cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of the asset or asset group. The factors considered by the Company in performing this assessment include current and projected operating results, trends and prospects, the manner in which the asset or asset group is used and the effects of obsolescence, demand, competition and other economic factors.

Intangible Assets

Definite-lived intangible assets consist primarily of member relationships, provider networks, technology, customer relationships, trade names and non-compete agreements and are amortized on a straight-line basis over their estimated useful lives. See Note 8 - Goodwill and Intangible Assets.

The Company reviews the carrying value of definite-lived intangible assets subject to amortization for impairment whenever events and circumstances indicate that the carrying value of the intangible asset subject to amortization may not be recoverable from the estimated cash flows expected to result from its use and eventual disposition. In cases where the undiscounted cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of the intangible asset subject to amortization on the measurement date. The factors considered by the Company in performing this assessment include current and projected operating results, trends and prospects, the manner in which the definite-lived intangible asset is used and the effects of obsolescence, demand and competition, as well as other economic factors.

The Company performed an analysis of the carrying value of intangible assets subject to amortization on the Contigo Health reporting unit as of March 31, 2024 and resulted in **\$113.5 million** in impairment losses (see Note 8 - Goodwill and Intangible Assets).

Goodwill

Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. The Company performs its annual goodwill impairment testing as of the first day of the last fiscal quarter of its fiscal year unless impairment indicators are present which could require an interim impairment test.

Under accounting rules, the Company may elect to perform a qualitative assessment to determine if an impairment is more likely than not to have occurred. This qualitative assessment requires an evaluation of any excess of fair value over the carrying value for a reporting unit and significant judgment regarding potential changes in valuation inputs, including a review of the Company's most recent long-range projections, analysis of operating results versus the prior year, changes in market values,

changes in discount rates and changes in terminal growth rate assumptions. If it is determined that an impairment is more likely than not to exist, then the Company is required to perform a quantitative assessment to determine whether or not goodwill is impaired and to measure the amount of goodwill impairment, if any.

A goodwill impairment charge is recognized for the amount by which the reporting unit's carrying amount exceeds its fair value. The Company determines the fair value of a reporting unit using a discounted cash flow analysis as well as market-based approaches. Determining Significant assumptions utilized in determining fair value requires the exercise of significant judgment, including judgment about appropriate discount rates, revenue growth rates (including perpetual growth rates), EBITDA margin percentages and the amount and timing of expected future cash flows. flows of the reporting unit's business. The cash flows employed in the discounted cash flow analyses are based on the most recent budget and long-term forecast, plus a terminal value based on capitalizing the last period's cash flows using a perpetual growth rate. The discount rates used in the discounted cash flow analyses are intended to reflect the risks inherent in the future cash flows of the respective reporting units. The market comparable approach estimates fair value using market multiples of various financial measures compared to a set of comparable public companies and recent comparable transactions.

Based on a qualitative analysis performed at March 31, 2024, the Company determined impairment indicators were present and the carrying value of certain reporting units more likely than not exceeded their fair value. The Company's most recent annual impairment testing as of April 1, 2023 consisted of Company performed a quantitative assessment and on the Contigo Health reporting unit which resulted in **\$56.7 million** **\$16.5 million** in goodwill impairment losses (see Note 8 - Goodwill and Intangible Assets). As a result, the Contigo Health reporting unit's goodwill was fully impaired.

The Company's most recent annual impairment testing as of April 1, 2024 consisted of a quantitative assessment over the Informatics and Technology Services ("ITS") reporting unit's \$578.9 million goodwill balance. Given the significant excess fair value and associated carrying value, the Company elected to perform a qualitative assessment to determine if an impairment is more likely than not to have occurred for the remaining reporting units. Based on the qualitative analysis performed, the Company determined that the remaining reporting units did not have indications that impairment was more likely than not to have occurred. As a result of the quantitative analysis performed on the ITS reporting unit, the Company determined that the fair value of the ITS reporting unit exceeded its carrying value and, therefore, goodwill is not impaired.

Treasury Stock and Share Retirement

Treasury stock purchases are recorded at cost. As the Company retires treasury shares acquired through share repurchases, the Company returns those shares to the status of authorized but unissued. When treasury shares are retired, the Company's policy is to allocate the excess of the repurchase price over the par value of shares acquired to retained earnings.

Contract Costs

Contract costs represent amounts the Company has capitalized and reflect the incremental costs of obtaining and fulfilling a contract, which include sales commissions and costs related to implementing SaaS informatics tools. For commissions on new contracts, these costs are amortized over the life of the expected relationship with the customer for the respective performance obligation. For renewals, commissions are amortized over the contract life with the customer. Implementation costs are amortized on a straight-line basis, once the tool is implemented, over the life of the expected relationship with the customer for the respective performance obligation, which is consistent with the transfer of services to the customer to which the implementation relates. The Company's contract costs are included in other assets in the Consolidated Balance Sheets. The associated amortization

related to sales commissions and implementation costs is included in selling, general and administrative expenses and cost of revenue, respectively, in the Consolidated Statements of Income and Comprehensive Income.

Deferred Revenue

Deferred revenue consists of unrecognized revenue related to advanced customer invoicing or member payments received prior to fulfillment of the Company's revenue recognition criteria. Substantially all deferred revenue consists of deferred subscription fees and deferred consulting fees. Subscription fees for Company-hosted SaaS applications are deferred until the customer's unique data records have been incorporated into the underlying software database or until customer site-specific software has been implemented and the customer has access to the software. Deferred consulting fees arise upon invoicing to customers prior to services being performed.

Liability Related to the Sale of Future Revenues

The Company accounts for the sale of future revenues as a liability, with both current and non-current portions. In order to determine the timing of the reduction in debt associated with the sale of future revenues, the Company estimates the total future revenues expected to be remitted to the purchaser. The Company recognizes interest expense based on an estimated effective annual interest rate. The Company determines the effective interest rate based on recognized and expected future revenue and maintains a consistent interest rate throughout the life of the agreement. This estimate contains significant assumptions that impact both the amount of debt and the interest expense recorded over the life of the agreement. To the extent the amount or timing of future payments varies materially from the original estimate, the Company will make a cumulative adjustment to the carrying amount of the debt, which will be recorded as a non-cash gain or loss in other income in the Consolidated Statements of Income and Comprehensive Income. See Note 10 - Liability Related to the Sale of Future Revenues.

Deferred Compensation Plan Assets and Related Liabilities

The Company maintains a non-qualified deferred compensation plan for the benefit of eligible employees. This plan is designed to permit employee deferrals in excess of certain tax limits and provides for discretionary employer contributions in excess of the tax limits applicable to the Company's 401(k) plan. The amounts deferred are invested in assets at the direction of the employee. Company assets designated to pay benefits under the plan are held by a rabbi trust and are subject to the general creditors of the Company.

The assets, classified as trading securities, and liabilities of the rabbi trust are recorded at fair value and are accounted for as assets and liabilities of the Company. The assets of the rabbi trust are designated to fund the deferred compensation plan liabilities owed to current and former employees. The deferred compensation plan contains both current and non-current assets. The current portion of the deferred compensation plan assets is comprised of estimated amounts to be paid within one year to departed participants following separation from the Company. The current portion, \$6.8 million and \$5.2 million at June 30, 2024 and \$5.3 million at June 30, 2023 and 2022, respectively, is included in prepaid expenses and other current assets in the accompanying Consolidated Balance Sheets. The corresponding current portion of deferred compensation plan liabilities is included in other current liabilities in the accompanying Consolidated Balance Sheets at June 30, 2023 June 30, 2024 and 2022, 2023. The non-current portion of the deferred compensation plan assets, \$54.4 million and \$50.3 million at June 30, 2024 and \$47.4 million at June 30, 2023 and 2022, 2023, respectively, is included in long-term assets in the accompanying Consolidated Balance Sheets. The corresponding non-current portion of deferred compensation plan liabilities is included in long-term liabilities in the accompanying Consolidated Balance Sheets at June 30, 2023 June 30, 2024 and 2022, 2023. Realized and unrealized gains and (losses) of \$8.8 million, \$5.4 million, and \$(9.4) million and \$12.7 million on plan assets for the years ended June 30, 2023 June 30, 2024, 2022 2023 and 2021, 2022, respectively, are included in other income (expense), net in the accompanying Consolidated Statements of Income and Comprehensive Income. Deferred compensation expense (income) from the change in the corresponding liability liabilities of \$8.8 million, \$5.4 million, and \$(9.4) million, and \$12.7 million, respectively, is included in selling, general and administrative expense in the accompanying Consolidated Statements of Income and Comprehensive Income for the years ended June 30, 2023 June 30, 2024, 2022 2023 and 2021, 2022, respectively.

Leases

The Company enters into lease contracts in which the Company is the lessee, substantially all of which are related to office space leased in various buildings used for general corporate purposes. The terms of these non-cancelable operating leases typically require the Company to pay rent and a share of operating expenses and real estate taxes, generally with an inflation-based rent increase included. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term beginning at the commencement date. Operating lease right-of-use assets are adjusted for lease incentives, deferred rent and initial direct costs, if incurred. The Company's leases generally do not include an implicit rate; therefore, the Company determined the present value of future minimum lease payments using an incremental borrowing rate based on information available as of July 1, 2019, the Company's transition to ASC Topic 842. For subsequent leases entered into after the transition to ASC Topic 842, the Company determined the present value of future minimum lease payments using an incremental borrowing rate based on information available as of the respective lease commencement date. The related lease expense is recognized on a straight-line basis over the lease term.

Redeemable Limited Partners' Capital

The fair value of redeemable limited partners' capital at July 31, 2020 was reclassified from temporary equity in the mezzanine section of the Consolidated Balance Sheets to additional paid-in capital as a component of permanent equity. Prior to July 31, 2020, the Company recorded redeemable limited partners' capital as temporary equity in the mezzanine section of the Consolidated Balance Sheets at the redemption amount, which represented the greater of the book value or redemption amount of Class B common units per the Amended and Restated Limited Partnership Agreement at the reporting date.

Revenue Recognition

The Company accounts for a contract with a customer when the contract is approved and the parties are committed to perform their respective obligations, the rights of the parties, including payment terms, are identified, the contract has commercial substance and consideration is probable of collection.

Revenue is recognized when, or as, control of a promised product or service transfers to a customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring those products or services. If the consideration promised in a contract includes a variable amount, the Company estimates the amount to which it expects to be entitled using either the expected value or most likely amount method. The Company's contracts may include terms that could cause variability in the transaction price, including, for example, revenue share, rebates, discounts and variable fees based on performance.

The Company only includes estimated amounts of consideration in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. These estimates require management to make complex, difficult or subjective judgments and to make estimates about the effect of matters inherently uncertain. As such, the Company may not be able to reliably estimate variable fees based on performance in certain long-term arrangements due to uncertainties that are not expected to be resolved for a long period of time or when the Company's experience with similar types of contracts is limited.

Estimates of variable consideration and the determination of whether to include estimated amounts of consideration in the transaction price are based on information (historical, current and forecasted) that is reasonably available to the Company, taking into consideration the type of customer, the type of transaction and the specific facts and circumstances of each arrangement. Additionally, management performs periodic analyses to verify the accuracy of estimates for variable consideration.

Although the Company believes that its approach in developing estimates and reliance on certain judgments and underlying inputs is reasonable, actual results could differ which may result in increases or decreases in revenue that could be material.

Performance Obligations

A performance obligation is a promise to transfer a distinct good or service to a customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Contracts may have a single performance obligation as the promise to transfer individual goods or services is not separately identifiable from other promises, and therefore, not distinct, while other contracts may have multiple performance obligations, most commonly due to the contract covering multiple deliverable arrangements such as licensing, fees, subscription, fees and professional fees for consulting services.

services, etc.

Net Administrative Fees Revenue

Net administrative fees revenue is a single performance obligation earned through a series of distinct daily services and includes maintaining a network of members to participate in the group purchasing program and providing suppliers efficiency in contracting and access to the Company's members. Revenue is generated through administrative fees received from suppliers and is included in service net administrative fees revenue in the accompanying Consolidated Statements of Income and Comprehensive Income.

The Company, through its GPO programs, aggregates member purchasing power to negotiate pricing discounts and improve contract terms with suppliers. Contracted suppliers pay the Company administrative fees which generally represent 1% to 3% of the purchase price of goods and services sold to members under the contracts the Company has negotiated. Administrative fees are variable consideration and are recognized as earned based upon estimated purchases by the Company's members utilizing analytics based on historical member spend and updates for current trends and expectations. Administrative fees are estimated due to the difference in timing of when a member purchases on a supplier contract and when the Company receives the purchasing information. Member and supplier contracts substantiate persuasive evidence of an arrangement. The Company does not take title to the underlying equipment or products purchased by members through its GPO supplier contracts. Administrative fee revenue receivable is included in contract assets in the accompanying Consolidated Balance Sheets.

Generally, the Company pays a revenue share to members equal to a percentage of gross administrative fees, which is estimated according to the members' contractual agreements with the Company using a portfolio approach based on historical revenue share percentages and adjusted for current or anticipated trends. Revenue share is recognized as a reduction to gross administrative fees revenue to arrive at a net administrative fees revenue, and the corresponding revenue share liability is included in revenue share obligations in the accompanying Consolidated Balance Sheets.

Products Revenue

The Company's direct sourcing business generates revenue primarily through products sold to the Company's members, other customers or distributors. Revenue is recognized once control of products has been transferred to the customer and is recorded net of discounts and rebates offered to customers. Discounts and rebates are estimated based on contractual terms and historical trends.

Software Licenses, Other Services and Support Revenue

The Company generates software licenses, other services and support revenue through Supply Chain Services and Performance Services.

Within Supply Chain Services, in addition to net administrative fee revenue and product revenue, revenue is generated through the GPO, supply chain co-management and SaaS-based purchased services activities.

GPO. The GPO generates revenue generating activities include revenue from technology solutions, including purchased services, and from suppliers through the members that participate in our the Company's performance groups.

Supply Chain Co-Management. Supply chain co-management activities generate revenue in the form of a service fee for services performed under the supply chain management contracts. Service fees are billed as stipulated in the contract, and revenue is recognized on a proportional performance method as services are performed.

Purchased Services. Purchased services generate revenue through subscription fees for SaaS-based products and term licenses. Subscription fees are generally billed on a monthly basis, and revenue is recognized as a single deliverable on a straight-line basis over the remaining contractual period following implementation. Revenue on licensing is recognized upon delivery of the software code and revenue from hosting and maintenance is recognized ratably over the life of the contract.

Within Performance Services, which provides technology with wrap-around service offerings, revenue is generated through the three sub-brands: PINC AI, Contigo Health and Remitra. The main sources of revenue under PINC AI consists of subscriptions to SaaS-based clinical intelligence, margin improvement and value-based care products subscriptions, licensing revenue, professional fees for consulting services and other miscellaneous revenue including PINC AI data licenses, annual subscriptions to performance improvement collaboratives, insurance services management fees and commissions from endorsed commercial insurance programs. Contigo Health's main sources of revenue are third-party administrator fees, fees from the centers of excellence program and cost containment and wrap network fees pursuant to the TRPN acquisition (as defined in Note 3 - Business Acquisitions). fees. Remitra's main source of revenue is fees from healthcare suppliers and providers.

PINC AI:

SaaS-based Products Subscriptions: SaaS-based clinical analytics subscriptions include the right to access the Company's proprietary hosted technology on a SaaS basis, training and member support to deliver improvements in cost management, margin improvement, quality and safety, value-based care and provider analytics. SaaS arrangements create a single performance obligation for each subscription within the contract in which the nature of the obligation is a stand-ready obligation, and each day of

service meets the criteria for over time recognition. Pricing varies by application and size of healthcare system. Clinical analytics products subscriptions are generally three- to five-year agreements with automatic renewal clauses and annual price escalators that typically do not allow for early termination. These agreements do not allow for physical possession of the software. Subscription fees are typically billed on a monthly basis and revenue is recognized as a single deliverable on a straight-line basis over the remaining contractual period following implementation. Implementation involves the completion of data preparation services that are unique to each member's data set in order to access and transfer member data into the Company's hosted SaaS-based clinical analytics products. Implementation is generally 60 to 240 days following contract execution before the SaaS-based clinical analytics products can be fully utilized by the member.

Software Licenses: Enterprise analytics licenses include term licenses that range from three to ten years and offer clinical analytics products, improvements in cost management, quality and safety, value-based care and provider analytics. Pricing varies by application and size of healthcare system. Revenue on licensing is recognized upon delivery of the software code, and revenue from hosting and maintenance is recognized ratably over the life of the contract.

Consulting Services: Professional fees for consulting services are sold under contracts, the terms of which vary based on the nature of the engagement. These services typically include general consulting, report-based consulting and cost savings initiatives. Promised services under such consulting engagements are typically not considered distinct and are regularly combined and accounted for as one performance obligation. Fees are billed as stipulated in the contract, and revenue is recognized on a proportional performance method as services are performed or when deliverables are provided. In situations where the contracts have significant contract performance guarantees, the performance guarantees are estimated and accounted for as a form of variable consideration when determining the transaction price. In the event that guaranteed savings levels are not achieved, the Company may have to perform additional services at no additional charge in order to achieve the guaranteed savings or pay the difference between the savings that were guaranteed and the actual achieved savings. Occasionally, the Company's entitlement to consideration is predicated on the occurrence of an event such as the delivery of a report for which client acceptance is required. However, except for event-driven point-in-time transactions, the majority of services provided within this service line are delivered over time due to the continuous benefit provided to the Company's customers.

Consulting arrangements can require significant estimates for the transaction price and estimated number of hours within an engagement. These estimates are based on the expected value which is derived from outcomes from historical contracts that are similar in nature and forecasted amounts based on anticipated savings for the new agreements. The transaction price is generally constrained until the target transaction price becomes more certain.

Other Miscellaneous Revenue:

- Revenue from PINC AI data licenses which provide customers data from the PINC AI healthcare database. The revenue from the data deliverables is recognized upon delivery of the data.
- Revenue from performance improvement collaboratives that support the Company's offerings in cost management, quality and safety, and value-based care **and** is recognized over the service period as the services are provided, which is generally one to three years. Performance improvement collaboratives revenue is considered one performance obligation and is generated by providing customers access to online communities whereby data is housed and available for analytics and benchmarking.
- Insurance services management fees are recognized in the period in which such services are provided. Commissions from insurance carriers for sponsored insurance programs are earned by acting as an intermediary in the placement of effective insurance policies. Under this arrangement, revenue is recognized at a point in time on the effective date of the associated policies when control of the policy transfers to the customer and is constrained for estimated early terminations.

Contigo Health:

Contigo Health revenue consists of third-party administrator fees, fees from the centers of excellence program, and cost containment and wrap network fees. Third-party administrator fees consist of integrated fees for the processing of self-insured healthcare plan claims. Revenue is recognized in the period in which the services have been provided. Fees from the centers of excellence program consist of administrative fees for access to a specialized care network of proven healthcare providers. Revenue is recognized in the period in which the services have been provided. Cost containment and wrap network fees consist of fees associated with the repricing of insurance claims. Revenue is estimated and recognized in the period in which the services have been provided.

Remitra:

Revenue for Remitra primarily consists of fees from healthcare suppliers and **providers**, **providers as well as members and other customers**. For fixed fee contracts, revenue is recognized in the period in which the services have been provided. For variable rate contracts, revenue is recognized as customers are invoiced. Additional revenue consists of fees from check replacement services which consist of monthly rebates from bank partners.

Within Supply Chain Services, in addition to net administrative fee revenue and product revenue, revenue is generated through the GPO, supply chain co-management and SaaS-based purchased services activities.

GPO: The GPO generates revenue from members that participate in our performance groups.

Supply Chain Co-Management: Supply chain co-management activities generate revenue in the form of a service fee for services performed under the supply chain management contracts. Service fees are billed as stipulated in the contract, and revenue is recognized on a proportional performance method as services are performed.

Purchased Services: Purchased services generate revenue through subscription fees for SaaS-based products and term licenses. Subscription fees are generally billed on a monthly basis, and revenue is recognized as a single deliverable on a straight-line basis over the remaining contractual period following implementation. Revenue on licensing is recognized upon delivery of the software code and revenue from hosting and maintenance is recognized ratably over the life of the contract.

Multiple Deliverable Arrangements

The Company enters into agreements where the individual deliverables discussed above, such as SaaS subscriptions, **term licenses** and consulting services, are bundled into a single service arrangement. These agreements are generally provided over a time period ranging from approximately three months to five years after the applicable contract execution date. **On occasion, agreements may range up to ten years. The Company uses judgment in determining the stand-alone selling price ("SSP") for products and services.**

Revenue, including both fixed and variable consideration, is allocated to the individual performance obligations within the arrangement based on the stand-alone selling price SSP. The Company typically establishes a SSP range for products and services which is reassessed on a periodic basis or when it is facts and circumstances change. Term licenses are sold separately only as a bundled arrangement that includes the rights to a term license and support. In determining the SSP of license and support in a stand-alone arrangement, the Company applies observable inputs using the value relationship between support and term license and the average economic life of the products.

Cost of Revenue and Operating Expenses

Cost of Revenue

Cost of services and software licenses revenue includes expenses related to employees (including compensation and benefits) and outside consultants who directly provide services related to revenue-generating activities, including consulting services to members and capitalized other customers, third-party administrator services and implementation services related to SaaS informatics products, tools and licensed software products along with associated amortization of certain capitalized contract costs. Cost of services and software licenses revenue also includes expenses related to hosting services, related data center capacity costs, third-party product license expenses and amortization of the cost of internally-developed software.

Cost of products revenue consists of purchase and logistics costs for direct sourced medical products and commodity products.

Operating Expenses

Selling, general and administrative expenses consist of expenses directly associated with selling and administrative employees, indirect expenses associated with employees that primarily support revenue generating activities (including compensation and benefits) and travel-related expenses, as well as occupancy and other indirect expenses, insurance expenses, professional fees, expenses incurred to maintain the Company's software-related products and services and other general overhead expenses. SG&A expenses can also include impairment of goodwill, intangibles or other long-lived assets.

Research and development expenses consist of employee-related compensation and benefits expenses and third-party consulting fees of technology professionals for internally-developed computer software that are incurred prior to reaching technological feasibility.

Amortization of purchased intangible assets includes the amortization of all identified definite-lived intangible assets resulting from acquisitions.

Advertising Costs

Advertising costs are expensed as incurred. Advertising costs are reflected in selling, general and administrative expenses in the accompanying Consolidated Statements of Income and Comprehensive Income and were \$7.0 million \$7.8 million, \$6.5 million \$7.0 million and \$4.8 million \$6.5 million for the years ended June 30, 2023 June 30, 2024, 2023 and 2022, and 2021, respectively.

Income Taxes

The Company accounts for income taxes under the asset and liability approach. Deferred tax assets or liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates as well as net operating losses and credit carryforwards, which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets when, based upon the available evidence, it is more likely than not that the deferred tax assets will not be realized.

The Company prepares and files tax returns based on interpretations of tax laws and regulations. The Company's tax returns are subject to examination by various taxing authorities in the normal course of business. Such examinations may result in future tax, interest and penalty assessments by these taxing authorities.

In determining the Company's tax expense for financial reporting purposes, the Company establishes a reserve when there are transactions, calculations and tax filing positions for which the tax determination is uncertain and it is more likely than not that such positions would not be sustained upon examinations.

The Company adjusts its tax reserve estimates periodically based on the changes in facts and circumstances, such as ongoing examinations by, and settlements with, various taxing authorities, as well as changes in tax laws, regulations and interpretations. The consolidated tax expense of any given year includes adjustments to prior year income tax reserves and related estimated interest charges that are considered appropriate. The Company's policy is to recognize, when applicable, interest and penalties on uncertain income tax positions as part of income tax expense.

Comprehensive Income

Comprehensive income includes all changes in stockholders' equity during a period from non-owner sources. Net income and other comprehensive income are reported, net of their related tax effect, to arrive at comprehensive income.

Basic and Diluted Earnings per Share ("EPS")

Basic EPS is calculated by dividing net income attributable to stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted EPS assumes the conversion, exercise or issuance of all potentially issuable dilutive shares of Class A common stock ("Common Stock"), unless the effect of such inclusion would result in the reduction of a loss or the increase in income per share. Diluted EPS is calculated by dividing net income attributable to stockholders by the weighted average number of shares of common stock increased by the dilutive effects of potentially issuable dilutive shares of Class A common stock Common Stock during the period. The number of potential common shares outstanding is determined in accordance with the treasury stock method.

Recently Adopted Issued Accounting Standards Not Yet Adopted

In October 2021, 2023, the Financial Accounting Standards Board issued Accounting Standards Update ("ASU") No. 2021-08 Business Combinations (Topic 805): Accounting for Contract Assets 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Contract Liabilities from Contracts with Customers, Simplification Initiative ("ASU 2021-08" 2023-06"), which requires that an acquirer recognize and measure contract assets and contract liabilities acquired modifies the

disclosure or presentation requirements of a variety of topics in a business combination in accordance with Topic 606, Revenue the codification. ASU 2023-06 will be effective for the Company on the date of the SEC's removal of the related guidance from Contracts with Customers. Regulation S-X or Regulation S-K becomes effective, or for the fiscal year beginning July 1, 2028, at the latest. Early adoption is prohibited. The Company adopted has preliminarily evaluated the new standard and acknowledges the standard will result in enhanced disclosures.

In November 2023, the Financial Accounting Standards Board issued Accounting Standards Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2021-08 during 2023-07"), which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant expenses. ASU 2023-07 will be effective for the second quarter of Company for the fiscal 2023 year beginning July 1, 2024. Early adoption is permitted. The Company has preliminarily evaluated the new standard did not have a material impact on and acknowledges the Company's financial statements nor its related standard will result in enhanced disclosures.

(3) BUSINESS ACQUISITIONS

Acquisition of TRPN Direct Pay, Inc. and Devon Health, Inc. Assets

On October 13, 2022, the Company, through its consolidated subsidiary Contigo Health, LLC ("Contigo Health"), acquired certain assets (the "TRPN Transferred Assets") of TRPN Direct Pay, Inc. and Devon Health, Inc. (collectively, "TRPN"), including contracts with more than 900,000 providers (collectively, the "Assumed Contracts"), and agreed to assume certain liabilities and obligations of TRPN with regard to the Assumed Contracts (referred to as the "TRPN acquisition"). The TRPN Transferred Assets relate to businesses of TRPN focused on improving access to quality healthcare and reducing the cost of medical claims through pre-negotiated discounts with network providers, including acute care hospitals, surgery centers,

physicians and other continuum of care providers in the United States. Contigo Health also agreed to license proprietary cost containment technology of TRPN.

The purchase price paid by the Company to complete the TRPN acquisition consisted of cash of \$177.5 million, funded with borrowings under the Company's Credit Facility (as defined in Note 9 - Debt and Notes Payable) and cash on hand, of which \$17.8 million was placed in escrow to satisfy indemnification obligations of TRPN to Contigo Health and its affiliates and other parties related thereto under the purchase agreement governing the TRPN acquisition.

The Company has accounted for the TRPN acquisition as a business combination whereby the purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based on their fair values. The total fair value initially assigned to intangible assets acquired was \$116.6 million, consisting primarily of the provider network.

The TRPN acquisition resulted in the initial recognition of \$60.9 million of goodwill attributable to the anticipated profitability of TRPN, based on the purchase price paid in the acquisition compared to the fair value of the net assets acquired. Subsequent to acquisition, the Company recorded an impairment charge, which reduced goodwill attributable to TRPN to \$16.5 million. The TRPN acquisition was considered an asset acquisition for income tax purposes. Accordingly, the Company expects tax goodwill to be deductible for tax purposes. As of June 30, 2024, the intangible assets and goodwill recognized as a result of the TRPN acquisition were fully impaired (see Note 8 - Goodwill and Intangible Assets).

TRPN has been integrated within Premier under Contigo Health and is reported as part of the Performance Services Segment.

Pro forma results of operations for the acquisition have not been presented because the effects on revenue and net income were not material to the Company's historical consolidated financial statements.

(4) INVESTMENTS

Investments in Unconsolidated Affiliates

The Company's investments in unconsolidated affiliates consisted of the following (in thousands):

		Carrying Value		Equity in Net Income		
		June 30,		Year Ended June 30,		
		2023	2022	2023	2022	2021
Carrying Value						
		June 30,				
		2024				
FFF	FFF	\$136,080	\$137,162	\$ 8,571	\$16,614	\$11,344
Exela	Exela	32,905	27,733	5,172	1,733	—
Qventus	Qventus	16,000	16,000	—	—	—
Prestige	Prestige	15,503	15,597	921	4,303	8,856
Other investments	Other investments	31,338	19,053	1,404	855	873
Total investments	Total investments	\$231,826	\$215,545	\$16,068	\$23,505	\$21,073
Carrying Value						
		June 30,				
		2024				
		2023				
		2024				
		2023				
		2022				

The Company, through its indirect, wholly owned subsidiary Premier Supply Chain Improvement, Inc. ("PSCI"), held a 49% interest in FFF Enterprises, Inc. ("FFF") through its ownership of stock of FFF at June 30, 2023 June 30, 2024 and 2022. The Company accounts for its investment in FFF as part of the Supply Chain Services segment.

2023. On March 3, 2023, the Company and the majority shareholder of FFF amended the FFF shareholders' agreement and in lieu of a distribution, the Company received an increase of \$24.8 million to its liquidation preferences on the Class B common stock in FFF, bringing the Company's total liquidation preference in FFF to \$32.3 million. In the event

of liquidation or dissolution of FFF, the Company will receive the liquidation preference of \$32.3 million prior to any pro rata distribution of FFF's proportional equity value between the Company and the majority shareholder of FFF. As a result of the increase to the liquidation preference and priority of the Company's Class B common stock in FFF in the event of liquidation or dissolution of FFF, the Company will no longer account for its investment in FFF using the equity method of accounting. As of the date of the amendment, the Company will account for its investment in FFF at cost less impairments, if any, plus or minus any observable changes in fair value (refer to the Annual Report on Form 10-K for the fiscal year ended June 30, 2023, the "2023 Annual Report," for additional information and details regarding the March 2023 amendment). The Company accounts for its investment in FFF as part of the Supply Chain Services segment.

The Company, through its consolidated subsidiary, ExPre Holdings, LLC ("ExPre"), held an approximate 6% interest in Exela Holdings, Inc. ("Exela") through its ownership of Exela Class A common stock at June 30, 2023, June 30, 2024 and 2023. At June 30, 2023, June 30, 2024 and 2023, the Company owned approximately 15% of the membership interest of ExPre, with the remainder of the membership interests held by 11 member health systems or their affiliates.

The Company, through its consolidated subsidiary, PRAM Holdings, LLC ("PRAM"), held an approximate 20% interest in Prestige Ameritech Ltd. ("Prestige") through its ownership of Prestige limited partnership units at June 30, 2023. At June 30,

2023, the Company owned approximately 26% of the membership interest of PRAM, with the remainder of the membership interests held by 16 member health systems.

The Company accounts for its investments in Exela and Prestige using the equity method of accounting and includes the investment as part of the Supply Chain Services segment.

On January 31, 2022, the Company, through PHSI, purchased held an approximate 7% interest in Qventus, Inc. ("Qventus") through its PHSI's ownership of Qventus Series C preferred stock, stock at June 30, 2024 and 2023. The Company accounts for its investment in Qventus at initial cost less impairments, if any, plus or minus any observable changes in fair value. The Company includes Qventus as part of the Performance Services segment.

The Company, through its consolidated subsidiary, PRAM Holdings, LLC ("PRAM"), held an approximate 20% interest in Prestige Ameritech Ltd. ("Prestige") through PRAM's ownership of Prestige limited partnership units at June 30, 2024 and 2023. At June 30, 2024 and 2023, the Company owned approximately 26% of the membership interest of PRAM, with the remainder of the membership interests held by 16 member health systems or their affiliates. The Company accounts for its investment in Prestige using the equity method of accounting and includes the investment as part of the Supply Chain Services segment.

Unconsolidated Significant Subsidiaries

In accordance with Rules 3-09 and 4-08(g) of Regulation S-X, the Company must determine which of its unconsolidated investments, if any, are considered "significant subsidiaries." In evaluating these investments, there are three tests utilized to determine if any unconsolidated subsidiaries are considered significant subsidiaries: the investment test, the asset test and the income test. Rule 3-09 of Regulation S-X requires the Company to include separate audited financial statements of any unconsolidated majority-owned subsidiary (unconsolidated subsidiaries in which the Company owns greater than 50% of the voting securities) in an annual report if any of the three tests exceed 20%. Rule 4-08(g) of Regulation S-X requires summarized financial information of unconsolidated subsidiaries in an annual report if any of the three tests exceeds 10%, and summarized financial information in a quarterly report if any of the three tests exceeds 20% pursuant to Rule 10-01(b)(1) of Regulation S-X.

As of June 30, 2022 and 2021, the Company held one unconsolidated investment whose assets represented greater than 10% of its total assets.

The following table shows summarized unaudited financial information for FFF, which met the 10% asset test for the year ended June 30, 2022 (in thousands):

	June 30,	
	2022	
Total current assets	\$	841,555
Total non-current assets		103,298
Total current liabilities		463,863
Total non-current liabilities		325,693
Non-controlling equity		76,096

The following table shows summarized unaudited results of operations information for FFF, which met the 10% asset test for the years year ended June 30, 2022 and 2021 (in thousands):

	Year Ended June 30,	
	2022	2021
Revenue	\$ 2,728,855	\$ 2,047,494
Gross profit	150,980	122,890
Income from operations	55,379	41,643
Net income	33,215	23,841
Net income attributable to non-controlling interest	16,275	11,682

	Year Ended
	June 30, 2022
Revenue	\$ 2,728,855
Gross profit	150,980
Income from operations	55,379
Net income	33,215
Net income attributable to non-controlling interest	16,275

(5) FAIR VALUE MEASUREMENTS

Recurring Fair Value Measurements

The following table represents the Company's financial assets and liabilities, which are measured at fair value on a recurring basis (in thousands):

	Fair Value of Financial Assets and Liabilities		Fair Value of Financial Assets and Liabilities	Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
	June 30, 2024						
Deferred compensation plan assets							
Deferred compensation plan assets							
Deferred compensation plan assets							
Total assets							
Earn-out liabilities							
Earn-out liabilities							
Earn-out liabilities							
Total liabilities							
	Quoted Prices in Active Markets for Significant Financial Assets Identical Assets and Liabilities (Level 1)		Quoted Prices in Active Markets for Significant Financial Assets Identical Assets and Liabilities (Level 2)		Quoted Prices in Active Markets for Significant Financial Assets Identical Assets and Liabilities (Level 3)		
June 30, 2023	June 30, 2023						
June 30, 2023							
June 30, 2023							
Cash equivalents							
Cash equivalents							
Cash equivalents	\$ 77	\$ 77	\$ —	\$ —	\$ —	\$ —	\$ —
Deferred compensation plan assets							
Deferred compensation plan assets							
Total assets	\$ 55,566	\$ 55,566	\$ —	\$ —	\$ —	\$ —	\$ —
Earn-out liabilities							
Earn-out liabilities	\$ 26,603	\$ —	\$ —	\$ —	\$ 26,603	\$ —	\$ —

Total liabilities	\$26,603	\$	—	\$	—	\$	26,603
June 30, 2022							
Cash equivalents	\$	75	\$	75	\$	—	\$
Deferred compensation plan							
assets		52,718		52,718		—	—
Total assets	\$52,793	\$52,793	\$	—	\$	—	\$
Earn-out liabilities							
Earn-out liabilities	Earn-out liabilities	\$22,789	\$	—	\$	—	\$ 22,789
Total liabilities	Total liabilities	\$22,789	\$	—	\$	—	\$ 22,789

Deferred compensation plan assets consisted of highly liquid mutual fund investments, which were classified as Level 1. The current portion of deferred compensation plan assets (\$**5.2** **6.8** million and **\$5.3 million** **\$5.2 million** at **June 30, 2023** **June 30, 2024** and **2022**, **2023**, respectively) was included in prepaid expenses and other current assets in the accompanying Consolidated Balance Sheets.

Financial Instruments Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)

FFF Put and Call Rights

On July 29, 2021, the FFF shareholders' agreement was amended resulting in the termination of the FFF Put Right and the derecognition of the FFF Put Right liability.

In the event of a Key Man Event (generally defined in the shareholders' agreement as the resignation, termination for cause, death or disability of the majority shareholder), the Company has a call right that requires the majority shareholder to sell its remaining interest in FFF to the Company, and is exercisable at any time within 180 calendar days after the date of a Key Man Event (the "Call Right", together with the FFF Put Right, the "Put and Call Rights"). As of **June 30, 2023** **June 30, 2024** and **2022**, **2023**, the Call Right had zero value. In the event that either of these rights are exercised, the purchase price for the additional interest in FFF will be at a per share price equal to the earnings before interest, taxes, depreciation and amortization ("FFF EBITDA") over the twelve calendar months prior to the purchase date multiplied by a market adjusted multiple, adjusted for any outstanding debt and cash and cash equivalents, divided by the number of shares of FFF common stock then outstanding ("Equity Value per Share").

Earn-out liabilities

At June 30, 2023, earn-out liabilities have been established in connection with certain acquisitions, including the acquisition of substantially all of the assets and certain liabilities of Acurity, Inc. and Nexera, Inc. (the "Acurity and Nexera asset acquisition") in February 2020 as well as other immaterial acquisitions. The earn-out liability related to the Acurity and Nexera asset acquisition was based upon the Company's achievement of a range of member renewals on terms to be agreed to by the Company and Greater New York Hospital Association based on prevailing market conditions in December 2023. Earn-out liabilities are classified as Level 3 of the fair value hierarchy.

Acurity and Nexera Earn-out (a)

The earn-out liability arising from expected earn-out payments related to the Acurity and Nexera asset acquisition was measured on the acquisition date using a probability-weighted expected payment model and ~~are~~ is remeasured periodically due to changes in management's estimates of the number of transferred member renewals and market conditions. In determining the fair value of the contingent liabilities, management reviews the current results of the acquired business, along with projected results for the remaining earn-out period, to calculate the expected earn-out payment to be made based on the contractual terms set out in the acquisition agreement. As of June 30, 2023 and 2022, At June 30, 2024, the most likely outcome was determined to be \$30.0 million from an undiscounted range of outcomes ~~is~~ between \$0 and \$30.0 million. A significant decrease in the probability could result in a significant decrease in the value of the earn-out liability. The fair value of the Acurity and Nexera earn-out liability at ~~June 30, 2023~~ June 30, 2024 and ~~2022~~ 2023 was \$28.5 million and \$23.1 million, and \$22.8 million, respectively.

As of June 30,		As of June 30,		As of June 30,	
Input	Input	Input	Input	Input	Input
assumptions	assumptions	2023	2022	Input assumptions	
Probability	Probability				
of	of				
transferred	transferred				
member	member				
renewal	renewal				
percentage	percentage				
< 50%	< 50%	5.0 %	5.0 %	Probability of transferred member renewal percentage < 50%	
				— %	5.0 %

Probability of transferred member renewal percentage between 50% and 65%	Probability of transferred member renewal percentage between 50% and 65%	10.0 %	10.0 %	Probability of transferred member renewal percentage between 50% and 65%	— %	10.0 %
Probability of transferred member renewal percentage between 65% and 80%	Probability of transferred member renewal percentage between 65% and 80%	25.0 %	25.0 %	Probability of transferred member renewal percentage between 65% and 80%	— %	25.0 %
Probability of transferred member renewal percentage > 80%	Probability of transferred member renewal percentage > 80%	60.0 %	60.0 %	Probability of transferred member renewal percentage > 80%	100.0 %	60.0 %
Credit spread	Credit spread	1.6 %	1.6 %	Credit spread	1.0 %	1.6 %

(a) The Acurity and Nexera earn-out liability was initially valued as of February 28, 2020.

A reconciliation of the FFF Put Right and earn-out liabilities is as follows (in thousands):

		Beginning Balance	Purchases (Settlements) ^(a)	(Gains)/Losses ^(b)	Ending Balance
Year Ended June 30, 2023					
Year Ended June 30, 2024	Beginning Balance				
Earn-out liabilities					
Earn-out liabilities	Earn-out liabilities	\$22,789	\$ 1,460	\$ 2,354	\$26,603
Total Level 3 liabilities	Total Level 3 liabilities	\$22,789	\$ 1,460	\$ 2,354	\$26,603
Year Ended June 30, 2022					
Year Ended June 30, 2023					
Year Ended June 30, 2023					
Earn-out liabilities	Earn-out liabilities	\$24,249	\$ —	\$ (1,460)	\$22,789

FFF put right	64,110	(64,110)	—	—
Earn-out liabilities				
Earn-out liabilities				
Total	Total			
Level 3 liabilities	liabilities	\$88,359	\$ (64,110)	\$ (1,460) \$22,789

(a) Settlements for the year ended June 30, 2024 represent payments on earn-out liabilities. Purchases for the year ended June 30, 2023 includes include an earn-out which has had not been earned or paid as of June 30, 2023. Settlements for the year ended June 30, 2022 includes non-cash gain recognized as a result of the termination of the FFF Put Right and the derecognition of the FFF Put Right liability.

(b) Gains on level 3 liability balances will decrease the liability ending balance and losses on level 3 liability balance balances will increase the liability ending balance. (Gains) losses on earn-out liabilities are included in selling, general and administrative expenses on the Consolidated Statements of Income and Comprehensive Income.

Non-Recurring Fair Value Measurements

During As a result of the year ended June 30, 2021, August 2020 Restructuring, the Company recorded non-interest bearing notes payable to former limited partners as a result during the first quarter of the August 2020 Restructuring, fiscal year 2021. Although these notes are non-interest bearing, they include a Level 2 input associated with the an implied fixed annual interest rate of 1.8% and are calculated as of August 11, 2020 (see Note 9 - Debt and Notes Payable).

During the year ended June 30, 2023 June 30, 2024, no non-recurring in conjunction with the Company's assessment to determine whether it was more likely than not that the fair value measurements values of any of its reporting units were required relating below their carrying amounts, the Company recorded pre-tax impairment charges in selling, general and administrative expense in the accompanying Consolidated Statements of Income and Comprehensive Income related to the measurement of Contigo Health reporting unit. The impairments, which included Level 3 inputs, related to property and equipment and goodwill and intangible assets for impairment. However, purchase price allocations required significant non-recurring Level 3 inputs. The preliminary fair values of the acquired intangible assets resulting from the TRPN acquisition were determined using the income approach (see Note 37 - Business Acquisitions). Supplemental Balance Sheet Information and Note 8 - Goodwill and Intangible Assets, respectively, as well as \$0.3 million for operating lease right-of-use assets.

Financial Instruments For for Which Fair Value is Only is Disclosed

The fair values of non-interest bearing notes payable, classified as Level 2, were equal to their carrying value at June 30, 2023 June 30, 2024 and \$0.1 million less than the carrying value at June 30, 2022, June 30, 2023 based on an assumed market interest rate of 1.6%.

Other Financial Instruments

The fair values of cash, accounts receivable, accounts payable, accrued liabilities, and the Credit Facility (as defined in Note 9 - Debt and Notes Payable) approximated carrying value due to the short-term nature of these financial instruments.

(6) CONTRACT BALANCES

Contract Assets, Deferred Revenue and Revenue Share Obligations

The timing of revenue recognition, billings and cash collections results in accounts receivables, contract assets (unbilled receivables) and deferred revenue on the Consolidated Balance Sheets. Contract assets increased by \$41.1 million \$39.3 million during the year ended June 30, 2023 compared to the year ended June 30, 2022 June 30, 2024 primarily due to the acceleration of revenue recognition from licensing contracts in Performance Services and increased gross administrative fees driven by higher members' purchases. The acceleration of revenue recognition from licensing contracts represents performance obligations that have been satisfied prior to customer invoicing offset by the timing of invoicing related to the licensing contracts as well as invoicing related to certain cost management consulting services and performance-based engagements where revenue is recognized as work is performed. Revenue share obligations increased by \$16.9 million \$30.5 million during the year ended June 30, 2023 June 30, 2024 compared to the year ended June 30, 2022 June 30, 2023 primarily due to the underlying revenue share arrangements which include an increase in gross administrative fees driven by higher members' purchases in addition to a higher average revenue fee share percentage. percentage in the underlying revenue share arrangements.

Revenue recognized during the year ended June 30, 2023 June 30, 2024 that was included in the opening balance of deferred revenue at June 30, 2022 June 30, 2023 was \$26.6 \$21.6 million, which is a result of satisfying performance obligations primarily within the Performance Services segment.

Performance Obligations

A performance obligation is a promise contractual obligation to transfer a distinct good or service to a customer. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Contracts may have a single performance obligation as the promise agreement to transfer individual goods or services is not separately identifiable from other promises contractual obligations and, therefore, not distinct, while other contracts may have multiple performance obligations, most commonly due to the contract covering multiple phases or deliverable arrangements (licensing fees, SaaS software-as-a-service ("SaaS") subscription fees, maintenance and support fees, and professional fees for consulting services).

Net revenue of \$13.0 million was recognized during the year ended June 30, 2024 from performance obligations that were satisfied or partially satisfied on or before June 30, 2023. The net revenue recognized was driven by an increase of \$7.8 million associated with revised forecasts from underlying contracts that include variable consideration components as well as additional fluctuations due to input method contracts which occur in the normal course of business and an increase of \$5.2 million in net administrative fees revenue related to under-forecasted cash receipts received in the current period.

Net revenue of \$4.1 million was recognized during the year ended June 30, 2023 from performance obligations that were satisfied or partially satisfied on or before June 30, 2022. The net revenue recognized was driven by an increase of \$7.8 million in net administrative fees revenue related to under-forecasted cash receipts received in the current period.

This increase was partially offset by a reduction of \$3.7 million associated with revised forecasts from underlying contracts that include variable consideration components as well as additional fluctuations due to input method contracts which occur in the normal course of business.

Net revenue of \$5.3 million was recognized during the year ended June 30, 2022 from performance obligations that were satisfied or partially satisfied on or before June 30, 2021. The net revenue recognized was driven by an increase of \$4.8 million in net administrative fees revenue related to under-forecasted cash receipts received in the current period and an increase of \$0.5 million associated with revised forecasts from underlying contracts that include variable consideration components as well as additional fluctuations due to input method contracts which occur in the normal course of business.

Remaining performance obligations represent the portion of the transaction price that has not yet been satisfied or achieved. As of **June 30, 2023** **June 30, 2024**, the aggregate amount of the transaction price allocated to remaining performance obligations was **\$699.0 million** **\$736.2 million**. The Company expects to recognize **40%** **37%** of the remaining performance obligations over the next twelve months, and an additional **24%** **23%** over the following twelve months and an additional **29%** over the following 36 months, with the remainder recognized thereafter.

Contract Costs

The Company capitalizes the incremental costs of obtaining and fulfilling a contract, which include sales commissions and costs associated with implementing SaaS informatics tools. At June 30, 2024, the Company had \$25.5 million in capitalized contract costs, including \$16.1 million related to sales commissions and sales commissions. \$9.4 million related to implementation costs. The Company recognized \$11.0 million of related amortization expense for the year ended June 30, 2024.

At June 30, 2023, the Company had \$24.4 million in capitalized contract costs, including \$14.9 million related to sales commissions and \$9.5 million related to implementation costs and \$14.9 million related to sales commissions. The Company recognized \$10.6 million of related amortization expense for the year ended June 30, 2023.

At June 30, 2022, the Company had \$22.9 million in capitalized contract costs, including \$10.7 million related to implementation costs and \$12.2 million related to sales commissions. The Company recognized \$8.9 million of related amortization expense for the year ended June 30, 2022.

(7) SUPPLEMENTAL BALANCE SHEET INFORMATION

Accounts Receivable, Net

Trade accounts receivable consisted of amounts due for services and products from hospital and healthcare members, distributors and other customers.

Accounts receivable, net consisted of the following (in thousands):

		June 30,			
		2023	2022		
		June 30,		June 30,	
2024		2024		2023	
Trade accounts receivable	Trade accounts receivable	\$117,655	\$114,214		
Other	Other	518	1,958		
Total accounts receivable	Total accounts receivable	118,173	116,172		
Allowance for credit losses	Allowance for credit losses	(2,878)	(2,043)		
Accounts receivable, net	Accounts receivable, net	\$115,295	\$114,129		

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

		June 30,			
		Useful life	2023	2022	
		June 30,			
2024		Useful life	2024	2023	June 30,
Capitalized software	Capitalized software	2-5 years	\$785,260	\$705,319	
Computer hardware	Computer hardware	3-5 years	63,281	60,399	

Furniture and other equipment	Furniture and other equipment	5 years	7,049	7,097
		Lesser of estimated useful life		
Leasehold improvements	Leasehold improvements	or term of lease	19,272	19,208
Total property and equipment	Total property and equipment		874,862	792,023
Accumulated depreciation and amortization	Accumulated depreciation and amortization		(662,554)	(578,644)
Property and equipment, net	Property and equipment, net		\$212,308	\$213,379

Depreciation and amortization expense related to property and equipment was \$85.7 million \$81.7 million, \$85.2 million \$85.7 million and \$76.3 million \$85.2 million for the years ended June 30, 2023 June 30, 2024, 2022 2023 and 2021 2022, respectively. Unamortized capitalized software costs were \$178.6 million and \$175.0 million at June 30, 2024 and \$177.6 million at June 30, 2023 and 2022, 2023, respectively.

During the year ended June 30, 2024, the Company incurred an impairment of long-lived assets of \$9.8 million related to the Contigo Health reporting unit as the carrying value of the assets was not recoverable. During the year ended June 30, 2022, the Company incurred an impairment of long-lived assets of \$12.7 million associated with capitalized software assets in the Supply Chain Services segment as the carrying value of the assets was not recoverable. The Company did not incur a material loss on disposal or impairment of long-lived assets during the years year ended June 30, 2023 and 2021.

Other Long-Term Assets

Other long-term assets consisted of the following (in thousands):

	June 30,		2024	June 30,	2023
	2023	2022			
Contract assets, less current portion	Contract assets, less current portion	\$ 56,372	\$ 54,441		
Capitalized contract costs	Capitalized contract costs	24,414	22,894		
Notes receivable					
Acuity prepaid contract administrative fee share, less current portion	Acuity prepaid contract administrative fee share, less current portion	9,700	29,099		
Notes receivable		4,700	—		
Other (a)	Other (a)	14,929	7,720		
Total other long-term assets	Total other long-term assets	\$110,115	\$114,154		

(a) Includes deferred loan costs, net of \$3.5 million \$2.7 million and \$0.9 million \$3.5 million as of June 30, 2023 June 30, 2024 and 2022, 2023, respectively.

Pursuant to the Acurity and Nexera asset acquisition, the Company capitalized one-time rebates pursuant to the purchase agreement with Acurity, Inc. as prepaid contract administrative fee share.

Contract costs include capitalized sales commissions and implementation costs. See Note 6 - Contract Balances for further information.

The Company recorded amortization expense on deferred loan costs of \$0.7 million \$0.8 million, \$0.6 million \$0.7 million and \$0.6 million the years ended June 30, 2023 June 30, 2024, 2022 2023 and 2021, 2022, respectively. Amortization expense on deferred loan costs was recognized based on the straight-line method, which approximates the effective interest method, and was included in interest expense, net in the Consolidated Statements of Income and Comprehensive Income.

Pursuant to the Acurity and Nexera asset acquisition, the Company capitalized one-time rebates pursuant to the purchase agreement with Acurity, Inc. as prepaid contract administrative fee share.

Other Long-Term Liabilities

Other long-term liabilities consisted of the following (in thousands):

		June 30,			
		2023	2022		
		June 30,		June 30,	
		2024		2024	2023
Reserve for uncertain tax positions					
Earn-out liability, less current portion	Earn-out liability, less current portion	\$23,128	\$22,789		
Reserve for uncertain tax positions		22,915	18,799		
Other	Other	1,159	986		
Total other long-term liabilities	liabilities	\$47,202	\$42,574		

Earn-out liabilities were established in connection with the Acurity and Nexera asset acquisition as well as other immaterial acquisitions. See Note 5 - Fair Value Measurements for further information.

(8) GOODWILL AND INTANGIBLE ASSETS

Goodwill

A reconciliation of goodwill by segment is as follows (in thousands):

	Supply Chain Services	Performance Services	Total
June 30, 2022	\$ 388,502	\$ 611,411	\$ 999,913
Acquisition of businesses and assets	—	69,160	69,160
Impairment	(2,296)	(54,422)	(56,718)
June 30, 2023	\$ 386,206	\$ 626,149	\$ 1,012,355

Goodwill increased primarily due to the TRPN acquisition (see Note 3 - Business Acquisitions). At June 30, 2023, accumulated impairment losses to goodwill were \$56.7 million.

Fiscal 2023 Annual Goodwill Year 2024 Impairment

The annual goodwill impairment testing ("annual test") was performed as in connection with the preparation of April 1, 2023. Based on a quantitative analysis performed, its quarterly financial statements during the third quarter of fiscal year 2024, the Company believed there were indicators assessed changes in circumstances that occurred during the carrying value of certain reporting units quarter to determine whether it was more likely than not exceeded their fair value at June 30, 2023. During the annual test, that the fair values of any of its reporting units were below their carrying amounts. While there was no single determinative event or factor, potential triggering events during the third quarter of fiscal year 2024 led the Company to conclude that when considering the events and factors in totality, it was more likely than not that the fair value of the Contigo Health reporting unit was below its carrying value at March 31, 2024. The Company also determined there were impairment indicators for the other long-lived assets within the Contigo Health

reporting unit, which also represents the asset group for purposes of assessing the potential impairment of long-lived assets. The fair value of the reporting unit was computed using a discounted cash flow analysis and market-based approach. The discounted cash flow model uses seven- to thirteen- year forecasted cash flows plus a terminal value based on capitalizing the last period's cash flows using a perpetual growth rate. The Company's significant assumptions in the discounted cash flow model include, but are not limited to, a discount rate utilizing a weighted average cost of capital and the amount and timing of expected future cash flows utilizing revenue growth rates (including perpetual growth rate), and EBITDA margin percentages and debt-free working capital of the reporting unit's business. These assumptions were developed in consideration of current market conditions and future expectations, which include, but were not limited to, new product offerings, market demand and impacts from competition. As a result, during the third quarter of fiscal year 2024, the Company recorded impairment charges related to the Contigo Health reporting unit recorded in selling, general and administrative expense in the accompanying Consolidated Statements of Income and Comprehensive Income. The pre-tax impairment charges comprised of \$16.5 million for goodwill, \$96.1 million for the provider network, \$11.9 million for customer relationships, \$0.6 million for technology, \$0.3 million for non-compete agreements and \$4.6 million for other intangible assets. At June 30, 2024, the Contigo Health reporting unit's goodwill and intangible assets were fully impaired.

Fiscal Year 2023 Impairment

During the year ended June 30, 2023, the Company recorded pre-tax goodwill impairment charges of \$54.4 million and \$2.3 million related to the Contigo Health and Direct Sourcing reporting units, respectively, for the year ended June 30, 2023, recorded in selling, general and administrative expense in the accompanying Consolidated Statements of Income and Comprehensive Income.

Fiscal Year 2022 Impairment

Intangible Assets, Net

Intangible assets, net consisted of the following (in thousands):

	Useful Life	June 30, 2023			June 30, 2022		
		Accumulated		Net	Accumulated		Net
		Gross	Amortization		Gross	Amortization	
Member relationships	14.7 years	\$ 386,100	\$ (136,751)	\$ 249,349	\$ 386,100	\$ (110,593)	\$ 275,507
Provider Network	15.0 years	106,500	(5,029)	101,471	—	—	—
Technology	7.1 years	99,317	(67,581)	31,736	98,017	(61,287)	36,730
Customer relationships	9.4 years	57,930	(31,846)	26,084	47,830	(27,339)	20,491
Trade names	6.7 years	18,920	(11,983)	6,937	17,210	(9,951)	7,259
Non-compete agreements	5.2 years	17,715	(9,738)	7,977	17,315	(6,781)	10,534
Other (a)	9.3 years	9,232	(2,756)	6,476	7,682	(1,631)	6,051
Total		\$ 695,714	\$ (265,684)	\$ 430,030	\$ 574,154	\$ (217,582)	\$ 356,572

(a) Includes a \$1.0 million indefinite-lived asset.

The net carrying value of intangible assets by segment was as follows (in thousands):

	June 30,	
	2023	2022
Supply Chain Services	\$ 269,710	\$ 301,611
Performance Services (a)	160,320	54,961
Total intangible assets, net	\$ 430,030	\$ 356,572

(a) Includes a \$1.0 million indefinite-lived asset.

Total intangible assets increased primarily due to the TRPN acquisition (see Note 3 - Business Acquisitions). As part of the TRPN acquisition, the total fair value assigned to intangible assets acquired was \$116.6 million, consisting primarily of the provider network of \$106.5 million. The weighted average useful life of the acquired intangible assets is 14.1 years, with the provider network having a useful life of 15.0 years.

The Company reviews the carrying value of definite-lived intangible assets subject to amortization whenever events and circumstances indicate that the carrying value of the intangible asset subject to amortization may not be recoverable. During the year ended June 30, 2022, the carrying value of \$4.4 million in customer relationships and \$1.7 million in trade names in the Performance Services segment were not recoverable and the Company recorded an impairment on assets of \$6.1 million in the accompanying Consolidated Statements of Income and Comprehensive Income. During

Goodwill

A reconciliation of goodwill by segment is as follows (in thousands):

	Supply Chain Services	Performance Services	Total
June 30, 2023	\$ 386,206	\$ 626,149	\$ 1,012,355
Impairment	—	(16,503)	(16,503)
June 30, 2024	\$ 386,206	\$ 609,646	\$ 995,852

At June 30, 2024, the years ended Company had accumulated impairment losses to goodwill at Supply Chain Services and Performance Services of \$2.3 million and \$70.9 million, respectively. At June 30, 2023, the Company had accumulated impairment losses to goodwill at Supply Chain Services and 2021, no impairment Performance Services of \$2.3 million and \$54.4 million, respectively.

Intangible Assets, Net

Intangible assets, net consisted of the following (in thousands):

	Useful Life	June 30, 2024			June 30, 2023		
		Accumulated		Net	Accumulated		Net
		Gross	Amortization		Gross	Amortization	
Member relationships	14.7 years	\$ 386,100	\$ (162,910)	\$ 223,190	\$ 386,100	\$ (136,751)	\$ 249,349
Provider network	15.0 years	—	—	—	106,500	(5,029)	101,471
Technology	7.1 years	98,517	(73,441)	25,076	99,317	(67,581)	31,736
Customer relationships	9.3 years	41,430	(31,612)	9,818	57,930	(31,846)	26,084
Trade names	6.8 years	18,420	(13,574)	4,846	18,920	(11,983)	6,937
Non-compete agreements	5.2 years	17,315	(12,063)	5,252	17,715	(9,738)	7,977
Other (a)	4.1 years	3,432	(2,355)	1,077	9,232	(2,756)	6,476
Total		\$ 565,214	\$ (295,955)	\$ 269,259	\$ 695,714	\$ (265,684)	\$ 430,030

(a) Includes a \$1.0 million indefinite-lived asset as of June 30, 2023.

The net carrying value of intangible assets by segment was recorded in the accompanying Consolidated Statements as follows (in thousands):

	June 30,	
	2024	2023
Supply Chain Services	\$ 238,622	\$ 269,710
Performance Services (a)	30,637	160,320
Total intangible assets, net	\$ 269,259	\$ 430,030

(a) Includes a \$1.0 million indefinite-lived asset as of Income and Comprehensive Income, June 30, 2023.

The estimated amortization expense for each of the next five fiscal years and thereafter is as follows (in thousands):

2024		\$ 49,761
2025	2025	48,136
2026	2026	46,892
2027	2027	44,240
2028	2028	39,197
2029		
Thereafter	Thereafter	200,804
Total amortization expense	Total amortization expense	\$ 429,030

(9) DEBT AND NOTES PAYABLE

Long-term debt and notes payable consisted of the following (in thousands):

	June 30,		
	2023	2022	
			June 30,
	2024		2023
Credit Facility	Credit Facility	\$215,000	\$150,000

Notes payable to members, net of discount	Notes payable to members, net of discount	201,188	298,994
Other notes payable	Other notes payable	2,280	5,333
Total debt and notes payable	Total debt and notes payable	418,468	454,327
Less: current portion	Less: current portion	(316,211)	(250,859)
Total long-term debt and notes payable	Total long-term debt and notes payable	\$102,257	\$203,468

Credit Facility

PHSI, along with its consolidated subsidiaries, Premier LP and PSCI ("Co-Borrowers"), and certain domestic subsidiaries of the Co-Borrowers, as guarantors, entered into a senior unsecured Amended and Restated Credit Agreement, dated as of December 12, 2022 (the "Credit Facility"). The Credit Facility has a maturity date of December 12, 2027, subject to up to two one-year extensions, at the request of the Co-Borrowers and approval of a majority of the lenders under the Credit Facility. The Credit Facility provides for borrowings of up to \$1.0 billion with (i) a \$50.0 million sub-facility for standby letters of credit and (ii) a \$100.0 million sub-facility for swingline loans. The Credit Facility also provides that Co-Borrowers may from time to time (i) incur incremental term loans and (ii) request an increase in the revolving commitments under the Credit Facility, together up to an aggregate of \$350.0 million, subject to the approval of the lenders providing such term loans or revolving commitment increase. The Credit Facility contains an unconditional and irrevocable guaranty of all obligations of Co-Borrowers under the Credit Facility by the current and future guarantors. Premier is not a guarantor under the Credit Facility.

The Credit Facility refinanced the Credit Agreement, dated as of November 9, 2018, as amended (the "Prior Loan Agreement"), and the Prior Loan Agreement, which was scheduled to mature on November 9, 2023, was terminated on December 12, 2022. The Prior Loan Agreement included a \$1.0 billion unsecured revolving credit facility. At the time of its termination, outstanding borrowings, accrued interest and fees and expenses under the Prior Loan Agreement totaled \$331.3 million, which was repaid with cash on hand and borrowings under the Credit Facility.

At the Company's option, committed loans under the Credit Facility may be in the form of secured overnight financing rate loans ("SOFR Loans") or base rate loans. SOFR Loans bear interest at Term SOFR plus an adjustment of 0.100% ("Adjusted Term SOFR") plus the Applicable Rate (defined as a margin based on the Consolidated Total Net Leverage Ratio (as defined in the Credit Facility)). Base rate loans bear interest at the Base Rate (defined as the highest of the prime rate announced by the administrative agent, the federal funds effective rate plus 0.500%, the one-month Adjusted Term SOFR plus 1.000% and 0.000%), plus the Applicable Rate. The Applicable Rate ranges from 1.250% to 1.750% for SOFR Loans and 0.250% to 0.750% for base rate loans. At **June 30, 2023** **June 30, 2024**, the interest rates for SOFR Loans and base rate loans were **6.491%** **6.687%** and **8.500%** **8.750%**, respectively. Co-Borrowers are required to pay a commitment fee ranging from 0.125% to 0.225% per annum on the actual daily unused amount of commitments under the Credit Facility. At June 30, 2023, the weighted average interest rate on outstanding borrowings under the Credit Facility was 6.470%. At **June 30, 2023** **June 30, 2024**, the commitment fee was 0.125%.

The Credit Facility contains customary representations and warranties as well as customary affirmative and negative covenants, including, among others, limitations on liens, indebtedness, fundamental changes, dispositions, restricted payments and investments. The Company was in compliance with all such covenants at **June 30, 2023** **June 30, 2024**. The Credit Facility also contains customary events of default, including cross-defaults of any indebtedness or guarantees in excess of \$75.0 million. If any event of default occurs and is continuing, the administrative agent under the Credit Facility may, with the consent, or shall, at the request of a majority of the lenders under the Credit Facility, terminate the commitments and declare all of the amounts owed under the Credit Facility to be immediately due and payable.

Proceeds from borrowings under the Credit Facility may generally be used to finance ongoing working capital requirements, including permitted acquisitions, repurchases of **Class A common stock** **Common Stock** pursuant to any then-existing stock repurchase programs, dividend payments, if and when declared, and other general corporate activities. For the year ended **June 30, 2023** **June 30, 2024**, the Company **borrowed \$285.0 million** **had no new borrowings** and **repaid \$135.0 million** of borrowings under the Prior Loan Agreement. For the year ended June 30, 2023 the Company borrowed \$185.0 million and repaid \$270.0 million \$215.0 million of outstanding borrowings under the Credit Facility. The Company had \$215.0 million in no outstanding borrowings under the Credit Facility at **June 30, 2023** **June 30, 2024** with **\$785.0 million** **\$995.0 million** of available borrowing capacity after reductions for outstanding borrowings and outstanding letters of credit.

During the years ended **June 30, 2023** **June 30, 2024** and **2022** **2023**, interest expense on borrowings under the Credit Facility was **\$2.5 million** and **\$12.7 million**, and **\$2.8 million**, respectively. All outstanding borrowings under the Credit Facility as of June 30, 2023 were repaid in July and August 2023.

Notes Payable

Notes Payable to Former Limited Partners

At June 30, 2024, the Company had \$101.5 million of notes payable to former limited partners, ("LP"), net of discounts on notes payable of \$1.2 million, all of which was recorded to current portion of notes payable to former LPs in the accompanying Consolidated Balance Sheets. At June 30, 2023, the Company had \$201.2 million of notes payable to former limited partners, LPs, net of discounts on notes payable of \$4.2 million, of which \$99.7 million was recorded to current portion of notes payable to former limited partners in the accompanying Consolidated Balance Sheets. At June 30, 2022, the Company had \$299.0 million of notes payable to former limited partners, net of discounts on notes payable of \$9.1 million, of which \$97.8 million was recorded to current portion of notes payable to former limited partners LPs in the accompanying Consolidated Balance Sheets. The notes payable to former limited partners LPs were issued in connection with the early termination of the TRA as part of the August 2020 Restructuring. Although the notes payable to former limited partners LPs are non-interest bearing, pursuant to GAAP requirements, they were recorded net of imputed interest at a fixed annual rate of 1.8%. During the year ended June 30, 2024, the Company paid \$102.7 million to members including imputed interest of \$3.0 million. During the year ended June 30, 2023, the Company paid \$102.7 million to members including imputed interest of \$6.7 million.

Other

At June 30, 2023 June 30, 2024 and 2022, 2023, the Company had \$2.3 million \$1.0 million and \$5.3 million \$2.3 million in other notes payable, respectively, of which \$1.5 million \$1.0 million and \$3.1 million \$1.5 million, respectively, were included in current portion of long-term debt in the accompanying Consolidated Balance Sheets. Other notes payable do not bear interest and generally have stated maturities of three to five years from their date of issuance.

Future minimum principal payments on the notes as of June 30, 2023 June 30, 2024 are as follows (in thousands):

2024	\$	104,231
2025		103,419
2026		—
2027		—
2028		—
Total principal payments	\$	207,650
2025 (a)	\$	103,693
Total principal payments	\$	103,693

(a) There are no future minimum principal payments after 2025.

(10) REDEEMABLE LIMITED PARTNERS' CAPITAL LIABILITY RELATED TO THE SALE OF FUTURE REVENUES

The fair value On July 25, 2023, the Company sold the equity interest in its wholly-owned subsidiary, Non-Healthcare Holdings, LLC, pursuant to an equity purchase agreement with OMNIA ("Equity Purchase Agreement") for a total purchase price of redeemable limited partners' capital was reclassified \$723.8 million. As of June 30, 2024, the Company had received cash of \$681.4 million, and in July 2024, the Company received the final payment of approximately \$42.4 million. See Note 15 - Income Taxes for further income tax considerations on cash proceeds received as of June 30, 2024.

Pursuant to the terms of the Equity Purchase Agreement, OMNIA acquired Premier's non-healthcare GPO member agreements which includes the associated net cash flows generated from temporary equity administrative fees from purchasing on supplier contracts. In conjunction with the execution of the Equity Purchase Agreement, the Company and OMNIA entered into a 10 year channel partnership agreement (the "Channel Agreement") pursuant to which OMNIA's existing and newly acquired members will have access to Premier's supplier portfolio in which 100% of the administrative fees generated will be remitted to OMNIA. Under the terms of the Channel Agreement, although the Company sold the rights to retain future net administrative fees from the non-healthcare GPO member agreements, the Company continues to maintain significant involvement in the mezzanine section generation of the gross administrative fees through its supplier portfolio. Additionally, the Company has the right to retain an "Royalty Fee" over the term of the Channel Agreement based on the continued growth of the non-healthcare GPO member agreements. Due to the Company's continued involvement, the Company will continue to record net administrative fees from the non-healthcare agreements as revenue. The Company recorded the net proceeds from this transaction as a liability related to the sale of future revenues on the accompanying Consolidated Balance Sheets, which will be amortized using the effective interest method over the remaining contractual life of the Channel Agreement. The Company has no obligation to additional paid pay OMNIA any principal or interest balance on the sale of future revenues liability outside of the cash flows generated for administrative fees from the Channel Agreement.

As payments for administrative fees are remitted to OMNIA, the balance of Premier's obligation will effectively be repaid over the term of the Channel Agreement. To determine the amortization of the liability related to the sale of future revenues, the Company estimated the total future revenues expected to be remitted over the life of the Channel Agreement less any Royalty Fees retained by the Company. Future payments will result in capital the reduction of the liability related to the sale of future revenues less interest expense. The Company calculated the effective interest rate based on future expected revenue, which resulted in an effective annual interest rate of 2.5%. The Company will maintain a consistent interest rate throughout the life of the Channel Agreement. This estimate contains significant assumptions that impact both the amount of liability and interest expense recorded over the life of the Channel Agreement, including estimated future revenues expected to be remitted to OMNIA, less any Royalty Fee retained and the effective annual interest rate. The Company will assess the estimated future cash flows related to the sale of future revenues for material changes at each reporting period. There are several factors that could materially affect the amount and timing of payments to OMNIA, and correspondingly, the amount of interest expense recorded, most of which are outside the Company's control. Such factors include, but are not limited to, retention by OMNIA of the non-healthcare GPO members, growing the existing portfolio of non-healthcare members and general competition of GPOs.

Changes to any of these factors could result in an increase or decrease to expected future revenue and interest expense related to the sale of future revenues. To the extent the amount or timing of future payments varies materially from the original estimate, the Company will make a cumulative adjustment to the carrying amount of the liability, which will be

recorded as a component of permanent equity at July 31, 2020. As a result, there were no adjustments to the fair value of redeemable limited partners' capital for the years ended June 30, 2023 and 2022.

For the year ended June 30, 2021, the Company recorded adjustments of \$(26.7) million to the fair value of redeemable limited partners' capital as an adjustment of redeemable limited partners' capital to redemption amount non-cash gain or loss in other income in the accompanying Consolidated Statements of Income and Comprehensive Income. Subsequent to July 31, 2020 For the year ended June 30, 2024, there were no the Company did not record cumulative adjustments to the fair value carrying amount of redeemable limited partners' capital the liability.

At June 30, 2024, the Company had \$651.2 million of debt related to the sale of non-healthcare GPO member contracts and associated future revenues, of which \$51.8 million was recorded to current portion of the liability related to the sale of future revenues in the accompanying Consolidated Balance Sheets. For the year ended June 30, 2024, the Company recorded \$55.3 million in revenue that was sold to OMNIA in net administrative fees and \$14.2 million in imputed interest expense related to the sale of future revenues in interest expense, net in the Consolidated Statements of Income and Comprehensive Income.

The following table below provides a summary shows the activity of the changes in liability related to the redeemable limited partners' capital for sale of future revenues since the year ended June 30, 2021 transaction inception through June 30, 2024 (in thousands). There were no changes in redeemable limited partners' capital for the years ended June 30, 2023 and 2022:

	Receivables From Limited Partners	Redeemable Limited Partners' Capital	Total Redeemable Limited Partners' Capital
June 30, 2020	(995)	1,721,304	1,720,309
Distributions applied to receivables from limited partners	141	—	141
Net income attributable to non-controlling interest in Premier LP	—	11,845	11,845
Distributions to limited partners	—	(1,936)	(1,936)
Exchange of Class B common units for Class A common stock by member owners	—	(2,437)	(2,437)
Adjustment of redeemable limited partners' capital to redemption amount	—	26,685	26,685
Reclassification to permanent equity	854	(1,755,461)	(1,754,607)
June 30, 2021	\$	\$	\$
			June 30, 2024
Proceeds from the sale of future revenues		\$ 681,427	
Imputed interest expense associated with the sale of future revenues		14,201	
Payments against the liability related to the sale of future revenues		(44,407)	
Liability related to the sale of future revenues		\$ 651,221	

(11) STOCKHOLDERS' EQUITY

As of June 30, 2023 June 30, 2024, there were 119,158,483 105,027,079 shares of the Company's Class A common stock, Common Stock, par value \$0.01 per share, outstanding.

On August 5, 2021 February 5, 2024, the Company announced that its Board of Directors authorized the approved a new share repurchase of authorization for up to \$250.0 million \$1.0 billion of our outstanding Class A its common stock during fiscal year 2022 and that the Company entered into entered into an accelerated share repurchase agreement (the "ASR Agreement") pursuant to the share repurchase authorization. Repurchases of the Company's common stock under the share repurchase authorization may occur from time to time through June 30, 2025, in open market purchases, or privately negotiated transactions. As transactions, accelerated or other structured repurchase programs or other means, subject to compliance with applicable securities laws and other legal requirements. After giving effect to the accelerated share repurchase transaction pursuant to the ASR Agreement, which was completed in July 2024, the Company has remaining authorization to repurchase up to \$600.0 million of June 30, 2022 its Common Stock pursuant to the share repurchase authorization.

On February 5, 2024, the Company completed its stock entered into the ASR Agreement with Bank of America, N.A. ("Bank of America") to repurchase program and purchased approximately 6.4 million an aggregate of \$400.0 million of shares of Class A the Company's Common Stock, excluding fees and expenses. Under the terms of the ASR Agreement, the Company made a payment of \$400.0 million to Bank of America and, on February 8 and 9, 2024, received initial deliveries of an aggregate of 15.0 million shares of the Company's Common Stock, or \$320.0 million, based on the closing price on February 7, 2024 of \$21.29 per share.

The initial delivery of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted-average common shares outstanding for basic and diluted earnings per share. The ASR Agreement was accounted for as a treasury stock transaction and forward stock purchase contract. The shares delivered were recorded in treasury stock and immediately retired and recorded to retained earnings, and the unsettled portion of the ASR Agreement was recorded in additional paid-in capital in the Company's Consolidated Balance Sheet. The forward stock purchase contract is considered indexed to the Company's own stock and is classified as an equity instrument. On July 11, 2024, as final settlement of the accelerated share repurchase transaction under the ASR Agreement, the Company received from Bank of America a delivery of 4.8 million shares of the Company's Common Stock which were recorded in treasury stock and immediately retired and recorded to retained earnings. In total, the Company repurchased 19.9 million shares of Common Stock at an average price of \$38.88 \$20.12 per share for a total purchase under the ASR Agreement, which represents the volume-weighted average share price of \$250.0 million. Common Stock during the term of the ASR Agreement less a price adjustment.

Holders of Class A common stock Common Stock are entitled to (i) one vote for each share held of record on all matters submitted to a vote of stockholders, (ii) receive dividends, when and if declared by the Board of Directors out of funds legally available, subject to any statutory or contractual restrictions on the payment of dividends and subject to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock or any class or series of stock having a preference over or the right to participate with the Class A common stock Common Stock with respect to the payment of dividends or other distributions and (iii) receive pro rata, based on the number of shares of Class A

common stock Common Stock held, the remaining assets available for distribution upon the dissolution or liquidation of Premier, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any.

The Company paid quarterly cash dividends of \$0.21 per share on outstanding shares of Class A common stock Common Stock to stockholders on each of September 15, 2022 September 15, 2023, December 15, 2022 December 15, 2023, March 15, 2023 March 15, 2024 and June 15, 2023 June 15, 2024. On August 10, 2023 August 8, 2024, the Board of Directors declared a quarterly cash dividend of \$0.21 per share, payable on September 15, 2023 September 15, 2024 to stockholders of record on September 1, 2023 September 1, 2024.

(12) EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income attributable to the Company's stockholders by the weighted average number of shares of common stock outstanding for the period. Except when the effect would be anti-dilutive, the diluted earnings per share calculation, which is calculated using the treasury stock method, includes the impact of all potentially issuable dilutive shares of Class A common stock.

the Company's Common Stock.

The following table provides a reconciliation of the numerator and denominator used for basic and diluted earnings per share (in thousands, except per share amounts):

		Year Ended June 30,		
		2023	2022	2021
		Year Ended June 30,		
		2024	2023	2022
Numerator for basic and diluted earnings per share:	Numerator for basic and diluted earnings per share:			
Net income attributable to stockholders (a)	Net income attributable to stockholders (a)	\$175,026	\$265,867	\$260,837
Net income attributable to stockholders (a)	Net income attributable to stockholders (a)			
Denominator for earnings per share:	Denominator for earnings per share:			
Denominator for earnings per share:	Denominator for earnings per share:			
Denominator for earnings per share:	Denominator for earnings per share:			
Basic weighted average shares outstanding (b)	Basic weighted average shares outstanding (b)			
Basic weighted average shares outstanding (b)	Basic weighted average shares outstanding (b)			
Basic weighted average shares outstanding (b)	Basic weighted average shares outstanding (b)	118,767	120,220	116,527
Effect of dilutive securities: (c)	Effect of dilutive securities: (c)			
Stock options	Stock options	81	206	301
Stock options	Stock options			
Restricted stock	Restricted stock	524	510	376

Performance share awards	Performance share awards	517	732	328
Diluted weighted average shares and assumed conversions		119,889	121,668	117,532
Diluted weighted average shares outstanding				
Earnings per share attributable to stockholders:	Earnings per share attributable to stockholders:			
Earnings per share attributable to stockholders:	Earnings per share attributable to stockholders:			
Basic	Basic	\$ 1.47	\$ 2.21	\$ 2.24
Diluted	Diluted	\$ 1.46	\$ 2.19	\$ 2.22

(a) Net income from continuing operations attributable to stockholders was calculated as follows (in thousands):

	Year Ended June 30,		
	2023	2022	2021
Net income from continuing operations	\$ 174,887	\$ 268,318	\$ 304,584
Net income from continuing operations attributable to non-controlling interest	139	(2,451)	(17,062)
Adjustment of redeemable limited partners' capital to redemption amount	—	—	(26,685)
Net income from continuing operations attributable to stockholders	\$ 175,026	\$ 265,867	\$ 260,837

	Year Ended June 30,		
	2024	2023	2022
Net income	\$ 106,719	\$ 174,887	\$ 268,318
Net loss (income) attributable to non-controlling interest	12,825	139	(2,451)
Net income attributable to stockholders	\$ 119,544	\$ 175,026	\$ 265,867

(b) Weighted average number of common shares used for basic earnings per share excludes the impact of all potentially issuable dilutive shares of **Class A common stock** **Common Stock** for the years ended **June 30, 2023**, **June 30, 2024**, **2022** **2023** and **2021**, **2022**.

(c) For the year ended June 30, 2024, the effect of 1.1 million stock options and restricted stock units was excluded from diluted weighted average shares outstanding as it had an anti-dilutive effect and the effect of 0.2 million performance share awards was excluded from diluted weighted average shares outstanding as the awards had not satisfied the applicable performance criteria at the end of the period.

For the year ended June 30, 2023, the effect of 0.4 million stock options and restricted stock units was excluded from diluted weighted average shares outstanding as it had an anti-dilutive effect and the effect of 0.3 million performance share awards was excluded from diluted weighted average shares outstanding as the awards had not satisfied the applicable performance criteria at the end of the period.

For the year ended June 30, 2022, the effect of 0.6 million stock options and restricted stock units were excluded from diluted weighted average shares outstanding as they had an anti-dilutive effect.

For the year ended June 30, 2021, the effect of 1.8 million stock options and restricted stock units and 5.6 million Class B common units were excluded from diluted weighted average shares outstanding as they had an anti-dilutive effect and the effect of less than 0.1 million performance share awards was excluded from diluted weighted average shares outstanding as the awards had not satisfied the applicable performance criteria at the end of the period.

(13) STOCK-BASED COMPENSATION

Stock-based compensation expense is recognized over the requisite service period, which generally equals the stated vesting period. **The Company does not estimate forfeiture rates but rather adjusts for forfeitures in the periods in which they occur.** For the years ended **June 30, 2023**, **June 30, 2024**, **2022** **2023** and **2021**, **2022**, the associated deferred tax benefit was calculated at rates of 25%, 25% and 26%, respectively, which represents the expected effective income tax rate at the time of the compensation expense deduction and differs from the Company's current effective income tax rate. See Note 15 - Income Taxes for further information.

Stock-based compensation expense and the resulting deferred tax benefits were as follows (in thousands):

	Year Ended June 30,			Year Ended June 30,
	2023	2022	2021	
	Year Ended June 30,			
	2024	2024	2023	2022
Pre-tax stock-based compensation expense	Pre-tax stock-based compensation expense	\$13,734	\$46,229	\$35,425
Deferred tax benefit ^(a)	Deferred tax benefit ^(a)	3,174	8,787	6,167
Total stock-based compensation expense, net of tax	Total stock-based compensation expense, net of tax	\$10,560	\$37,442	\$29,258

(a) For the years ended **June 30, 2023**, **June 30, 2024**, **2022**, **2023** and **2021, 2022**, the deferred tax benefit was reduced by **\$0.3**, **\$0.9** million, **\$3.0**, **\$0.3** million and **\$3.0** million, respectively, attributable to stock-based compensation expense that is nondeductible for tax purposes pursuant to Section 162(m) as amended by the Tax Cuts and Jobs Act of 2017.

Premier 2013 Equity Incentive Plan

The Premier 2013 Equity Incentive Plan, as amended and restated (and including any further amendments thereto, the "2013 Equity Incentive Plan") provides for grants of up to 14.8 million shares of Class A common stock, the Company's Common Stock, all of which are eligible to be issued as non-qualified stock options, incentive stock options, stock appreciation rights, restricted stock, restricted stock units or performance share awards. On September 24, 2023, the 2013 Equity Incentive Plan expired; no new grants will be issued under the plan.

Premier 2023 Equity Incentive Plan

The Premier 2023 Equity Incentive Plan (the "2023 Equity Incentive Plan"), which became effective December 1, 2023 upon approval of Premier's stockholders, provides for grants of up to 6.0 million shares of the Company's Common Stock, all of which are eligible to be issued as non-qualified stock options, incentive stock options, stock appreciation rights, restricted shares, restricted stock units or performance share awards. As of **June 30, 2023** **June 30, 2024**, there were approximately **3.6 million** **5.9 million** shares available for grant under the **2013** **2023** Equity Incentive Plan.

The following table includes information related to restricted stock, performance share awards and stock options for the year ended **June 30, 2023** **June 30, 2024**:

Stock options outstanding and exercisable at June 30, 2024

Stock options outstanding and exercisable at June 30, 2024

Stock options outstanding and exercisable at June 30, 2024

Prior to June 1, 2023, restricted stock units and restricted stock awards issued and outstanding prior to June 1, 2023 generally vest over in full at the end of a three-year period for employees and a one-year period for directors. Beginning June 1, 2023, restricted stock units and restricted stock awards issued and outstanding for employees generally vest ratably in equal annual installments over the service a three-year period. Performance share awards issued and outstanding generally vest over at the end of a three-year period if subject to whether and to what extent performance targets are met. Stock options generally vest in equal annual installments over a three-year period. Stock options have a term of ten years from the date of grant. Vested stock options will generally expire either on the earlier of the scheduled expiration date and twelve months after an employee's termination with the Company or Company; however, in certain termination circumstances, vested stock options will expire on the earlier of the scheduled expiration date and 90 days after an employee's termination with the Company, depending on the termination circumstances. Stock options generally vest in equal annual installments over three years. Company.

Unrecognized stock-based compensation expense at June 30, 2023 June 30, 2024 was as follows (in thousands):

	Unrecognized Stock-Based Compensation Expense	Weighted Average Amortization Period
Restricted stock	\$ 34,517 31,037	2.3 1.9 years
Performance share awards	15,446 6,075	1.8 1.6 years
Total unrecognized stock-based compensation expense	\$ 49,963 37,112	2.1 1.8 years

At June 30, 2023 June 30, 2024, there was no unrecognized stock-based compensation expense for outstanding stock options. The There were no stock options exercised during the year ended June 30, 2023 had an aggregate intrinsic value of \$1.3 million June 30, 2024, and the stock options outstanding and exercisable at June 30, 2023 June 30, 2024 had zero aggregate intrinsic value.

(14) POST-RETIREMENT BENEFITS

The Company maintains a defined contribution 401(k) retirement savings plan which covers employees who meet certain age and service requirements. This plan allows for employee contributions of up to 30% and matching employer contributions of up to 4% of the total contributions, not to exceed certain limits. The Company's 401(k) expense related to such matching of employee contributions was \$12.8 million \$13.3 million, \$12.1 million \$12.8 million and \$11.2 million \$12.1 million for the years ended June 30, 2023 June 30, 2024, 2022 2023 and 2021, 2022, respectively.

The Company also maintains a non-qualified deferred compensation plan for the benefit of eligible employees. This plan is designed to permit employee deferrals in excess of certain tax limits and provides for discretionary employer contributions in excess of certain tax limits.

(15) INCOME TAXES

At the consummation of the Subsidiary Reorganization on December 1, 2021, the Company recorded a one-time deferred tax benefit of \$33.5 million, primarily driven by deferred tax remeasurement due to tax rate changes and a valuation allowance release.

Significant components of consolidated income tax expense (benefit) are as follows (in thousands):

Year Ended June 30,			Year Ended June 30,		
	2023	2022	2021		2022
Year Ended June 30,			2024	2024	2023
Current:	Current:				
Federal					
Federal					
Federal	\$ 692	\$ 864	\$ 22,356		
State	3,016	926	7,393		
Total	Total				
current	current				
tax	tax				
expense	expense	3,708	1,790	29,749	
Deferred:	Deferred:				
Federal	Federal	54,146	49,335	22,165	
Federal					

Federal					
State	State	17,257	7,457	(105,857)	
Total deferred tax expense (benefit)		71,403	56,792	(83,692)	
Total income tax expense (benefit)		\$75,111	\$58,582	\$(53,943)	
Total deferred tax (benefit) expense					
Total income tax expense					

The reconciliation

Reconciliations between the Company's income tax expense (benefit) and taxes computed at the federal statutory tax rate of 21.0% for fiscal years ended **June 30, 2023** **June 30, 2024**, **2023** and **2022** and **2021**, is were as follows (in thousands):

		Year Ended June 30,					
		2023	2022	2021			
		Year Ended June 30,			Year Ended June 30,		
		2024	2023	2022	2024	2023	2022
Tax at federal statutory rate	Tax at federal statutory rate	\$51,658	\$68,649	\$ 52,635			
Partnership income not subject to tax		47	(701)	(4,375)			
Partnership loss (income) not subject to tax							
State taxes (net of federal benefit)	State taxes (net of federal benefit)	11,212	14,138	9,880			
Remeasurement adjustments and other permanent items	Remeasurement adjustments and other permanent items	4,628	8,118	7,124			
Change in valuation allowance	Change in valuation allowance	52	(31,361)	(25,328)			
Deferred tax remeasurement	Deferred tax remeasurement	7,720	(242)	(113,213)			
Uncertain tax position	Uncertain tax position	1,092	842	1,293			
Change in tax status		—	—	19,514			
Research and development credit							
Other	Other	(1,298)	(861)	(1,473)			
Total income tax expense (benefit)	\$75,111	\$58,582	\$(53,943)				
Total income tax expense							
Effective tax rate	Effective tax rate	30.0 %	17.9 %	(21.5)%	Effective tax rate	28.8 %	30.0 %

The fiscal year 2024 effective tax rate of 28.8% differs from the statutory income tax rate of 21.0% largely driven by non-controlling interest portion of the consolidated partnership loss not subject to tax by the Company and other permanent items offset by research and development credits. The increase in partnership loss (income) not subject to tax is driven by impairment charges related to the Contigo Health reporting unit.

The fiscal year 2023 effective tax rate of 30.0% differs from the statutory income tax rate of 21.0% largely driven by deferred tax remeasurement due to state tax rate changes.

The fiscal year 2022 effective tax rate of 17.9% differs from the statutory income tax rate of 21.0% primarily driven by the aforementioned one-time deferred tax remeasurement and valuation allowance release as a result of the Subsidiary Reorganization.

The fiscal year 2021 effective tax rate of (21.5)% differs from the statutory income tax rate of 21.0% primarily driven by At the consummation of the merger Subsidiary Reorganization on August 11, 2020. The Company simplified its tax structure, resulting in the Company and its subsidiaries forming one consolidated filing group for federal income tax purposes. As a result, December 1, 2021, the Company recorded a one-time deferred tax benefit of \$108.8 million \$33.5 million, primarily driven by deferred tax remeasurement due to tax rate changes and a valuation allowance release.

Deferred Income Taxes

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities as of June 30, 2023 June 30, 2024 and 2022 are presented below 2023 were as follows (in thousands):

	June 30,		June 30,	
	2024		2023	
Deferred tax assets				
Purchased intangible assets and depreciation	June 30,			
	2023	2022		
Deferred tax asset				
Purchased intangible assets and depreciation				
Purchased intangible assets and depreciation	Purchased intangible assets and depreciation	\$558,622	\$631,415	
Stock compensation	Stock compensation	9,818	15,125	
Accrued expenses	Accrued expenses	51,158	49,161	
Net operating losses and credits	Net operating losses and credits	38,271	50,742	
Sale of member contracts and associated future revenues to OMNIA				
Partnership basis differences				
Other	Other	12,681	5,787	
Total deferred tax assets	Total deferred tax assets	670,550	752,230	
Valuation allowance for deferred tax assets	Valuation allowance for deferred tax assets	(4,604)	(4,552)	
Deferred tax assets, net of valuation allowance				
Deferred tax liabilities				
Equity earnings				
Equity earnings				

Equity earnings					
Other liabilities					
Deferred tax liability					
Net deferred tax assets	Net deferred tax assets	665,946	747,678		
Other liabilities		(12,317)	(22,646)		
Net deferred tax asset		\$653,629	\$725,032		

As of June 30, 2023 June 30, 2024 and 2022, 2023, the Company had net deferred tax assets of \$653.6 million \$776.2 million and \$725.0 million \$653.6 million, respectively. The decrease increase is largely attributable to the sale of member contracts and associated future revenues to OMNIA. During the year, the Company recorded a \$162.5 million cash tax deductible goodwill intangible obligation associated with the sale of non-healthcare GPO member contracts and associated future revenues to OMNIA. During the year ended June 30, 2024, the Company made payments of \$162.3 million for taxes related to the proceeds received from the sale of future revenues to OMNIA. The remaining \$0.2 million is due during first quarter of fiscal year 2025. Additionally, the Company recorded an offsetting deferred tax asset of \$163.0 million to be recorded to current income tax expense as the Company recognizes revenues associated with non-healthcare GPO member contracts.

At June 30, 2023 June 30, 2024, the Company had federal and state net operating loss carryforwards of \$100.2 million \$72.3 million and \$125.5 million \$110.2 million, respectively, primarily attributable to PHSI and PSCI. The resulting federal and state deferred tax assets are \$21.1 million were \$15.2 million and \$6.3 million \$5.0 million, respectively. The definite-lived federal and state net operating loss carryforwards, primarily generated prior to fiscal year 2019, expire between the years ended June 30, 2024 June 30, 2025 through June 30, 2038 June 30, 2039 while the remaining federal and state net operating losses, primarily generated in fiscal year 2019 and beyond, can be carried forward indefinitely until utilized. A valuation allowance was established for federal and state losses as the Company believes it is more likely than not that a portion of these losses will not be realized in the near future.

At June 30, 2023 June 30, 2024, the Company had federal research and development credit carryforwards of \$12.4 million \$12.1 million. The federal credit carryforwards expire at various times between the years ended June 30, 2024 June 30, 2025 through June 30, 2040, until utilized. As a result of the Subsidiary Reorganization, the Company believes it is more likely than not that the majority of federal and state credit carryforwards will be realized in the near future, so the previously recorded future; however, an additional valuation allowance was released recorded during the year ended June 30, 2022, June 30, 2024 for \$1.1 million of research and development credit carryforwards that the Company does not expect to be utilized before expiration.

Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and income tax purposes. The Company assessed the future realization of the tax benefit of its existing deferred tax assets and concluded that it is more likely than not that a portion of the deferred tax assets will not be realized in the future. As a result, the Company recorded a valuation allowance of \$4.6 million \$5.4 million against its deferred tax assets at June 30, 2023 June 30, 2024. The valuation allowance remained flat increased compared to the \$4.6 million valuation allowance recorded as of June 30, 2022 June 30, 2023.

Unrecognized Tax Benefits

The Company recognizes income tax benefits for those income tax positions determined more likely than not to be sustained upon examination, based on the technical merits of the positions. The reserve for uncertain income tax positions is included in other liabilities in the Consolidated Balance Sheets. A reconciliation Reconciliations of the beginning and ending gross amounts of the Company's uncertain tax position reserves for the years ended June 30, 2023 June 30, 2024, 2023 and 2022 and 2021 are were as follows (in thousands):

Year Ended June 30,					
2023			2022		
Year Ended June 30,					
2024	2024	2023	2023	2022	2022
Beginning of year balance	Beginning of year balance	\$17,124	\$16,704	\$15,596	
Increases in prior period tax positions	Increases in prior period tax positions	189	120	111	
Decreases in prior period tax positions	Decreases in prior period tax positions	(752)	(63)	—	
Reductions on settlements and lapse in statute of limitations	Reductions on settlements and lapse in statute of limitations	(16)	(21)	(27)	

Increases in current period tax positions	Increases in current period tax positions	367	384	1,024
End of year	End of year			
balance	balance	\$16,912	\$17,124	\$16,704

If the Company were to recognize the benefits of these uncertain tax positions, the income tax provision would be impacted by **\$16.3 million** **\$16.8 million**, **\$15.6 million** **\$16.3 million** and **\$14.8 million** **\$15.6 million**, including interest and penalties and net of the federal and state benefit for income taxes, for the years ended **June 30, 2023** **June 30, 2024, 2022** **2023** and **2021** **2022**, respectively. The Company recognizes interest and penalties accrued on uncertain income tax positions as part of the income tax provision. The amount of accrued interest and penalties was **\$6.1 million** and **\$5.5 million** at **June 30, 2024** and **\$4.4 million** at **June 30, 2023** and **2022, 2023**, respectively.

Federal tax returns for tax years **June 30, 2019** **June 30, 2020** through **2022** **2023** remain open as of **June 30, 2023** **June 30, 2024**. The Company is subject to ongoing state and local examinations for various periods. Activity related to these examinations did not have a material impact on the Company's financial position or results of operations.

(16) RELATED PARTY TRANSACTIONS

The Company's 49% ownership share of net income of FFF, which was acquired on July 26, 2016, included in equity in net income of unconsolidated affiliates in the accompanying Consolidated Statements of Income and Comprehensive Income was **\$8.6 million**, **\$16.6 million** and **\$11.3 million** for the years ended **June 30 2023, 2022** **2023** and **2021** **2022**, respectively. As of March 3, 2023, the Company no longer recognizes equity earnings from FFF (see Note 4 - Investments). The Company maintains group purchasing agreements with FFF and receives administrative fees for purchases made by the Company's members and other customers pursuant to those agreements. Net administrative fees revenue recorded from purchases under those agreements was **\$5.7 million** **\$1.8 million**, **\$6.3 million** **\$5.7 million** and **\$6.0 million** **\$6.3 million** during the years ended **June 30, 2023** **2024, 2022** **2023** and **2021** **2022**, respectively.

(17) COMMITMENTS AND CONTINGENCIES

Operating Leases

Operating lease expense was **\$10.0 million** **\$9.7 million**, **\$10.1 million** **\$10.0 million** and **\$10.8 million** **\$10.1 million** for the years ended **June 30, 2023** **June 30, 2024, 2022** **2023** and **2021** **2022**, respectively. As of **June 30, 2023** **June 30, 2024**, the weighted average remaining lease term was **2.9** **2.1** years and the weighted average discount rate was 4%.

Future minimum lease payments under noncancelable operating leases with initial lease terms in excess of one year were as follows (in thousands):

2024	\$	12,381
2025		12,389
2026		9,005
2027		1,324
2028		—
2029		
Thereafter		
Total future minimum lease payments	Total future minimum lease payments	35,099
Less: imputed interest	Less: imputed interest	1,947
Total operating lease liabilities (a)	Total operating lease liabilities (a)	\$ 33,152

(a) As of **June 30, 2023** **June 30, 2024**, total the Company had **\$12.3 million** of operating lease liabilities included **\$11.3 million** within other current liabilities in the accompanying Consolidated Balance Sheets.

Other Matters

The Company is not currently involved in any litigation it believes to be material. The Company is periodically involved in litigation, arising in the ordinary course of business or otherwise, which from time to time may include stockholder derivative or other similar litigation, claims relating to commercial, product liability, tort and personal injury, employment, antitrust, intellectual property, or other regulatory matters. If current or future government regulations, including but not limited to those with respect to antitrust or healthcare laws, are interpreted or enforced in a manner adverse to the Company or its business, the Company may be subject to regulatory inquiries or investigations, enforcement actions, penalties and other material limitations which could have a material adverse effect on the Company's business, financial condition and results of operations.

(18) SEGMENTS

The Company delivers its solutions and manages its business through two reportable business segments, the Supply Chain Services segment and the Performance Services segment. The Supply Chain Services segment includes the Company's GPO, supply chain co-management, purchased services and direct sourcing activities. The Performance Services segment consists of three sub-brands: PINC AI, the Company's technology and services platform; Contigo Health, the Company's direct-to-employer business; and Remitra, the Company's digital invoicing and payables automation business.

The following table presents disaggregated revenue by reportable business segment and underlying source (in thousands):

Year Ended June 30,

		2023	2022	2021			
		Year Ended June 30,					
		2024	2024		2023	2022	
Net revenue:	Net revenue:						
Supply Chain Services	Supply Chain Services						
Supply Chain Services	Supply Chain Services						
Net administrative fees	Net administrative fees						
Net administrative fees	Net administrative fees	\$ 611,035	\$ 601,128	\$ 572,700			
Software licenses, other services and support	Software licenses, other services and support	44,261	37,312	26,812			
Services and software licenses	Services and software licenses	655,296	638,440	599,512			
Products	Products	244,659	393,506	744,122			
Total Supply Chain Services (a)(b)		899,955	1,031,946	1,343,634			
Total Supply Chain Services (a)							
Performance Services	Performance Services						
Software licenses, other services and support	Software licenses, other services and support						
Software licenses, other services and support	Software licenses, other services and support						
SaaS-based products subscriptions	SaaS-based products subscriptions						
SaaS-based products subscriptions	SaaS-based products subscriptions						
SaaS-based products subscriptions	SaaS-based products subscriptions	187,618	193,586	198,512			
Consulting services	Consulting services	80,292	64,087	58,851			
Software licenses	Software licenses	72,376	65,621	56,157			
Other	Other	95,891	77,689	63,998			
Other (b)							
Total Performance Services (a)	Total Performance Services (a)	436,177	400,983	377,518			
Total segment net revenue	Total segment net revenue	1,336,132	1,432,929	1,721,152			
Eliminations (a)	Eliminations (a)	(37)	(28)	—			
Net revenue	Net revenue	\$1,336,095	\$1,432,901	\$1,721,152			

(a) Includes intersegment revenue that is eliminated in consolidation. Intersegment revenue is not separately identified in Segments as the amounts are not material.

(b) Consolidated net includes revenue for the fiscal year ended June 30, 2021 included from Contigo Health and certain revenue generated from our largest customer, a non-healthcare customer, which accounted for approximately 15% of our consolidated net revenue. The significant increase in revenue generated from our largest customer in the fiscal year ended June 30, 2021 was due to the increase in products revenue primarily as a result of the COVID-19 pandemic. Remitra and PINC AI.

Additional segment information related to depreciation and amortization expense, capital expenditures and total assets was as follows (in thousands):

Year Ended June 30,			Year Ended June 30,					
Depreciation and amortization expense (a):	Depreciation and amortization expense (a):	2023	2022	2021	Depreciation and amortization expense (a):	2024	2023	2022
Supply Chain Services	Supply Chain Services	\$ 54,425	\$ 55,424	\$ 37,073				
Performance Services	Performance Services	71,006	64,674	75,391				
Corporate	Corporate	8,362	9,009	8,598				
Total depreciation and amortization expense	Total depreciation and amortization expense	\$133,793	\$129,107	\$121,062				
Capital expenditures:	Capital expenditures:							
Supply Chain Services	Supply Chain Services							
Supply Chain Services	Supply Chain Services	\$ 26,545	\$ 29,677	\$ 10,408				
Performance Services	Performance Services	51,532	51,298	72,068				
Corporate	Corporate	4,225	6,465	6,400				
Total capital expenditures	Total capital expenditures	\$ 82,302	\$ 87,440	\$ 88,876				
Year Ended June 30,			Year Ended June 30,			Year Ended June 30,		
Total assets:	Total assets:	2023	2022	Total assets:		2024		2023
Supply Chain Services	Supply Chain Services	\$1,317,076	\$1,406,108					
Performance Services	Performance Services	1,209,353	1,054,687					
Corporate	Corporate	845,062	896,336					
Total assets before eliminations								
Eliminations								
(b)								
Total assets	Total assets	3,371,491	3,357,131					
Eliminations (b)		(4)	(4)					
Total assets, net		\$3,371,487	\$3,357,127					

(a) Includes amortization of purchased intangible assets.

(b) Includes eliminations of intersegment transactions which occur during the ordinary course of business.

The Company uses Segment Adjusted EBITDA (a financial measure not determined in accordance with generally accepted accounting principles ("Non-GAAP")) as its primary measure of profit or loss to assess segment performance and to determine the allocation of resources. The Company also uses Segment Adjusted EBITDA to facilitate the comparison of the segment operating performance on a consistent basis from period to period. The Company defines Segment Adjusted EBITDA as the segment's net revenue less cost of revenue and operating expenses directly attributable to the segment excluding depreciation and amortization, amortization of purchased intangible assets, merger and acquisition-related expenses and non-recurring or non-cash items, and including equity in net income of unconsolidated affiliates items. Operating expenses directly attributable to the segment include expenses associated with sales and marketing, general and administrative, and product development activities specific to the operation of each segment. General and administrative corporate expenses that are not specific to a particular segment are not included in the calculation of Segment Adjusted EBITDA. Segment Adjusted EBITDA also excludes any income and expense that has been classified as discontinued operations.

For more information on Segment Adjusted EBITDA and the use of Non-GAAP financial measures, see "Our Use of Non-GAAP Financial Measures" within Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

A reconciliation of income before income taxes to the unaudited Segment Adjusted EBITDA, a Non-GAAP financial measure, is as follows (in thousands):

		Year Ended June 30,		
		2023	2022	2021
		Year Ended June 30,		
		2024	2023	2022
Income before income taxes	Income before income taxes	\$249,998	\$326,900	\$250,641
Equity in net income of unconsolidated affiliates ^(a)		(16,068)	(23,505)	(21,073)
Interest expense, net		14,470	11,142	11,964
(Gain) loss on FFF put and call rights ^(b)		—	(64,110)	27,352
Equity in net loss (income) of unconsolidated affiliates ^(a)				
Interest (income) expense, net				
Gain on FFF put and call rights ^(b)				
Other (income) expense, net	Other (income) expense, net	(6,307)	9,646	(11,967)
Operating income	Operating income	242,093	260,073	256,917
Depreciation and amortization	Depreciation and amortization	85,691	85,171	76,309
Amortization of purchased intangible assets	Amortization of purchased intangible assets	48,102	43,936	44,753
Stock-based compensation ^(c)	Stock-based compensation	14,355	46,809	35,915
Acquisition- and disposition-related expenses	Acquisition- and disposition-related expenses	17,151	11,453	18,095

Strategic initiative and financial restructuring-related expenses	Strategic initiative and financial restructuring-related expenses	13,831	18,005	6,990
Equity in net income of unconsolidated affiliates ^(a)		16,068	23,505	21,073
Deferred compensation plan expense ^{(income) (d)}	Deferred compensation plan expense ^{(income) (d)}	5,422	(9,401)	12,745
Impairment of assets				
Impairment of assets				
Impairment of assets	Impairment of assets	56,718	18,829	—
Other reconciling items, net	Other reconciling items, net	352	302	433
Adjusted EBITDA		\$499,783	\$498,682	\$473,230
Total Non-GAAP Adjusted EBITDA ^(e)				
Segment Adjusted EBITDA:				
Supply Chain Services ^(e)		\$499,431	\$500,854	\$467,868
Performance Services ^(e)		123,859	126,938	132,225
Non-GAAP Adjusted EBITDA				
^{(e):}				
Non-GAAP Adjusted EBITDA				
^{(e):}				
Non-GAAP Adjusted EBITDA				
^{(e):}				
Supply Chain Services ^(f)				
Supply Chain Services ^(f)				
Supply Chain Services ^(f)				
Performance Services ^(f)				
Segment Adjusted EBITDA				
Corporate	Corporate	(123,507)	(129,110)	(126,863)
Adjusted EBITDA		\$499,783	\$498,682	\$473,230
Total Non-GAAP Adjusted EBITDA				

(a) Refer to Note 4 - Investments for further information.

(b) Refer to Note 5 - Fair Value Measurements for more information.

(c) Represents non-cash employee stock-based compensation expense and stock purchase plan expense of \$0.6 million, ~~\$0.6 million and \$0.5 million~~ for the years ended ~~June 30, 2023~~ ~~June 30, 2024~~, ~~2022~~ ~~2023~~ and ~~2021~~, respectively ²⁰²².

(d) Represents changes in deferred compensation plan liabilities resulting from realized and unrealized gains and losses and dividend income on deferred compensation plan assets.

(e) The definition for Non-GAAP Adjusted EBITDA was revised from the definition reported in the 2023 Annual Report to exclude the impact of equity earnings in unconsolidated affiliates. For comparability purposes, prior year Non-GAAP financial measures are presented based on the current definition.

(f) Includes intersegment revenue which is eliminated in consolidation.

(19) QUARTERLY FINANCIAL DATA (UNAUDITED)

The following tables present unaudited summarized financial data by quarter for the years ended **June 30, 2023** **June 30, 2024** and **2022** **2023** (in thousands, except per share data):

Fiscal Year 2024	First Quarter		Second Quarter		Third Quarter		Fourth Quarter	
Net revenue	\$	318,752	\$	334,745	\$	342,596	\$	350,268
Gross profit		210,582		221,283		220,333		235,814
Net income (loss)		42,410		52,866		(49,162)		60,605
Net loss attributable to non-controlling interest		2,351		1,436		8,967		71
Net income (loss) attributable to stockholders		44,761		54,302		(40,195)		60,676
Weighted average shares outstanding:								
Basic		119,344		119,702		111,156		104,838
Diluted		120,133		120,057		111,156		105,596
Earnings (loss) per share attributable to stockholders:								
Basic	\$	0.38	\$	0.45	\$	(0.36)	\$	0.58
Diluted	\$	0.37	\$	0.45	\$	(0.36)	\$	0.57
Fiscal Year 2023	First Quarter		Second Quarter		Third Quarter		Fourth Quarter	
Net revenue	\$	313,873	\$	359,626	\$	322,232	\$	340,364
Gross profit		201,985		242,741		219,070		232,493
Net income		42,959		64,374		48,649		18,905
Net (income) loss attributable to non-controlling interest		(243)		(328)		(1,848)		2,558
Net income attributable to stockholders		42,716		64,046		46,801		21,463
Weighted average shares outstanding:								
Basic		118,351		118,787		118,872		119,064
Diluted		120,033		119,652		119,816		120,061
Earnings per share attributable to stockholders:								
Basic	\$	0.36	\$	0.54	\$	0.39	\$	0.18
Diluted	\$	0.36	\$	0.54	\$	0.39	\$	0.18
Fiscal Year 2022	First Quarter		Second Quarter		Third Quarter		Fourth Quarter	
Net revenue	\$	365,147	\$	379,215	\$	347,833	\$	340,706
Gross profit		211,976		236,500		212,477		224,086
Net income		121,306		77,232		39,069		30,711
Net loss (income) attributable to non-controlling interest		698		(1,687)		(654)		(808)
Net income attributable to stockholders		122,004		75,545		38,415		29,903
Weighted average shares outstanding:								
Basic		122,945		121,181		118,697		118,001
Diluted		124,573		122,473		119,813		119,760
Earnings per share attributable to stockholders:								
Basic	\$	0.99	\$	0.62	\$	0.32	\$	0.25
Diluted	\$	0.97	\$	0.62	\$	0.32	\$	0.25

(20) SUBSEQUENT EVENTS

On July 25, 2023, the Company sold the equity interest in its wholly-owned subsidiary, Non-Healthcare Holdings LLC, to OMNIA for a purchase price estimated to be approximately \$800.0 million, subject to certain adjustments, including a true-up adjustment to the purchase price to be paid within approximately eight months following such closing date. The Company subsequently received \$689.2 million in cash consideration which includes \$151.0 million in escrow subject to release upon certain members agreeing to consents.

Non-Healthcare Holdings LLC held contracts pursuant to which the Company's non-healthcare members participate in its group purchasing organizations. Pursuant to the terms of the equity purchase agreement, OMNIA purchased non-healthcare member agreements and the associated revenues from these agreements. For a period of at least 10 years following the closing of the transaction, the non-healthcare GPO members will continue to be able to make purchases through Premier's group purchasing contracts. Both the

Company and OMNIA will have aligned growth incentives and have the opportunity to economically benefit from non-healthcare GPO members' continued purchasing through Premier's contract portfolio. While the accounting for the transaction will be finalized in the first quarter of fiscal 2024, the Company anticipates recording the transaction as a sale of future revenues and the proceeds as debt on the Consolidated Balance Sheets. As the non-healthcare GPO members will continue to be able to make purchases and generate cash flows through the Company's group purchasing contracts, the Company will continue to record revenue from these purchases with net proceeds provided to OMNIA being accounted for as a reduction to the debt.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Not applicable.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As of the end of the period covered by this Annual Report, our chief executive officer and chief financial officer carried out an evaluation of the effectiveness of our disclosure controls and procedures. Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of **June 30, 2023** **June 30, 2024**.

Management's Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on its financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

Our chief executive officer and chief financial officer conducted an assessment of the effectiveness of our internal control over financial reporting as of **June 30, 2023** **June 30, 2024**. In making this assessment, the chief executive officer and chief financial officer used the criteria set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, the COSO framework. Based upon this evaluation, our chief executive officer and chief financial officer concluded that, as of **June 30, 2023** **June 30, 2024**, our internal control over financial reporting was effective.

Management's annual evaluation of internal controls over financial reporting did not include an assessment of and conclusion on the effectiveness of disclosure controls and procedures of the business combination related to certain acquired assets of TRPN, which were acquired during the year ended June 30, 2023 and is included in our consolidated financial statements as of June 30, 2023 and for the period from the acquisition date through June 30, 2023. This acquisition accounted for 3.9% of total assets and less than 1% of total net revenue of our consolidated financial statements as of and for the year ended June 30, 2023, respectively.

The effectiveness of our internal control over financial reporting as of **June 30, 2023** **June 30, 2024** has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their report which appears herein.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act) during the quarter ended **June 30, 2023** **June 30, 2024**, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

Item 9B. Other Information

None. Adoption of 10b5-1 Trading Plans by Our Officers and Directors

The table below sets forth SEC Rule 10b5-1 trading plans adopted by certain directors and executive officers (as defined in SEC Rule 16a-(f)) during the quarter ended **June 30, 2024**. All of these plans were adopted during the quarterly trading window under our Insider Trading Policy. Other than as set forth in the table, during the three months ended **June 30, 2024**, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(c) or any "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(c) of Regulation S-K).

Name and Title	Trading Arrangement				Scheduled Expiration	
	Action	Date	Rule 10b5-1(a)	Non-Rule 10b5-1(b)	Total Shares to be Sold(c)	Date(d)
Andrew F. Brailo, Chief Commercial Officer	Adopt	06/03/2024	X		21,390	12/27/2024
Jody R. Davids, Director	Adopt	05/30/2024	X		13,600	12/27/2024

(a) 10b5-1 trading plan intended to satisfy the affirmative defense of SEC Rule 10b5-1(c).

- (b) "Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K.
- (c) The numbers in this column represent the maximum number of shares of our Common Stock that may be sold pursuant to each trading plan. The actual number of shares sold pursuant to each trading plan will depend on the satisfaction of certain conditions set forth therein prior to expiration or termination of the plan.
- (d) Each trading plan terminates on the earlier to occur of: (i) the expiration date listed in the table above; (ii) the first date on which all trades set forth in the plan have been executed; or (iii) such date the plan otherwise terminates according to its terms.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

PART III

We expect to file a definitive proxy statement relating to our **2023 2024** Annual Meeting of Stockholders with the SEC pursuant to Regulation 14A, not later than 120 days after the end of our most recent fiscal year. Accordingly, certain information required by Part III of this Annual Report has been omitted under General Instruction G(3) to Form 10-K. Only the information from the definitive proxy statement that specifically addresses disclosure requirements of Items 10-14 below is incorporated by reference.

Item 10. Directors, Executive Officers and Corporate Governance

We will provide information that is responsive to this Item 10 in our definitive proxy statement for our **2023 2024** Annual Meeting of Stockholders or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report, in either case under the captions "Item 1 - Election of Directors," "Corporate Governance and Board Structure," "Delinquent Section 16(a) Reports" and "Executive Officers," and possibly elsewhere therein. That information is incorporated in this Item 10 by reference.

Code of Ethics

We maintain a Corporate Code of Conduct for all of our employees and officers, including the principal executive officer, principal financial officer, and principal accounting officer or controller, or persons performing similar functions, and, where applicable, to directors. In addition, the Board of Directors is subject to a separate Board Code of Ethics and Board Conflict of Interest Policy (collectively, the "Board Codes"). The Corporate Code of Conduct, along with the Board Codes, can be found on our Investor Relations website at investors.premierinc.com under "Corporate Governance-Governance Documents." A copy of the Corporate Code of Conduct is available to any stockholder who requests it by writing to Investor Relations, Premier, Inc., 13034 Ballantyne Corporate Place, Charlotte, North Carolina 28277. We will disclose any substantive amendments to, or waivers (for directors or executive officers) from, certain provisions (relating to one or more elements of Item 4.06(b) of Regulation S-K) of the Corporate Code of Conduct and Board Codes on our website promptly following the date of such amendment or waiver.

Our website and information contained on it or incorporated in it are not intended to be incorporated in this Annual Report or other filings with the SEC.

Item 11. Executive Compensation

We will provide information that is responsive to this Item 11 in our definitive proxy statement for our **2023 2024** Annual Meeting of Stockholders or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report, in either case under the captions "Executive Compensation" and "Corporate Governance and Board Structure," "Compensation of Directors," "Compensation Discussion and Analysis," "Compensation Committee Interlocks and Insider Participation," "Compensation Committee Report," "Compensation Tables," "Employment Agreements," "Potential Payments Upon Termination," "CEO Pay Ratio," "Pay Versus Performance" and possibly elsewhere therein. That information is incorporated in this Item 11 by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

We will provide information that is responsive to this Item 12 in our definitive proxy statement for our **2023 2024** Annual Meeting of Stockholders or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report, in either case under the caption "Security Ownership of Certain Beneficial Owners and Management" and possibly elsewhere therein. That information is incorporated in this Item 12 by reference.

Equity Compensation Plan Information

We have granted equity awards to employees and directors under the Amended and Restated Premier, Inc. 2013 Equity Incentive Plan, which initially was approved by our stockholders prior to our IPO and was subsequently amended and restated and approved by our stockholders in December 2018. The following table sets forth certain information as of June 30, 2023 concerning about the shares of our Class A common stock authorized for issuance ("Common Stock") that may be issued under this equity incentive plan. No shares our stockholder approved Amended and Restated 2013 Equity Incentive Plan, 2023 Equity Incentive Plan and

2015 Employee Stock Purchase Plan as of Class B common stock are authorized for issuance under this plan, and we June 30, 2024. We do not have no any equity compensation plans under which shares of our Common Stock may be issued that have not been approved by our stockholders.

Plan Category	Plan Category	Number of securities remaining available for future issuance			Plan Category	Number of securities to be issued upon exercise of outstanding options, warrants and rights	Weighted-average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column a)
		Number of securities to be issued	Weighted-average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column a)				
(a)	(b)	(c)	(a)	(b)	(c)	(a)	(b)	(c)
Equity compensation plans approved by security holders:								
Amended and Restated Premier, Inc. 2013 Equity Incentive Plan		3,783,936	\$33.15	3,595,245				
Equity compensation plans approved by security holders					Equity compensation plans approved by security holders	4,223,512	\$28.72	8,690,709
Equity compensation plans not approved by security holders	Equity compensation plans not approved by security holders	n/a	n/a	n/a	Equity compensation plans not approved by security holders			n/a
Total	Total	3,783,936	\$33.15	3,595,245	Total	4,223,512	\$28.72	8,690,709

(a) Assumes restricted stock unit (RSU), performance share (PSA) and The number reported in this column includes the following shares of our Common Stock: 0.4 million shares issuable upon the exercise of stock option awards outstanding under our 2013 Equity Incentive Plan; 2.2 million shares issuable upon the vesting and settlement of restricted stock units (RSUs) and performance share awards (PSAs) outstanding under our Amended and Restated 2013 Equity Incentive Plan; and 1.6 million shares issuable upon the vesting and settlement of RSUs and PSAs outstanding under our 2023 Equity Incentive Plan. The reported number assumes that outstanding PSAs are paid at target performance level. Actual shares awarded of Common Stock that vest and are delivered pursuant to the PSAs may be higher or lower based upon actual performance over the measurement period. For more detailed information, see Note 13 - Stock-Based Compensation to our Consolidated Financial Statements, the accompanying consolidated financial statements.

(b) This The weighted average price calculation in this column only reflects outstanding stock option awards, awards and not RSUs or PSAs. RSUs and PSAs vest and settle into shares of our Common Stock if and when specified conditions are achieved and without the payment of any exercise price by the award recipient.

(c) As The shares of June 30, 2023, reflects Common Stock reported in this column include 5.9 million shares reserved that were available for future grants issuance as of stock options, RSUs, RSAs, PSAs and/or other June 30, 2024 as equity awards. Any awards under our 2023 Equity Incentive Plan as well as 2.8 million shares withheld to satisfy tax withholding obligations or tendered to pay the exercise price of an option shall again be that were available for grant future issuance as of June 30, 2024 under the terms of the plan, our 2015 Employee Stock Purchase Plan. Our 2013 Equity Incentive Plan expired in September 2023 and no new equity awards were issuable under that plan after its expiration.

Item 13. Certain Relationships and Related Transactions, and Director Independence

We will provide information that is responsive to this Item 13 in our definitive proxy statement for our 2023 2024 Annual Meeting of Stockholders or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report, in either case under the captions "Related Person Transactions," and "Corporate Governance and Board Structure," and possibly elsewhere therein. That information is incorporated in this Item 13 by reference.

Item 14. Principal Accounting Fees and Services

We will provide information that is responsive to this Item 14 in our definitive proxy statement for our 2023 2024 Annual Meeting of Stockholders or in an amendment to this Annual Report not later than 120 days after the end of the fiscal year covered by this Annual Report, in either case under the caption "Item 2 - Ratification of Appointment of Independent Registered Public Accounting Firm," and possibly elsewhere therein. That information is incorporated in this Item 14 by reference.

PART IV

Item 15. Exhibits and Financial Statement Schedules

Documents as part of this Report:

(a) (1) The following consolidated financial statements are filed herewith in Item 8 of Part II above.

- (i) Report of Independent Registered Public Accounting Firm
- (ii) Consolidated Balance Sheets
- (iii) Consolidated Statements of Income and Comprehensive Income
- (iv) Consolidated Statements of Stockholders' Equity
- (v) Consolidated Statements of Cash Flows
- (vi) Notes to Consolidated Financial Statements

(2) Financial Statement Schedule

Schedule II Valuation and Qualifying Accounts

(in thousands)	(in thousands)	Additions/(Reductions)			Ending Balance (in thousands)	Beginning Balance	Additions/(Reductions)	to Expense or Other Accounts	Deductions	Ending Balance
		Beginning Balance	Accounts	Deductions						
Year ended June 30, 2024										
Allowance for credit losses										
Allowance for credit losses										
Allowance for credit losses										
Deferred tax assets valuation allowance										
Year ended June 30, 2023	Year ended June 30, 2023									
Year ended June 30, 2023										
Year ended June 30, 2023										
Allowance for credit losses										
Allowance for credit losses										
Allowance for credit losses										
Allowance for credit losses		\$ 2,798		1,775	810	\$ 3,763				
Deferred tax assets valuation allowance		Deferred tax assets valuation allowance		52	—	4,604				
Year ended June 30, 2022	Year ended June 30, 2022									
Year ended June 30, 2022										
Year ended June 30, 2022										

Allowance for credit losses	Allowance for credit losses				
Allowance for credit losses	Allowance for credit losses				
Allowance for credit losses	Allowance for credit losses	\$ 2,284	2,153	1,639	\$ 2,798
Deferred tax assets valuation allowance	Deferred tax assets valuation allowance	35,913	(31,361)	—	4,552
Year ended June 30, 2021					
Allowance for credit losses	Allowance for credit losses	\$ 731	1,883	330	\$ 2,284
Deferred tax assets valuation allowance	Deferred tax assets valuation allowance	61,241	(25,328)	—	35,913

All other supplemental schedules are omitted because of the absence of conditions under which they are required.

(3) Exhibits

The exhibits listed in the accompanying Exhibit Index at the end of this Item 15 are filed as a part of this report.

(b) Exhibits

See Exhibit Index at the end of this Item 15.

(c) Separate Financial Statements and Schedule

None.

Exhibit Index

Exhibit No.	Description
2.1	Asset Purchase Agreement, dated as of September 6, 2022, among Contigo Health, LLC, TRPN Direct Pay, Inc. and Devon Health, Inc. (Incorporated by reference to Exhibit 2.1 of our Current Report on Form 8-K filed September 7, 2022)
3.1	Certificate of Incorporation of Premier, Inc. (Incorporated by reference to Exhibit 3.1 of our Registration Statement on Form S-1 filed on August 26, 2013)
3.2	Amended and Restated Bylaws of Premier, Inc., effective as of January 25, 2024 (Incorporated by reference to Exhibit 3.1 of our Current Report on Form 8-K filed on January 26, 2024) August 10, 2023*
4.1	Form of Class A common stock certificate (Incorporated by reference to Exhibit 4.1 of our Registration Statement on Form S-1, Amendment No. 1, filed on September 16, 2013)
4.1.1	Description of Securities (Incorporated by reference to Exhibit 4.1.1 of our Annual Report on Form 10-K filed on August 25, 2020)
10.1	Premier, Inc. 2023 Equity Incentive Plan, effective December 1, 2023 (Incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed on December 4, 2023)+
10.2	Form of Restricted Stock Unit Agreement for Non-Employee Directors under the Premier, Inc. 2023 Equity Incentive Plan (Incorporated by reference to Exhibit 10.2 of our Quarterly Report on Form 10-Q filed on February 6, 2024)+
10.3	Amended and Restated Premier, Inc. 2013 Equity Incentive Plan, effective December 7, 2018 (Incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed on December 7, 2018)+
10.2 10.4	Form of Performance Share Award Agreement under the Amended and Restated Premier, Inc. 2013 Equity Incentive Plan (Incorporated by reference to Exhibit 10.7 of our Annual Report on Form 10-K filed on August 23, 2019)+
10.3 10.5	Form of Restricted Stock Unit Agreement under the Amended and Restated Premier, Inc. 2013 Equity Incentive Plan* Plan (Incorporated by reference to Exhibit 10.3 of our Annual Report on Form 10-K filed on August 23, 2023)+
10.4 10.6	Form of Special Retention Restricted Stock Unit Agreement under the Amended and Restated Premier, Inc. 2013 Equity Incentive Plan* Plan (Incorporated by reference to Exhibit 10.4 of our Annual Report on Form 10-K filed on August 23, 2023)+
10.5 10.7	Form of Restricted Stock Unit Agreement under the Amended and Restated Premier, Inc. 2013 Equity Incentive Plan (Incorporated by reference to Exhibit 10.8 of our Annual Report on Form 10-K filed on August 23, 2019)+
10.5.1 10.8	Form of Special Restricted Stock Unit Agreement under the Amended and Restated Premier, Inc. 2013 Equity Incentive Plan (Incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed on April 26, 2022)+
10.6 10.9	Form of Restricted Stock Unit Agreement for Non-Employee Directors under the Amended and Restated Premier, Inc. 2013 Equity Incentive Plan (Incorporated by reference to Exhibit 10.9 of our Annual Report on Form 10-K filed on August 23, 2018)+
10.7 10.10	Form of Stock Option Agreement under the Amended and Restated Premier, Inc. 2013 Equity Incentive Plan (Incorporated by reference to Exhibit 10.8 of our Annual Report on Form 10-K filed on August 23, 2017)+
10.8 10.11	Premier, Inc. Annual Incentive Compensation Plan, amended and restated effective August 5, 2020 (Incorporated by reference to Exhibit 10.8 of our Annual Report on Form 10-K filed on August 25, 2020)+
10.9 10.12	Senior Executive Employment Agreement dated as of September 13, 2013, by and between Craig S. McKasson and Premier Healthcare Solutions, Inc. (Incorporated by reference to Exhibit 10.23 of our Registration Statement on Form S-1, Amendment No. 1, filed on September 16, 2013)+
10.10 10.13	Senior Executive Employment Agreement dated as of February 1, 2021 (effective May 1, 2021) by and between Michael J. Alkire and Premier Healthcare Solutions, Inc. (Incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K, filed on February 2, 2021)+
10.11 10.14	Executive Employment Agreement dated as of July 1, 2016, by and between Leigh Anderson and Premier Healthcare Solutions, Inc. (Incorporated by reference to Exhibit 10.21 of our Annual Report on Form 10-K filed on August 25, 2016)+
10.12 10.15	Executive Employment Agreement effective as of July 1, 2016, by and between David Klatsky and Premier Healthcare Solutions, Inc. (Incorporated by reference to Exhibit 10.22 of our Annual Report on Form 10-K filed on August 25, 2016)+
10.13 10.16	Executive Employment Agreement effective as of July 1, 2017, by and between David A. Hargraves and Premier Healthcare Solutions, Inc. (Incorporated by reference to Exhibit 10.21 of our Annual Report on Form 10-K filed on August 23, 2017)+

10.14 Exhibit	Description
No.	
10.17	Executive Employment Agreement dated September 18, 2013, by and between Andy Brailo and Premier Healthcare Solutions, Inc. (Incorporated by reference to Exhibit 10.1 of our Quarterly Report on Form 10-Q filed on November 7, 2023)+
10.18	Executive Employment and Restrictive Covenant Agreement dated September 26, 2022, by and between Crystal Climer and Premier Healthcare Solutions, Inc. (Incorporated by reference to Exhibit 10.2 of our Quarterly Report on Form 10-Q filed on November 7, 2023)+
10.19	Premier, Inc. Directors' Compensation Policy, as amended on January 23, 2020 (Incorporated by reference to Exhibit 10.1 of our Current Report on Form 8-K filed on January 23, 2020)+
10.15 10.20	Premier, Inc. Form of Director Cash Award Agreement under the Premier, Inc. Directors' Compensation Policy (Incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K filed on August 11, 2016)+

Exhibit	Description
No. 10.21	
10.16	Form of Indemnification Agreement by and between each director and executive officer and Premier, Inc. (Incorporated by reference to Exhibit 10.29 of our Registration Statement on Form S-1, Amendment No. 1, filed on September 16, 2013)+
10.17 10.22	Premier, Inc. 2015 Employee Stock Purchase Plan (as amended and restated effective August 4, 2020) (Incorporated by reference to Exhibit 10.19 of our Annual Report on Form 10-K filed on August 25, 2020)+
10.18 10.23	Premier Healthcare Solutions, Inc. Amended and Restated Deferred Compensation Plan, dated September 26, 2014 (effective January 1, 2015), as amended on September 25, 2015 and October 24, 2018 (Incorporated by reference to Exhibit 10.19 of our Annual Report on Form 10-K filed on August 25, 2020)+

(Incorporated by
reference to
Exhibit 10.20 of
our Annual Report
on Form 10-K filed
on August 25,
2020)+

10.19 10.24 Amended and
Restated Credit
Agreement, dated
as of December
12, 2022, by and
among Premier
Healthcare
Alliance, L.P.,
Premier Supply
Chain
Improvement, Inc.
and Premier
Healthcare
Solutions, Inc., as
Co-Borrowers,
certain domestic
subsidiaries of
Premier Services,
LLC, as
Guarantors, Wells
Fargo Bank,
National
Association, as
Administrative
Agent, Swing Line
Lender and an L/C
Issuer, other
lenders from time
to time party
thereto, and Wells
Fargo Securities,
LLC, BofA
Securities, Inc.
JPMorgan Chase
Bank, N.A., PNC
Capital Markets
LLC, and Truist
Securities, Inc. as
Joint Lead
Arrangers and
Joint Book
Managers.
(Incorporated by
reference to
Exhibit 10.1 of our
Current Report on
Form 8-K filed
December 16,
2022)

10.20 10.25 Form of Restricted
Stock Unit
Agreement for
Consultants
(Incorporated by
reference to

reference to
Exhibit 10.4 of our
Current Report on
Form 8-K filed on
September 7,
2021)

10.21 10.26 Equity Purchase
Agreement, dated
June 14, 2023, by
and among
OMNIA Partners,
LLC, Non-
Healthcare
Holdings LLC,
Premier Supply
Chain
Improvement, Inc.,
Premier
Healthcare
Alliance, L.P.,
Acurity, LLC,
Innovatix, LLC,
Essensa Ventures,
LLC, Premier
Healthcare
Solutions, Inc.,
and Premier, Inc.
(Incorporated by
reference to
Exhibit 10.1 of our
Current Report on
Form 8-K filed on
June 15, 2023)

10.27 Issuer Forward
Repurchase
Transaction
agreement dated
February 5, 2024,
between Premier,
Inc. and Bank of
America, N.A.
(Incorporated by
reference to
Exhibit 10.1 of our
Current Report on
Form 8-K filed on
February 7, 2024)

10.28 Form of Unit
Exchange and Tax
Receivable
Acceleration
Agreement, dated
as of August 10,
2020 and
effective as of July
1, 2020, by and
among certain
limited partners of
Premier
Healthcare
Alliance, L.P.

	PremierHealthcare Alliance, L.P. Premier Services, LLC and Premier, Inc. (Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on August 11, 2020)
19.1	Insider Trading Policy of the Company*
19.2	Rule 10b5-1 Plan Policy of the Company*
21	Subsidiaries of the Company*
23	Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm*
24	Power of Attorney (included on the signature page hereof)*
31.1	Certification as adopted of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2	Certification as adopted of principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1	Certification required by of principal executive officer pursuant to 18 United States Code Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002‡
32.2	Certification required by of principal financial officer pursuant to 18 United States Code Section 1350, as adopted

1350, as adopted
pursuant to
Section 906 of the
Sarbanes-Oxley
Act of 2002‡

97 Dodd-Frank
Compensation
Recoupment
Policy of the
Company*

101.INS Inline XBRL
Instance
Document*

101.SCH Inline XBRL
Taxonomy
Extension Schema
Document*

Exhibit No.	Description
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104	The cover page from the Premier, Inc. Annual Report on Form 10-K for the year ended June 30, 2023 June 30, 2024 , formatted in Inline XBRL (included in the Exhibit 101).*

* Filed herewith

+ Indicates a management contract or compensatory plan or arrangement

‡ Furnished herewith

Our SEC file number for documents filed with the SEC pursuant to the Securities Exchange Act of 1934, as amended, is 001-36092. The SEC file number for our Registration Statement on Form S-1 is 333-190828.

Item 16. Form 10-K Summary

We have elected not to provide a summary.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PREMIER, INC.

By: /s/ MICHAEL J. ALKIRE

Name: Michael J. Alkire

Title: President and Chief Executive Officer

Date: August **22, 2023** **20, 2024**

POWER OF ATTORNEY

Each person whose signature appears below hereby severally constitutes and appoints each of Craig S. McKasson and David L. Klatsky his/her true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for him/her in his/her name, place and stead, in any and all capacities, to sign any and all amendments to this report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to each such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature	Capacity	Date
/s/ MICHAEL J. ALKIRE Michael J. Alkire	President and Chief Executive Officer and Director (principal executive officer)	August 22, 2023 20, 2024
/s/ CRAIG S. MCKASSON Craig S. McKasson	Chief Administrative and Financial Officer and Senior Vice President (principal financial and accounting officer)	August 22, 2023 20, 2024
/s/ CRYSTAL B. CLIMER Crystal B. Climer	Chief Accounting Officer and Senior Vice President, Finance (principal accounting officer)	August 20, 2024
/s/ JOHN T. BIGALKE John T. Bigalke	Director	August 22, 2023 20, 2024
/s/ HELEN M. BOUDREAU Helen M. Boudreau	Director	August 22, 2023 20, 2024
/s/ JODY R. DAVIDS Jody R. Davids	Director	August 22, 2023 20, 2024
/s/ PETER S. FINE Peter S. Fine	Director	August 22, 2023 20, 2024
/s/ MARC D. MILLER Marc D. Miller	Director	August 22, 2023 20, 2024
/s/ MARVIN R. O'QUINN Marvin R. O'Quinn	Director	August 22, 2023 20, 2024
/s/ TERRY D. SHAW Terry D. Shaw	Director	August 22, 2023
/s/ RICHARD J. STATUTO Richard J. Statuto	Director	August 22, 2023 20, 2024
/s/ ELLEN C. WOLF Ellen C. Wolf	Director	August 22, 2023 20, 2024

120 126

Exhibit 19.1

Insider Trading Policy

AMENDED AND RESTATED BYLAWS

OF PREMIER, INC. 1. Purpose

To promote compliance with applicable securities laws by Premier, Inc., Premier Healthcare Solutions, Inc., Premier Healthcare Alliance, L.P. and their respective subsidiaries ("Premier" or the "Company") and all directors, officers and employees thereof, in order to preserve the reputation and integrity of Premier as well as that of persons affiliated therewith.

ARTICLE I2. Scope

STOCKHOLDERS

Section 1. The annual meeting Applies to all to all directors, officers and employees of the stockholders of Premier, Inc. (the "Corporation") for the purpose of electing directors and for the transaction of such other business Company as may properly be brought before the meeting shall be held on such date, and at such time and place, if any, within well as contractors or without the State of Delaware consultants designated as may be designated being covered from time to time. Every director, officer and employee of the Company and other designated covered individuals must read and retain this

Policy. Unless the context otherwise requires, references to the "Company" in this Policy refer to the Company, Premier Healthcare Alliance, L.P. and their respective subsidiaries.

3. Definitions

Company Securities – Shares of Class A Common Stock or other capital stock or securities of the Company.

Covered Person – Any (i) director, officer or other employee or designated contractor or consultant of the Company, (ii) agent or advisor of the Company (such as its auditors or attorneys), (iii) person identified as a Restricted Insider, or (iv) Related Person thereof.

Insider – Any person (including Covered Persons) who possesses material, nonpublic information.

Material Information – The materiality of information depends upon the circumstances. Information is considered "material" if there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision, or if the facts would have been viewed by the **Board** reasonable investor as having significantly altered the "total mix" of **Directors** information publicly available. Material information can be positive or negative and can relate to virtually any aspect of a company's business and impact the Corporation (the "Board"). value of any type of security – debt or equity. Examples:

Section 2. Subject • Unpublished financial results or projections

- News of a pending or proposed transaction, such as a significant merger, acquisition, divestiture or joint venture
- Stock splits or dividends, stock repurchases, calls for redemption of securities and other events regarding the Company's outstanding securities
- Acquisition or loss of a significant member contract
- Development of a significant new product or process
- Change in control or a change in management
- Change in auditors or auditor notification that the Company can no longer rely on an auditor's report
- New equity or debt offerings or purchases (whether publicly or privately)
- Significant change in strategy or development involving corporate relationships
- Significant litigation exposure or regulatory action
- Significant cybersecurity incidents, vulnerabilities and breaches
- Impending bankruptcy or receivership

The above list is only illustrative; many other types of information may be considered "material," depending on the circumstances. The materiality of particular information should be reviewed on a frequent basis. The Securities and Exchange Commission (SEC) has stated that there is no fixed quantitative threshold amount for determining materiality, and that even small quantitative changes can be qualitatively material.

Nonpublic Information – Information is "nonpublic" if it is not available to the **rights** general public. In order for information to be considered public, it must be widely disseminated in a manner making it generally available to investors through such media as Dow Jones, Thomson Reuters, The Wall Street Journal, the Associated Press or United Press International. The circulation of the **holders** of any class or series of Preferred Stock (as defined) rumors, even if accurate and reported in the **certificate of incorporation of the Corporation** of the Corporation, special meetings of the stockholders of the Corporation may be called only by or at the direction of the Board, the Chair of the Board or the Chief Executive Officer of the Corporation. media, does not constitute effective public dissemination.

Section 3. Except In addition, even after a public announcement of material information, a reasonable period of time must elapse in order for the market to react to the information. Generally, and for purposes of this Policy, two full trading days following publication is viewed as otherwise provided by law, the **certificate of incorporation of the Corporation** or these **Bylaws**, notice of the date, a reasonable time place (if any), the means of remote communications, if any, by which stockholders and proxy holders may be period before such information is deemed to be present public. Therefore, if an announcement is made before the commencement of trading on a Monday, **Covered Persons** may trade in person **Company Securities** starting on Wednesday of that week, because two full trading days would have elapsed by then (all of Monday and vote at such meeting, Tuesday). If the record date for determining announcement is made on Monday after trading begins, **Covered Persons** may not trade in **Company Securities** until Thursday. If the stockholders entitled to vote at the meeting (if such date announcement is different from the record date for stockholders entitled to notice made on Friday after trading begins, **Covered Persons** may not trade in **Company Securities** until Wednesday of the meeting) and, in the case of a special meeting, the purpose or purposes of the meeting of stockholders shall be given not more than sixty (60), nor less than ten (10), days previous thereto, to each stockholder of record entitled to vote at the meeting as of the record date for determining stockholders entitled to notice of the meeting at such address as appears on the records of the Corporation.

Section 4. The holders of a majority in voting power of the stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business, except as otherwise provided herein, by statute or by the certificate of incorporation of the Corporation; but if at any meeting of stockholders there shall be less than a quorum present, the chair of the meeting or the stockholders present may, to the extent permitted by law, adjourn the meeting from time to time without further notice other than announcement at the meeting of the date, time and place, if any, of the adjourned meeting, until a quorum shall be present or represented. At such adjourned meeting at which a quorum shall be present or represented any business may be transacted which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days, or if, after the adjournment, a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to notice of the meeting, and such notice shall include the record date for determining stockholders entitled to vote at the meeting if such date is different from the record date for determining stockholders entitled to notice of the meeting. Notwithstanding the foregoing, where a separate vote by a class or series or classes or series is required, a majority of the outstanding shares of such class or series or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter.

Section 5. The Chair of the Board, or in the Chair's absence or at the Chair's direction, the Lead Independent Director, or in the Lead Independent Director's absence or at the Lead Independent following week.

Director's Restricted Insider direction, any – Any Company director or executive officer of the Corporation shall call all meetings of the stockholders required to order and shall act as chair of any such meetings. The Secretary of the Corporation or, in such officer's absence, an Assistant Secretary shall act as secretary of the meeting. If neither the Secretary nor an Assistant Secretary is present, the chair of the meeting shall appoint a secretary of the meeting. Unless otherwise determined by the Board prior to the meeting, the chair of the meeting shall determine the order of business and shall have the authority in his or her discretion to regulate the conduct of any such meeting, including, without limitation, convening the meeting and adjourning the meeting (whether or not a quorum is present), imposing restrictions on the persons (other than stockholders of record of the Corporation or their duly appointed proxies) who may attend any such meeting, whether any stockholder or stockholder's proxy may be excluded from any meeting of stockholders based upon any determination by the chair of the meeting, in his or her sole discretion, that any such person has unduly disrupted or is likely to disrupt the proceedings thereat, and the circumstances in which any person may make a statement or ask questions at any meeting of stockholders.

Section 6. At all meetings of stockholders, any stockholder entitled to vote thereat shall be entitled to vote in person or by proxy, but no proxy shall be voted after three years from its date, unless such proxy provides for a longer period. Without limiting the manner in which a stockholder may authorize another person or persons to act for the stockholder as proxy file reports pursuant to the General Corporation Law of the State of Delaware (the "DGCL"), the following shall constitute a valid means by which a stockholder may grant such authority: (i) a stockholder may execute a writing authorizing another person or persons to act for the stockholder as proxy, and execution of the writing may be accomplished by the stockholder or the stockholder's authorized officer, director, employee or agent signing such writing or causing his or her signature to be affixed to such writing by any reasonable means including, but not limited to, by facsimile signature; or (ii) a stockholder may authorize another person or persons to act for the stockholder as proxy by transmitting or authorizing the transmission of a telegram, cablegram, or other means of electronic transmission to the person who will be the holder of the proxy or to a proxy solicitation firm, proxy support service organization or like agent duly authorized by the person who will be the holder of the proxy to receive such transmission, provided that any such telegram, cablegram or other means of electronic transmission must either set forth or be submitted with information from which it can be determined that the telegram, cablegram or other electronic transmission was authorized by the stockholder. If it is determined that such telegrams, cablegrams or other electronic transmissions are valid, the inspector or inspectors of stockholder votes or, if there are no such inspectors, such other persons making that determination shall specify the information upon which they relied.

A proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke any proxy which is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary of the Corporation a revocation of the proxy or a new proxy bearing a later date.

Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission created pursuant to the preceding paragraph of this Section 6 may be substituted or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission.

Proxies shall be filed with the secretary of the meeting prior to or at the commencement of the meeting to which they relate.

Section 7. When a quorum is present at any meeting, the vote of the holders of a majority of the votes cast shall decide any question brought before such meeting, unless the question is one upon which by express provision of the certificate of incorporation of the Corporation, these Bylaws or the DGCL a different vote is required, in which case such express provision shall govern and control the decision of such question. Notwithstanding the foregoing, where a separate vote by a class or series or classes or series is required and a quorum is present, the affirmative vote of a majority of the votes cast by shares of such class or series or classes or series shall be the act of such class or series or classes or series, unless the question is one upon which by express provision of the certificate of incorporation of the Corporation, these Bylaws or the DGCL a different vote is required, in which case such express provision shall govern and control the decision of such question.

Section 8.

(a) Record Date(s) for Stockholders Entitled to Notice of Meeting or to Vote at Such Meeting. In order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof, the Board may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board and which record date shall, unless otherwise required by law, not be more than sixty (60) nor less than ten (10) days prior to the date of such meeting. If the Board so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the Board determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board, the record date for determining stockholders entitled to notice of and to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; *provided*, however, that the Board may fix a new record date for determination of stockholders entitled to vote at the adjourned meeting, and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance with the foregoing provisions at the adjourned meeting.

(b) Record Date for Distributions. In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which shall not be more than sixty (60) days prior to any such corporate action. If not fixed by the Board, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.

(c) Transfers after a Record Date. Stockholders on a record date are entitled to notice, to vote or to receive the dividend, distribution or allotment of rights or to exercise the rights, as the case may be, notwithstanding any transfer of any shares on the books of the Corporation after the applicable record date, except as otherwise provided by agreement or by applicable law.

Section 9. At any time when the certificate of incorporation of the Corporation permits action by one or more classes of stockholders of the Corporation to be taken by written consent, the provisions of this section shall apply. All consents properly delivered in accordance with the certificate of incorporation of the Corporation, this section and the DGCL shall be deemed to be recorded when so delivered. No written consent shall be effective to take the corporate action referred to therein unless, within sixty (60) days of the earliest dated consent delivered to the Corporation as required by this section, written consents signed by the holders of a sufficient number of shares to take such corporate action are so recorded. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date of the meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the Corporation. Any action taken pursuant to such written consent or consents of the stockholders shall have the same force and effect as if taken by the stockholders at a meeting thereof. In order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board, and which date shall not be more than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board. If no record date has been fixed by the Board, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by the Board is required by statute, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. If no record date has been fixed by the Board and prior action by the Board is required by statute, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the day on which the Board adopts the resolution taking such prior action.

Section 10. The officer who has charge of the stock ledger of the Corporation shall prepare and make at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting (*provided*, however, if the record date for determining the stockholders entitled to vote is less than ten (10) days before the date of the meeting, the list shall reflect the stockholders entitled to vote as of the 10th day before the meeting date) showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of at least ten (10) days prior to the meeting: (i) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours, at the principal place of business of the Corporation. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be held at a place, then a list of stockholders entitled to vote at the meeting shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting.

Section 11. The Board, in advance of all meetings of the stockholders, shall appoint one or more inspectors of stockholder votes, who may be employees or agents of the Corporation or stockholders or their proxies, but not directors of the Corporation or candidates for office. In the event that the

Board fails to so appoint one or more inspectors of stockholder votes or, in the event that one or more inspectors of stockholder votes previously designated by the Board fails to appear or act at the meeting of stockholders, the chair of the meeting may appoint one or more inspectors of stockholder votes to fill such vacancy or vacancies. Inspectors of stockholder votes appointed to act at any meeting of the stockholders, before entering upon the discharge of their duties, shall take and sign an oath to faithfully execute the duties of inspector of stockholder votes with strict impartiality and according to the best of their ability and the oath so taken shall be subscribed by them. Inspectors of stockholder votes shall, subject to the power of the chair of the meeting to open and close the polls, take charge of the polls, and, after the voting, shall make a certificate of the result of the vote taken.

Section 12.

(a) Annual Meetings of Stockholders.

(i) Nominations of persons for election to the Board and the proposal of other business to be considered by the stockholders may be made at an annual meeting of stockholders only (A) pursuant to the Corporation's notice of meeting (or any supplement thereto) delivered pursuant to Article I, Section 3 of these Bylaws, (B) by or at the direction of the Board or any committee thereof or (C) by any stockholder of the Corporation who is entitled to vote on such election or such other business at the meeting, who complied with the notice procedures set forth in subparagraphs (ii) and (iii) of this paragraph (a) of this Bylaw and who was a stockholder of record at the time such notice is delivered to the Secretary of the Corporation.

(ii) For nominations or other business to be properly brought before an annual meeting by a stockholder, the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation, and, in the case of business other than nominations of persons for election to the Board, such other business must be a proper matter for stockholder action. To be timely, a stockholder's notice shall be delivered to the Secretary at the principal executive offices of the Corporation not less than ninety (90) days nor more than one hundred twenty (120) days prior to the first anniversary of the preceding year's annual meeting; provided, however, that in the event that the date of the annual meeting is advanced by more than twenty (20) days, or delayed by more than seventy (70) days, from such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting or the 10th day following the day on which public announcement of the date of such meeting is first made; and provided further, that for purposes of the application of Rule 14a-4(c) 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act" "Exchange Act") (or, and any successor provision, other individual designated as a Restricted Insider at the date for notice specified in this paragraph (a)(ii) shall be the earlier sole discretion of the date calculated as hereinbefore provided or the date specified in paragraph (c)(l) of Rule 14a-4. Company.

Related Person – For purposes of this Policy includes (i) a Covered Person's spouse and minor children and anyone else living in such person's household, (ii) partnerships in which a Covered Person is a general partner, (iii) trusts of which a Covered Person is a trustee, (iv) estates of which a Covered Person is an executor and (v) other equivalent legal entities that a Covered Person controls. Although a Covered Person's parent or sibling is not considered a Related Person (unless living in the first annual meeting of stockholders following the adoption of these Bylaws, the date same household), a parent or sibling may be a "tippee" for securities laws purposes. See item 9 below for a discussion of the first anniversary prohibition on "tipping."

POLICY

1. It is the Company's policy that no Covered Person having material, nonpublic information relating to the Company may buy or sell Company Securities or engage in any other action to take advantage of, or pass on to others, such information. This Policy also applies to material, nonpublic information relating to any other company with publicly traded securities, including our members or suppliers, obtained in the course of employment by or association with Premier.
2. To avoid even the appearance of impropriety, additional restrictions on trading Company Securities apply to Restricted Insiders. Refer to items 13-16 below for more information.
3. Investing in Company Securities provides an opportunity to share in the future growth of the preceding year's annual meeting shall Company. Investment in the Company and sharing in the growth of the Company, however, does not mean short-range speculation based on fluctuations in the market. Such activities may put the personal gain of a Covered Person in conflict with the best interests of the Company and its stockholders.

Trading Requirements and Guidelines

4. Non-disclosure of Material Nonpublic Information.
 - 4.1 Material, nonpublic information is strictly confidential and must not be deemed disclosed whether through written, oral or electronic means to be October 5, 2013 anyone, except for legitimate authorized business purposes to persons within the Company or to external advisors such as investment banking advisors, outside legal counsel, and contractors or consultants whose positions or roles require them to know such information and who are bound by confidentiality obligations, until such information has been publicly released by the Company.

5. Prohibited Trading in Company Securities.

5.1 No Covered Person may place a purchase or sell order or recommend that another person place a purchase or sell order in Company Securities including initial elections, changes in elections or reallocation of funds relating to 401(k) plan accounts, when such person has knowledge of material, nonpublic information concerning the Company. Further, no Covered Person may make loans, pledges, gifts, charitable donations or other contributions of Company Securities when such person has knowledge of material, nonpublic information concerning the Company. However, the following transactions are not covered by the foregoing restrictions ("Excepted Transactions"): (i) the exercise of options granted by the Company to purchase Company common stock, whether by paying the exercise price in cash or, if permitted under the terms of the stock option, via net exercise or other surrender of Company Securities, but expressly excluding any market sale of shares acquired upon exercise; (ii) the surrender of Company Securities to the Company, or the Company's withholding of Company Securities otherwise issuable to a Covered Person, to satisfy any tax withholding obligations upon the exercise of stock options, the vesting of restricted stock, or the settlement of restricted stock units granted by the Company, in each case if permitted under the terms of the applicable equity award, (iii) purchases under the ESPP (as defined in item 6 below) pursuant to valid elections under the ESPP made as and when permitted under items 6 and 16 below, (iv) transactions mandated under a judicial divorce decree or marital settlement agreement which do not benefit any Covered Person (other than the benefit of any tax deductions that may result from such transaction), and (v) transactions pursuant to a compliant Rule 10b5-1 Plan (as defined in item 7 below).

Such stockholder's notice shall 6. Participation in the Premier Employee Stock Purchase Plan.

6.1 Employees may participate in the Premier, Inc. Employee Stock Purchase Plan (ESPP) pursuant to its terms, subject to the limitations set forth (A) in the ESPP and this Policy. Participation in the ESPP is equivalent to the decision to purchase Company Securities. Accordingly, transactions related to the ESPP, including elections to participate and sales of Company Securities acquired under the ESPP, must be made in accordance with this Policy though as provided in item 5.1 above ESPP purchases made under validly implemented ESPP elections are Excepted Transactions. See item 16 below for additional limitations on ESPP transactions by Restricted Insiders.

7. Sales Under SEC Rule 10b5-1.

7.1 Covered Persons may elect to each person whom the stockholder proposes to nominate for election or re-election as a director all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case Company Securities pursuant to Section 14(a) contracts, plans or instructions complying with the requirements of Rule 10b5-1(c)(1) under the Exchange Act ("Rule 10b5-1 Plans"). Rule 10b5-1 Plans must be entered into in good faith while the Covered Person is not in possession of material, nonpublic information, and the rules adoption and regulations promulgated thereunder, including maintenance of any such person's written consent to being named in the proxy statement as Rule 10b5-1 Plan by a nominee Covered Person must comply with all other requirements of Rule 10b5-1(c) any and to serving as a director if elected; (B) as to any other business that the stockholder proposes to bring before the meeting, a brief description all policies of the business desired to be brought before the meeting (including the text of any resolutions proposed for consideration and, in the event that such business includes a proposal to amend these Bylaws, the language of the proposed amendment), the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made; (C) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made (i) the name and address of such stockholder, as they appear on the Corporation's books, and of such beneficial owner, (ii) the class and number of shares of the Corporation which are owned beneficially and of record by such stockholder and such beneficial owner, (iii) a representation that the stockholder intends to appear in person or by proxy at the meeting to propose such business or nomination, (iv) a representation whether the stockholder or the beneficial owner, if any, intends or is part of a group which intends (v) to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation's outstanding capital stock required to approve or adopt the proposal or elect the nominee and/or (w) otherwise to solicit proxies from stockholders in support of such proposal or nomination, (v) any other information relating Company applicable to such stockholder and beneficial owner, if any, required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for the election of directors in an election contest pursuant to and in accordance with Section 14(a) of the Exchange Act and the rules and regulations promulgated thereunder, (vi) a description of any agreement, arrangement or understanding Covered Person with respect to the nomination adoption and maintenance of Rule 10b5-1 Plans.

7.2 The Company has established a Rule 10b5-1 Plan Policy that sets forth required terms, conditions, and procedures relating to the adoption, amendment and termination of Rule 10b5-1 Plans, and which specifies Covered Persons that are required to use Rule 10b5-1 Plans to buy or proposal and/ sell Company Securities in public markets.

8. Twenty-Twenty Hindsight.

8.1 If securities transactions ever become the subject of scrutiny, they are likely to be viewed after-the-fact with the benefit of hindsight. As a result, before engaging in any transaction relating to the Company Securities, an Insider should carefully consider how such person's transaction may be construed in the bright light of hindsight.

9. "Tipping" Information to Others.

9.1 Insiders may be liable for communicating or tipping material, nonpublic information to any third party ("tippee"), even if such third party is not a Related Person. Further, insider trading violations are not limited to trading or tipping by Insiders. Persons other than Insiders also can be liable for insider

trading, including tippees who trade on material, nonpublic information tipped to them and individuals who trade on material, nonpublic information which has been misappropriated.

9.2 Tippees inherit an Insider's duties and are liable for trading on material, nonpublic information illegally tipped to them by an insider. Similarly, just as Insiders are liable for the voting of shares of any class or series of stock of the Corporation between or among the stockholder giving the notice, the beneficial owner, if any, on whose behalf the nomination or proposal is made, any insider trading of their respective affiliates tippees, tippees who pass such information along to others who trade on such information will be liable. In other words, a tippee's liability for insider trading is no different from that of an Insider. Tippees can obtain material, nonpublic information by receiving overt tips from others or associates and/or through, among other things, conversations at social, business or other gatherings.

10. Speculation and Hedging Transactions Prohibited.

10.1 No Covered Person may trade in options, warrants, puts or calls or similar instruments involving Company Securities or sell Company Securities "short." Further, no Covered Person may hold Company Securities in margin accounts. Anyone may, of course, in accordance with this Policy and other Company policies, hold and exercise options granted to such person by the Company.

10.2 Covered Persons are prohibited from engaging in transactions that hedge or offset, or are designed to hedge or offset, any others acting decrease in concert with any the market value of Company Securities granted as compensation or held directly or indirectly by the foregoing (collectively, "proponent persons"), and (vii) a description of any agreement, arrangement or understanding (including without limitation any contract to Covered Person).

11. Trading in Other Securities.

11.1 No Covered Person may place purchase or sell acquisition orders or grant of any option, right or warrant to recommend that another person place a purchase or sell swap order involving the securities of another company if such Covered Person learns of material, nonpublic information about such other company in the course of such Covered Person's employment or other instrument relationship with Premier.

12. Post-Termination/Separation Transactions.

12.1 This Policy (other than the intent pre-clearance requirements of item 14) continues to apply to transactions in the Company Securities by a Covered Person following termination of employment or effect other services with the Company until the later of which may be (x) (i) 60 days following termination of employment or services or (ii) the date such Covered Person is no longer aware of material, nonpublic information.

Additional Restrictions and Requirements for Restricted Insiders

13. Trading Window.

13.1 In addition to transfer being subject to or from any proponent person, in whole or in part, any all of the economic consequences of ownership of any security other limitations in this Policy, Restricted Insiders may only buy or sell Company Securities in the public market during the period beginning two full trading days after the release of the Corporation, (y) to increase Company's quarterly earnings (by press release or decrease filing of a Form 8-K current report) and ending at 4:00 pm Charlotte, North Carolina time on the voting power of any proponent person with respect to shares of any class or series of stock seventh day of the Corporation and/or (z) to provide any proponent person, directly or indirectly, with the opportunity to profit or share in any profit derived from, or to otherwise benefit economically from, any increase or decrease in the value of any security third month of the Corporation. A stockholder providing notice of a proposed nomination for election to then-current fiscal quarter (i.e., March 7, June 7, September 7 and December 7). Additionally, the Board or other business proposed to be brought before a meeting (whether given pursuant to this paragraph (a)(ii) or paragraph (b) of this Bylaw) shall update and supplement such notice Company may establish event-specific black-out periods from time to time which will further limit the time during which Restricted Insiders may buy or sell Company Securities in the public market. These blackout restrictions do not apply to the extent necessary so that the information provided or required to be provided in such notice shall be true and correct as of the record date for the meeting and as of the date that is fifteen (15) days prior to the meeting or any adjournment or postponement thereof; such update and supplement shall be delivered in writing to the Secretary at the principal executive offices of the Corporation not later than five (5) days after the record date for the meeting (in the case of any update and supplement required to be made as of the record date), and not later than ten (10) days prior to the date for the meeting or any adjournment or postponement thereof (in the case of any update and supplement required to be made as of fifteen (15) days prior to the meeting or any adjournment or postponement thereof). The Corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility of such proposed nominee to serve as a director of the Corporation. Excepted Transactions.

(iii) Notwithstanding anything in 14. Pre-Clearance.

14.1 Restricted Insiders must obtain prior clearance from the second sentence of paragraph (a)(ii) of this Bylaw to the contrary, in the event that the number of directors to be elected to the Board is increased and there is no public announcement naming all of the nominees for director Company's General Counsel or specifying the size of the increased Board made by the Corporation at least eighty (80) days prior to the first anniversary of the preceding year's annual meeting, a stockholder's notice required by this Bylaw shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the 10th day following the day on which a public announcement of such increase is first made by the Corporation; provided that, if no such announcement is made at least ten (10) days before the meeting, then no such notice shall be required.

(b) Special Meetings of Stockholders. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation's notice of meeting pursuant to Article I, Section 3 of these Bylaws. Nominations of persons for

election to the Board may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation's notice of meeting (i) by or at the direction of the Board or (ii) by any stockholder of the Corporation who is entitled to vote on such election at the meeting, who complies with the notice procedures set forth in this Bylaw and who is a stockholder of record at the time such notice is delivered to the Secretary of the Corporation. Nominations by stockholders of persons for election to the Board may be made at such a special meeting of stockholders if the stockholder's notice (containing the information required by paragraph (a)(ii) of this Section 12) shall be delivered to the Secretary at the principal executive offices of the Corporation not earlier than the 120th day prior to such special meeting and not later than the close of business on the later of the 90th day prior to such special meeting or the 10th day following the day on which public announcement is first made of the date of the special meeting and of the nominees proposed by the Board to be elected at such meeting. Notwithstanding the foregoing, a special meeting at which directors are to be elected may only be called when such special meeting will be held in lieu of an annual meeting of stockholders.

(c) General.

(i) Only persons who are nominated in accordance with the procedures set forth in this Bylaw shall be eligible to serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Bylaw. Except as otherwise provided by law, the certificate of incorporation of the Corporation or these Bylaws, the chair of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made in accordance with the procedures set forth in this Bylaw and, if any proposed nomination or business is not in compliance with this Bylaw, to declare that such defective nomination shall be disregarded or that such proposed business shall not be transacted. Notwithstanding the foregoing provisions of this Section 12, if the stockholder (or a qualified representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a nomination or business, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Section 12, to be considered a qualified representative of the stockholder, a person must be a duly authorized officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders.

(ii) For purposes of this Bylaw, "public announcement" shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press, PR Newswire or comparable national news service or in a document publicly filed or furnished by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.

(iii) For purposes of this Bylaw, no adjournment or postponement or notice of adjournment or postponement of any meeting shall be deemed to constitute a new notice of such meeting for purposes of this Section 12, and in order for any notification required to be delivered by a stockholder pursuant to this Section 12 to be timely, such notification must be delivered within the periods set forth above with respect to the originally scheduled meeting.

(iv) Notwithstanding the foregoing provisions of this Bylaw, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this Bylaw; provided, however, that any references in these Bylaws to the Exchange Act or the rules and regulations promulgated thereunder are not intended to and shall not limit any requirements applicable to nominations or proposals as to any other business to be considered pursuant to this Bylaw (including paragraphs (a)(i)(C) and (b) hereof), and compliance with paragraphs (a)(i)(C) and (b) of this Bylaw shall be the exclusive means for a stockholder to make nominations or submit other business. Nothing in this Bylaw shall (A) be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation's proxy statement pursuant to Rule 14a-8 under the Exchange Act or (B) apply to the right, if any, of the holders of any series of Preferred Stock to elect directors pursuant to any applicable provisions of the certificate of incorporation of the Corporation.

ARTICLE II

BOARD OF DIRECTORS

Section 1. Subject to the provisions of the certificate of incorporation relating to the rights of any holders of the Corporation's Preferred Stock, the number of directors constituting the full Board shall be fixed from time to time by the vote of a majority of the full Board; provided, however, that the number of directors shall not exceed eleven (11). On and after August 15, 2013, the Board shall be divided into three classes designated Class I, Class II and Class III. Each class shall consist, as nearly as possible, of one-third of the total number of directors constituting the entire Board, and in the event the size of the Board is increased or decreased, for any reason or none, such increase or decrease shall be apportioned, as nearly as possible, equally among the three classes. The initial terms of the directors serving in Class I shall expire at the Corporation's first annual meeting of stockholders. The initial terms of the directors serving in Class II shall expire at the Corporation's second annual meeting of stockholders. The initial terms of the directors serving in Class III shall expire at the Corporation's third annual meeting of stockholders. Thereafter, each director shall serve for a term expiring at the third annual meeting following his or her election. No director shall serve for more than three consecutive terms except for (i) Excepted Transactions, and (ii) the Chief Executive Officer; (ii) each director who is not a party to any Rule 10b5-1 Plan. The General Counsel or his or her designee may consult as they deem necessary or appropriate with senior management of and/or counsel

to the Company before clearing any proposed trade or trading plan. The determination of whether to clear a director, officer, employee proposed purchase and sale or agent of, trading plan will be based on whether it raises insider trading concerns or otherwise affiliated with, any stockholder of other concerns under the Corporation; federal or state securities laws and (iii) a director serving as Chair of the Board, whose term may be extended at regulations, and in the discretion of the Board. Nothing in the Certificate of Incorporation General Counsel or these By-Laws shall prohibit any incumbent director from serving the balance of his or her term. Directors shall (except as hereinafter designee may be based on any representations or certifications provided for the filling of vacancies and newly created directorships) be elected by the holders pursuant to item 14.2 below. Clearance of a plurality transaction or a trading plan does not constitute guidance regarding the validity of the votes cast by the holders of shares present in person transaction or represented by proxy at the meeting trading plan under applicable laws and entitled to vote on the election of directors. A majority regulations; and no representative of the total number Company assumes responsibility for, and pre-clearance of directors constituting a transaction or plan

will not protect a trading party from, the entire Board shall consequences of prohibited insider trading. Furthermore, clearance of transaction or trading plans will not constitute advice regarding the investment aspects of any transaction. Clearance of a quorum transaction, if given, is valid only for a 48-hour period. If the transaction order for a purchase or sale of business. Except as otherwise provided by law, these Bylaws or the certificate of incorporation of the Corporation, any act of the Board shall require the affirmative vote of a majority of the unrecused directors voting at a meeting at which a quorum Company Securities is present. Directors need not be stockholders. The Board shall, at its next meeting following each annual meeting of stockholders, elect a current director as Chair of the Board. The position of Chair of the Board shall not be an officer of the Corporation. The Chair of the Board shall perform such tasks and duties as may be set forth in these Bylaws and as from time to time prescribed by the Board in all cases placed within the Chair of the Board's duties as a director and not as an officer of the Corporation including, by way of clarification and for the avoidance of doubt without expanding or contracting the role or duties of the Chair of the Board or the Board, as Chair of the Board when the Board is authorizing the actions of the Corporation in its capacity as sole member of Premier Services, LLC, a Delaware limited liability company ("Premier Services"), the general partner of Premier Healthcare Alliance, L.P., a California limited partnership ("Premier LP"). The Corporation through its capacity as sole member of Premier Services, manages Premier LP. For the avoidance of doubt, the Board shall have the power to authorize the actions of the Corporation in this capacity except as delegated by the Board by resolution. At the next meeting of the Board following each annual meeting of the stockholders, the independent directors shall elect a current independent director as Lead Independent Director upon review and recommendation by the Nominating and Governance Committee. The position of Lead Independent Director shall not be an officer of the Corporation. The Lead Independent Director shall perform such tasks and duties as may be set forth in these Bylaws and as from time to time prescribed by the Board in all cases within the Lead Independent Director's duties as a director and not as an officer of the Corporation.

Section 2. Subject to the certificate of incorporation of the Corporation, unless otherwise required by law, any newly created directorship on the Board that results from an increase in the number of directors and any vacancy occurring in the Board shall be filled only by a majority of the directors then in office,

although less than a quorum, or by a sole remaining director. Any director elected to fill a vacancy or newly created directorship shall hold office until the next election of the class for which such director shall have been chosen and until his or her successor shall be elected and qualified, or until his or her earlier death, resignation, retirement, disqualification or removal.

Section 3. Unless otherwise restricted by the laws of the State of Delaware, by the certificate of incorporation or by these Bylaws, any director or the entire Board may be removed, but only for cause, by the holders of a majority of the shares then entitled to vote at an election of directors, voting together as a single class. No reduction of the authorized number of directors shall have the effect of removing any director prior to the expiration 48-hour period, clearance of such director's term of office.

Section 4. Meetings of the Board shall be held at such place, if any, within purchase or without the State of Delaware as may from time to time be fixed by resolution of the Board or as may be specified in the notice of any meeting. Regular meetings of the Board shall be held at such times as may from time to time be fixed by resolution of the Board and special meetings may be held at any time upon the call of the Chair of the Board, or in the Chair's absence or at the Chair's direction, the Chief Executive Officer, by written notice, including transmission of a telecopy, e mail or other means of electronic transmission, duly served on or sent and delivered to each director to such director's address, e-mail address or telecopy number as shown on the books of the Corporation not less than twenty-four (24) hours before the meeting. The notice of any meeting need not specify the purposes thereof. A meeting of the Board may be held without notice immediately after the annual meeting of stockholders at the same place, if any, at which such meeting is held. Notice need not be given of regular meetings of the Board held at times fixed by resolution of the Board. Notice of any meeting need not be given to any director who shall attend such meeting (except when the director attends a meeting for the express purpose of objecting at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened), or who shall waive notice thereof, before or after such meeting, in writing (including by electronic transmission).

Section 5. Notwithstanding the foregoing, whenever the holders of any one or more series of Preferred Stock issued by the Corporation shall have the right, voting separately as a series or separately as a class with one or more such other series, to elect directors at an annual or special meeting of stockholders, the election, term of office, removal, and other features of such directorships shall be governed by the terms of the certificate of incorporation of the Corporation (including any certificate of designation relating to any series of Preferred Stock) applicable thereto. The number of directors that may be elected by the holders of any such series of Preferred Stock shall be in addition to the number fixed pursuant to the certificate of incorporation of the Corporation and these Bylaws. Except as otherwise expressly provided in the terms of such series, the number of directors that may be so elected by the holders of any such series of stock shall be elected for terms expiring at the next annual meeting of stockholders, and vacancies among directors so elected by the separate vote of the holders of any such series of Preferred Stock shall be filled by the affirmative vote of a majority of the remaining directors elected by such series, or, if there are no such remaining directors, by the holders of such series in the same manner in which such series initially elected a director.

Section 6. If at any meeting for the election of directors, the Corporation has outstanding more than one class of stock, and one or more such classes or series thereof are entitled to vote separately as a class to elect directors, and there shall be a quorum of only one such class or series of stock, that class or series of stock shall be entitled to elect its quota of directors notwithstanding absence of a quorum of the other class or series of stock.

Section 7. The Board may from time to time establish one or more committees of the Board to serve at the pleasure of the Board, which shall be comprised of such members of the Board and have such duties as the Board shall from time to time determine. Any director may belong to any number of committees of the

Board. The Board may also establish such other committees with such members (whether or not directors) and with such duties as the Board may from time to time determine. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Unless otherwise provided in the certificate of incorporation of the Corporation, these Bylaws or the resolution of the Board designating the committee, a committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and delegate to a subcommittee any or all of the powers and authority of the committee.

Section 8. Unless otherwise restricted by the certificate of incorporation of the Corporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board or of any committee thereof may be taken without a meeting if all members of the Board or committee, sale, as the case may be, consent thereto in writing (including must be re-requested. If clearance is denied, the fact of such denial must be kept confidential by electronic transmission), the person requesting such clearance.

14.2 The General Counsel may establish such processes and the writing procedures as he or writings are filed with the minutes of proceedings she deems necessary or appropriate for purposes of the Board.

Section 9. The members of the Board or any committee thereof pre-clearance under 14.1 above. Such processes and procedures may participate in a meeting of such Board or committee, as the case may be, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this subsection shall constitute presence in person at such a meeting.

Section 10. The Board may establish policies for the compensation of directors and for the reimbursement of the expenses of directors, in each case, in connection with services provided by directors to the Corporation.

ARTICLE III

OFFICERS

Section 1. The Board, at its next meeting following each annual meeting of the stockholders, shall elect officers of the Corporation, including a President, Chief Executive Officer and a Secretary. The Board may also from time to time elect such other officers (including, include, without limitation, a Chief Financial Officer, process for written notification of a Chief Operating Officer, a Chief Technology Officer, a proposed transaction or trading plan, along with such representations relating to the clearance request as the General Counsel one or more Presidents, Vice Presidents, a Treasurer, one his or more Assistant Vice Presidents, one or more Assistant Secretaries her designee may specify, and one or more Assistant Treasurers) accompanied by such certifications as it they may deem proper necessary or may delegate appropriate as a condition to any elected officer of the Corporation the power to appoint and remove any such other officers and to prescribe their respective terms of office, authorities and duties. Any Vice President may be designated Executive or Senior or may be given such other designation or combination of designations as the Board or the Chief Executive Officer may determine. Any two or more offices may be held by the same person.

Section 2. All officers of the Corporation elected by the Board shall hold office for such terms as may be determined by the Board or until their respective successors are chosen and qualified. Any officer may be removed from office at any time either with or without cause by affirmative vote Company clearance of a majority of the members of the Board then in office, transaction or in the case of appointed officers, by any elected officer upon whom such power of removal shall have been conferred by the Board.

Section 3. Each of the officers of the Corporation elected by the Board or appointed by an officer in accordance with these Bylaws shall have the powers and duties prescribed by law, by these Bylaws or by the

Board and, in the case of appointed officers, the powers and duties prescribed by the appointing officer, and, unless otherwise prescribed by these Bylaws or by the Board or such appointing officer, shall have such further powers and duties as ordinarily pertain to that office. Subject to the authority of the Board, the Chief Executive Officer shall have authority over the general direction of the affairs of the Corporation.

Section 4. Unless otherwise provided in these Bylaws, in the absence or disability of any officer of the Corporation, the Board may, during such period, delegate such officer's powers and duties to any other officer or to any director and the person to whom such powers and duties are delegated shall, for the time being, hold such office.

ARTICLE IV

INDEMNIFICATION trading plan.

Section 1. To 15. Hardship Exceptions.

15.1 In limited circumstances, the fullest extent permitted Company's General Counsel may grant a hardship exception to a Covered Person who is subject to a blackout period and who has an unexpected and urgent need to sell Company Securities in order to generate cash.

However, a hardship exemption from a blackout period under this Policy is not an exception to insider trading laws. A transaction that may be necessary or seem justifiable for independent reasons including a need to raise money for a personal financial emergency is neither a general exception to this Policy nor a safeguard against prosecution for violation of insider trading laws. Hardship exemptions may be granted only by the laws General Counsel and must be requested at least two business days in advance of the State of Delaware, as it presently exists proposed trade. Under no circumstances will a hardship exception be granted during an event-specific blackout period or may hereafter be amended, the Corporation shall indemnify and hold harmless any person (and such person's heirs, executors or administrators) who was or is made or is threatened to be made a party to or is otherwise involved (including, without limitation, as a witness) in any threatened, pending or completed action, suit, arbitration, alternative dispute resolution mechanism, investigation, inquiry, administrative hearing or any other threatened or actual proceeding (brought in the right of the Corporation or otherwise), whether civil, criminal, administrative, legislative, congressional or investigative, and whether formal or informal, and whether the basis of such proceeding is alleged action in an official capacity as a director or executive officer.

16. ESPP Transactions by Restricted Insiders.

16.1 Because transactions in the Company ESPP consist of purchases of Company Securities, Restricted Insiders must make their election to participate in the next upcoming ESPP purchase period during an open trading window and only after receipt of pre-clearance under this Policy, though as provided in item 5.1 above ESPP purchases made under validly implemented ESPP elections are Excepted Transactions. Automatic renewals of ESPP participants under the terms of the ESPP need not be pre-cleared if the terms of participation are not changed by the participant. Any participation changes permitted under the ESPP during a purchase period (such as payroll deduction amounts or withdrawals from the ESPP) must be pre-cleared during an open trading window by Restricted Insiders under this Policy prior to making any such changes.

The Consequences of Insider Trading

Individuals who trade on material, non-public information or tip information to others can be subject to an array of civil and criminal penalties. Violations are taken very seriously by the SEC, the federal agency responsible for enforcing the law in this area.

17. Potential sanctions include:

17.1.1 Disgorgement of profits gained or losses avoided and interest thereon.
17.1.2 A civil penalty of up to three times the profit gained or loss avoided.
17.1.3 A bar from acting as an officer or in any other capacity while serving as director of a director publicly traded company.
17.1.4 A criminal fine (no matter how small the profit or officer, including appeals (all such actions, suits or proceedings, including appeals, are referred the lack thereof) of up to herein as "\$5 million.
17.1.5 Actions orProceedings"), by reason A jail term of up to 20 years.

18. These penalties can apply even if the fact that such person, or a person for whom such person was the legal representative, individual is or was not a director or officer of the Corporation Company. The SEC has imposed large penalties even when the disclosing person did not profit from the trading. The SEC, NASDAQ Capital Market and Financial Industry Regulatory Authority use sophisticated electronic surveillance techniques to uncover insider trading. In addition to the potentially severe civil and criminal penalties for violation of the

insider trading laws, violation of this Policy may result in the imposition by the Company of sanctions, including dismissal from the Company. A conviction or while finding of liability for insider trading can also result in individuals being banned generally from employment in the securities or financial services industries or other employment, and even a director mere allegation of insider trading can result in severe harm to professional and personal reputation.

Certification

19. It is a condition of employment or officer continued employment with the Company that every employee read and acknowledge acceptance of this Policy as requested by the Company.

Where to Go with Questions and Concerns

Direct questions regarding this Policy to the General Counsel or any person to whom the General Counsel has delegated responsibility for advising on this Policy.

Exhibit 19.2

Rule 10b5-1 Plan Policy

1. Purpose

To be read in conjunction with the Company's Insider Trading Policy (the "Insider Trading Policy"). Terms used in this Rule 10b5-1 Plan Policy and not otherwise defined have the meanings set forth in the Insider Trading Policy. Unless the context otherwise requires, references to the "Company" in this Policy refer to the Company, Premier Healthcare Solutions, Inc., Premier Healthcare Alliance, L.P., and their respective subsidiaries.

2. Scope

Applies to all to all directors, officers and employees of the Corporation, is Company as well as contractors or was serving at the request consultants designated as being covered from time to time. Every director, officer and employee of the Corporation Company and other designated covered individuals must read and retain this Policy. Unless the context otherwise requires, references to the "Company" in this Policy refer to the Company, Premier Healthcare Alliance, L.P. and their respective subsidiaries.

3. Definitions

Executive Team – The Company's Chief Executive Officer, all of the Company's other executive officers (those officers of the Company who are required by Section 16 of the Exchange Act to file reports on their transactions in the Company's securities), as a director, officer, partner, trustee, employee, representative well as all other individuals on the Company's executive leadership team from time to time.

Material Amendment or agent of another corporation, partnership, joint venture, trust, limited liability company, nonprofit entity or other enterprise (including, Modification – Includes, without limitation, any trade associations), change to the amount, price or timing of the purchase or sale of securities (or change to a formula, algorithm or computer program that affect those terms).

Rule 10b5-1(c)under the Exchange Act – Provides an affirmative defense against allegations of insider trading. This affirmative defense is often referred to as a "safe harbor" from such allegations. The Rule 10b5-1(c) safe harbor is available to the Company's employees, officers and directors who make trades pursuant to a trading "plan" that meets the requirements of the rule. A plan that meets the requirements of the Rule 10b5-1(c) safe harbor is referred to herein as a "Rule 10b5-1 Plan." Rule 10b5-1 Plans may be used for purchases, sales, gifts or other transfers of securities.

POLICY

1. The Insider Trading Policy provides that covered persons may use Rule 10b5-1 Plans to transact in Company securities and transactions under such plans are exempt from certain requirements of the Insider Trading Policy.
2. As specified below, this Policy requires that certain covered persons must use Rule 10b5-1 Plans to conduct market transactions in Company securities, other than excepted transactions.
 - 2.1. All Rule 10b5-1 Plans entered into by a covered person (and any amendment to, modification of, or termination of such a Rule 10b5-1 Plan) must comply with Rule 10b5-1 (including any amendment thereof).
 - 2.2. In addition, all Rule 10b5-1 Plans entered into by covered persons from and against all loss and liability suffered and expenses (including, without limitation, attorneys' fees and ERISA excise taxes after the adoption of this Policy (and any amendment to, modification of, or penalties), judgments, fines and amounts paid in settlement

reasonably incurred by such person or such heirs, executors or administrators in connection with such Action or Proceeding, all to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case termination of any covered person's Rule 10b5-1 Plan from and after such amendment, only adoption, regardless of when the Rule 10b5-1 Plan was entered into) must meet the requirements of this Policy, except to the extent that such amendment permits the Corporation this Policy is inconsistent with Rule 10b5-1 as it may be amended from time to provide broader indemnification rights than permitted prior thereto). Without limiting the scope of this Section 1, the foregoing indemnification shall cover any acts or omissions by any person described in this Section 1 with respect to any subsidiary or other entity controlled by the Corporation (including, without limitation, Premier LP). Notwithstanding the preceding sentences, except as otherwise provided in Article IV, Section 4 of these Bylaws, the Corporation shall be required to indemnify a person described in such sentences in connection with any Action or Proceeding (or part thereof) commenced by such person only if the commencement of such Action or Proceeding (or part thereof) by such person was authorized by the Board. time.

Section 2. 3. The Corporation may, by action Company has adopted this Policy in light of the current requirements of Rule 10b5-1 to promote compliance with that rule and to enable the Company's efficient administration of Rule 10b5-1 Trading Plans.

4. However, at all times it remains a covered person's responsibility to comply with laws and regulations relating to their transactions in Company securities, including any future changes that may be made to Rule 10b5-1.

Required Use of Rule 10b5-1 Plans

5. Members of the Company's Board of Directors and the executive team are prohibited from buying or selling Company securities in the public market except pursuant to a compliant Rule 10b5-1 Plan or any Excepted Transaction.

Plan and Approval

6. Each Rule 10b5-1 Plan proposed to be entered into by a covered person must be approved in writing by the General Counsel or his/her designee prior to its effectiveness.

- 6.1. The Rule 10b5-1 Plan must be in writing and signed by the covered person.
- 6.2. The Rule 10b5-1 Plan must include a written representation by the covered person that the individual is not aware of any material nonpublic information concerning the Company and that he/she is adopting the Rule 10b5-1 Plan in good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b) and Rule 10b-5 of the Exchange Act.
- 6.3. The Company keeps a copy of each Rule 10b5-1 Plan in its files.

Timing of Plan

7. Each Rule 10b5-1 Plan used by a covered person must be adopted (a) when the trading window for the covered person is open under the Insider Trading Policy, if applicable, and (b) when the covered person does not otherwise possess material nonpublic information about the Company.

Timing of Plan Amendment and Modification; Termination of Plans

8. Rule 10b5-1 Plans may be amended or modified only: (a) when the trading window for the covered person is open under the Insider Trading Policy, if applicable; (b) when the covered person does not possess material nonpublic information about the Company; and (c) with the written approval of the General Counsel or his/her designee.

9. The Company must be promptly notified of any Rule 10b5-1 Plan termination.

Delayed Effectiveness of Adoption or Amendment/Modification

10. Each Rule 10b5-1 Plan used by a covered person must include a "cooling off" period prior to the first trade under the plan, described below.

- 10.1. The "cooling off" period becomes applicable again to the same Rule 10b5-1 Plan if there is any material amendment or modification of that plan.

11. For executive officers and directors, the Rule 10b5-1 Plan must provide indemnification that the first transaction executed pursuant to the Rule 10b5-1 Plan may not occur until the later of (i) the 90th day after adoption or material amendment or modification of the plan and (ii) two business days following the disclosure of the Company's financial results in a Form 10-Q or Form 10-K for the fiscal quarter in which the plan was adopted, amended or modified.

- 11.1. With respect to the period described in clause (ii), the required cooling off period need not exceed 120 days.

12. For covered persons who are not covered by Article IV, Section 1 of these Bylaws, and who are executive officers or were employees or directors, the Rule 10b5-1 Plan must provide that the first transaction executed pursuant to the Rule 10b5-1 Plan may not occur until thirty (30) days following the adoption or agents material amendment or modification of the Corporation, or who are or were serving at the request of the Corporation Rule 10b5-1 Plan, as employees or agents of another corporation, partnership, joint venture, trust, limited liability company, nonprofit entity or other enterprise, applicable.

Relationships with the same or lesser scope and effect as the indemnification provided by Article IV, Section 1. Plan Broker/Administrator; No Subsequent Influence

Section 3. To 13. Each Rule 10b5-1 Plan used by a covered person must provide that the fullest extent permitted by covered person may not communicate any material nonpublic information about the laws of Company to the State of Delaware, broker or other third party administering the Corporation shall promptly pay expenses (including attorneys' fees) incurred by plan or attempt to influence how the broker or such party executes (or exercises its discretion in executing) orders or other transactions under the Rule 10b5-1 Plan in any person described in Article IV, Section 1 of these Bylaws in appearing at, participating in or defending any threatened, pending or completed Action or Proceeding in advance of the final disposition of such threatened, pending or completed Action or Proceeding, upon presentation of an undertaking on behalf of such person to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified under this Article IV or otherwise. Notwithstanding the preceding sentence, except as otherwise provided in Article IV, Section 4 of these Bylaws, the Corporation shall be required to advance expenses of a person described in such sentence in connection with any Action or Proceeding (or part thereof) commenced by such person only if the commencement of such Action or Proceeding (or part thereof) by such person was authorized by the Board.

Section 4. If a claim for indemnification (following Plan Specifications; Discretion Regarding Transactions Under the final disposition of such Action or Proceeding) or advancement of expenses under this Article IV is not paid in full within thirty (30) days after a written claim therefor by any person described in Article IV, Section 1 of these Bylaws has been received by the Corporation, such person may file suit to recover the unpaid amount of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim. In any such action, the Corporation shall have the burden of proving that such person is not entitled to the requested indemnification or advancement of expenses under this Article IV. Plan

Section 5. Notwithstanding 14. The Rule 10b5-1 Plan must authorize the requirements of Article IV, Section 1 of these Bylaws, the Corporation shall not be obligated to indemnify any person pursuant to this Article IV in connection with any Action or Proceeding (or any part thereof): (a) for which payment has actually been made to or on behalf of such person under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond such amount paid; (b) for an accounting or disgorgement of profits pursuant to Section 16(b) of the Exchange Act, or similar provisions of federal, state or local statutory law or common law, if such person is held liable therefor (including pursuant to any settlement arrangements); (c) for any reimbursement of the Corporation by such person of any bonus broker or other incentive-based third party administering the plan to effect the transactions called for by the plan without any control or equity-based compensation or of any profits realized influence by such person from the sale of securities of the Corporation, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Corporation pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act"), or the payment to the Corporation of profits arising from the purchase and sale by such person of securities in violation of Section 306 of the Sarbanes-Oxley Act), if such person is held liable therefor (including pursuant to any settlement arrangements); or (d) if prohibited by applicable law.

Section 6. To 15. The Rule 10b5-1 Plan must specify the fullest extent permitted material parameters for the transactions to be effected under the plan. For example, for a plan that will provide for the purchase or sale of stock, the plan must specify the amount of stock to be purchased or sold during specified time periods and the price at which such stock is to be purchased or sold, or the plan may specify or set an objective formula (e.g., stock price thresholds) for determining the price and amount of stock to be purchased or sold during specified time periods.

16. The Company may require that the specified time periods contained in a covered person's Rule 10b5-1 Plan during which sales could occur shall not coincide with the specified time periods in similar Rule 10b5-1 Plans adopted by other insiders (e.g., to avoid a particular part of a quarter when earnings will be released), or make other arrangements (such as sale volume limitations) to avoid a large number of sales occurring simultaneously or to comply with any required Company policy regarding stock ownership.

Only One Plan in Effect at Any Time

17. Unless otherwise approved by the laws of the State of Delaware, the Corporation may purchase and maintain insurance on behalf of any person described Company's General Counsel or his/her designee in Article IV, Section 1 of these Bylaws against any liability asserted against such person, whether or not the Corporation would have the power to indemnify such person against such liability situations where having multiple plans in place at one time is permissible under the provisions of Rule 10b5-1, a covered person may have only one Rule 10b5-1 Plan in effect at any time.

- 17.1. However, a covered person may adopt a new Rule 10b5-1 Plan to replace an existing Rule 10b5-1 Plan before the scheduled termination date of such existing Rule 10b5-1 Plan so long as the new Rule 10b5-1 Plan does not become effective prior to the completion or expiration of transactions under the existing Rule 10b5-1 Plan, in all cases consistent with Rule 10b5-1, and the new Rule 10b5-1 Plan must comply with the cooling off period and other requirements of this Article IV Policy.
- 17.2. In addition, a covered person may have in place an additional Rule 10b5-1 Plan in connection with sell-to-cover transactions as necessary to satisfy tax withholding obligations incident to the vesting of a compensatory award from the Company such as restricted stock, restricted stock units or otherwise, stock appreciation rights and where the covered person does not control the timing of such sales.

Section 7. Persons who after the date of the adoption of this Article IV become or remain directors or officers of the Corporation or who, while a director or officer of the Corporation, serves or remains at the request of the Corporation as a director, officer, partner, trustee, employee, representative or agent of a subsidiary, shall be conclusively presumed to have relied on the rights to indemnification, advancement of expenses and other rights contained in this Article IV in entering into or continuing such service. The rights to indemnification and to the advancement of expenses conferred in this Article IV shall apply to claims made against such directors and officers arising out of such service which occurred or occurs both prior and subsequent to the adoption hereof.

Section 8. The provisions of this Article IV shall be applicable to all Actions or Proceedings made or commenced after the adoption hereof, whether arising from acts or omissions to act occurring before or after its adoption, and shall continue as to a person who has ceased to be a director or officer and shall inure to the benefit of the heirs, executors or administrators of such person. The provisions of this Article IV shall be deemed to be a contract between the Corporation and each director or officer (or legal representative thereof) who serves in such capacity at any time while this Article IV and the relevant provisions of the law of the State of Delaware and other applicable law, if any, are in effect, and any alteration, amendment or repeal hereof shall not affect any rights or obligations then existing with respect to any state of facts or any Action or Proceeding then or theretofore existing, or any Action or Proceeding thereafter brought or threatened based in whole or in part on any such state of facts. If any provision of this Article IV shall be found to be invalid or limited in application by reason of any law or regulation, it shall not affect the validity of the remaining provisions hereof. The rights of indemnification and advancement of expenses provided in this Article IV shall neither be exclusive of, nor be deemed in limitation of, any rights to which any person may otherwise be or become entitled or permitted by contract, the certificate of incorporation of this Corporation, these Bylaws, vote of stockholders or directors or otherwise, or as a matter of law, both as to actions in such person's official capacity and actions in any other capacity, it being the policy of the Corporation that indemnification of, and advancement of expenses to, any person whom the Corporation is obligated to indemnify or advance expenses pursuant to this Article IV hereof shall be made to the fullest extent permitted by law.

This Article IV shall not limit the right of the Corporation, to the extent and in the manner permitted by law, to indemnify and to advance expenses to, and purchase and maintain insurance on behalf of, persons other than persons described in Article IV, Section 1 of these Bylaws.

Section 9. For purposes of this Article IV, references to "fines" shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to "serving at the request of the Corporation" shall include any service as a director, officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries.

ARTICLE V

CORPORATE BOOKS

The books of the Corporation may be kept inside or outside of the State of Delaware at such place or places as the Board may from time to time determine.

ARTICLE VI

CHECKS, NOTES, PROXIES, ETC.

All checks and drafts on the Corporation's bank accounts and all bills of exchange and promissory notes, and all acceptances, obligations and other instruments for the payment of money, shall be signed by such officer or officers or agent or agents as shall be authorized from time to time by the Board or such officer or officers who may be delegated such authority. Proxies to vote and consents with respect to securities of other corporations owned by or standing in the name of the Corporation may be executed and delivered from time to time on behalf of the Corporation by the Chair of the Board, the Chief Executive Officer, or by such officers as the Chair of the Board, the Chief Executive Officer or the Board may from time to time determine.

ARTICLE VII

FISCAL YEAR

The fiscal year of the Corporation shall end on June 30, or at such other time as the Board may determine by resolution.

ARTICLE VIII

STOCK CERTIFICATES, CORPORATE SEAL

Shares of the Corporation's capital stock may be certificated or uncertificated, as provided under the laws of the State of Delaware. Any corporate seal shall have inscribed thereon the name of the Corporation. In lieu of the corporate seal, when so authorized by the Board or a duly empowered committee thereof, a facsimile thereof may be impressed or affixed or reproduced.

ARTICLE IX

FORUM FOR ADJUDICATION OF CERTAIN DISPUTES

Unless the Corporation consents in writing to the selection of an alternative forum (an "Alternative Forum Consent"), the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer, stockholder, employee or agent of the Corporation to the Corporation or the Corporation's stockholders, (iii) any action asserting a claim against the Corporation or any director, officer, stockholder, employee or agent of the Corporation arising out of or relating to any provision of the DGCL or the Corporation's Certificate of Incorporation or these Bylaws (in each case, as amended from time to time), or (iv) any action asserting a claim against the Corporation or any director, officer, stockholder, employee or agent of the Corporation governed by the internal affairs doctrine of the State of Delaware; provided, however, that (i) in the event the Court of Chancery of the State of Delaware lacks subject matter jurisdiction over any such action or proceeding or personal jurisdiction over an indispensable party named as a defendant therein, the sole and exclusive forum for such action or proceeding shall be another state court located in the State of Delaware and (ii) in the event no state court in the State of Delaware has subject matter jurisdiction over such action or proceeding and personal jurisdiction over the indispensable parties named as defendants therein, the sole and exclusive forum for such action or proceeding shall be a federal court located in the State of Delaware. Any person or entity purchasing or otherwise acquiring any interest in or shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article IX. The existence of any prior Alternative Forum

Consent shall not act as a waiver of the Corporation's ongoing consent right as set forth above in this Article IX with respect to any current or future actions or claims.

ARTICLE X

AMENDMENTS Single Trade Plans

These Bylaws 18. During any 12-month period, a covered person may be made, amended, altered, changed, added only enter into one Rule 10b5-1 Plan that is designed to or repealed at any meeting of effect the Board purchase or of the stockholders; provided, in the case of a meeting of the stockholders, that notice of the proposed change was given in the notice of the meeting of the stockholders; provided further, that notwithstanding any other provisions of these Bylaws or any provision of law which might otherwise permit a lesser vote of the stockholders, the affirmative vote of the holders of at least 66 2/3% of the voting power of all the then outstanding shares of stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required for the stockholders to make, amend, alter, change, add to or repeal any provision of these Bylaws.

Adopted May 17, 2013

Amended and Restated December 4, 2015

Amended and Restated October 24, 2019

Amended and Restated January 20, 2022

Amended and Restated August 10, 2023

15

RESTRICTED STOCK UNIT AGREEMENT

Participant:

[Participant Name]

Grant Date:

[Grant Date]

Number of Award Shares:

[Number of Awards Granted]

Vesting Schedule:

1/3rd of Award Shares vest on each of the first, second and third anniversaries of Grant Date

This Restricted Stock Unit Agreement (the "Award Agreement") evidences the grant to the Participant by Premier, Inc. (the "Company") of the right to receive shares the Company's Class A common stock, \$0.01 par value ("Shares"), upon the terms and conditions provided for herein under

the Amended and Restated Premier, Inc. 2013 Equity Incentive Plan, as amended (the "Plan"). Except as specifically set forth herein, the rights granted under this Award Agreement (the "Award") are expressly subject to all of the terms, definitions, and provisions of the Plan. Capitalized terms in this Award Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

1. Grant of Restricted Stock Units. Subject to the terms and provisions of this Award Agreement and the Plan, the Company hereby grants to the Participant the right to receive the number of Shares set forth above (the "Award Shares") in one-third increments on each of the first, second and third anniversaries of Grant Date.

2. Terms and Conditions. The terms, conditions, and restrictions applicable to this Award are specified in the Plan and this Award Agreement, including Exhibit A – Section 280G Rules, and summarized in the Plan prospectus and any applicable prospectus supplement (together, the "Prospectus"). The terms, conditions and restrictions in the Plan include, but are not limited to, provisions relating to amendment, vesting, cancellation, and settlement, all of which are hereby incorporated by reference into this Award Agreement to the extent not otherwise set forth herein.

By accepting the Award, the Participant acknowledges receipt of the Prospectus and that he or she has read and understands the Prospectus. The Prospectus summarizes the material provisions of the Plan. The summary in the Prospectus is not complete and is qualified in its entirety by reference to the provisions of the Plan. You should consult the Plan and the terms of this Award Agreement for more complete information about this Award. The Plan and Award Agreement, in that order, shall govern any inconsistency between the Prospectus on the one hand, and the Plan and the Award Agreement on the other.

The Participant understands that this Award and all other incentive awards are entirely discretionary and that no right to receive an award exists absent a prior written agreement with the Company to the contrary. The Participant also understands that the value that may be realized, if any, from this Award is contingent, and depends on, the future market price of the Shares, among other factors. The Participant further confirms the Participant's understanding that this Award is intended to promote employee retention and stock ownership and to align employees' interests with those of shareholders, is subject to vesting conditions and will be cancelled if the vesting conditions are not satisfied. Thus, the Participant understands that (a) any monetary value assigned to this Award in any communication regarding this Award is contingent, hypothetical, or for illustrative purposes only, and does not express or imply any promise or intent by the Company to deliver, directly or indirectly, any certain or determinable cash value to the Participant; (b) receipt of this Award or any incentive award in the past is neither an indication nor a guarantee that an incentive award of any type or amount will be made in the future, and that absent a written agreement to the contrary, the Company is free to change its practices and policies regarding incentive awards at any time; and (c) vesting may be subject to confirmation and final determination by the Committee that the vesting conditions have been satisfied. The Participant shall have no rights as a stockholder of the Company with respect to any shares covered by this Award unless and until this Award is vested and settled in Shares.

3. Vesting. This Award shall vest in one-third increments on each of the first, second and third anniversaries of Grant Date set forth above, provided the Participant is continuously employed by a member of the Premier Group. Notwithstanding the foregoing:

(a) In the event that a Participant terminates employment due to being a Good Leaver (as defined below) prior to the third anniversary of Grant Date, the Participant shall immediately vest in a portion of the Award equal to the number of Award Shares outstanding times a fraction, the numerator of which is the number of days of active service elapsed since the immediately preceding anniversary of Grant Date or, if the first anniversary of Grant Date has not lapsed, the Grant Date, and the denominator of which is: (i) 1,095 if the termination is prior to the first anniversary of Grant Date; (ii) 730 if the termination is between the first and second anniversaries of Grant Date; or (iii) 365 if the termination is after the second anniversary of Grant Date. A Participant is a "Good Leaver" on account of (i) terminating employment with the Premier Group due to death, Disability or an Approved Retirement (as defined in Section 14 below) or (ii) the termination of the Participant's employment with the Premier Group Without Cause (as defined in Section 14 below) prior to a Change in Control; and

(b) In the event a member of the Premier Group (or a successor) terminates the Participant's employment Without Cause or the Participant terminates his employment for Good Reason (as defined in Section 14 below) within the twelve month period commencing upon a Change in Control (as defined in the Plan), the Award shall vest in full.

The Participant shall be credited with an amount in cash (without interest) equal to the dividends the Participant would have received if the Participant had been the owner of a number of Shares equal to the number of Award Shares; provided, however, that no amount shall be credited with respect to Shares that have been delivered to the Participant as of the applicable record date. Dividend equivalents shall be subject to the same terms and conditions as the Award Shares, and shall vest (or, if applicable, be forfeited) at the same time as the Award Shares. Notwithstanding the foregoing, nothing in this Award Agreement shall be interpreted to require the Company to grant dividends or dividend equivalents on any Shares or Award Shares.

4. Forfeiture; Break in Service. The unvested portion of this Award, determined after first applying Section 3 above, shall expire and be permanently forfeited upon employment termination with the Premier Group.

5. Settlement of Award. Subject to Section 7 below, the Company shall deliver or cause to be delivered to or on the behalf of the Participant the number of Award Shares as soon as administratively practicable after becoming vested under Section 3, but in no event later than

sixty (60) days after such date. The dividend equivalents corresponding to Award Shares that vest as described in Section 3 above shall be paid in cash at the same time as the delivery of such Shares under this Section 5. Vested Shares to be delivered due to death shall be paid to the Participant's Beneficiary designated according to the terms of the Plan.

6. **Compliance with Certain Obligations; Compensation Recovery.** The Award Shares shall be subject to forfeiture as a result of the Participant's violation of any obligations contained in any agreement between the Company and the Participant relating to non-competition, non-interference, non-solicitation and confidentiality (the "Employment Obligations"), and shall be subject to being recovered under any compensation recovery policy that may be adopted from time to time by the Company or any of its Affiliates. For avoidance of doubt, compensation recovery rights to Award Shares shall extend to the proceeds realized by the Participant due to the sale or other transfer of the Award Shares. The Participant's prior execution total amount of agreements containing the Employment Obligations and confirmation of such obligations was a material inducement for the Company's grant of the Award under this Award Agreement.

7. **Taxes; Limitation on Excess Parachute Payments.** The settlement of this Award is conditioned on the Participant making arrangements reasonably satisfactory to the Company for the withholding of all applicable federal, state, local or foreign taxes as may be required under applicable law. The Participant shall bear all expense of, and be solely responsible for, all federal, state, local or foreign taxes due with respect to any payment received under this Award Agreement. The Committee, in its sole discretion, may satisfy the Participant's withholding tax obligations by reducing the number of Award Shares to which the Participant is entitled under the Award. Notwithstanding any other provision in this Award Agreement to the contrary, any payment or benefit received or to be received securities covered by the Participant Rule 10b5-1 Plan in a single transaction; provided, however, a covered person may have in place an additional non-concurrent single-trade Rule 10b5-1 Plan during this same 12-month period in connection with a Change in Control or the termination of employment (whether payable under the terms of this Award Agreement or any other plan, arrangement or agreement with a member of the Premier Group (collectively, the "Payments") that would constitute a "parachute payment" within the meaning of Section 280G of the Code, shall be reduced sell-to-cover transactions as necessary to satisfy tax withholding obligations incident to the extent necessary so that no portion thereof shall be subject to vesting of a compensatory award from the excise tax imposed by Section 4999 of Company such as restricted stock, restricted stock units or stock appreciation rights and where the Code (the "Excise Tax"), but only if, by reason covered person does not control the timing of such reduction, the net after-tax benefit received by the Participant shall exceed the net after-tax benefit that would be received by the Participant if no such reduction was made. Whether and how the limitation under this Section 7 is applicable shall be determined under the Section 280G Rules set forth in Exhibit A, which shall be enforceable as if set forth in this Award Agreement.

8. **Consent to Electronic Delivery.** In lieu of receiving documents in paper format, the Participant agrees, to the fullest extent permitted by law, to accept electronic delivery of any documents that the Company may be required to deliver (including, but not limited to, prospectuses, prospectus supplements, grant or award notifications and agreements, account statements, annual and quarterly reports, and all other agreements, forms and communications) in connection with this and any other prior or future incentive award or program made or offered by the Company or its predecessors or successors. Electronic delivery of a document to the Participant may be via a Company e-mail system or by reference to a location on a Company intranet site to which the Participant has access.

Suspensions

9.19. **Administration.** In administering the Each Rule 10b5-1 Plan or to comply with applicable used by a covered person must provide for suspension of transactions under such plan if legal, regulatory, tax, or accounting requirements, it may be necessary for a member of contractual restrictions are imposed on the Premier Group to transfer certain Participant data to another member of the Premier Group, or to its outside service providers or governmental agencies. By accepting the Award, the Participant consents, to the fullest extent permitted by law, to the use and transfer, electronically or otherwise, of the Participant's personal data to such entities for such purposes.

10. **Entire Agreement/Amendment/Survival/Assignment.** The terms, conditions and restrictions set forth in the Plan and this Award Agreement constitute the entire understanding between the parties hereto regarding this Award and supersede all previous written, oral, or implied understandings between the parties hereto about the subject matter hereof. This Award Agreement may be amended by a subsequent writing (including e-mail covered person, or other electronic form) agreed events occur, that would prohibit transactions under such plan.

Compliance with Rule 144

20. Executive officers and directors are responsible for compliance with Rule 144 under the Securities Act of 1933, as amended, including the filing of Form 144, as relating to between the Company and the Participant. Section headings herein are for convenience only and have no effect on the interpretation of this Award Agreement. The provisions of this Award Agreement that are intended to survive the Participant's termination of employment shall survive such date. The Company may assign this Award Agreement and its rights and obligations hereunder to any current or future member of the Premier Group.

11. **No Right to Employment.** The Participant agrees that nothing in this Award Agreement constitutes a contract of employment with a member of the Premier Group for a definite period of time. The employment relationship is "at will," which affords the Participant or a member of the Premier Group the right to terminate the relationship at any time for any reason or no reason not otherwise prohibited by applicable law. The Premier Group retains the right to decrease the Participant's compensation and/or benefits, transfer or demote the Participant or otherwise change the terms or conditions of the Participant's employment.

12. **Transfer Restrictions.** The Participant may not sell, assign, transfer, pledge, encumber or otherwise alienate, hypothecate or dispose of this Award or the Participant's right hereunder to receive Award Shares, except as otherwise provided in the Committee's sole discretion consistent with the Plan and applicable securities laws.

13. **Conflict.** This Award Agreement is subject to the terms and provisions of the Plan, including but not limited to the adjustment provisions under Section 12 of the Plan. In the event of a conflict between the Plan and this Award Agreement, the Plan shall control.

14. **Definitions.** For purposes of this Award Agreement, the following terms shall be as defined below:

(a) **"Approved Retirement"** shall mean a Participant's voluntary resignation from the Premier Group on or after attaining age 59 ½ or age 55 with 5 or more years of service; provided that prior to such employment termination, the Participant has: (i) given the Company's Chief Human Resources Officer (or such person performing a similar function) ("CHRO") or the Participant's immediate supervisor at least three months' prior written notice (or such shorter period of time approved in writing by the CHRO or the Participant's immediate supervisor) of the Participant's intended retirement date; and (ii) completed transition duties and responsibilities as determined by the CHRO and/or the Participant's immediate supervisor during the notice period in a satisfactory manner, as reasonably determined by either of them, their Rule 10b5-1 Plans.

(b) **"Just Cause"** means termination Approved Brokers; Broker Obligation to Provide Notice of the Participant's employment with the Premier Group by a member of the Premier Group as a result of conduct by the Participant amounting to: (i) commission or omission of any act of dishonesty, moral turpitude, fraud, embezzlement, theft, misappropriation, breach of fiduciary duty, or breach of the duty of loyalty in connection with the Participant's employment with a Premier Group member or against any Premier Group partner hospital, affiliated health care organization or customer; (ii) willful misconduct, insubordination, or repeated refusal or unwillingness to follow the reasonable directives of the Board of Directors / Managers of a Premier Group member and/or the Participant's Premier Group employer, the Chief Executive Officer of the Participant's Premier Group employer, or the Participant's immediate supervisor(s); (iii) willful action or inaction with respect to the Participant's performance of his or her employment duties that constitutes a violation of law or governmental regulations or that causes a Premier Group member to violate such law or regulation; (iv) a material breach of any securities or other law or regulation or any Premier Group policy governing inappropriate disclosures or "tipping" related to (or the trading or dealing of) securities, stock or investments; (v) excessive absenteeism not related to authorized sick leave, authorized family/medical leave, authorized disability leave, authorized vacation, authorized military leave or other authorized statutory leave within the parameters set forth in accordance with Premier Group policies and procedures regarding the same; (vi) a conviction, guilty plea or plea of nolo contendere by the Participant for any crime involving moral turpitude or dishonesty or for any felony; (vii) material breach or violation of the terms of employment or other agreements to which the Participant and one or more members of the Premier Group are party; or (viii) breach or violation of material policies, rules, procedures or instructions of a Premier Group member.

For purposes of this definition only, no act or failure to act by a Participant shall be deemed "willful" if done or omitted to be done by the Participant in good faith and with the reasonable belief that the Participant's act or omission was in the best interest of the Premier Group and consistent with Premier Group policies and applicable law. Further, any act or failure to act based on and consistent with (a) instructions pursuant to a resolution duly adopted by the Board of Directors / Managers of a Premier Group member, (b) instructions of the applicable Board Chair as authorized by such Boards, or (c) the advice of Premier Group counsel shall be presumed to be done or omitted to be done by the Participant in good faith and in the best interests of the Premier Group.

(c) **"Disability"** means any of the following: (i) the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of at least twelve months, or the Participant's entitlement to and receipt of disability benefits under a disability insurance program that pays benefits on the basis of the foregoing definition; (ii) the Participant is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of at least twelve months, receiving either (a) income replacement benefits for a period of at least three months under an accident and health plan covering employees of the Participant's Premier Group employer, or (b) disability benefits under a disability insurance program that pays

benefits on the basis of the foregoing definition; or (iii) the Participant is determined to be totally disabled by the Social Security Administration or Railroad Retirement Board.

(d) **"Good Reason"** means a Participant's resignation of employment from the Premier Group due to: (i) a material reduction of the Participant's base salary without the Participant's consent; (ii) a material reduction in the Participant's authority, duties or responsibilities without the Participant's consent, but excluding any such reductions made in good faith to conform with applicable law or accounting/public company standards; or (iii) a relocation of the Participant to a location outside a fifty (50) mile radius of the Participant's primary office location. In all instances, a Participant must provide the Chair of the Board of Directors / Managers of the Participant's Premier Group employer (in the case of the CEO) or the CEO of the Participant's Premier Group employer (in the case of other Participants) written notice of the asserted instances constituting "Good Reason" within ninety (90) calendar days of the initial existence of the condition(s). Further, "Good Reason" shall not mean or include resignation by a Participant for conditions (i) – (iii) if cured or remedied by the appropriate Premier Group member(s) within thirty (30) calendar days of receiving the Participant's notice.

(e) **"Premier Group"** shall mean the Company, its Subsidiaries and Affiliates.

(f) **"Without Cause"** means a termination of the Participant's employment with the Premier Group by a member of the Premier Group for a reason other than death, Disability or for Just Cause.

15. **Section 409A.** This Award Agreement will be construed to comply, and administered in compliance, with Section 409A of the Code. Notwithstanding anything in this Award Agreement to the contrary, if as of employment termination the Participant is a "specified employee" as defined under the Company's 409A specified employee policy in effect on the Grant Date and the deferral of any payment otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section 409A of the Code, then the Company will defer commencement of any such payments hereunder (without any reduction in such payments or benefits ultimately paid or provided to the Participant) until the first business day of the seventh month following employment termination (or the earliest date as is permitted under Section 409A of the Code). For purposes of Section 409A of the Code and the payment provisions of this Agreement (including without limitation Section 5), references herein to "employment termination", "termination of employment" or the like refer shall refer to the Participant's separation from service with the entity employing the Participant on the Grant Date (the "Employer") within the meaning of Section 409A after applying a 20% ownership test for purposes of determining who is the service recipient and employer under Treas. Reg. Sect. 1.409A-1(h)(3) and the presumptions under Treas. Reg. Sect. 1.409A-1(h)(1)(ii). For avoidance of doubt, a Participant who remains employed with the Employer does not incur a separation from service solely because the Company at a later time no longer holds a direct or indirect 20% ownership interest in the Employer.

16. **Nature of Award.** This Award represents the Company's unfunded and unsecured promise to issue Shares at a future date, subject to the terms of this Award Agreement and the Plan. The Participant has no rights under this Agreement other than the rights of a general

unsecured creditor of the Company. The Participant shall have the rights of a shareholder with respect to the Award Shares only to the extent that Shares are issued to the Participant in accordance with the terms and conditions of this Award Agreement and the Plan.

17. **Governing Law.** This Award Agreement shall be legally binding and shall be executed and construed and its provisions enforced and administered in accordance with the laws of the State of Delaware without regard to the principles of conflicts of law thereunder.

Trades

Exhibit A21. —Section 280G Rules

To Restricted Stock Unit Agreement

When you receive benefits in connection Rule 10b5-1 Plans must be entered into with a Change in Control

The following rules shall apply for purposes of determining whether and how the limitations provided under Section 7 brokers that are applicable to the Participant.

1. The "net after-tax benefit" shall mean (i) the Payments (as defined in Section 7) which the Participant receives or is then entitled to receive from the Company or an Affiliate that would constitute "parachute payments" within the meaning of Section 280G of the Code, less (ii) the amount of all federal, state and local income and employment taxes payable approved by the Participant with respect to General Counsel or his/her designee, which he/she may accept or reject in his/her sole discretion based on factors he/she considers relevant, and which may include, without limitation, whether the foregoing calculated at the highest marginal income tax rate for each year in which the foregoing shall be paid to the Participant (based on the rate in effect for such year as set forth in the Code as in effect at the time of the first payment of the foregoing), less (iii) the amount of Excise Tax imposed with respect to the payments and benefits described in (i) above.

2. All determinations under Section 7 of this Award Agreement and this Exhibit A will be made by an accounting firm or law firm that is selected for this purpose Rule 10b5-1 Plan used by the Company's Chief Executive Officer prior to a Change in Control (the "280G Firm"). All fees and

expenses of the 280G Firm shall be borne by the Company. The Company will direct the 280G Firm to submit any determination it makes under Section 7 of this Award Agreement and this Exhibit A and detailed supporting calculations to both the Participant and the Company as soon as reasonably practicable.

3. If the 280G Firm determines that one or more reductions are required under Section 7 of this Award Agreement, the 280G Firm shall also determine which Payments shall be reduced (first from cash payments and then from non-cash benefits) to the extent necessary so that no portion thereof shall be subject to the excise tax imposed by Section 4999 of the Code, and the Company shall pay such reduced amount to the Participant. The 280G Firm shall make reductions required under Section 7 of this Award Agreement in a manner that maximizes the net after-tax amount payable to the Participant.

4. As a result of the uncertainty in the application of Section 280G at the time that the 280G Firm makes its determinations under this Section, it is possible that amounts will have been paid or distributed to the Participant that should not have been paid or distributed (collectively, the "Overpayments"), or that additional amounts should be paid or distributed to the Participant (collectively, the "Underpayments"). If the 280G Firm determines, based on either the assertion of a deficiency by the Internal Revenue Service against the Company or the Participant, which assertion the 280G Firm believes has a high probability of success or controlling precedent or substantial authority, that an Overpayment has been made, the Participant must repay to the Company, without interest; provided, however, that no loan will be deemed to have been made and no amount will be payable by the Participant to the Company unless, and then only to the extent that, the deemed loan and payment would either reduce the amount on which the Participant is subject to tax under Section 4999 of the Code or generate a

refund of tax imposed under Section 4999 of the Code. If the 280G Firm determines, based upon controlling precedent or substantial authority, that an Underpayment has occurred, the 280G Firm will notify the Participant and the Company of that determination and the amount of that Underpayment will be paid to the Participant promptly by the Company.

5. The Participant will provide the 280G Firm access to, and copies of, any books, records, and documents in the Participant's possession as reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by Section 7 of this Award Agreement and this Exhibit A.

SPECIAL RETENTION RESTRICTED STOCK UNIT AGREEMENT

Participant:

[Participant Name]

Grant Date:

[Grant Date]

Number of Award Shares:

[Number of Awards Granted]

Vesting Dates:

1/3rd of Award Shares vest on each of the first, second and third anniversaries of Grant Date

This Special Retention Restricted Stock Unit Agreement (the "Award Agreement") evidences the grant to the Participant by Premier, Inc. (the "Company") of the right to receive shares of the Company's Class A common stock, \$0.01 par value ("Shares"), upon the terms and conditions provided for herein under the Amended and Restated Premier, Inc. 2013 Equity Incentive Plan, as amended (the "Plan"). Except as specifically set forth herein, the rights granted under this Award Agreement (the "Award") are expressly subject to all of the terms, definitions, and provisions of the Plan. Capitalized terms in this Award Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

1. Grant of Restricted Stock Units. Subject to the terms and provisions of this Award Agreement and the Plan, the Company hereby grants to the Participant the right to receive the number of Shares set forth above (the "Award Shares") in one-third increments on each of the first, second and third anniversaries of Grant Date.

2. Terms and Conditions. The terms, conditions, and restrictions applicable to this Award are specified in the Plan and this Award Agreement, including Exhibit A – Section 280G Rules, and summarized in the Plan prospectus and any applicable prospectus supplement (together, the "Prospectus"). The terms, conditions and restrictions in the Plan include, but are not limited to, provisions relating to amendment, vesting, cancellation, and settlement, all of which are hereby incorporated by reference into this Award Agreement to the extent not otherwise set forth herein.

By accepting the Award, the Participant acknowledges receipt of the Prospectus and that he or she has read and understands the Prospectus. The Prospectus summarizes the material provisions of the Plan. The summary in the Prospectus is not complete and is qualified in its

entirely by reference to the provisions of the Plan. You should consult the Plan SEC rules and the terms of this Award Agreement for more complete information about Policy, and whether the broker processes and procedures are compliant with this Award. The Plan Policy and Award Agreement, in that order, shall govern any inconsistency between the Prospectus on the one hand, and the Plan and the Award Agreement on the other.

The Participant understands that this Award and all other incentive awards are entirely discretionary and that no right to receive an award exists absent a prior written agreement consistent with the Company Company's processes and procedures relating to the contrary. The Participant also understands that the value that may be realized, if any, from this Award is contingent, execution, recording and depends on, the future market price reporting of the Shares, among other factors. The Participant further confirms the Participant's understanding that this Award is intended to promote employee retention and stock ownership and to align employees' interests with those of shareholders, is subject to vesting conditions and will be cancelled if the vesting conditions are not satisfied. Thus, the Participant understands that (a) any monetary value assigned to this Award in any communication regarding this Award is contingent, hypothetical, or for illustrative purposes only, and does not express or imply any promise or intent by the Company to deliver, directly or indirectly, any certain or determinable cash value to the Participant; (b) receipt of this Award or any incentive award in the past is neither an indication nor a guarantee that an incentive award of any type or amount will be made in the future, and that absent a written agreement to the contrary, the Company is free to change its practices and policies regarding incentive awards at any time; and (c) vesting may be subject to confirmation and final determination by the Committee that the vesting conditions have been satisfied. The Participant shall have no rights as a stockholder of the Company with respect to any shares covered by this Award unless and until this Award is vested and settled in Shares.

3. **Vesting.** This Award shall vest in one-third increments on each of the first, second and third anniversaries of Grant Date set forth above, provided the Participant is continuously employed by a member of the Premier Group. Notwithstanding the foregoing:

4. (a) In the event that a Participant terminates employment due to being a Good Leaver (as defined below) prior to the third anniversary of Grant Date, the Participant shall immediately vest in a portion of the Award equal to the number of Award Shares outstanding times a fraction, the numerator of which is the number of days of active service elapsed since the immediately preceding anniversary of Grant Date or, if the first anniversary of Grant Date has not lapsed, the Grant Date, and the denominator of which is: (i) 1,095 if the termination is prior to the first anniversary of Grant Date; (ii) 730 if the termination is between the first and second anniversaries of Grant Date; or (iii) 365 if the termination is after the second anniversary of Grant Date. A Participant is a "Good Leaver" on account of (i) terminating employment with the Premier Group due to death, Disability or an Approved Retirement (as defined in Section 14 below) or (ii) the termination of the Participant's employment with the Premier Group Without Cause (as defined in Section 14 below) prior to a Change in Control; and

(b) In the event of a Change in Control (as defined in the Plan) or the sale or other disposition of an operating unit within the Premier Group, as determined in the sole discretion of the Committee, 100% of the Award Shares shall become vested, provided the Participant is continuously employed by a member of the Premier Group up until any such event.

The Participant shall be credited with an amount in cash (without interest) equal to the dividends the Participant would have received if the Participant had been the owner of a number of Shares equal to the number of Award Shares; provided, however, that no amount shall be credited with respect to Shares that have been delivered to the Participant as of the applicable record date. Dividend equivalents shall be subject to the same terms and conditions as the Award Shares, and shall vest (or, if applicable, be forfeited) at the same time as the Award Shares. Notwithstanding the foregoing, nothing in this Award Agreement shall be interpreted to require the Company to grant dividends or dividend equivalents on any Shares or Award Shares.

5. **Forfeiture; Break in Service.** The unvested portion of this Award, determined after first applying Section 3 above, shall expire and be permanently forfeited upon employment termination with the Premier Group, securities transactions.

6.22. **Settlement Without limitation of Award.** Subject the foregoing, executive officers and directors are responsible for ensuring that their broker will provide notice of any transactions under the Rule 10b5-1 Plan to Section 7 below, the covered person and the Company shall deliver or cause to be delivered to or promptly after close of trading markets on the behalfday of the Participant the number of Award Shares as soon as administratively practicable after becoming vested under Section 3, but in no event later than sixty (60) days after such date. The dividend equivalents corresponding to Award Shares that vest as described in Section 3 above shall be paid in cash at the same time as the delivery of such Shares under this Section 5. Vested Shares to be delivered due to death shall be paid to the Participant's Beneficiary designated according to the terms of the Plan.

7. **Compliance with Certain Obligations; Compensation Recovery.** The Award Shares shall be subject to forfeiture as a result of the Participant's violation of any obligations contained in any agreement between the Company and the Participant relating to non-competition, non-interference, non-solicitation and confidentiality (the "Employment Obligations"), and shall be subject to being recovered under any compensation recovery policy that may be adopted from time to time by the Company or any of its Affiliates. For avoidance of doubt, compensation recovery rights to Award Shares shall extend to the proceeds realized by the Participant due to the sale or other transfer of the Award Shares. The Participant's prior execution of agreements containing the Employment Obligations and confirmation of such obligations was a material inducement for the Company's grant of the Award under this Award Agreement.

8. **Taxes; Limitation on Excess Parachute Payments.** The settlement of this Award is conditioned on the Participant making arrangements reasonably satisfactory to the Company for the withholding of all applicable federal, state, local or foreign taxes as may be required under applicable law. The Participant shall bear all expense of, and be solely responsible for, all federal, state, local or foreign taxes due with respect to any payment received under this Award Agreement. The Committee, in its sole discretion, may satisfy the Participant's withholding tax obligations by reducing the number of Award Shares to which the Participant is entitled under the Award. Notwithstanding any other provision in this Award Agreement to the contrary, any payment or benefit received or to be received by the Participant in connection with a Change in Control or the termination of employment (whether payable under the terms of this Award Agreement or any other plan, arrangement or agreement with a member of the Premier Group (collectively, the "Payments") that would constitute a "parachute payment" within the meaning of Section 280G of the Code, shall be reduced to the extent necessary so that no portion thereof shall be subject to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), but only if, by reason of such reduction, the net after-tax benefit received by the Participant shall exceed the net after-tax benefit that would be received by the Participant if no such reduction was made. Whether and how the limitation under this Section 7 is applicable shall be determined under the Section 280G Rules set forth in Exhibit A, which shall be enforceable as if set forth in this Award Agreement.

9. **Consent to Electronic Delivery.** In lieu of receiving documents in paper format, the Participant agrees, to the fullest extent permitted by law, to accept electronic delivery of any documents that the Company may be required to deliver (including, but not limited to, prospectuses, prospectus supplements, grant or award notifications and agreements, account statements, annual and quarterly reports, and all other agreements, forms and communications) in connection with this and any other prior or future incentive award or program made or offered by transaction.

the Company or its predecessors or successors. Electronic delivery of a document **Insider Obligation** **to the Participant may be via a Company e-mail system or by reference to a location on a Company intranet site to which the Participant has access. Make Exchange Act Filings**

10. **Administration.** In administering Covered persons are responsible for making all filings required by the Plan, or Exchange Act to comply with applicable legal, regulatory, tax, or accounting requirements, it may be necessary for a member of the Premier Group to transfer certain Participant data to another member of the Premier Group, or to its outside service providers or governmental agencies. By accepting the Award, the Participant consents, to the fullest extent permitted by law, to the use and transfer, electronically or otherwise, of the Participant's personal data to such entities for such purposes.

11. **Entire Agreement/Amendment/Survival/Assignment.** The terms, conditions and restrictions set forth in the Plan and this Award Agreement constitute the entire understanding between the parties hereto regarding this Award and supersede all previous written, oral, or implied understandings between the parties hereto about the subject matter hereof. This Award Agreement may be amended by a subsequent writing (including e-mail or other electronic form) agreed to between the Company and the Participant. Section headings herein are for convenience only and have no effect on the interpretation of this Award Agreement. The provisions of this Award Agreement that are intended to survive the Participant's termination of employment shall survive such date. The Company may assign this Award Agreement and its rights and obligations hereunder to any current or future member of the Premier Group.

12. **No Right to Employment.** The Participant agrees that nothing in this Award Agreement constitutes a contract of employment with a member of the Premier Group for a definite period of time. The employment relationship is "at will," which affords the Participant or a member of the Premier Group the right to terminate the relationship at any time for any reason or no reason not otherwise prohibited by applicable law. The Premier Group retains the right to decrease the Participant's compensation and/or benefits, transfer or demote the Participant or otherwise change the terms or conditions of the Participant's employment.

13. **Transfer Restrictions.** The Participant may not sell, assign, transfer, pledge, encumber or otherwise alienate, hypothecate or dispose of this Award or the Participant's right hereunder to receive Award Shares, except as otherwise provided in the Committee's sole discretion consistent with the Plan and applicable securities laws.

14. **Conflict.** This Award Agreement is subject to the terms and provisions of the Plan, including but not limited to the adjustment provisions **report transactions** under Section 12 of the Plan. In the event of a conflict between the Plan and this Award Agreement, the Plan shall control.

15. **Definitions.** For purposes of this Award Agreement, the following terms shall be as defined below:

(a) **"Approved Retirement"** shall mean a Participant's voluntary resignation from the Premier Group on or after attaining age 59 ½ or age 55 with 5 or more years of service; provided that prior to such employment termination, the Participant has: (i) given the Company's Chief Human Resources Officer (or such person performing a similar function) ("CHRO") or the Participant's immediate supervisor at least three months' prior written notice (or such shorter **Rule 10b5-1 Plans**).

period of time approved in writing by the CHRO or the Participant's immediate supervisor) of the Participant's intended retirement date; Required Footnote Disclosure

24. **Executive officers and (ii) completed transition duties** **directors must footnote all trades disclosed on Form 144 and responsibilities as determined by the CHRO and/or the Participant's immediate supervisor during the notice period in a satisfactory manner, as reasonably determined by either of them.**

(b) "Just Cause" means termination of the Participant's employment comply with the Premier Group by a member of the Premier Group as a result of conduct by the Participant amounting to: (i) commission or omission of any act of dishonesty, moral turpitude, fraud, embezzlement, theft, misappropriation, breach of fiduciary duty, or breach of the duty of loyalty in connection with the Participant's employment with a Premier Group member or against any Premier Group partner hospital, affiliated health care organization or customer; (ii) willful misconduct, insubordination, or repeated refusal or unwillingness checkbox requirement on Form 4 to follow the reasonable directives of the Board of Directors / Managers of a Premier Group member and/or the Participant's Premier Group employer, the Chief Executive Officer of the Participant's Premier Group employer, or the Participant's immediate supervisor(s); (iii) willful action or inaction with respect to the Participant's performance of his or her employment duties that constitutes a violation of law or governmental regulations or that causes a Premier Group member to violate such law or regulation; (iv) a material breach of any securities or other law or regulation or any Premier Group policy governing inappropriate disclosures or "tipping" related to (or the trading or dealing of) securities, stock or investments; (v) excessive absenteeism not related to authorized sick leave, authorized family/medical leave, authorized disability leave, authorized vacation, authorized military leave or other authorized statutory leave within the parameters set forth in accordance with Premier Group policies and procedures regarding the same; (vi) a conviction, guilty plea or plea of nolo contendere by the Participant for any crime involving moral turpitude or dishonesty or for any felony; (vii) material breach or violation of the terms of employment or other agreements to which the Participant and one or more members of the Premier Group are party; or (viii) breach or violation of material policies, rules, procedures or instructions of a Premier Group member.

For purposes of this definition only, no act or failure to act by a Participant shall be deemed "willful" if done or omitted to be done by the Participant in good faith and with the reasonable belief indicate that the Participant's act or omission was in the best interest of the Premier Group and consistent with Premier Group policies and applicable law. Further, any act or failure to act based on and consistent with (a) instructions trades were made pursuant to a resolution duly adopted by the Board of Directors / Managers of a Premier Group member, (b) instructions of the applicable Board Chair as authorized by such Boards, or (c) the advice of Premier Group counsel shall be presumed to be done or omitted to be done by the Participant in good faith and in the best interests of the Premier Group.

(c) "Disability" means any of the following: (i) the Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of at least twelve months, or the Participant's entitlement to and receipt of disability benefits under a disability insurance program that pays benefits on the basis of the foregoing definition; (ii) the Participant is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous Rule 10b5-1 Plan.

period of at least twelve months, receiving either (a) income replacement benefits for a period of at least three months under an accident Where to Go with Questions and health plan covering employees of the Participant's Premier Group employer, or (b) disability benefits under a disability insurance program that pays benefits on the basis of the foregoing definition; or (iii) the Participant is determined to be totally disabled by the Social Security Administration or Railroad Retirement Board. Concerns

(d) "Good Reason" means a Participant's resignation of employment from Contact the Premier Group due to: (i) a material reduction of the Participant's base salary without the Participant's consent; (ii) a material reduction in the Participant's authority, duties General Counsel with questions or responsibilities without the Participant's consent, but excluding any such reductions made in good faith to conform with applicable law or accounting/public company standards; or (iii) a relocation of the Participant to a location outside a fifty (50) mile radius of the Participant's primary office location. In all instances, a Participant must provide the Chair of the Board of Directors / Managers of the Participant's Premier Group employer (in the case of the CEO) or the CEO of the Participant's Premier Group employer (in the case of other Participants) written notice of the asserted instances constituting "Good Reason" within ninety (90) calendar days of the initial existence of the condition(s). Further, "Good Reason" shall not mean or include resignation by a Participant for conditions (i) – (iii) if cured or remedied by the appropriate Premier Group member(s) within thirty (30) calendar days of receiving the Participant's notice.

(e) "Premier Group" shall mean the Company, its Subsidiaries and Affiliates.

(f) "Without Cause" means a termination of the Participant's employment with the Premier Group by a member of the Premier Group for a reason other than death, Disability or for Just Cause.

16. Section 409A. This Award Agreement will be construed to comply, and administered in compliance, with Section 409A of the Code. Notwithstanding anything in concerns about this Award Agreement to the contrary, if as of employment termination the Participant is a "specified employee" as defined under the Company's 409A specified employee policy in effect on the Grant Date and the deferral of any payment otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section 409A of the Code, then the Company will defer commencement of any such payments hereunder (without any reduction in such payments or benefits ultimately paid or provided to the Participant) until the first business day of the seventh month following employment termination (or the earliest date as is permitted under Section 409A of the Code). For purposes of Section 409A of the Code and the payment provisions of this Agreement (including without limitation Section 5), references herein to "employment termination", "termination of employment" or the like refer shall refer to the Participant's separation from service with the entity employing the Participant on the Grant Date (the "Employer") within the meaning of Section 409A after applying a 20% ownership test for purposes of determining who is the service recipient and employer under Treas. Reg. Sect. 1.409A-1(h)(3) and the presumptions under Treas. Reg. Sect. 1.409A-1(h)(1)(ii). For avoidance of doubt, a Participant who remains employed with the Employer does not incur a separation from service solely Policy.

because the Company at a later time no longer holds a direct or indirect 20% ownership interest in the Employer.

17. Nature of Award. This Award represents the Company's unfunded and unsecured promise to issue Shares at a future date, subject to the terms of this Award Agreement and the Plan. The Participant has no rights under this Agreement other than the rights of a general unsecured creditor of the Company. The Participant shall have the rights of a shareholder with respect to the Award Shares only to the extent that Shares are issued to the Participant in accordance with the terms and conditions of this Award Agreement and the Plan.

18. Governing Law. This Award Agreement shall be legally binding and shall be executed and construed and its provisions enforced and administered in accordance with the laws of the State of Delaware without regard to the principles of conflicts of law thereunder.

Exhibit A—Section 280G Rules

To Restricted Stock Unit Agreement

When you receive benefits in connection with a Change in Control

The following rules shall apply for purposes of determining whether and how the limitations provided under Section 7 are applicable to the Participant.

1. The "net after-tax benefit" shall mean (i) the Payments (as defined in Section 7) which the Participant receives or is then entitled to receive from the Company or an Affiliate that would constitute "parachute payments" within the meaning of Section 280G of the Code, less (ii) the amount of all federal, state and local income and employment taxes payable by the Participant with respect to the foregoing calculated at the highest marginal income tax rate for each year in which the foregoing shall be paid to the Participant (based on the rate in effect for such year as set forth in the Code as in effect at the time of the first payment of the foregoing), less (iii) the amount of Excise Tax imposed with respect to the payments and benefits described in (i) above.

2. All determinations under Section 7 of this Award Agreement and this Exhibit A will be made by an accounting firm or law firm that is selected for this purpose by the Company's Chief Executive Officer prior to a Change in Control (the "280G Firm"). All fees and expenses of the 280G Firm shall be borne by the Company. The Company will direct the 280G Firm to submit any determination it makes under Section 7 of this Award Agreement and this Exhibit A and detailed supporting calculations to both the Participant and the Company as soon as reasonably practicable.

3. If the 280G Firm determines that one or more reductions are required under Section 7 of this Award Agreement, the 280G Firm shall also determine which Payments shall be reduced (first from cash payments and then from non-cash benefits) to the extent necessary so that no portion thereof shall be subject to the excise tax imposed by Section 4999 of the Code, and the Company shall pay such reduced amount to the Participant. The 280G Firm shall make reductions required under Section 7 of this Award Agreement in a manner that maximizes the net after-tax amount payable to the Participant.

4. As a result of the uncertainty in the application of Section 280G at the time that the 280G Firm makes its determinations under this Section, it is possible that amounts will have been paid or distributed to the Participant that should not have been paid or distributed (collectively, the "Overpayments"), or that additional amounts should be paid or distributed to the Participant (collectively, the "Underpayments"). If the 280G Firm determines, based on either the assertion of a deficiency by the Internal Revenue Service against the Company or the Participant, which assertion the 280G Firm believes has a high probability of success or controlling precedent or substantial authority, that an Overpayment has been made, the Participant must repay to the Company, without interest; provided, however, that no loan will be deemed to have been made and no amount will be payable by the Participant to the Company unless, and then only to the extent that, the deemed loan and payment would either reduce the amount on which the Participant is subject to tax under Section 4999 of the Code or generate a

refund of tax imposed under Section 4999 of the Code. If the 280G Firm determines, based upon controlling precedent or substantial authority, that an Underpayment has occurred, the 280G Firm will notify the Participant and the Company of that determination and the amount of that Underpayment will be paid to the Participant promptly by the Company.

5. The Participant will provide the 280G Firm access to, and copies of, any books, records, and documents in the Participant's possession as reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by Section 7 of this Award Agreement and this Exhibit A.

SUBSIDIARIES OF PREMIER, INC.
As of **August 22, 2023** **August 20, 2024**

<u>Name of Subsidiary</u>	<u>State/Province of Incorporation</u>
Premier Healthcare Solutions, Inc. (1)	Delaware
Premier Services II, LLC (2)	Delaware
Premier Healthcare Alliance, L.P. (3)	California
Premier Marketplace, LLC (4)	Delaware
Premier Supply Chain Holdings, LLC (4)	Delaware
Premier Supply Chain Improvement, Inc. (4)	Delaware
Care to Care IPA, LLC (2)	New York
CECity.com, Inc. (2)	Pennsylvania
Contigo Health Holdings, LLC (2)	Delaware
Healthcare Insights, LLC (2)	Illinois
Premier IDS, LLC (2)	Delaware
Premier Insurance Management Services, Inc. (2)	Illinois
Premier Pharmacy Benefit Management, LLC (2)	Delaware
Stanson Health, Inc. (2)	Delaware
SUM Total, LLC	Delaware
TheraDoc, Inc. (2)	Delaware
Catavert, LLC (5)	North Carolina
Contigo Health, LLC (6)(5)	Ohio
Acurity, LLC (7)(6)	Delaware
Conductiv, Inc. (7)(6)	North Carolina
Conductiv Contracts, LLC (7)(6)	Delaware
Elements Canada, LLC (7)(6)	Delaware
Essensa Ventures, LLC (7)	New York
Innovatix, LLC (7)(6)	Delaware
InnovatixCares, LLC (7)(6)	Delaware
Innovatix Network, LLC (7)(6)	Delaware
Intersectta, LLC (7)(6)	Delaware
Nexera, LLC (7)(6)	Delaware
Non-Healthcare Holdings LLC (7)(6)	Delaware
NS3Health, LLC (7)(6)	Florida
ProvideGx, LLC (7)(6)	Delaware
SVS LLC (7)(6)	North Carolina
Acro Pharmaceutical Services LLC (8)(7)	Pennsylvania
Commcare Pharmacy - FTL, LLC (8)(7)	Florida
Premier Specialty Pharmacy Solutions, LLC (7)	Florida
Premco LLC (8)	Florida Virginia
Ostonics Quality Systems LLC (9)	Delaware

(1) Wholly owned by Premier, Inc.

(2) Wholly owned by Premier Healthcare Solutions, Inc.

(3) Wholly owned (directly and indirectly) by Premier Healthcare Solutions, Inc. Premier Healthcare Solutions, Inc. is the sole general partner, and Premier Services II, LLC is the sole limited partner of Premier Healthcare Alliance, L.P.

(4) Wholly owned by Premier Healthcare Alliance, L.P.

(5) Wholly owned by Contigo Health Holdings, LLC.

(6) Contigo Health Holdings, LLC holds a 93% interest.

(7)(6) Wholly owned by Premier Supply Chain Improvement, Inc.

(8)(7) Wholly owned by NS3Health, LLC.

(8) Premier Supply Chain Holdings, LLC holds a 51% interest.

(9) CECity.com, Inc. holds a 50% interest.

Premier, Inc. subsidiaries may conduct business under the Premier name, as well as under their entity name or variants thereof, and may also conduct business under the brand names of products and/or services offered by such entities as described on Premier's internet website at www.premierinc.com.

Exhibit 23

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

- (1) Registration Statement (Form S-8 No. 333-191484) pertaining to the 2013 Equity Incentive Plan of Premier, Inc.,
- (2) Registration Statement (Form S-8 No. 333-229531) pertaining to the 2013 Equity Incentive Plan of Premier, Inc. (as amended and restated effective December 7, 2018),
- (3) Registration Statement (Form S-8 No. 333-267009) pertaining to the 2013 Equity Incentive Plan of Premier, Inc. (as amended and restated effective December 7, 2018),
- (4) Registration Statement (Form S-3 No. 333-199158) of Premier, Inc.,
- (5) Registration Statement (Form S-8 No. 333-204628) pertaining to the 2015 Employee Stock Purchase Plan of Premier, Inc.,
- (6) Registration Statement (Form S-3/ASR No. 333-244415) of Premier, Inc., and
- (7) Registration Statement (Form S-3/ASR S-8 No. 333-249826) pertaining to the 2023 Equity Incentive Plan of Premier, Inc.,

of our reports dated **August 22, 2023** **August 20, 2024**, with respect to the consolidated financial statements of Premier, Inc. and the effectiveness of internal control over financial reporting of Premier, Inc. included in this Annual Report on Form 10-K (Form 10-K) of Premier, Inc. for the year ended **June 30, 2023** **June 30, 2024**.

/s/ Ernst & Young LLP

Raleigh, North Carolina
August 22, 2023

20, 2024

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael J. Alkire, certify that:

1. I have reviewed this annual report on Form 10-K of Premier, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **August 22, 2023** August 20, 2024

/s/ Michael J. Alkire

Michael J. Alkire

President and Chief Executive Officer

Exhibit 31.2

**CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Craig S. McKasson, certify that:

1. I have reviewed this annual report on Form 10-K of Premier, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **August 22, 2023** August 20, 2024

/s/ Craig S. McKasson

Craig S. McKasson

Chief Administrative and Financial Officer and Senior Vice President

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Premier, Inc. ("Premier") on Form 10-K for the period ended June 30, 2023June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Michael J. Alkire, President and Chief Executive Officer of Premier, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Premier.

/s/ Michael J. Alkire
Michael J. Alkire
President and Chief Executive Officer

August 22, 202320, 2024

A signed original of this written statement required by Section 906 has been provided to Premier, Inc. and will be retained by Premier, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This written statement shall not be deemed filed by Premier, Inc. for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to liability under that section, and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Premier, Inc. specifically incorporates it by reference.

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Premier, Inc. ("Premier") on Form 10-K for the period ended June 30, 2023June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Craig S. McKasson, Chief Administrative and Financial Officer and Senior Vice President of Premier, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Premier.

/s/ Craig S. McKasson
Craig S. McKasson
Chief Administrative and Financial Officer and Senior Vice President

August 22, 202320, 2024

A signed original of this written statement required by Section 906 has been provided to Premier, Inc. and will be retained by Premier, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This written statement shall not be deemed filed by Premier, Inc. for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to liability under that section, and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Premier, Inc. specifically incorporates it by reference.

Exhibit 97

DODD-FRANK COMPENSATION RECOUPMENT POLICY

The Board of Directors of Premier, Inc. has adopted the following Dodd-Frank Compensation Recoupment Policy effective as of [•], 2023. It is the intention of the Board that this Dodd-Frank Recoupment Policy be interpreted and administered in a manner consistent with applicable laws and regulations and Securities Exchange listing requirements, including Section 304 of the Sarbanes-Oxley Act of 2002, Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (and Rule 10D-1 promulgated thereunder), and Nasdaq Listing Rules 5608 and 5810(c)(2)(A)(iii). This Dodd-Frank Recoupment Policy applies to awards of Incentive-Based Compensation received on or after the Effective Date by Executive Officers of the Company. The prior Compensation Recoupment Policy shall apply to awards of Incentive-Based Compensation received before the Effective Date.

Definitions

"Board" means the Board of Directors of the Company.

"Committee" means the Compensation Committee of the Board of Directors of the Company.

"Company" means Premier, Inc.

"Effective Date" means [•].

"Executive Officer" means the Company's president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policymaking functions for the Company. Executive officers of the Company's subsidiaries are deemed Executive Officers of the Company if they perform such policymaking functions for the Company.

"Excess Incentive-Based Compensation" means the amount of Incentive-Based Compensation received by a current or former Executive Officer that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had the amount of such Incentive-Based Compensation been determined based on the accounting restatement, computed without regard to taxes paid by the Executive Officer. With regards to Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Excess Incentive-Based Compensation is not subject to mathematical recalculation directly from the information in an accounting restatement, Excess Incentive-Based Compensation means a reasonable estimate of the effect of the accounting restatement on the applicable Financial Reporting Measure.

"Financial Reporting Measure" means any measure that is determined and presented in accordance with the accounting principles used to preparing the Company's financial statements, and any measures that are derived wholly or in part from such measures. "Stock price" and "total shareholder return" metrics are also Financial Reporting Measures. For the avoidance of doubt, a Financial Reporting Measure need not be presented in the Company's financial statements or included in a filing with the U.S. Securities and Exchange Commission.

"Incentive-Based Compensation" means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure.

"Lookback Period" means the three-year period preceding the date on which the Company is required to prepare an accounting restatement. For purposes of this definition, the date on which the Company is required to prepare an accounting restatement shall be deemed to be the earlier of (i) the date the Company's Board, a committee of the Board, or the officer(s) of the Company authorized to take such action (if Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare an accounting restatement; and (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an accounting restatement.

"Securities Exchange" means the securities exchange upon which the Company's Class A Common Stock, par value \$0.01 per share, trades.

Recoupment for an Accounting Restatement

The Company shall recover reasonably promptly any Excess Incentive-Based Compensation in the event that the Company is required to restate its financial statements due to the material noncompliance of the Company with any financial reporting requirement under the federal securities laws, including any required accounting restatement to correct an error (i) in previously issued financial statements that is material to the previously issued financial statements or (ii) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. The preceding sentence shall apply to Excess Incentive-Based Compensation received by any current or former Executive Officer: (a) after beginning service as an Executive Officer; (b) who served as an Executive Officer at any time during the performance period for the applicable Incentive-Based Compensation; (c) while the Company has a class of securities listed on a national securities exchange or a national securities association; and (d) during the Lookback Period. For purposes of this paragraph, Incentive-Based Compensation is deemed "received" in the Company's fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period.

If the Company is required to recoup Excess Incentive-Based Compensation following an accounting restatement based on adjustments to stock price or total shareholder return, the Company shall determine the amount of such Excess Incentive-Based Compensation subject to recoupment, which amount shall be a reasonable estimate of the effect of the accounting restatement on the applicable Financial Reporting Measure.

Notwithstanding the foregoing, if the Committee makes a determination that recovery would be impracticable, and one of the following enumerated conditions is satisfied, the Company need not recover such Excess Incentive-Based Compensation.

- Expenses Exceed Recovery Amount: The Company need not recover the Excess Incentive-Based Compensation at issue if the direct expense to be paid to a third party to assist in enforcing this Dodd-Frank Recoupment Policy would exceed the amount to be recovered; provided, however, that the Company must make a reasonable attempt to recover the Excess Incentive-Based Compensation and document such attempt(s) prior to the Committee's determination that recovery would be impracticable. The Company must provide the documentation evidencing the attempt(s) to the Securities Exchange consistent with the listing standards of the Securities Exchange.
- Recovery Would Violate Home Country Law: The Company need not recover the Excess Incentive-Based Compensation at issue if recovery would violate home country law where that law was adopted prior to November 28, 2022; provided, however, that the Company must obtain an opinion of home country counsel, in a form acceptable to the Securities Exchange, that recovery would result in such violation. The Company must provide the opinion to the Securities Exchange consistent with the listing standards of the Securities Exchange.
- Recovery Would Violate ERISA Anti-Alienation Provisions: The Company need not recover the Excess Incentive-Based Compensation at issue if recovery would violate the anti-alienation provisions of the Employee Retirement Income Security Act of 1974, as amended, contained in 26 U.S.C. § 401(a)(13) or 26 U.S.C. § 411(a), or regulations promulgated thereunder.

Method of Recoupment

The Committee shall have the sole discretion and authority to determine the means, timing (which shall in all circumstances be reasonably prompt) and any other requirements by which any recoupment required by this Dodd-Frank Recoupment Policy shall occur and impose any other terms, conditions or procedures (e.g., the imposition of interest charges on un-repaid amounts) to govern the current or former Executive Officer's repayment of Excess Incentive-Based Compensation.

Other Policy Terms

Any applicable award agreement, plan or other document setting forth the terms and conditions of any Incentive-Based Compensation or other compensation covered by this Dodd-Frank Recoupment Policy received on or after the Effective Date shall be deemed to (i) include the restrictions imposed herein; (ii) incorporate the Dodd-Frank Recoupment Policy by reference; and (iii) govern the terms of such award agreement, plan or other document in the event of any inconsistency. Eligibility for participation in and for payment under any such award agreement, plan or other document is contingent upon acceptance of the terms of this Dodd-Frank Recoupment Policy.

Any recoupment under this Dodd-Frank Recoupment Policy is in addition to, and not in lieu of, any other remedies or rights that may be available to the Company or its affiliates under applicable law, including, without limitation: (i) dismissing the current or former Executive Officer; (ii) adjusting the future compensation of the current or former Executive Officer; or (iii) authorizing legal action or taking such other action to enforce the current or former Executive Officer's obligations to the Company or its affiliates as it may deem appropriate in view of all of the facts and circumstances surrounding the particular case.

Incentive-Based Compensation and other compensation paid to employees of the Company and its affiliates may also be subject to other recoupment or similar policies, and this policy does not supersede any such other policies. However, in the event of any conflict between any such policy and this Dodd-Frank Recoupment Policy, this policy shall govern. In addition, no Executive Officer shall be subject to recoupment more than one time with respect to the same compensation.

Current or former Executive Officers shall not be entitled to any indemnification by or from the Company or its affiliates with respect to any amounts subject to recoupment pursuant to this Dodd-Frank Recoupment Policy.

Administration

The Board has delegated the administration of this policy to the Committee. The Committee is responsible for monitoring the application of this policy with respect to all Executive Officers. The Committee shall have the sole authority to review, interpret, construe and implement, the provisions of this Dodd-Frank Recoupment Policy and to delegate to one or more executive officers and/or employees certain administrative and record-keeping responsibilities, as appropriate, with respect to the implementation of this Dodd-Frank Recoupment Policy; provided, however, that no such action shall contravene the federal securities laws. Any determinations of the Board or Committee under this Dodd-Frank Recoupment Policy shall be binding on the applicable individual.

The Board may amend, modify or change this Dodd-Frank Recoupment Policy, as well as any related rules and procedures, at any time and from time to time as it may determine, in its sole discretion, is necessary or appropriate.

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.